

## Implementation Planning Study for the Integration of Medical Event Reporting Input and Data Structure for Reporting to AHRQ, CDC, CMS, and FDA

Final Report Volume 2 – Appendixes Contract No. 290-96-0010 Task Order 5

Submitted to: James Battles, Ph.D. Center for Quality Improvement and Patient Safety Agency for Healthcare Research and Quality 6011 Executive Blvd., Suite 200 Rockville, Maryland 20852

> Submitted by: The MEDSTAT Group, Inc. 5425 Hollister Avenue, Suite 140 Santa Barbara, CA 93111

> > June 11, 2002

### Appendixes

Appendix A Glossary of Terms and Definitions Appendix B Detailed Descriptions of Adverse Event Reporting Systems of Four DHHS Agencies Appendix C Members of the External Advisory Panel Appendix D Goals for Integrated Reporting System as Derived from EAP Working Sessions Appendix E Anticipated and Potential User Groups Affected by Development of Integrated System Appendix F Sample Data Collection Forms Appendix G Definitions and Classification Systems Appendix H HIPAA Standards for Demographic and Other Characteristics of Individuals Appendix I NQF and JCAHO Serious Reportable Events Appendix J Health Level 7 Reference Information Model Appendix K The Unified Medical Language System (UMLS) Appendix L Examples of New ICD-10-CM Codes Related to Medical Misadventures Appendix M NCCMERP Adverse Event Classification Regarding Harm to the Patient Appendix N The Aviation Safety Reporting System (ASRS)

Term	Definition	Source <sup>1</sup>
Accident	An accident is a series of events that involves damage to a defined system disrupting the ongoing or future output of the system.	(IOM, 1999)
Active error (or active failure)	Active errors (or active failures) occur when the actions and decisions of individuals result in failures that can immediately or directly impact patient safety.	(MERS-TM, undated)
Active error	Active errors are errors that occurs at the level of the frontline operator and whose effects are felt almost immediately.	(IOM, 1999)
Active failure and ypes of active ailure	Active failures can be thought of as occurring at the sharp end of a continuum of decisions, environmental factors, and actions that affect patient care. There are three major types of active failures: 1) Knowledge-based failure – occurs when individuals are unable to apply their existing knowledge to new situations; 2)Rule-based failure – occurs when a person fails to carry out a procedure or protocol correctly or chooses the wrong procedure; 3) Skill-based failure – occurs when a person fails in the performance of a routine task that normally requires little conscious effort. Most of us operate in the skill-based mode for many of the activities that we perform on a daily basis. If a routine is changed or interrupted, an error	
Active failure	may occur. An error which is precipitated by the commission of errors and violations. These are difficult to anticipate and have an immediate adverse impact on safety by breaching, bypassing, or disabling existing defenses.	
0	Any incident in which the use of a medication (drug or biologic) at any dose, a medical device, or a special nutritional product (e.g., dietary supplement, infant formula, medical food) may have resulted in an adverse outcome in a patient.	(JCAHO, undated(a))
Adverse drug eaction (ADR) Adverse event	An undesirable response associated with use of a drug that either compromises therapeutic efficacy, enhances toxicity, or both. An untoward, undesirable, an usually unanticipated event, such as death of a patient, and employee, or a visitor in a health care organization. Incidents such as patient falls or improper administration of medications are also considered adverse events even if there is no permanent effect on the patient.	(JCAHO, undated(a)) f (JCAHO, undated(a))
dverse event	An injury caused by medical mismanagement rather than the underlying disease.	(Brennan et al, 1991)
dverse event	An injury that was caused by medical management and that results in measurable disability.	(QuIC, 2000)
Adverse event Adverse event	An injury resulting from a medical intervention. Adverse Events that may be candidates for root cause analysis are untoward incidents, therapeutic misadventures, iatrogenic injuries, or other adverse occurrences directly associated with care or services provided within the jurisdiction of a medical center.	(IOM, 1999) (VA NCPS, 2002)
Adverse reaction eading to disability	If the adverse reaction caused a significant or permanent change in a patient's body function, physical activities, or quality of life (examples: strokes or nervous system disorders brought on by drug therapy).	(Henkel, 1998)
dverse reaction eading to death	If an adverse reaction to a medical product is a suspected cause of a patient's death.	(Henkel, 1998)
dverse reaction eading to ospitalization	If a person is admitted or has a prolonged hospital stay because of a serious adverse reaction(e.g. a serious allergic reaction to latex)	(Henkel, 1998)
Adverse reaction eading to need for	If use of a medical product required medical or surgical treatment to prevent impairment (examples: burns from radiation equipment or	(Henkel, 1998)

Appendix A Glossary of Terms and Definitions

Term	Definition	Source <sup>1</sup>
intervention to	breakage of a screw supporting a bone fracture).	
avoid permanent		
damage		
Adverse reaction	If exposure to a medical product before conception or during pregnancy is	(Henkel, 1998)
leading to birth	suspected of causing an adverse outcome in the child (example:	
	, malformation in the child caused by the acne drug Accutane, or	
stillbirth or birth	isotretinoin).	
with disease		
Adverse reaction	If the patient was at risk of dying at the time of the adverse reaction or if it	(Henkel, 1998)
leading to life-	is suspected that continued use of a product would cause death (examples:	
threatening hazard	pacemaker breakdown or failure of an intravenous (IV) pump that could	
	cause excessive drug dosing.	
Antecedent event	An antecedent describes the preceding event, condition, or cause.	(MERS-TM,
	Therefore, antecedent events are those actions and decisions that led up to	undated)
	the consequent event. An event may have multiple antecedent (or	
	preceding) events leading up to the consequent event. Antecedent events	
Damian	and conditions can be discovered by asking why of the consequent event.	MEDS TM
Barrier	A barrier is any action or process built into the work flow to check for	(MERS-TM,
	accuracy or quality and that may prevent an event. Although barriers are	undated)
	designed to avert accidents (or facilitate recovery), recovery does not always occur as the result of a barrier.	
Blunt end of health	Those at the blunt end of the system affect safety through their effect on	(Cook and Woods,
care system	the constraints and resources acting on the practitioners at the sharp end.	(Cook and woods, 1994)
care system	In medicine, the blunt end includes government regulators, hospital	1994)
	administrators, nursing managers, and insurance companies.	
Classification	The categorizing of errors into distinguished levels based upon their	(NPSF, 1997)
system	behavior, accountability, outcome, context or process. Behavior	(11151, 1)))))
system	classifications - omission vs commission, misuse vs overuse vs. underuse;	
	Accountability classifications - individual vs system and intentional vs.	
	unintentional; Outcome classification - a scale from no harm to death;	
	Context classification - low staff; Process classification - wrong dose vs.	
	wrong process.	
Close Calls	An event or situation that could have resulted in an accident, injury or	(VA NCPS, 2002)
	illness to a patient, a visitor, or staff, but did not, either by chance or	
	through timely intervention.	
Complication	A detrimental patient condition that arises during the process of providing	(JCAHO,
	health care, regardless of the setting in which the care is provided. For	undated(a))
	instance, perforation, hemorrhage, bacteremia, and adverse reactions to	
	medication (particularly in the elderly) are four complications of	
	colonoscopy and its associated anesthesia and sedation. A complication	
	may prolong an inpatient's length of stay or lead to other undesirable	
	outcomes.	
Device-related	An injury or illness that is life-threatening; results in permanent	(USUHS and FDA,
serious injury	impairment/damage to body function or structure; or necessitates	1997)
	medical/surgical intervention to prevent impairment/ damage of body	
<b>F</b> 6 · ·	function/structure.	
Error of commission	An error which occurs as a result of an action taken. Examples include	(JCAHO,
	when a drug is administered at the wrong time, in the wrong dosage, or	undated(a))
	using the wrong route; surgeries performed on the wrong side of the body;	
Error of omission	and transfusion errors involving blood cross-matched for another patient.	
Error of omission	An error which occurs as a result of an action not taken, for example, when a delay in performing an indicated cesarean section results in a fetal	(JCAHO, undated(a))
	death, when a nurse omits a dose of a medication that should be	unualcu(a))
	administered, or when a patient suicide is associated with a lapse in	
	auministered, or when a patient suicide is associated with a tapse in	

carrying out frequent patient checks in a psychiatric unit. Errors of	Source <sup>1</sup>
omission may or may not lead to adverse outcomes.	
The failure of a planned action to be completed as intended or the use of a	(QuIC, 2000)
wrong plan to achieve an aim. Errors can include problems in practice,	
products, procedures, and systems.	
See "active failure" or "latent failure".	(MERS-TM,
	undated)
Failure of a planned action to be completed as intended or use of a wrong	(IOM, 1999)
plan to achieve an aim; the accumulation of errors results in accidents.	
	(MERS-TM,
	•
Centers each have their own set of event codes because they perform	
different functions and processes.	
An occurrence with a potentially negative outcome that most often results	(MERS-TM,
from both latent conditions and human/active error.	undated)
Something that prevents the behavior from continuing until the problem	(Reason, 1990)
has been corrected.	
The characteristic collection of factors that lead to the surface.	(NPSF, 1997)
	(MERS-TM,
	undated)
Study of the interrelationships between humans, the tools they use, and the	,
	((( emger, 1)))))
•	(VA NCPS 2002)
	(1111015,2002)
	(MERS-TM,
	undated)
	(MERS-TM,
	undated)
	unduced)
	(IOM, 1999)
	(,)
	(JCAHO,
	undated(a))
	unduted(u))
	(OuIC 2000)
	(Quie, 2000)
6	(ICAHO 2001)
	(001110,2001)
	(Cooper et al.,
	(Cooper et al., 2001)
	2001)
· ·	(NCCMERP, 2001
	UNCOMERF, 2001
mappropriate metrication use of patient narm write the metrication is in	
	The failure of a planned action to be completed as intended or the use of a wrong plan to achieve an aim. Errors can include problems in practice, products, procedures, and systems. See "active failure" or "latent failure". Failure of a planned action to be completed as intended or use of a wrong plan to achieve an aim; the accumulation of errors results in accidents. Part of describing an event involves assigning codes that tell what happened and where the event first occurred in the organizational process, what happened (or what could have happened) and where it was later discovered in the organizational process. Transfusion Services and Blood Centers each have their own set of event codes because they perform different functions and processes. An occurrence with a potentially negative outcome that most often results from both latent conditions and human/active error. Something that prevents the behavior from continuing until the problem

	Definition	Source <sup>1</sup>
	the control of the health care professional, patient, or consumer. Such	
	events may be related to professional practice, health care products,	
	procedures, and systems, including prescribing; order communication;	
	product labeling, packing and nomenclature; compounding; dispensing;	
	distribution; administration; education; monitoring; and use.	
Mistake	Result of conscious deliberation, when a person generalizes too rapidly,	(Norman, 1990)
	classifying a new situation as similar to an old one when, in fact there are	
	significant discrepancies; false generalizations. Contrasted to slips, which	
	are almost always small things: a misplaced action, the wrong thing	
	moved, a desired action undone. They are relatively easy to discover by	
	simple observation and monitoring. Mistakes can be major events, and they are difficult or even impossible to detectafter all, the action	
	performed is appropriate for the goal.	
Near miss	An event in which the unwanted consequences were prevented because	(Van der Schaaf et
vear miss	there was a recovery by identification and correction of the failure, either	(Van der Senaar et al., 1991)
	planned or unplanned.	un, 1991)
Near miss	An event or situation that could have resulted in an accident, injury or	(QuIC, 2000)
	illness, but did not, either by chance or through timely intervention.	
Near miss	A near miss event is an event for which unwanted consequences were	(MERS-TM,
	prevented because some recovery action was taken that identified and	undated)
	corrected the failure. Recovery actions, which are present in all near miss	
	events, can be planned or unplanned. The recovery is planned if it results	
	from a barrier, such as a check point in the work process, that was	
	designed to catch mistakes or ensure quality. However, the recovery is	
	unplanned if it results from an accidental or lucky catch. MERS-TM	
	categorizes events into three types: misadventures, no harm events, and near miss events.	
Near miss	Any process variation which did not affect the outcome, but for which a	(JCAHO,
tour miss	recurrence carries a significant chance of a serious adverse outcome.	undated(a))
Negligence	Failure to use such care as a reasonably prudent and careful person would	(JCAHO,
8 8	use under similar circumstances.	undated(a))
No harm event	A no harm event is an event that has actually occurred (no recovery action	
	was taken) but where no actual harm has come to the patient or the	undated)
	organization. Except for "luck" (or in health care, the robust nature of	
	human physiology), these accidents would have become misadventures.	
Omission	Failure to carry out some of the actions necessary to achieve a desired	(Reason, 1990)
	goal.	(70) ( 4000)
Patient safety	Freedom from accidental injury; ensuring patient safety involves the	(IOM, 1999)
	establishment of operational systems and processes that minimize the	
	likelihood of errors and maximize the likelihood of intercepting them when they occur.	
Patient safety	The avoidance, prevention and amelioration of adverse outcomes or	(NPSF, 1999)
ation safety	injuries stemming from the processes of health care. These events include	(11151, 1999)
	"errors," "deviations," and "accidents." Safety emerges from the	
	device or department. Improving safety depends on learning how safety	
	emerges from the interactions of the components. Patient safety is a subset	
	of healthcare quality.	
Patient safety		(AHRQ, 1999)
attent surery		
-	The phonetype of an incident is what happens, what people estually do or	(NPSE 1007)
Phenotype		(1151, 1997)
-	what they do wrong, what you can observe. They are specific to the local	(1151,1997)
-		(JCAHO,
Patient safety	interaction of the components of the system; it does not reside in a person, device or department. Improving safety depends on learning how safety emerges from the interactions of the components. Patient safety is a subset	(AHRQ, 1999

Term	Definition	Source <sup>1</sup>
	is the superficial or obvious cause for an occurrence. Treating only the "symptoms," or the proximate special cause, may lead to some short-term improvements, but will not prevent the variation from recurring.	undated(a))
Quality of care	Degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge.	(IOM, 1999)
Risk containment	Immediate actions taken to safeguard patients from a repetition of an unwanted occurrence. Actions may involve removing and sequestering drug stocks from pharmacy shelves and checking or replacing oxygen supplies or specific medical devices.	(JCAHO, undated(a))
lisk management	Clinical and administrative activities undertaken to identify, evaluate, and reduce the risk of injury to patients, staff, and visitors and the risk of loss to the organization itself.	(JCAHO, undated(a))
Root cause analysis	A process for identifying the basic or causal factor(s) that underlie variation in performance, including the occurrence or possible occurrence of a sentinel event.	(JCAHO, undated(a))
Root cause	The underlying factors that, if eliminated, could reduce the risk of similar errors in the future.	(JCAHO, undated(a))
Rule-based failure	When a person fails to carry out a procedure or protocol correctly or chooses the wrong procedure.	(MERS-TM, undated)
afety	Freedom from accidental injury. This definition recognizes that this is the primary safety goal from the patient's perspective.	(NPSF, 1999)
entinel event	An unexpected occurrence involving death or serious physical or psychological injury, or the risk thereof. Serious injury specifically includes loss of limb or function. The phrase, "or the risk thereof" includes any process variation for which a recurrence would carry a significant chance of a serious adverse outcome. Such events are called "sentinel" because they signal the need for immediate investigation and response.	(JCAHO, undated(a)); (VA NCPS, 2002)
harp end of ealthcare system	Practitioners at the sharp end actually interact with the hazardous process in their roles. In medicine, these practitioners are anesthesiologists, surgeons, nurses, and some technicians who are physically and temporally close to the patient.	(Cook and Woods 1994)
kill-based failure	When a person fails in the performance of a routine task that normally requires little conscious effort. (Most of us operate in the skill-based mode for many of the activities that we perform on a daily basis. If a routine is changed or interrupted, an error may occur.)	(MERS-TM, undated)
lip	Type of error that results from automatic behavior, when subconscious actions that are intended to satisfy our goals get waylaid en route.	(Norman, 1990)
ystem	A regularly interacting or interdependent group of items forming a unified whole.	
ystem	A set of interdependent elements interacting to achieve a common aim. These elements may be both human and non-human (equipment, technologies, etc.).	(IOM, 1999)
ystems error	An error that is not the result of an individual's actions, but the predictable outcome of a series of actions and factors that comprise a diagnostic or treatment process.	(QuIC, 2000)
Inderlying cause	The systems or process cause that allow for the proximate cause of an event to occur. Underlying causes may involve special-cause variation, common-cause variation, or both.	(JCAHO, undated(a))
Jnpreventable dverse event	An adverse event resulting from a complication that cannot be prevented given the current state of knowledge.	(QuIC, 2000)
	National Quality Forum were not included because their Website denies per	mission to quote

<sup>1</sup>References for the National Quality Forum were not included because their Website denies permission to quote.

# Appendix B Detailed Descriptions of Adverse Event Reporting Systems of Four DHHS Agencies

AERS

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products	
Part I. Data Acquisition:		
A. General Information		
1. Report Title	N/A	
2. Internet Location: http://	http://www.fda.gov/cder/aers/	
3. Host Organization(s)	The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)	
4. Primary contact information (e.g. Address, Phone)	Ralph Lillie - (301) 827-3513 LILLIE@CDER.FDA.GOV Roger Goetsch - (301) 770-9299 GOETSCH@CDER.FDA.GOV Sandra Valencia - VALENCIA@CDER.FDA.GOV Carol Holquist – (301) 827-0195	
<b>B.</b> Overall System Features		
<ul> <li>5. System purpose/mandate (any information on role in mission, eadership support, integration with quality assurance activities and history)</li> <li>6. What is the geographic scope of data collection (national, state, local, facility etc)?</li> </ul>	The Adverse Event Reporting System (AERS) is an information workflow system (including a computerized information database) designed to support the FDA's post-marketing safety surveillance program for all approved drug and therapeutic biologic products. The ultimate goal of AERS is to improve the public health by providing the best available tools for storing and analyzing safety reports. Reports from AERS are used by FDA staff in conducting post marketing drug surveillance and compliance activities and in responding to outside requests for information. One major function of AERS data is to ensure that a product's labeling information correctly captures the adverse events associated with the product. This data can also be used to re-evaluate an approval decision on an established product. The majority of adverse event activity is seen in the first three years of post market surveillance. Among AERS system features are: the on-screen review of reports; searching tools; and various output reports. The reports in AERS are evaluated by clinical reviewers in the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) to detect safety signals and to monitor drug safety. They form the basis for further epidemiological studies when appropriate. Adverse event reports received through form 3500a (mandatory – manufacturers/distributors/packers) or 3500 (voluntary – health professional/consumer) are received by MedWatch and triaged by Logistics Applications also adds MedDRA codes to describe event/outcome. Also get reports from USP and CIOMS forms (international). Mandatory reporting of serious and unlabelled adverse events is required within 15 days. Periodic reporting of non-serious (labeled or unlabelled) and serious-labeled events. Manufacturer can get exemption from reporting of labeled, non-serious events. Note that this is different from medical device reporting that requires reporting of serious events only. For non-serious, reporter can enter a "medically importan	

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
7. What is the unit of data entry (e.g., event, patient, product)?	Events covered by AERS include special nutritional products, drugs, and licensed biological products. An adverse event is any undesirable event associated with the use of a drug or therapeutic biologic in humans. An Individual Safety report will not be entered into the database unless it passes certain quality parameters. One of those is to meet a minimum data set - having a valid reported drug, an event (reaction), patient, and reporter.
8. Who is allowed/required to input information?	For licensed biological products - any person whose name appears on the label of a licensed biological product as its manufacturer, packer, or distributor has reporting responsibilities, as does the individual or corporate entity that holds the product license. For drugs - The manufacturer applicant is required to report. In addition, any person whose name appears on the label of a marketed drug as its manufacturer, packer, or distributor has reporting responsibilities, as does the individual or corporate entity that holds an approved new drug application (NDA), abbreviated new drug application (ANDA), or antibiotic application. For purposes of this guideline, "applicant" includes all persons with reporting responsibility under 21 CFR 310.305 and 314.80. Reporting may also be done (and is encouraged) on a voluntary basis from health care professionals and consumers through the MedWatch program. AERS also receives input from the USP Medication Errors Reporting Program. The appropriate fields from these forms are entered into AERS using a MedDRA preferred term of "medication error".
9. What are the regulations/laws affecting reporting?	Drug manufacturers of NDA and ANDA drugs (See http://www.fda.gov/medwatch/report/mfg.htm) and licensed manufacturers of approved biologic product license applications are required to report adverse experiences to the FDA under 21 CFR 310.305, 314.80, 314.98, and 600.80. See http://www.fda.gov/medwatch/report/guide2.htm and http://www.fda.gov/medwatch/report/mfg.htm for details. Regulations Sheet also has more details on the specific regulations.
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	E.5 (Voluntary Form 3500) - Option not to disclose identity to manufacturer to avoid FDA providing reporter name, address and phone number to manufacturer of a suspect drug or biologic. For mandatory reporting (Form 3500a): FDA has promulgated a regulation [21 CFR §20.63(2)] that extends protection against disclosure of voluntary reports held by medical device, pharmaceutical, and biologics manufacturers by preempting state discovery laws. User facility name will not be released to the public under the FDA Modernization Act. FDA will also not release the identity of the patient or any information that can be used to identify the patient, such as the serial number of an implanted device. Nor will it release the name of any person other than the MDR contact. The name of the reporter and facility are deleted from disclosed data. Please note that the FDA is required under the Freedom of Information and Privacy Acts (SEC 552, Title 5, USC) (PL 93-579) to delete, prior to public disclosure, any information that constitutes trade secrets, and confidential, commercial, or financial information; and any personal, medical and similar information that would constitute a clearly unwarranted invasion of personal privacy. Included in the deletion requirements are all identification of the reporters and userfacilities associated with the events. The USP Medication Error Reporting Program allows reporters to submit anonymously but this is rarely done. The system asks for reporter identification but not institution where error occurred. Reporter may maintain confidentiality beyond USP for data sent onto FDA, manufacturers and ISMP.

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
11. What is the mode of data acquisition	MedWatch Voluntary form 3500 can be sent by: mail, phone, fax or
or input (mail, web form, phone etc)?	<b>completed</b> on-line via the MedWatch homepage:
or input (intuit, web form, phone etc).	https://www.accessdata.fda.gov/scripts/medwatch/
	Mandatory 3500A forms and the foreign form CIOMS I can be mailed
	to:
	Central Document Room (when duplicate copies for drugs)
	Center for Drug Evaluation and Research
	Food and Drug Administration
	12229 Wilkins Avenue
	Rockville, MD 20852
	When single copies for drugs are required by regulation:
	Office of Drug Safety HFD-400
	Center for Drug Evaluation and Research
	Food and Drug Administration
	5600 Fishers Lane
	Rockville, MD 20857
	Biologics:
	Epidemiology Branch, HFM-220
	Food and Drug Administration
	1401 Rockville Pike
	Rockville, MD 20852-1448
	There are optional electronic versions available for filling out the form
	using a PC. There is also work being done to report electronically
	(Expedited Safety Reports) and draft guidance is available at
	http://www.fda.gov/cder/guidance/4153dft.pdf. 4 Companies are currently
	using electronic submission. 2 of these have stopped submission via paper
	reporting. When a report is received, AERS assigns an individual safety
	report (ISR) for each report with a bar code. As part of processing, paper submissions are scanned and stored in retrieval software. Faxes of
	biologics and drug forms are also accepted, but only for periodic reports.
	The USP MERS form is first sent to USP, then sent periodically via courier
	to AERS where it is entered into the system. Analysts from the Office of
	Drug safety pull mediation error reports from AERS each month. These
	reports are used by a staff member at the FDA Office of Drug Safety to
	enter the ISR# and derived NCCMERP codes into an Oracle database
	maintained by the Office of Drug Safety.
12. What are the methods of editing	The 3500a form allows follow-up information:Field H.2 - Correction:
information (e.g. correcting/add more	Changes to previously submitted information. Additional information:
information to records)	Information not know when the original report was submitted Response to
	FDA request: Additional information requested by FDA concerning the
	device/event. Device evaluation: analysis of eventAny change to a previous
	report must be submitted in writing via a follow-up report. 3500 form -
	reporter can send in a follow-up form or call to make changes.
13. Where is the collected data stored	AERS is the database. The data from all sources eventually arrives at the
(name of database, number of data	AERS triage unit – either directly (MedWatch forms) or from USP, CBER
storage locations)?	or CDER. Under the supervision of FDA staff, data is entered and question
	and answered by PSI International staff. The database programming and
	design was created and is maintained by Booz-Allen and Hamilton. Data
	storage requirements are specified in detailed specifications.

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
14. How often is the system revised (annual, semi-annual etc)?	A timeline was provided that shows the various versions of the AERS database (See PMSS process evolutionary timeline Nov. 1997 to Dec 2001 document.) The timeline shows a total of about 14 revisions over the past 5 years with an average of about 6 months between revisions. Revisions are made based upon issues brought up via Change Control Requests and reviewed by the Change Control Board. One item which is updated on a regular basis is the MedDRA portion of the system. MedDRA is updated 2x per year. AERS updates one time per year to accommodate the semi-annual MedDRA updates.
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	Federal register notice - public comments
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	No minimum. Form 3500 can be written out and mailed to FDA.
17. What new features are being planned and/or are on wish lists?	Providing regulatory submissions of periodic reports in electronic format - see http://www.fda.gov/cder/guidance/4153dft.pdf. Currently 4 companies are submitting electronically using ICH E2B as the standard format for transmission. Goal is to increase this over time in order to reduce processing costs from \$18/ISR to \$5/ISR
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	MERS data is entered into AERS, then entered into an Office of Drug Safety Oracle database. This data is used to make recommendations for drug name changes and/or issuing of alerts. No links to state systems
D. Fields related to contributor/participant Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
	(P)E.2 - Health professional. If you are not a health professional, write NA Yes No (N) E.3 - OccupationG. All Manufacturers(N) G.1 - Contact Office (name/address and manufacturing site)(N) G.2 - Phone number(P) G.3 - Manufacturer Report source (check all that apply) - Check the box(es) that most accurately describe(s) how the manufacturer [contact office] became aware of the reported adverse event or from where the information about the adverse event originated.Foreign - foreign country etcStudy - study that involves a systematic collection of adverse events from a protocolLiterature - If the report source is the scientific literature or an unpublished manuscript, a copy of the article or manuscript must be attached. Foreign language articles should be translated into English. Record the date of the article as the date of the event (block B3), and provide a full literature citation in block H10;Drugs and Biologics: A separate 3500A form must be completed for each identifiable patient described in the article or manuscript. Consumer - recommend help of care provider; Health professional; User facility - User facility should be checked if the manufacturer received the report from the MDR contact in a user facility as identified in section F. Company rep, Distributor Other - Any source not covered by the previous categories. Note: AERS gets it product/manufacturer information from FDA's CDER dictionaries.

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
20. Is participation mandatory or voluntary?	Mandatory for manufacturers, distributors, packers, and licensees. See items 8 and 9.
21. List fields related to contributor/participant contact information	(N)E.1 - Reporter Address and Phone #
22. List fields related to facility contact information(include type of facility, teaching status, id information)	N/A
23. List fields related to distributor contact information	N/A
24. List fields related to manufacturer contact information	<ul> <li>G. All Manufacturers</li> <li>(N) G.1 - Contact Office (name/address and manufacturing site)</li> <li>(N) G.2 - Phone number</li> <li>(N) G.9 - Manufacturer Report # - used by AERS staff to identify potential multiple submission of information on the same event. Mulitple ISRs with the same manufacturer number are stored in the system as a case.</li> </ul>
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
25. List fields related to Provider of Care identification	N/A
26. List fields that identify types of care providers included in system	N/A
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	(N)A.1 - Identifier - patient's initials or some other type of information that will allow you, the reporter to readily locate the case if you are contacted for more information. Do not use patient's name or SSN.
28. List fields related to patient contact information (e.g. address, zip code, county, region)	N/A
29. List fields related to patient demographics (e.g. age, sex, race)	<ul> <li>(N)A.2 - Age at time of event OR Date of Birth - provide the most precise information available. For age, indicate time units (3 years+-use years, less than 3 years old, use months; less than 1 month old, use days)</li> <li>(P)A.3 - Sex (if congenital anomaly, report sex of the child)</li> <li>Female</li> <li>Male</li> <li>(N)A.4 - Weight (in lbs OR kg)</li> <li>**Race could be included by reporter in medical history of patient, but not a separate field (see question 31)</li> </ul>
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)?	No traceable data - patient initials or other reporter assigned ID are entered in database.

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
31. List fields related to pre-existing conditions and/or medical history of patient	<ul> <li>(N)Drugs and Biologics - C.10 - Concomitant medical products and therapy dates (exclude tx of event)</li> <li>List and provide therapy dates for any other medical products (drugs, biologics, medical devices, etc.) that a patient was using at or around the time of the event. DO NOT include products used to treat the event.</li> <li>(N)B.7 - Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)</li> <li>(P)Categories for race (as specified in instructions):</li> <li>Am. Indian – Alaska Native= American Indian or Alaska Native Asian= Asian Continent to include Indian Subcontinent</li> <li>Native Hawaiian or other Pacific Islander= Native Hawaiian or other Pacific Islander</li> <li>Black= Black, not of Hispanic origin</li> <li>Hispanic= Hispanic</li> <li>White= White, not of Hispanic origin</li> </ul>
32. List fields that capture the clinical condition of patient at time of event	C.4 - Diagnosis for use of drug, biologic
<ul> <li>33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)</li> </ul>	N/A
34. List any other types of information collected about the patient	(P) B.2 - Outcome attributed to adverse event - these are regulatory definitions of serious outcomedeath (date in fixed format)life- threateninghospitalization - initial or prolongeddisabilitycongenital anomaly required intervention to prevent permanent impairment/damageother (narrative description)Note: this is used to classify report and sort for data entry
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Pick list items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	Drugs, biological products Product problems include, but are not limited to, such concerns as: Suspected contamination; Therapeutic failures; Product confusion (caused by name, labeling, design or packaging); Suspected super potent or subpotent medication; Labeling problems caused by printing errors/omissions.

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
36. List fields associated with	A separate form should be submitted for each individual product problem
medication-related events (e.g. drug	report.
name, dose, dates of therapy,	(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if
manufacturer)	known) Use the trade name as marketed.
	If unknown use the generic name (with the manufacturer or labeler's name,
	if known). For quality problem reports, include the manufacturer's name
	and the labeled strength for both prescription and non-prescription products.
	(N)C.2 - Dose frequency & route used. Describe how the product was used
	by the patient.
	For reports involving overdoses, overdose amt, not prescribed amount.
	(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started
	(or best estimate) and the date stopped (or best estimate). If no dates are known, an estimated
	duration is acceptable or if therapy was less than one day, then duration is
	appropriate.
	(P) C.5 - Event abated after medication use stopped or dose reduced
	Yes
	No
	Doesn't apply
	(N) C.6 - Lot # (if known). If known, include the lot number(s) with all
	product problem reports,
	or any adverse event report with a biologic or medication
	(N) C.7 - Exp. Date (if known). Include with all product problem reports ONLY.
	(P) C.8 - Event reappeared after reintroduction
	Yes, No, doesn't apply
	(S-NDC codes) C.9 - NDC# - for product problems only (if known)
	National drug code
36. List fields associated with	(N) G.5 - Manufacturers should provide whatever information is applicable
medication-related events (e.g. drug	to the suspect medication identified in section C(S-NDA#)(A)NDA #: The
name, dose, dates of therapy,	abbreviated new drug application or the new drug application (NDA)
manufacturer) continued	number. The report should be filed to the first approved NDA if a product
	has several NDAs and the specific one cannot be determined (S-IND#)
	IND #: The investigational new drug (IND) application number (S-PLA#)
	PLA #: Composed of the 4-digit U.S. License Number followed by a slash,
	followed by the 4-character Product Code Pre-1938: Check the box if the
	suspect medication was marketed prior to 1938 and does not have an NDA
	# OTC Check the box if the suspect medication can be purchased over-
	Product: the-counter (without a prescription) (S-Protocol #) G.6 - If IND,
	protocol# Note: CBER supplies a list of products to the contractor(BAH)
	for insertion into AERS.
37. List fields associated with medical	N/A
device-related events (e.g. brand name	
of device, type of device, usage, manufacturer name, operator of device)	
38. List fields associated with vaccine	N/A
related events.	
	N/A
related events.	

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
40. List fields associated with any other	N/A
type of event. List type of event.	
41. List fields that allow input and/or	(P) B.1 - Classification
classification of the event/harm	Adverse Event
(narratives, problem codes, adverse	Product Problem (defects/malfunctions)
event terms)	(N) B.5 - Describe event or problem
	For an adverse event:
	Description of the event in detail, including a summary of all relevant clinical information (medical status prior to the event; signs and/or symptoms; differential diagnosis for the event in question; clinical course; treatment; outcome, etc.). If available and if relevant, includes synopses of any office visit notes or the hospital discharge summary. Copies of these records are attached with any confidential information deleted. If it is determined that reuse of a medical device labeled for single use may have caused or contributed to an adverse patient outcome, report the facts of the incident in B5 and the perceived contribution of reuse to the occurrence. For a medication or special nutritional product problem, indicate if a sample is available for use by FDA (S-MedDRA, WHOART or custom) G.8 - Adverse event term(s) - Include a list of adverse event terms that most accurately characterize the adverse event described in narrative format in block B5. Terms should be listed with the most important term(s) first. The terminology may be an accepted standard (e.g., MEDDRA or WHOART), a verbatim term, or the
	manufacturer's own terms. AERS staff use MEDDRA classification of narrative.
42. List fields associated with when the event occurred	(FF) B.3 - Date of event (mo/day/yr) - Provide the actual or best estimate of the date of first onset of the adverse event. If day is unknown, month and year are acceptable. If day and month are unknown, year is acceptable. When a newborn baby is found to have a congenital anomaly, the event onset date is the date of birth of the child. When a fetus is aborted because of a congenital anomaly, or is miscarried, the event onset date is the date pregnancy is terminated. If information is available as to time during pregnancy when exposure occurred, indicate that information in narrative block B5.
43. List fields associated with tracking	(FF) B.4 - Date of this report (initial reporter)(FF) G.4 - Date received by
the time between the event, when reported, when acted upon etc	manufacturer (mm/dd/yy)(P) G.7 - Type of report For licensed biological products, the regulations describe types of adverse experience reports: (a) 15-day Alert reports (15-day)(b) Periodic Adverse Experience reports. (Periodic)For drug adverse events - (a) 15-Day Reports of Serious, Unlabeled Events - ones that AERS staff really look at - manufacturers have responsibility for indicating whether a report involves serious, unlabeled event. Note: AERS only accepts CIOMS reports for this type of event(b) Periodic Reports (serious, labeled or non-serious unlabeled - everything but those identified by manufacturer as 15-day) required for each approved NDA, ANDA, and antibiotic application. Periodic reports are due quarterly for the first three years after approval, and annually thereafter. Serious defined as involving death, life-threatening, hospitalization, disabled, congenital anomaly, important medical event. Reported in H.1 - Type of Reportable event on 3500aThere are also high profile reports that can be for drugs or biologics and involve MedWatch or 15-day reports. These involve drugs which are identified as having potential safety issues. The above are labeled on the 3500a form as:15- dayperiodic

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
44. List fields associated with where the	N/A
event occurred	
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event	(N) B.6 - Relevant tests/laboratory data (with dates) Include: relevant negative test and laboratory findings, in order to most completely convey how the medical work-up/ assessment led to strong consideration of medical product-induced disease as etiology for clinical status, as other differential diagnostic considerations were being eliminated; relevant baseline laboratory data prior to the administration or use of the medical product; laboratory data used in diagnosing the event; available laboratory data/engineering analyses (for devices) that provide further information on the course of the event If available, include: any pre- and post-event medication levels and dates (if applicable);synopses of any relevant autopsy, pathology, engineering, or
	lab reports
46. List fields related to follow-up of event that are not associated with a particular patient (medication/manufacturing/policy	<ul> <li>(P) E.4 - Initial reporter also sent report to FDA? Yes, No, unknown</li> <li>(Allows staff to track multiple reporting of same event)</li> <li>(P) G.7 Type of report - one of the choices is for follow-up with number</li> <li>[manufacturer only]</li> </ul>
actions to correct/update event)	Follow-up: Check if the report is a follow-up to a previously submitted report. Allows user to provide additional or corrected information on the previously reported event. Follow-up reports on drugs and biologics should contain information that was submitted in the original report if the information is still correct.
47. List fields related to the outcome of event	(P) B.2 - Outcome attributed to adverse eventdeath (date in fixed format)life-threateninghospitalization - initial or prolonged disability congenital anomaly required intervention to prevent permanent impairment/damage other (narrative description)
48. List any other fields related to the	Note - PSI international staff receive several sources of information that are
event or any other information collected by the reporting system (e.g. root cause analysis, results of investigations etc)	not the 3500 or 3500A form - e.g. USP Medication Error Reporting Program, MedWatch direct reports on Biologic Products, international CIOMS I form for reporting of international drug events. Fields in AERS are based upon the 3500a form so whenever data is entered into AERS the data from these forms are 'forced' to fit into the existing AERS fields.
H. Implications	
49. Integration with other systems	Integration with other systems is performed as part of the AERS information flow process. The AERS central triage unit receives and distributes MedWatch direct reports to appropriate divisions of FDA or CDC(See PMSS Document/ISR Process Flow Diagram) - ie MAUDE data goes to CDER, VAERS data goes to CDC, MERS data comes from USP - treated as direct report - sent to Jerry Phillips for entry into his database with addition of NCCMERS, then back to AERS for entry, Biologic Products and Therapeutic biologics go to CBER, Food and Nutrition and Herbal Supplements go to CFSAN. AERS does integrate with the MERS system by accommodating the fields in this reporting system (See template for MERS system for more details on fields used). AERS also allows the use of an international form - CIOMS I. If the CIOMS I form is used, it will be accepted in place of the form FDA 3500A or VAERS form for foreign serious and unexpected reports only (15 day reports) and should contain, at a minimum, information including an identifiable source, a patient (even if not precisely identified by name and date of birth), a suspect product and a suspect event. Also, while the therapeutic biologics (about 10% of reports) are not exactly the same as drugs,

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
	fields identified on the 3500a that refer to drug information are the fields used for entering therapeutic biologic information. Some blood product information is entered into AERS, but that is only if it comes in as a direct report (MedWatch) and can be easily entered into AERS.
50. Methods used to de-identify data	No automated didaction - FOI office - has access to AERS database. They receive a request for information, gets line listing of, send to copy of report to requester, after remove fields. The following fields are removed for MAUDE by FDA The name of the reporter and facility are deleted from disclosed data before release of the report. In addition, an automated process is used to delete the following fields and any proper names in narrative fields (this often must be done manually by an analyst). Double checked by an analyst:A.1 - Patient identifier A.2 - Age at time of event or Date of birth A.3 - Sex A.4 - WeightB.6 - Relevant tests/laboratory data, including dates B.7 - Other relevant history, including preexisting medical conditionsD.7 - If implanted, give date D.8 - If explanted, give date E.1 - Name, address & phone # E.3 - Occupation F.2 - UF/Dist/Importer report number F.3 - User facility or distributor/Importer name & address F.4 - Contact person F.5 - Phone Number F.10 - Event problem codes H.6 - Evaluation codes
51. Technical Information	

# Part II. Data Structure & Storage:

I. Facility/Location	
52. What is the address of the data storage facility?	
53. What type of facility is used to store data (3rd party data center, secured computer room, someone's cubicle)?	secured computer room
54. Is there a network interconnect for physically distributed systems?	fast ethernet
55. What type (private lines, VPN, Internet) of network interconnect is used?	Internet
56. What is the network protocol (TCP/IP, IPX, etc.)?	TCP/IP
57. What is the bandwidth of network the interconnect (dial-up, ISDN, T1, T3, etc.)?	10/100mb
58. What is the network (WAN) topology, including diagram if available?	Fiber Optic with Switches.
WHO OPERATES THE SYSTEM?	Booz, Allen, Hamilton designed/developed/maintains the applications; PSI International staffs the operations, including data entry and document management.
J. Data Storage System/Server	<ul><li>(1) SIMBA - AERS Production Server (2) eSub Gateway server</li><li>(3) RetrievalWare Server</li></ul>
60. Who is the manufacturer (Sun, HP, IBM, Compaq, etc.)?	(1) Compaq (2) Sun (3) Compaq
61. What is the model number (Sun Enterprise 10000, HP 9000, etc.)?	(1) Alphaserver 4100 5/600 (2) Sun Ultra II (3) Proliant 6400

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
62. What is the number/speed (Mhz) of processors?	(1) 3 @ 600 Mhz (2) 200 MHz, 256MB (3) 4/500 mhz
63. How much memory is available (Gb)?	(1) 3Gb (2) 1Gb (3) 4Gb (26B in use)
64. What is the disk - manufacturer, amount (Gb) & type (SAN, RAID Array, etc.)?	<ul> <li>(1) 6 internal drives (capacity each = 4Gb, 9Gb) and ~30 external drives (capacity each = 9Gb, 18Gb, 36Gb)</li> <li>(2) 6 * 9Gb Drives = 54Gb</li> <li>(3) Internal - 4/9 GB disks(2 are Raid 1). 44/18 GB Disks (Raid 0+1) and 4/9 gb Disks, 4/18 GB disks(not mounted)</li> </ul>
65. What is the operating system (e.g. Sun Solaris 2.6.1)?	(1) VMS 7.2.1 (2) NT 4.0 / SP6 (3) NT 4.0 / SP6a
OTHER COTS	(1) Oracle 7.3.4, MedDRA v4.0 (2) RetrievalWare, eSub v2.1, Oracle forms, Templar 4.2 (3) Tomcat 2.3, Apache Server 1.3, JRE 1.3
K. For Each Application	
Query/Reporting Tools, etc.) is utilized?	Oracle Client, Oracle Forms 5.0.6.10, Reports 3.05.9, MS Word 7.0, Rational Rose CASE tool, KAWA 4.0 (Integrated Development Environment for JAVA)
67. What custom-programmed application software is utilized? Using which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	Java
68. Which categories best describe this system?	
- Is there an operational data store	Yes
- Is there an all-encompassing data warehouse versus focused data mart(s)?	No
- Is there an Online Transaction Processing (OLTP) system utilizing a normalized relational database design?	Yes
- Is there a data warehouse utilizing a normalized relational database design?	No
- Is there a dimensional data warehouse utilizing a star schema design?	No
- Is there Statistical analysis system utilizing flat files, either raw data or in a format intrinsic to the system (e.g. SAS or SPSS internal system format)?	No
- Is there an Online Analytical Processing (OLAP) utilizing denormalized relational design such as star-schema or snowflake schema?	No
- Is there an OLAP system utilizing multidimensional design (e.g. hypercubes)?	No
- Are there other structured data format, such as XML, HTML, or other?	Yes. EDI
- Is there a Data Mart?	Yes

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
69.How is the data structured?	
- An event occurrence (EO) table with one row per event	Event Occurrence data stored in multiple tables in normalized data base structure; ERD provided
- A person table with one row per person, linked to events by PERSONID	No
- An adverse-event (AE) taxonomy table, with one row per event type, linked one-to-many to the EO table by AEID	Adverse Event Categories adhered to in data submission process.
70. How much disk space is currently allocated to the system?	116 GB
71. How much disk space is available on this system?	22 GB
L. For Each Major Data Structure	
72. What is the width of the table / file / subject data area (bytes)?	No information
73. How many data elements (approximate) in the table / file / subject data area?	ISR (Individual Safety Report) table has 50 columns with another 30 columns normalized into 5 other related tables, including free text comment tables.
74. What is the raw data record size (bytes) or structured raw data such as HTML or XML?	The row length is in bytes, and so is the size of each one of those tables TABLE_NAME,AVG_ROW_LEN SIZE, AERS_CASES,46 115343360;AERS_INDIVIDUAL_SAFETY_REPORTS,208, 602931200; AERS_REACTIONS,86, 555745280;AERS_REPORTED_DRUG_PRODUCTS,166,996147200;AE RS_SEARCH_CRITERIA, 198,4014080. We only listed some of the major tables.
75. What is the approximate number of rows in the table, or observations?	suspected drug adverse events reported = 5,500/week or 286K/year; other data=689 (per month?)
76. What time period is currently represented in the database? Projected change over the next 1-3 years?	at least 4 years observed in sample reports - may grow continually with no roll-off
- · ·	According to the hardware configuration that we currently have on the SIMBA (AERS production box) we can support roughly 300-500 concurrent users. To the best of my knowledge, this is the only limitation that out system has.
How many physical tables in the database?	150-200
How many tables containing key data for analysis?	< 10
Part III. Data Use & Analysis:	
78. System Contact	Min Chen, Associate Director of Drug Risk Evaluation, Office of Drug Safety
79. Contact Address	CDER- 5600 Fishers Lane, Rockville, MD, Rm 15B-08
80. Contact Phone	301-827-3169
81. Contact Email	N/A
82. Hardware Platform	N/A
83. Operating System	N/A

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
84. Who is the developer?	The database programming and design was created and is maintained by Booz, Allen, Hamilton
85. Who is responsible for the system architecture?	Booz, Allen, Hamilton
86. User Types	FDA – CDER (Office of Drug Safety, Office of New Drug, Office of Compliance - for drugs), CBER (for biologics/vaccines), users of publicly available FOI available data, FDA also has agreement to allow Canada access to AERS
87. What is the frequency of Reports?	As needed to investigate specific Adverse Event reports
88. Who generates the reports?	See User Types
89. What is the method of access?	AERS software or AERS data mart
90. What is the turnaround time?	Real time
91. What is the level of automation?	N/A – AERS software
92. Type Of Reports	Workload and operational reports to track flow and follow up on AE reports. Query function supports complex querying and a variety of content/format outputs. Can do frequency counts. Approx. 12 - 13 "canned reports". TAS, an MS-Access database tool developed by PSI, captures management metrics allowing the monitoring of reports as they flow through the PMSS process. AERS "data mart" also available to internal FDA users (e.g., Office of New Drug, Review Division). AERS FOI information is made publicly available by providing quarterly CD ROMs in ASCII format and SGML (ICH e2B) format for six AERS data tables. Available through NTIS. Data currently not made publicly available through the FOI or Web because of resource limitations.
93. What is the unit of observation?	Individual report of adverse event associated with a drug or biologic product
94. What are the available data fields?	The terminology may be an accepted standard (e.g., MEDDRA or WHOART), a verbatim term, or the manufacturer's own terms. Contractor adds/updates MEDDRA classification of narrative.
95. Is there a controlled vocabulary?	Event described using MedDRA codes assigned by Logistics Applications.
96. Exportability	Cannot download directly to Excel but can do so indirectly.
97. User Profile	Safety Evaluators in Office of Drug Safety (follow up on AE reports, primarily pharmacists). Office of New Drug (Review Division), Office of Compliance
98. How are the reports used?	Workload module routes reports to inbox of safety evaluators (15 day mandatory report and voluntary reports from consumers/professionals are priority). Biologics reports routed to CBER staff. Safety evaluators determine if event is, in fact, linked to the drug based on their clinical knowledge/experience. Often call reporter for information (eg. missing pat history, labs, diagnosis, duration of therapy, concomitant drugs). Will also use query function to search AERS by drug, MedDRA code, age, timeframes, reporter, and location code. Canned reports used to investigate case series for a specific drug/event. Goal is to determine that there is a "safety signal" to prompt further action. Focus is on investigation of serious, unlabeled events. Will summarize data from the "case series" in AERS. Recommendation may be made to Office of New Drug, Review Division re: labeling change (adverse reaction, precaution, warning, boxed warning, restricted use or contraindication). If warranted, "Dear Doctor" letter sent. If can't find option to manage risk, may result in withdrawal. Reports may prompt further epidemiological studies where appropriate. Once "safety signal" identified, office tries to assess size of risk. Assessment may involve use of other data (see below). Review Division

Reporting or Database System:	Adverse Events Reporting System (AERS) - Drugs and Therapeutic Biological Products
	may also use AERS data as part of acting on safety alert.
99. Report Dissemination	Internal within FDA divisions
100. What is the primary goal?	Meet regulatory compliance demands by identifying and assessing individual reports of adverse drug reactions and taking appropriate action within the scope of FDA authority.
101. Integration	MERS data is entered into AERS. No links to state systems. Safety Evaluators primarily use AERS to investigate reports. May also use Medline to search for published reports. When assessing risk of potential problem, Safety Evaluators attempt to estimate patient exposure (ie. Denominator information) and how much the reported rate truly reflects incidence. This may involve analysis of IMS data (purchased by FDA and available in house). Requests can also be made to have specific analysis done using other databases per FDA cooperative agreements. These include Boston University, Harvard Pilgrim Health Cooperative, Johns Hopkins, Vanderbilt, United Health Group, HMO Research Network, Aetna, State Medicaid databases. FDA in process of acquiring more databases in house. "CBER piloting a large-linked database project that utilizes databases of several MCO's, which will provide the opportunity to study potential rare adverse outcomes".
	<ul> <li>Other related systems:</li> <li>COMIS (CDER's tracking of IND and NDA info, e.g., pending application, previous reviews etc.)</li> <li>Drug Filing System (contains information related to new drug application, e.g. pre-approval reviews)</li> <li>Given the specific nature of the analyses conducted, direct integration of AERS with other databases my not produce a significantly enhanced knowledge base. Access to other databases to conduct epidemiological assessment supports follow up regarding specific drug/biologic problems.</li> </ul>
102. HIPAA Compliant	Yes
Future	There is a list of possible AERS enhancements (as yet unimplemented) developed during initial system design. Increased data mining. Development of tool to identify change in reporting incidence to alert FDA to potential problems
Note:	There is a Drug Quality Reporting System dealing with product quality problems (eg. Labeling, broken safety seals, wrong dosage dispense, wrong color tablets).
Comments:	AERs has 2 purposes. (1)To meet regulatory requirements that manufacturers report serious problems. (2) As a tool for evaluating post marketing drug safety.

ASR	
Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
Part I. Data Acquisition:	
A. General Information	
1. Report Title	Medical Device Reporting-Alternative Summary Program
2. Internet Location: http://	http://www.fda.gov/cdrh/osb/guidance/315.html
3. Host Organization(s)	LAI enters data; TRW works on data storage
4. Primary contact information (e.g. Address, Phone)	Primary Contact - Joyce Siwarski - 301-594-4550 x166; JCS@CDRH.FDA.GOV Data Acquisition - Mary Brady - mwb@cdrh.fda.gov Data Storage – Isaac Hantman 301-827-0036 Data Use/Analysis - 301-594-4550 x166; JCS@CDRH.FDA.GOV
B. Overall System Features	
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	The alternative summary reporting system replaces individual mandatory reporting from manufacturers for those devices where documented problems with the devices are well understood and there is diminished return in the evaluation of individual event reports for these devices. The manufacturer must request to be accepted into the Alternative Summary program. Products approved for summary reporting require the periodic submission of adverse event data in tabular format. The reason this system was implemented was to reduce the amount of time spent entering these type of events into MAUDE so that the focus could be on less well known or previously undetected events. It also provides significant economies for both the device industry and FDA. In the past year, FDA received approximately 50,000 reports in summary format. While this is a separate database from the MAUDE system, it does access MAUDE for some limited information.
<ul><li>6. What is the geographic scope of data collection (national, state, local, facility etc)?</li><li>7. What is the unit of data entry (e.g., event, patient, product)?</li></ul>	Same as MAUDE - products used in US, but could have international manufacturer The unit of data entry is a medical device with documented problems. Adverse events included in summary reports should be submitted in a line- item format, reporting selected data elements by individual adverse event, rather than by the previous method of grouping adverse events by device identification number.

Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
8. Who is allowed/required to input information?	This is a voluntary system which provides major time savings to manufacturers and FDA. Authorized OSB reviewers can identify candidates and offer exemptions or manufacturers can file for an exemption which is entered into the ASR database and must be approved by the FDA in order to participate in the program.
9. What are the regulations/laws affecting reporting?	<ul> <li>21 CFR Part 803.19 - provides authority for the creation of the Alternative Summary Reporting Program</li> <li>21 CFR Part 803.19(b) specifies that all requests to participate in the ASR program must be in writing and contain the following information:</li> <li>*statement notifying FDA of request to participate</li> <li>*identification of the device manufacturer</li> <li>*product classification code(s) for the device(s) that will be included in the ASR report</li> <li>*the reporting site registration number, contact person and address of the firm who will be submitting the ASR reports to the FDA</li> <li>21 CFR Part 803.55 - requires filing of initial baseline reports and subsequent annual updates for devices involved in adverse events that are submitted to the FDA on form 3500a for the first time.</li> </ul>
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	FDA will disclose to a patient requesting a report, all information in the report concerning them, except for trade secret and confidential commercial information. FDA [21 CFR §20.63(2)] extends protection against disclosure of voluntary reports held by medical device, pharmaceutical, and biologics manufacturers by preempting state discovery laws. User facility name will not be released to the public under the FDA Modernization Act of 1997. FDA will also not release the identity of the patient or any information that can be used to identify the patient, such as the serial number of an implanted device. Nor will it release the name of any person other than the MDR contact. The name of the reporter and facility are deleted from disclosed data.Please note that the FDA is required under the Freedom of Information and Privacy Acts (SEC 552, Title 5, USC) (PL 93-579) to delete, prior to public disclosure, any information; and any personal, medical and similar information that would constitute a clearly unwarranted invasion of personal privacy. Included in the deletion requirements are all identification of the reporters and user facilities associated with the events.
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	ASR reports are to be mailed to the following address in an envelope or other mailing container marked "ASR Report": Food and Drug Administration Center for Devices and Radiological Health Medical Device Reporting P.O. Box 3002 Rockville, MD 20847-3002 Request for exemption are to be mailed to: Alternative Summary Reporting Coordinator Reporting Systems Monitoring Branch, HFZ-533 Division of Surveillance Systems Office of Surveillance and Biometrics Center for Devices and Radiologic Health 1350 Piccard Drive Rockville, MD 20850

Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
12. What are the methods of editing information (e.g. correcting/add more information to records)	The following updates could occur. *Updates to the Periodic Report detail information - device identifier, event type, mfr aware date, QA functions. These are submitted under Part II - Reportable events page as a separate attachment with the firm's next ASR report. The system has a module called Data Entry/Update-QC which allows the user to select certain records and edit periodic report detail as well as perform a QA review of the data entered into the system. Various reporting functions exist to assist with QA as well as reviewing trends in data and looking for outlying and unusual events- e.g. summary trend analysis, unusual event reports etc. *Updates to exemption information - e.g. status, reviewer, comments, contact information *Updates to exempted Products information - e.g included products, trend groups, unusual events
13. Where is the collected data stored (name of database, number of data storage locations)?	ASR - Oracle based DBMS linked to existing MAUDE DBMS via baseline report information. The FDA is in the process of eliminating baseline reporting. It's initial purpose was to obtain the most updated product and manufacturer contact information. The problem is that manufacturers often do not send the FDA appropriate updates and the FDA ends up making pseudo-baseline entries. FDA staff are working on a different system to validate data entry and link the MAUDE to Alternative Summary Report information.
14. How often is the system revised (annual, semi-annual etc)?	System initiated in February 2000. Revised as needed to meet data entry and reporting requirements.
<ul> <li>15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?</li> <li>16. What are the minimal interface requirements for contributors (e.g. and the system).</li> </ul>	ASR can add to the fields collected if the item is already required for MAUDE. However, if any additional information is requested (or goes outside existing regulations), then must send out the proposed change for public comments. No minimum requirements. Manufacturers send mailed reports to FDA for data entry.
requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	data entry
17. What new features are being planned and/or are on wish lists?	<ol> <li>Acceptance of electronic summary reports from Manufacturers</li> <li>Addition of trending analysis for ASR and MAUDE-only data</li> <li>Trending analysis using combination of chi2 and poisson</li> </ol>
C. Potential to link to other information systems	
<ul><li>18. Is information from this system</li><li>linked to other systems (including</li><li>State or other Federal Reporting</li><li>Systems? If yes, which data is linked?</li></ul>	This system is linked to MAUDE via the MAUDE baseline tables. Product codes specified in the Exempted Products Information screen on ASR must also be valid codes in MAUDE.

Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
contributor/participant	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify); N- Narrative; FF - Fixed Format (e.g. date)
	ASR Reporting Site Information ASR Exemption Key - system generated (S) - ASR Reporting Site CFN - the unique number assigned to each manufacturing site. After initial creation, it will remain permanently associated with the record (unless on rare occasion it is changed by the system administrator). Accurate entry of a valid CFN will automatically populate the rest of the ASR Reporting Site Information, as well as the Contact Information. (N) - Name - name of reporting site (defaults to manufacturer unless specified) (N) - Street - street of reporting site (N) - City - city, state, zip, country of reporting site (S) - State, (S) Zip Code, (S) Country Code
20. Is participation mandatory or voluntary?	<ul> <li>Voluntary - but must meet exemption requirements</li> <li>Fields on Exemption screen:</li> <li>(P) - Offer/Acceptance Letter Required? Y,N</li> <li>(FF) - Date of Offer/Request Letter</li> <li>(FF) - Date of Grant Letter</li> <li>(P) - Exemption No - the exemption number associated with the product code(s)</li> <li>(P) - Status (Pending Approval, Granted, Closed, Revoked, or Denied). If status is granted, must have exemption no.</li> <li>Note: An exemption number must exist and the exemption status must be "Granted" in order to proceed with data entry of periodic summary reports.</li> <li>(FF) - Status comment - description of the clinical condition specified for an exemption.</li> <li>(P) - Assigned Reviewer (list of allowable reviewers) - field is required if exemption status is granted</li> </ul>
21. List fields related to contributor/participant contact information	N/A
contact information (include type of facility, teaching status, id information) 23. List fields related to distributor	N/A N/A
contact information 24. List fields related to manufacturer contact information (ASR - Exemption Information)	<ul> <li>(N) - Name - the name of the contact person at the reporting site. This information is editable.</li> <li>(N) - Phone No - phone of contact person at reporting site, editable</li> <li>(N) - Fax No - fax number of contact person at reporting site, editable</li> <li>(N) - Email - email of contact person at reporting site, editable</li> </ul>

Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify); N- Narrative; FF - Fixed Format (e.g. date)
25. List fields related to Provider of Care identification	N/A
26. List fields that identify types of care providers included in system	N/A
F. Fields related to Patient Information:	
27. List fields related to identifying patient – initial data entry (e.g. SSN, initials, system-assigned ID etc)	N/A
28. List fields related to patient contact information (e.g. address, zip code, county, region)	N/A
29. List fields related to patient demographics (e.g. age, sex, race)	N/A
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow- up/outcome information)	N/A
31. List fields related to pre-existing conditions and/or medical history of patient	N/A
condition of patient at time of event	N/A
<ul> <li>33. List fields related to</li> <li>financial/charge information (e.g.</li> <li>length of stay, charge or payment for</li> <li>care, insurance coverage – Medicare,</li> <li>Medicaid, private, CHAMPUS,</li> <li>uninsured etc)</li> </ul>	N/A
34. List any other types of information collected about the patient	N/A

Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify); N- Narrative; FF - Fixed Format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	Medical device events associated with a particular event code, patient problem, device problem, evaluation result and/or evaluation conclusion that have been determined to be exempt from individual event reporting. When an exemption is filed, the FDA enters inclusion and exclusion criteria that fit the exemption. Note that the exemption is only for a particular problem associated with a particular device. The following types of events are always excluded from the ASR system and must be reported as specified in 21 CFR 803.50 and 803.52:*Events that require the submission of a 5-day report under the requirements of 21 CFR 803.53. *Events where the device, other than a mechanical heart valve (product code LWQ), may have caused or contributed to a death. *Events involving mechanical heart valves (product code LWQ) where the implant duration was less than five (5) years. *Events involving a permanent pacemaker electrode (product code DTB) where the manufacturer confirmed a device failure. *Events involving a Class III device that has been marketed under an approved PMA for less than two (2) years. *The occurrence of multiple serious injuries as a result of a single event or device failure. *Events associated with explosion or fire. *Events that the manufacturer considers unusual, unique or uncommon and that would be given an evaluation conclusion code of 66-Unusual event (see Instructions for Completing Form 3500A with Coding Manual for Form 3500A, dated December 14, 1995). FDA also reserves the right to request the submission of an individual event report on Form 3500a for any event included in an ASR report if it determines it needs the report to evaluate the event.
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy)	N/A
	<ul> <li>Each line item on the ASR report represents one adverse event.</li> <li>(S) - Product Code – enter a product code already associated with the exemption number. Once the product code is saved as part of the record, it may no longer be edited or deleted unless done so by the system administrator. (Same as MAUDE product codes)</li> <li>Report ID No – unique internal identification number assigned by the manufacturer to the individual complaint. This number must be unique within this product code. It must also be different than summary report line item numbers entered in previous reporting periods.</li> <li>(N) - Device Identifier – (same as D.6 - Product Identification Information on Form 3500A) Device code assigned during exemption entry. This will be (S)Model # Found on the device label or accompanying packaging (S)Catalog# Exact number as it appears in the manufacturer's catalog, device labeling, or packaging.</li> <li>(S)Lot# This number can be found on the label or packaging material.</li> <li>(S)Other# Any other applicable identification number</li> </ul>
38. List fields associated with vaccine related events	N/A

Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
39. List fields associated with infection related events	N/A
40. List fields associated with any other type of event. List type of event.	N/A
classification of the event/harm (narratives, problem codes, adverse event terms)	(P) F.10 - Event problem codes (see http://www.fda.gov/cdrh/mdr/appendixc.pdf - Note: UF is supposed to complete. Mfr fills in if missing.) Patient codes - describe what happened to the patient as a result of the event - approximately 1600 codes (device and patient mixed) Device codes – device problems or failures encountered during the event (P) - Event Type – enter a valid event type code d-death, i-serious injury, m-malfunction.
42. List fields associated with when the event occurred	N/A
the time between the event, when reported, when acted upon etc	<ul> <li>(P) - Reporting Period (Quarterly, Semi-Annually) - on exemption screen; when mfr will provide periodic reports</li> <li>(FF) - First Period Start Date - when manufacturer will begin to report</li> <li>Report Date – This is a required field. It is the date on which the summary report is prepared by the manufacturer Report Received Date - the date on which the report was received by CDRH Starting Quarter Number – the starting and ending quarters selected must reflect either a quarterly reporting cycle (e.g., Quarter 1 through Quarter 1 of the same year), or if a semi-annual reporting cycle, then two quarters (e.g., Quarter 1 and Quarter 2 of the same year, or Quarter 3 and Quarter 4 of the same year). Reporting periods are defined in the exemption entry process. Starting Quarter Year – the year in which the periodic summary report submissions begin. Ending Quarter Number – See explanation in Starting Quarter Number. This number will be populated based on the reporting period defined for the exemption. Ending Quarter Year - the year of the ending quarter Year - the year of the ending quarter Year - the year.</li> <li>(FF) - Event Aware Date – enter the date on which the manufacturer Year.</li> <li>(FF) - Event Aware Date – enter the date on which the manufacturer became aware of the event. If an Event Aware Date is not entered, it will default to the first day of the reporting period quarter/year, as entered on the previous screen. If the event aware date falls within quarter for which a report was previously submitted, it will be considered a supplemental line item entry to the previous quarter's report. The line item will appear on the Correction/Supplemental Report.</li> </ul>
the event occurred	N/A N/A

Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
46. List fields related to follow-up of event that are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event)	(S-FDA Evaluation Codes for Manufacturers) H.6 - Evaluation codes (4 codes per subtypesee http://www.fda.gov/cdrh/mdrcode.pdf for list of codes - approx 50 codes) Enter the applicable codes from the codes manual for one or more of the categories listed. Conclusion codes must be entered even if the device was not evaluated. If the reuse of a device may have caused or contributed to the adverse event, then the appropriate manufacturer Result codes are to be entered from the codes manual. Applicable reuse codes are 230-233 and may be used alone or with any other applicable results codes. (see H8). Method - Enter Source of evaluated device, type of evaluation performed (4 codes) Results - Enter type of result code (see www.fda.gov/cdrh/mdr/appendixd.pdf- approx 350 codes) Conclusions - Enter conclusions code (approx 20 codes)(S) – Evaluation/Conclusion CodeFor codes listed above, the reporter may provide more than one code per category but should group by category. Should represent the best knowledge of the AE and firm's evaluation results and conclusion codes. Note that 90% of the information is done at the product code level.Special guidelines for reporters - e.g If multiple product codes have been approved under one ASR exemption number, then only one quarterly report is required. If no eligible events in a quarter, must still send in a report saying that.
47. List fields related to the outcome of event	N/A
event or any other information collected by the reporting system (e.g.	Assigned Reviewer – if the reviewer assigned to the report needs to be changed, the data entry user must go to a supervisor who can perform the action under Utilities/Assign Reviewer. By default, the reviewer assigned to the summary report is the reviewer assigned to the exemption. Comment - the user may enter comments regarding the summary report information. Quality Control Completion Flag – this field is checked after the data entry user has quality controlled the information submitted by the manufacturer against that which was entered into the ASR System by the data entry user. Mfr QA Flag – this checkbox is accessible after the Quality Control Completion Flag is checked. The box will be checked once any discrepancies in the information submitted by the manufacturer have been cleared up through communication with the manufacturer. Once this box is checked, trend review can be initiated and information in that summary report may no longer be edited.
H. Implications	
49. Integration with other systems	MAUDE
50. Methods used to de-identify data 51. Technical Information	Aggregate data
Part II: Data Structure & Storage:	
I. Facility / Location	
52.What is the address of the data storage facility?	OSM - 2098 Gaither Road, Rockville, MD 20850
53. What type of facility is used to store data (3 <sup>rd</sup> party data center, secured computer room, someone's	Secured computer room

Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
cubicle)?	
54.Is there a network Interconnect for physically distributed systems?	Yes
55. What type (private lines, VPN, Internet) of network interconnect is used?	WAN
56. What is the network protocol (TCP/IP, IPX, etc.)?	TCP/IP
57. What is the bandwidth of the network interconnect (dial-up, ISDN, T1, T3, etc.)?	Τ3
58. What is the Network (WAN) topology, including diagram if available?	Not available
J. Data Storage System / Server	
59. Who is the Manufacturer (Sun, HP, IBM, Compaq, etc.)?	Compaq
60. What is the Model Number (Sun Enterprise 10000, HP 9000, etc.)?	AlphaServer 4100
61. What is the number/speed (Mhz) of processors?	4/600
62. How much memory is available (Gb)?	4Gb
63. What is the disk – manufacturer, amount (Gb) & type (SAN, RAID Array, etc.)?	Compaq StorageWorks 610GB net RAID
64. What is the operating System (e.g. Sun Solaris 2.6.1)?	OpenVMS 7.2-1
K. For Each Application	
65. What commercial off-the-shelf (COTS) software (e.g. RDBMS, Query/Reporting Tools, etc.) is utilized?	Oracle RDBMS, Oracle Forms, SQR ReportWriter
66. What custom-programmed application software is utilized? Using which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	C, VB
67. Which categories best describe this system?	
<ul> <li>Is there an operational data store?</li> <li>Is there an all-encompassing data warehouse versus focused data mart(s)?</li> </ul>	Yes No
- Is there an Online Transaction Processing (OLTP) system utilizing a normalized relational database design?	No

Reporting or Database System: Program ID:	FDA-CDRH Alternative Summary Reporting - Medical Devices
- Is decision support normalized?	Yes
- Is there a dimensional data	No
warehouse utilizing a star schema	
design?	
- Is there a statistical analysis system	No
utilizing flat files, either raw data or in	
a format intrinsic to the system (e.g.	
SAS or SPSS internal system format)?	
- Is there an Online Analytical	No
Processing (OLAP) utilizing	
denormalized relational design such as	
star-schema or snowflake schema?	
- Is there an OLAP system utilizing	No
multidimensional design (e.g.	
hypercubes)?	
- Are there other structured data	No
format, such as XML, HTML, or	
other?	
68. How is the data structured?	Total tables = 50; dictionary provided
-Is there an event occurrence (EO)	Logical data model has one row per time period that captures # of adverse
table with one row per event?	events of a type for that period.
-Is there a person table with one row	events of a type for that period.
per person, linked to events by	
PERSONID?	
- Is there an adverse-event (AE)	
taxonomy table, with one row per	
event type, linked one-to-many to the	
EO table by AEID?	
69. How much disk space is currently	188 Mb
allocated to the system?	
70. How much disk space is available	81 Mb
on this system?	
on die system.	
L. Major Data Structure	
71. What is the width of the table/file /	50 tables with approximately 30-5000 bytes per table.
subject data area (bytes)?	
72. How many data elements	50 tables with approximately 1-30 columns per table.
(approximate) in the table/file/subject	
data area?	
73. What is the raw data record size	N/A
(bytes) or structured raw data such as	
HTML or XML?	
	50 tables with approximately 0-90,000 rows per table. A total of about
rows in the table, or observations?	562,248 rows.
75. What time period is currently	
represented in the database? Projected	
change over the next 1-3 years?	
76. Are there any theoretical	
maximums that cannot be exceeded?	
(e.g. # providers, # recipients, etc.)	

#### Part III. Data Use & Analysis:

Part III. Data Use & Analysis:	
78. System Contact	Pat Kingsley (Division of Post-Market Surveillance), Howard Press (Division of Surveillance Systems, Chief of Information Analysis), Suzanne Rich (Division of Post-Market Surveillance)
79. Contact Address	1350 Piccard Drive, Rockville, MD, 20850
80. Contact Phone	PK: 301-594-2784, HP: 301-827-2983, SR: 301-594-2581
81. Contact Email	PK: pak@cdrh.fda.gov HP: <u>hap@cdrh.fda.gov</u> SR: SER@CDRH.FDA.GOV
82. Hardware Platform	VAX Cluster
83. Operating System	
84. Who is the developer?	TRW under contract
85. Who is responsible for the system architecture?	ORACE-based DBMS linked to existing MAUDE DBMS
86. User Types	FDA -
87. What is the frequency of reports?	Being established
88. Who generates the reports?	CDRH – departmental responsibility being determined
89. What is the method of access?	ASR software
90. What is the turnaround time?	Real time
91. What is the level of automation?	N/A
92. Type Of Reports	Main monitoring reports triggered if the change in rate of reports for a particular product/problem a specified threshold. Statistical tests (Chi-squared, Cox-Stuart) used to assess change in incidence. Software provides a set of reports but, to date, not frequently used. Data most often exported to Excel for ad hoc analysis.
93. What is the unit of observation?	ASR reports cover all adverse events associated with a qualifying device/problem occurring within the reporting timeframe. Line level detail corresponds to an individual adverse event covered within the device/problem exemption.
94. What are the available data fields?	Primary fields are patient, device, product and evaluation codes. See Input template for complete list.
95. Is there a controlled vocabulary?	Patient, device, product and evaluation codes come from list maintained by CDRH. They correspond to the codes captured in MAUDE.
96. Exportability	Yes and frequently done
97/ User Profile	CDRH - Division of Post-Market Surveillance, Division of Surveillance Systems
98. How are the reports used?	Reports ostensibly used to monitor incidence of events, however, most problems are so well known that reports require and prompt little follow up. Unusual change incidence would prompt follow up investigation. Use of system still evolving. May be opportunity to improve existing reports/reporting function. Most assessment done by exporting data and performing specialized analysis in Excel or other software.
99. Report Dissemination	CDRH - Division of Post-Market Surveillance, Division of Surveillance Systems.
100. Primary Goal	Monitoring of known medical devices problems.
101. Linkable to Detail/Integration	Some reports available providing comparative statistics/trends between MAUDE and ASR, however, ASR and MAUDE software and data are not currently connected. Integrating data would allow a complete search of all events related to a specific product type, manufacturer etc Currently, reports of exempted product/problem combination are kept separately in ASR, requiring separate querying.
	Facilities reporting to MedSuN may previously have reported to

	MAUDE. Manufacturers still required to report to MAUDE (through MedWatch). Therefore, if a manufacturer becomes aware of an error within a MedSuN participating facility, it is possible that a report of the same error would be made to MAUDE by the manufacturer and MedSuN by the facility. Note that the post-market surveillance follow up on the MAUDE report may produce information useful to the MedSuN team.
102. HIPAA Compliant	No protected health information collected
Note:	In contrast to MAUDE requirements, manufacturers are required to submit patient and device codes in ASR reports.
	In the past year, FDA received approximately 50,000 reports in summary format.

BPD	
Reporting or Database System: Program ID:	<b>Biological Product Deviation Reporting (BPDR) System (BIODEV)</b>
Part I. Data Acquisition:	
A. General Information	
1. Report Title	Biological Product Deviation Report
2. Internet Location: http://	http://www.fda.gov/cber/biodev/biodev.htm
3. Host Organization(s)	The Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER)
4. Primary contact information (e.g. Address, Phone)	Stan Pawlowski, (301) 827-2728, pawlowski@cber.fda.gov
B. Overall System Features	
<ul> <li>(any information on role in mission, leadership support, integration with quality assurance activities and history)</li> <li>6. What is the geographic scope of data collection (national, state, local, facility etc)?</li> </ul>	FDA/CBER is responsible for regulatory oversight of the U.S. blood supply. FDA promulgates and enforces standards for blood collection and for the manufacturing of blood products, including both transfusible components of whole blood, pharmaceuticals derived from blood cells or plasma, and related medical devices. CBER works closely with other parts of the Public Health Service (PHS) to establish blood standards, and to identify and respond to potential threats to blood safety or supply. The Biological Product Deviation Reporting system is one method CBER uses to monitor product deviation in manufacturing of products, including testing, processing, packing, labeling, or storage, or with the holding or distribution of a licensed biological product or a blood or a blood component, in which the safety, purity, or potency of a distributed product may be affected. There are approximately 25,000 reports submitted per year. Electronic reporting just started in June 2001. On Nov. 7, 2000, the FDA published a final rule to amend the requirements of reporting errors and accidents in manufacturing of products. The amended regulation at 21 CFR 600.14 and the new regulation at 21 CFR 606.171 require reporting of any event associated with the manufacturing, to include testing, processing, packing, labeling, or storage, or with the holding or distribution of a licensed biological product or a blood or a blood component, in which the safety, purity, or potency of a distributed product may be affected. To facilitate reporting the FDA developed a standardized reporting format that may be submitted electronically or in paper form by mail. The BPDR is used to collect this information. Licensed manufacturers, unlicensed registered blood establishments and transfusion services are required to report (must have FDA Establishment Identifier or CLIA #). FDA Consumer Safety Officials then monitor the information coming into BPDR, conduct analyses and take appropriate actions. The Biologics Compliance Information System (BCIS), of which
7. What is the unit of data entry	The unit of data entry is a biological product deviation which includes deviations and unexpected events that may affect distributed products.

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
	Licensed manufacturers of blood and blood components including source plasma, unlicensed registered blood establishments, and transfusion services are required to report any event associated with biologics, including blood and blood components and source plasma, that represents a deviation in manufacturing to the BPD system. Specifically, the manufacturer who had "control" over the product when a deviation or event occurred must submit the report. Control includes occurrence at manufacturer's facility or any facility under contract with manufacturer. Can also do via mail or fax All hard copies are entered into the BCIS database by a data entry clerk. All web copies are stored in FDA UUNET, transferred to CBER 1x/day, FDA analysts pull up BIODEV (web) reports via BCIS, then has ability to accept, reject (duplicate), pending (notes button for email to firm). Analysts are notified of possible duplicates when the EIN and tracking number are checked. Coding of events - getting better. Used to write narrative, then assign codes. Now, allow users to enter codes. If code incorrectly, then analyst sends e-mail as feedback to correct code. Most of the time - no harm to patient - has potential to harm. Sometimes even if infused in patient, no harm. The Food and Drug Administration amended the regulation at 21 CFR 600.14 for licensed biological products, and added a requirement at 21 CFR 600.171 applicable to all manufacturers of blood and blood components. Requires reporting of any event associated with the manufacturing, to include testing, processing, packing, labeling, or storage, or with the holding or distribution of a licensed biological product or a blood or a blood component, in which the safety, purity, or potency of a distributed product. In addition, any unexpected or unforeseeable event associated with manufacturing that may affect the safety, purity, or potency of a distributed product. In addition, any unexpected or
	purity, or potency of a distributed product must be reported. The reports must be submitted as soon as possible but not to exceed 45 calendar days from the date the manufacturer acquires information suggesting that a reportable event has occurred. 21 CFR11 – transmission requirements. Required form for input is OMB Form FDA 3486.
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	The FDA is required under the Freedom of Information and Privacy Acts (SEC 552, Title 5, USC) (PL 93-579) to delete, prior to public disclosure, any information that constitutes trade secrets, and confidential, commercial, or financial information; and any personal, medical and similar information that would constitute a clearly unwarranted invasion of personal privacy. Included in the deletion requirements are all identification of the reporters and user facilities associated with the events. All requests for reports for BPDR system go through the FDA FOIA office.
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	Form 3486. The report can be sent by mail to: Director, Office of Compliance and Biologics Quality (HFM-600) Center for Biologics Evaluation and Research 1401 Rockville Pike, Suite 200N Rockville, MD 20852-1448 or submitted electronically via the web at: http://www.fda.gov/cber/biodev/biodev.htm

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
	Amended or follow-up reports can be sent via regular mail or e-mail. Follow-up information is tracked in the Remarks section of the BCIS system and the Web Notes window. These are used for internal communication by FDA staff. The system also has a status flag - accepted, rejected, not reviewed, and pending. These flags are used by CBER staff to track a report and to follow-up with reporter if necessary.
of data storage locations)?	After a user has entered all required BIODEV information, the report can either be saved or submitted to the FDA. Users receive a confirmation number to identify saved reports. Saved reports can be edited, but are automatically deleted if they are not completed and submitted to FDA/CBER within 30 days of creation. Once a report is submitted it is no longer available to the reporting facility for update. Mailed information is entered into the biological product deviation module (BPD) of the Biologics Compliance Information System (BCIS) - an Oracle 7.3.4 database-by CBER staff. CBER staff also accepts web- based reports via this system. The BCIS not only collects the reporting data, but tracks recall alerts, enforcement actions, and maintains a list of non-blood facilities for use by CBER. Note that the data is initially stored at UUNET, then an automated procedure pull the data inside FDA firewall.
14. How often is the system	As needed, but done approximately quarterly
revised (annual, semi-annual etc)?	
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	User feedback or change to FDA business rules with approval by BCIS control board
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	Contributors can either mail the BPDR or enter the information in an on-line web browser form. Netscape or IE 4.0 or higher
17. What new features are being planned and/or are on wish lists?	<ul> <li>* To allow users to query their submission history - individual reports and aggregate information. Dependent on having an ID/PW protection system.</li> <li>* To Require User ID/PW for web access; currently Consumer Safety Officer at FDA does have user id and password to get into BCIS system, but no ID required to enter reports into BIODEV.</li> <li>Wish list would include wanting to have list of facilities, hospitals, size of facilities - ways to identify who is reporting and who is not reporting (denominator information)</li> </ul>
C. Potential to link to other information systems	
	Potential link to MERS-TM - both dealing with blood related issues ** See last row at bottom of spreadsheet for narrative of how BPDR differs from MERS- TM

D. Fields related to contributor/participant Information:       Only those facilities that have been issued a included in data acquisition? List fields that indicate who/what facility submitted the data.         19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.       Only those facilities that have been issued a Establishment Identifier (FEI), or Clinical I (CLIA). The number is validated against a from an unidentified facility, then there is f data entry error or if the facility should be a *(S) A.2 - Reporting establishment identifi- identify facility         CFN Number, FEI Number, CLIA Code [ty otherwise enter in appropriate field on mail In addition to above - the following fields a information on each facility; Facility unique identifiers: registration num 7 digit number ), or FDA Establishment Ide 10 digits assigned to your facility if you ha blood establishments, FDA Form #2656 for #2891 for device manufacturers. If you hav a registration number), or CLIA number - a by Center for Medicare and Medicaid Servi facilities who are eligible for Medicare rein number if you do not have a registration num Accomplishments and Compliance Trackin (P) Establishment identification number ty - see above         20. Is participation mandatory or voluntary?       Mandatory for the facilities and under the c regulations. See item 9.         21. List fields related to contributor/participant contact information       From Reporting Establishment information *(N) - Telephone - telephone number of the for the report *(N) - Telephone - telephone number of the for the report gfacility, teaching status, id information)         22. List fields related to facility contact information (include type of facility, teaching status, id information)	ing (BPDR) System (BIODEV)
included in data acquisition? List fields that indicate who/what facility submitted the data. facility unique identifiers: registration num facility unique identifiers: registration num facility unique identifiers: registration num facility unique identifiers: registration num facilities who are eligible for Medicare rein number if you do not have a registration number ty - see above 20. Is participation mandatory or voluntary? 21. List fields related to contributor/participant contact information facility, teaching status, id information) facility, teaching status, id information) facility teaching status, id information) facility, teaching status, id information) facility the teaching tables facility the teaching tables facil	
voluntary?regulations. See item 9.21. List fields related to contributor/participant contact informationFrom Reporting establishment information *(N) - Point of contact name – Name of the for the report *(N) - Telephone - telephone number of the (N) - Email address of contact – e-mail address of contact22. List fields related to facility contact information (include type of facility, teaching status, id information)*(N) A.1 - Reporting Establishment Name: Street Address Line 1 Street Address Line 2 City State Zip Code Country [not required] Point of contact	Laboratory Improvement Act number ist of existing entries. If the report is oblow up to determine if there was a dded to the valid manufacturer list. cation number - unique ID used to rpe required for on-line access, -in form] re pulled from the registration ber, (CFN - Central File Number - a entification (FEI - which may be up to ve completed an FDA Form #2830 for drug manufacturers or FDA Form e a license number you will also have 10 character number that is assigned ces (CMS - formerly HCFA) to abursement. Only provide this mber etc Numbers assigned by Field g System maintained by ORA
<ul> <li>contributor/participant contact information</li> <li>*(N) - Point of contact name – Name of the for the report</li> <li>*(N) - Telephone - telephone number of the (N) - Email address of contact – e-mail add is the point of contact</li> <li>22. List fields related to facility contact information (include type of facility, teaching status, id information)</li> <li>*(N) A.1 - Reporting Establishment Name: Street Address Line 1</li> <li>Street Address Line 2</li> <li>City State</li> <li>Zip Code</li> <li>Country [not required]</li> <li>Point of contact</li> <li>Telephone #</li> <li>E-mail [not required]</li> </ul>	onditions specified in the federal
22. List fields related to facility contact information (include type of facility, teaching status, id information) (information)	person who is the point of contact
information) City State Zip Code Country [not required] Point of contact Telephone # E-mail [not required]	
Defaults from registration information Reporting Establishment Parent Name - Lo American Red Cross - legal name of facility Reporting Establishment Province Name Reporting Establishment Foreign Postal Co 23. List fields related to distributor N/A	they are operating under

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
24. List fields related to	Facility = Manufacturer in this reporting system. Definition of manufacturer is
manufacturer contact information	specified in regulation.
E. Fields related to Provider of Care Information:	
25. List fields related to Provider	N/A
of Care identification	
26. List fields that identify types of care providers included in system	N/A
F. Fields related to Patient Information:	
27. List fields related to	Not included- form instructions, "DO NOT include donor, patient, or employee
identifying patient - initial data	personal identification information or other confidential information"
entry (e.g. SSN, initials, system-	A
assigned ID etc)	
28. List fields related to patient	N/A
contact information (e.g. address,	
zip code, county, region)	
29. List fields related to patient	N/A
demographics (e.g. age, sex, race)	
30. What patient identification is	N/A
retained after verification of event	
information (e.g. all contact	
information or pseudo id assigned,	
is patient ID available for follow-	
up/outcome information)	
31. List fields related to pre-	Could be included in these:
	* (N) B.5 - Description of BPD – Describe the event in detail, including
history of patient	description of what happened and a summary of all relevant information (labeling, test results, reason for donor deferral, etc.). Do not include any
	confidential information, such as patient, donor, or employee names
	* (N) B.6 - Description of Contributing Factors or Root Cause. Describe all
	contributing factors or root causes of the deviation or unexpected event. Please
	indicate, if after investigation, a root cause cannot be determined. Use page 3 for
	additional space.
	*(N) B.7 - Follow-up field: describe intended long-term and short-term follow-
	up action plans.
32. List fields that capture the	Could be included in these:
	* (N) B.5 - Description of BPD – Describe the event in detail, including
of event	description of what happened and a summary of all relevant information
	(labeling, test results, reason for donor deferral, etc.). Do not include any
	confidential information, such as patient, donor, or employee names
	* (N) B.6 - Description of Contributing Factors or Root Cause. Describe all
	contributing factors or root causes of the deviation or unexpected event. Please
	indicate, if after investigation, a root cause cannot be determined. Use page 3 for
	additional space. *(N) P.7. Follow up field: describe intended long term and short term follow.
	*(N) B.7 - Follow-up field: describe intended long-term and short-term follow- up action plans.
33. List fields related to	N/A
financial/charge information (e.g.	
length of stay, charge or payment	
for care, insurance coverage -	

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
Medicare, Medicaid, private, CHAMPUS, uninsured etc)	
34. List any other types of information collected about the patient	N/A
G. Fields related to Event/Error/Product Information:	
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	Any event associated with manufacturing to include testing, processing, packing, labeling, or storage and the holding or distribution of blood or blood component. The event must have the potential to affect the purity, safety or potency of a distributed biological product. Deviations and unexpected events that occur after release or distribution of products from the blood establishment, including those related to the administration of blood or blood or blood components are not reportable under 21 CFR 606.171. If patient dies as result of problem - reportable under 21 CFR 606.171
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy)	N/A
37. List fields associated with medical device-related events (e.g. brand name of device, type of device, usage, manufacturer name, operator of device)	N/A
38. List fields associated with vaccine related events	N/A
39. List fields associated with infection related events	N/A
40. List fields associated with any other type of event. List type of event.	Blood Related Unit/Product. (P) C.1 Type of Product Blood - includes products manufactured by blood and plasma establishments, such as whole blood, red blood cells, fresh frozen plasma, platelets, plasma for further manufacture and Source Plasma Non-blood – includes products manufactured by a facility other than blood establishments, such as vaccines, therapeutics, allergenics, in-vitro diagnostics, and plasma derivatives. For Blood related (N)Total number of units - Info on up to 18 different unit #s can be entered; reflects total number of components potentially affected. For example, if one unit of whole blood was manufactured into Red Blood Cells, Fresh Frozen Plasma and Platelets, the total number of units is 1(N) - Unit # - donor or bleed number(FF) – Collection date(MM/DD/YYYY) - date unit was collected(FF) - Expiration date(MM/DD/YYYY) - date the component expires(S) - Product Code - code that identifies the blood product [approximately 50 codes for blood products; approximately 1650 for non-blood products - these are broken down into the following categories: Allergenics, Derivatives, In-Vitro Diagnostics, Therapeutics, and Vaccines] Use the code YY01 for products for further manufacture, such as recovered plasma. Use the code DB00 for products not listed on the Blood Product Codes list, such as IVIG or albumin (if the blood establishment distributed it) and specify the product in the comments section.

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
Program ID:	<ul> <li>(N) - Disposition - description of disposition – DO NOT list any products that were not distributed</li> <li>Allowable list in BCIS:</li> <li>Specify if the unit was distributed:</li> <li>In-house (IH) - distributed from the blood bank within a hospital to another department, e.g., emergency room, surgery, nursing floor, etc.</li> <li>To another facility (AF) - distributed from a blood center to a hospital, from one hospital to another, or from a blood or plasma establishment to a manufacturer of biological products other than blood and blood components.</li> <li>Valid dispositions are:</li> <li>No information - product distributed, information regarding final disposition not available at time of reporting</li> <li>Corrected by consignee - product distributed and deviation corrected by consignee</li> <li>Destroyed by consignee - product distributed and destroyed by consignee</li> <li>Expired - product distributed and is now expired, no other information available</li> <li>Returned and corrected - product distributed, returned to manufacturer and deviation corrected</li> <li>Returned and destroyed - product distributed, returned to manufacturer and destroyed</li> <li>Sent for further manufacturing or non-injectable products only - product distributed for further manufacture Sent for further manufacturing of non-injectable products only Transfused - product distributed and transfused to a patient</li> <li>Other - if other is selected, please explain in Additional Comments</li> <li>(P) - Noification - whether consignee was notified</li> <li>Y, N, RN (reverse notification - if consignee notified reporter)</li> <li>Additional Comments (not clear on form)</li> <li>For Non-blood related - (N) - Total number of lots - Info on up to 18 different unit #s can be entered; reflects total number of potentially affected lots</li> <li>(N) - Lot #</li> <li>(FF) - Expiration date(MM/DD/YYYY)</li> <li>(N) - Product ode (Enter size of coding system)</li> <li>(N) - Disposition - on form it is narrative. IN BCIS - destroyed</li></ul>
	sent to distributor other (P) - Notification Y,N Use comments section if do not have all of the required fields for at least one of the affected components.

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	<ul> <li>* (N) B.5 - Description of BPD - Describe the event in detail, including description of what happened and a summary of all relevant information (labeling, test results, reason for donor deferral, etc.). Do not include any confidential information, such as patient, donor, or employce names</li> <li>* (N) B.6 - Description of Contributing Factors or Root Cause. Describe all contributing factors or root causes of the deviation or unexpected event. Please indicate, if after investigation, a root cause cannot be determined. Use page 3 for additional space. There are no specific cause codes defined in BPD.</li> <li>* (N) B.7 - Follow up: action plan for follow-up. Describe the intended short term and long term follow-up action plans, if applicable. Any corrective actions identified do not have to be implemented at the time of filing this report. If consigne notification or product retrieval was performed, please include the date and method (letter, telephone, fax, etc.) of notification. Use page 4 for additional space.</li> <li>* (S) B.8 - BPD code - 6 character code made up of three levels. The first level (XX) identifies the system affected in which there was a breakdown or failure, which resulted in the distribution of an unsuitable product. The second level (YY) of the code is a subset of the system affected. The thrid level (ZZ) contains more detailed information regarding the BPD. Select the code that most closely describes the deviation or unexpected event (see list of Deviation Codes). If you cannot determine the appropriate code, enter question marks. For example ??-??? or LA-????</li> <li>Blood Codes are divided into the following major categories: Donor Suitability:</li> <li>PD - Post Donation Information - 82 codes</li> <li>DS - Donor Deferral - 127 codes</li> <li>RT - Routine Testing - 19 codes</li> <li>Labering - 17 codes</li> <li>RT - Routine Testing - 10 codes</li> <li>M - Incoming Material Specifications - 12 codes</li> <li>M - Miscellaneous -</li></ul>
42. List fields associated with when the event occurred	(N) B.2 - Date BPD occurred

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
43. List fields associated with tracking the time between the event, when reported, when acted upon etc	<ul> <li>FDA USE ONLY at top of mail in form:</li> <li>(N) - Date Received</li> <li>(N) - Date Reviewed</li> <li>In BCIS</li> <li>(FF) - Entered date (MM/DD/YYYY)</li> <li>(FF) - Reported date (MM/DD/YYYY)</li> <li>(N) B.2 - Date BPD Occurred - instructions say to use MM/DD/YYYY format</li> <li>*(N) B.3 - Date BPD discovered - The date the deviation or unexpected event was discovered. The date discovered is the date you acquire information reasonably suggesting that a reportable event has occurred. If the event occurred at your contractor, the date of discovery is when the contractor learns about the deviation or unexpected event. Please enter using the format mm/dd/yyyy</li> <li>*(N) B.4 - Date BPD reported - corresponds to reported date in BCIS. The date the report is submitted.</li> </ul>
44. List fields associated with where the event occurred	Can either be A.1 Reporting establishment information - see item 19 above OR 'Deviation establishment' *A.3 If the BPD occurred somewhere other than the reporting facility. (N) - Establishment name (N) - Establishment name (N) - Street Address Line 1[not required] (N) - Street Address Line 2 [not required] (N) - City (N) - State (N) - Zip Code [not required] (N) - Country (S) A.4 - Establishment identification number (P) Establishment identification number type – type of number entered in A.4 CFN Number, FEI Number, CLIA Code [type required for on-line access, otherwise enter number in appropriate field on mail-in form] In addition to above, the following fields are pulled from initial registration information: Deviation Establishment province name Deviation Establishment foreign postal code * (S) B.8 BPD code
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event	Could be included in these: * (N) B.5 - Description of BPD * (N) B.6 - Description of Contributing Factors or Root Cause * (N) B.7 - Follow-up field: describe intended long-term and short-term follow- up action plans. * (S) B.8 BPD Code
<ul> <li>46. List fields related to follow-up of event that are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event)</li> <li>47. List fields related to the outcome of event</li> </ul>	<ul> <li>*(N) B.7 - Follow-up field: describe intended long-term and short-term follow-up action plans.</li> <li>Could be included in narrative of this field</li> <li>*(N) B.7 - Follow-up field: describe intended long-term and short-term follow-up action plans.</li> <li>(N) C.1, C.2 - Disposition (see item 40 for list of dispositions)</li> <li>(P) C.1, C.2 - Notification - Y,N, RN</li> </ul>

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
48. List any other fields related to the event or any other information collected by the reporting system (e.g. root cause analysis, investigations)	After reviewing the entry of a BioDev Web report, the person at BCIS determines if it is valid. If valid, the user presses the transfer button to transfer all available and appropriate info to the BPD Data table. When all required fields are completed, user presses Save button to save the BPD report to BCIS. BPD ID - generated when BPDR is saved to system BPD No - generated when BPDR is saved to system - status flag changed to "A" for accepted. Also B.1 - Establishment tracking # - user defined number used for internal report identification This number could consist of no more than 14 numbers and/or characters. Additional comments - use this section to further explain any missing information or product information such as product code, product disposition, or notification. If multiple units have the same information (i.e., collection date, expiration date, product, disposition and notification) enter the information for the first unit number and list the additional unit numbers in this section. If more than 18 units were potentially affected, enter the product information for the first 18 units and enter the remaining unit numbers in this section. Would like to use MERS-TM Root Cause Codes.
H. Implications	
49. Integration with other systems	See MERS-TM/Electronic Biological Product Deviation System Interface Feasibility Study dated 11/16/01 – preliminary findings are that varying formats and input rules make building a single portal interface less feasible. (p.15) Integrates with other CBER system to get facility information linked to CFN and FEI #: Regulatory Management System - Biological License Application, and RMS -Blood Establishment Registration. Connecting to get facility information from these.
50. What are the methods used to de-identify data?	Done manually at FDA FOIA office according to CBER regulations.
51. Technical information	
Part II. Data Structure & Stora	ge:
I. Facility/Location	
52. What is the address of data storage facility?	
53. What is the Facility type (3rd party data center, secured computer room, someone's cubicle)?	3rd party data center
54. Is there a network interconnect for physically distributed systems?	Internet
55. What type (private lines, VPN, Internet) of network interconnect?	Internet
56. What is the network protocol (TCP/IP, IPX, etc.)?	n/a
57. What is the bandwidth of network interconnect (dial-up, ISDN, T1, T3, etc.)?	n/a
58. Network (WAN) topology, including diagram if available	

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
59. Who designed the system? Who operates the system?	
J. Data Storage System / Server	
60. Who is the manufacturer (Sun, HP, IBM, Compaq, etc.)?	
61. What is the model number (Sun Enterprise 10000, HP 9000, etc.)?	
62. What is the number/speed (Mhz) of processors?	
63. How much memory (Gb), is available?	
64. What is the disk – manufacturer, amount (Gb) & type (SAN, RAID Array, etc.)?	
65. What operating system is used (e.g. Sun Solaris 2.6.1)?	
K. For Each Application	
66. What commercial off-the-shelf (COTS) software (e.g. RDBMS, Query/Reporting Tools, etc.) is utilized?	Cold Fusion; Oracle 7.3.4
67. What custom-programmed application software is utilized? Using which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	SQL; HTML; Cold Fusion
68. Which categories best describe this system?	Internet Web Application
- Is there an Operational Data Store?	No
- Is there an all-encompassing data warehouse versus focused data mart(s)?	No
- Is there an Online Transaction Processing (OLTP) system utilizing a normalized relational database design?	No
- Is there a data warehouse utilizing a normalized relational database design?	No
- Is there a dimensional data warehouse utilizing a star schema design?	No

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
- Is there a statistical analysis system utilizing flat files, either raw data or in a format intrinsic to the system (e.g. SAS or SPSS internal system format)?	No
- Is there an Online Analytical Processing (OLAP) utilizing denormalized relational design such as star-schema or snowflake schema?	No
- Is there an OLAP system utilizing multidimensional design (e.g. hypercubes)?	No
- Are there other structured data formats, such as XML, HTML, or other?	No
69. How is the data structured?	
- Is there an event occurrence (EO) table with one row per event?	
-Is there a person table with one row per person, linked to events by PERSONID?	
- Is there an adverse-event (AE) taxonomy table, with one row per event type, linked one-to-many to the EO table by AEID?	
70. How much disk space is currently allocated to the system?	
71. How much disk space is available on this system?	
L. For Each Major Data Structure	
72. What is the width of the table / file / subject data area (bytes)?	
73. How many data elements (approximate) in the table/file/ subject data area?	
74. What is the raw data record size (bytes) or structured raw data such as HTML or XML?	
75. What is the approximate number of rows in the table, or observations?	

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
76. What time period is currently	
represented in the database?	
Projected change over the next 1-3	
years?	
77. Are there any theoretical maximums that cannot be	
exceeded? (e.g. # providers, #	
recipients, etc.)	
Part III. Data Use & Analysis:	
78. System Contact	David El-Naggar
79. Contact Address	
80. Contact Phone	301-827-2461
81. Contact Email	El-Naggar@cber.FDA.gov
82. Hardware Platform	Windows 2000 NT
83. Operating System	Oracle 734 with intention to move to 8i later this year
84. Who is the developer?	•
-	Information Management Consultants (IMC)
85. Who is responsible for the system architecture?	web-enable front-end for data collection. Oracle Developer/6i (32-bit) in a client-server architecture. No registration or security (also fax, phone, mail).
86. User Types	1. Manufacturers reporting deviations - after reporting, they do not have access
so. eser rypes	to data or reports. FDA is working on setting up and assigning logons to valid
	manufacturers who would then be able to access information related to their
	organization. 2. Internal FDA users, principally Office of Compliance and
	Biologic Quality (OCBQ), Division of Inspections and Surveillance (DIS) and
	Division of Case Management (DCM). DIS Consumer Safety Officials review
	submitted reports (web, mail etc.) and accept or reject before being added to
	BPD Data tab (may also update/correct BPD code). Office of Regulatory Affairs
	inspectors can also access data through FDA intranet (e.g., prior to site visit).
	ColdFusion -based query page supports function. Provides summary info with
	drill down capability and 5-6 search/sort fields. Queries BCIS in real time. Must
87. What is the frequency of	have secured access to FDA intranet. Generated as needed by users. Annual Report published on website.
reports?	Generated as needed by users. Annual Report published on website.
88. Who is the report generated	Principally Consumer Safety Officials.
by?	
89. What is the method of access?	Through BCIS software. Set of standard reports. Oracle Discoverer used for ad
	hoc queries.
90. What is the turnaround time?	real time
91. What is the level of	Oracle Discoverer
automation?	
	Three principal standard report types: 1) remarks by error code (can produce freq
	dist) 2) by a number of selection criteria (type of facility, facility ID, facility
	name, BPD Report #, facility log#, received date, error code, remarks) with sort order options (by facility ID, received date, type of facility, error code (primary
	and secondary) 3) the Biological Product Deviation Report listing all info for a
	specific report submitted via the web. Majority of reports generated through
	Oracle Discoverer. Queries can be saved and rerun. IS team will respond to ad
	hoc report requests as well.
93. What is the unit of	Incident of deviation in product manufacture
observation?	

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)
94. What are the available data fields?	facility, products, error class, suspected root cause information, follow up information, recall recommendation, manufacturing lot#/unit#, internal FDA comments re: follow up
95. Is there a controlled vocabulary?	Yes for product, type of error (Biological Product Deviation Codes). Open ended text description of problem contained in Biological Product Deviation Report form.
96. Exportability	Can export to other applications using Oracle Discoverer
97. User Profile	DIS Consumer Safety Officers. Also, DIS staff conducting statistical analyses etc DCM staff. Office of Regulatory Affairs inspectors can also access data through FDA internet (e.g., prior to site visit).
98. How are the reports used?	Used to meet regulatory compliance obligations. DIS Consumer Safety Officers responsible for review and follow up of reports, initiations of inspections. DCM responsible for reviewing inspectors "list of observations" and following up as needed up to initiating recalls (Class 1, 2, 3), "non-concurrence", market withdrawals and enforcement actions.
99. Report Dissemination	Reports are largely internal to BCIS users who generate and print their own reports from system. DIS, through a series of Oracle Discoverer queries, generates information that feeds into Annual Report which is available on web. Annual Report provides descriptive statistics by type of facility, action taken and BPD code. Also have queries to assess timely submission of reports to FDA. To date, little trend or root cause analysis completed although planned for the future. List of root cause codes applied but may need to be updated. Standard reports not widely used.
100. What is the primary goal	To support identification of manufacturing problems and appropriate recall of biologic products.
101. Integration with other systems	See below re: MERTS-TM/BIODEV integration feasibility study. May be opportunity to rationalize BPD root cause codes with MERS-TM codes. BCIS users draw on CBER/ORA databases to validate FEI information. No other linkages or data sharing with any systems including MedWatch or AERS/VAERS. In most cases, BPD reports do not result in harm, therefore, would not be reported to AERS. Non-blood establishments reporting to BPD include vaccine manufacturers, therefore, may be some overlap with AERS/VAERS.
102. HIPAA Compliant	Yes, no patient-specific information contained in original reports, most data elements are available under FOI (CFR 21 Part 11).
Future	Developing internet-based function to allow manufacturers/reporters to access their reports. Currently working out issues re: protecting data, audit trail etc Access to be restricted by logon/password system. Also further opportunity to more completely identify ongoing reporting needs and develop appropriate standard reports.

Reporting or Database System: Program ID:	Biological Product Deviation Reporting (BPDR) System (BIODEV)	
Notes:	<ul> <li>Recall Alert, Tracking and Enforcement modules also provide reporting functions</li> <li>"Interface Feasibility Study" was undertaken to assess integration of MERS-TM and BIODEV. Study concludes that: <ul> <li>"At this time, a recommendation to proceed with interface development cannot be given without numbers to show that sufficient overlap of events reported to both systems exists.". "Data indicating the total number of MERS-TM reports which are FDA reportable should be revisited"</li> <li>"A comparison of the information reported to each system has identified that similar information is being captured by MERS-TM and BIODEV but often in different formats and where formats are similar different input rules apply."</li> </ul> </li> <li>Therefore, single portal interface considered "less feasible". "A one way interface from MERS-TM to BIODEV appears to be the most feasible. Since MERS-TM coded information can be can be translated into BIODEV format by the interface."</li> <li>FDA is also consolidating its recall tracking systems (Sandra Whetstone, Office of Regulatory Affairs - not interviewed)</li> <li>Approx. 25,000 reports per year. Only 348 non-blood facility reports (including vaccine manufacturers)</li> <li>Desired Information: Data on facility characteristics (e.g., total number of facilities, #units transfused/collected, type of facility etc)</li> <li>Note that there is no mandatory reporting of injuries to FDA (only deaths). This may be a gap in overall assessment of medical errors. These may be reported to to the mater is on materia.</li> </ul>	
Comments	MERS-TM but system is voluntary. *How BPDR differs from MERS-TM- BPDR is a mandatory requirement based upon federal regulations. MERS-TM is a voluntary reporting system. The MERS-TM focuses on adverse events specifically associated with a blood transfusion. Reporting is done by blood centers and transfusion services. The BPDR system focuses specifically on the manufacturers of blood products, and biological non-blood products, although transfusion services are also included. Events reported are any associated with the manufacturing, testing, processing, labeling, packing, storage, holding or distribution of both licensed and unlicensed blood or blood components that represent a deviation from current good manufacturing practices OR represents an unexpected <i>event potentially</i> <i>affecting the purity, safety, or potency of the product.</i> Note that BPD codes are changed every year. Regulations for reporting are complex in terms of which group should report and when gives 7 different scenarios to try to clarify for the reporter. Also gives examples of reportable and non-reportable events by system: Donor suitability variation collection deviation or unexpected event labeling deviation or unexpected event labeling deviation or unexpected event BIODEV vs BPDR vs BCIS BIODEV is the web front end. BPDR is client server at FDA. BCIS is for entire Biologic Compliance Information System – includes BPDR, but also alerts, recalls etc	

Dialy	sis	Surv	eillan	ce
		~ • • • •		~~

Reporting or Database System: Program ID:

## Dialysis Surveillance Network (DSN)

## Part I. Data Acquisition:

A. General Information	
1. Report Title	Dialysis Surveillance Network (DSN)
2. Internet Location: http://	www.cdc.gov/ncidod/hip/DIALYSIS/dsn.htm
3. Host Organization(s)	Centers for Disease Control and Prevention
4. Primary contact information (e.g. Address,	Teresa C. Horan, MPH, CIC (404) 498-1114
Phone)	thoran@cdc.gov
	Jerome I. Tokars, MD, MPH jit1@cdc.gov
<b>B.</b> Overall System Features	
5. System purpose/mandate	(DSN) is a voluntary surveillance system-monitoring
(any information on role in mission, leadership	bloodstream and vascular access infections-initiated by CDC in
support, integration with quality assurance	1999 and includes adult/pediatric outpatient dialysis centers
activities and history)	caring for chronic hemodialysis patients. Dialysis patients are at
	high risk for infection with antimicrobial-resistant bacteria. The
	purposes of the DSN are as follows: 1-To provide a method for individual hemodialysis centers to record and track rates of
	vascular access infections, other bacterial infections,
	hospitalizations, and intravenous antimicrobial starts. 2-To
	provide a method to aggregate, compare and distribute data to
	cooperating dialysis centers and the public health and medical
	communities. 3-To use these data to prevent infections and slow
	the spread of antimicrobial resistance. A secondary purpose is to
	record rates and syndromes prompting use of IV antimicrobials
	in hemodialysis centers.
	Participating centers may enter data on paper forms provided by
	CDC and receive a data analysis report every quarter.
	Alternatively, they may use the Internet-based system for data
	entry and analysis and generate and print reports whenever
	desired. There are no fees or financial remuneration for participating in this system. While summary data are released,
	the data from individual centers are confidential and cannot be
	released to anyone other than the dialysis center reporting it.
	Unique features of the DSN include:
	User-friendly methods simplify reporting.
	Data collectors record the presence or absence of criteria for
	infections, not the infections themselves.
	A computer algorithm determines whether the infection case
	definitions are met.
	The data collector does not have to memorize case definitions.
	The frequency of blood culturing, a factor that may influence reported infection rates, is determined.
	Several different rates are reported to better characterize the
	situation at any given center. For information about enrollment,
	see the procedure manual for the study or call 404-498-1109.
6. What is the geographic scope of data collection	
(national, state, local, facility etc)?	

Reporting or Database System: Program ID:	Dialysis Surveillance Network (DSN)
7. What is the unit of data entry (e.g., event, patient, product)?	Events are hospitalization or in-unit intravascular antimicrobial starts among chronic dialysis patients.
8. Who is allowed/required to input information?	Dialysis center personnel, such as Dialysis RN, dialysis technician, administrator, hospital-affiliated infection control practitioner
9. What are the regulations/laws affecting reporting?	See confidentiality laws in #10.
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	In accordance with 'Assurance of confidentiality'Sections 304, 306, and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and m(d), the information obtained for the surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution. At CDC, all data, including personal identifiers, is stored unencrypted in password-protected data files in a locked file or room, with access restricted to study personnel.
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	Dialysis center personnel may collect data on paper forms and send to CDC, who will enter the data electronically, or use CDC's Internet-based data entry and analysis system. If the Internet version is used, the data are transmitted to CDC via the CDC/ATSDR Secure Data Network, a secure transmission mechanism that meets the requirements of CDC's Internet security policy.
12. What are the methods of editing information (e.g. correcting/add more information to records)	Correcting and adding data to complete a record are allowed. Monthly submission of data to add to database.
13. Where is the collected data stored (name of database, number of data storage locations)?	Centers for Disease Control and Prevention
14. How often is the system revised (annual, semi- annual etc)?	Revised as needed. Currently in revision, see #17
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	User input is constantly sought and evaluated; internal review and design is ongoing.
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	If using the electronic data capture, Internet access
17. What new features are being planned and/or are on wish lists?	Currently in major revision to move to the new National Healthcare Safety Network (NHSN) using the National Electronic Disease Surveillance System as the architectural foundation. The NHSN will integrate three surveillance systems: NNIS, National Surveillance System for Hospital Healthcare Workers and Dialysis Surveillance Network; revisions include protocols, forms, data elements, web access technology, format etc.
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	No linkage, certain data (e.g.race/ethnicity distribution, age distribution, cause of renal failure, standardized mortality and hospitalization ratios, lists of hospitalizations) is obtained as

Reporting or Database System: Program ID:	Dialysis Surveillance Network (DSN)
	possible from CMS and the US Renal Data Systems and is used to assess representativeness by comparing centers that do with those that do not participate in the surveillance system, and possibly to control for differences among participating centers in patient populations (data is confidential and comply with data user agreements established).
D. Fields related to contributor/participant Information:	
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	Survey form completed when enrolling and annually thereafter. Fields include: name of dialysis center, HCFA provider number, ownership of center (for profit, not for profit, government), location (hospital based, freestanding, freestanding but owned by a hospital), part of a chain or not (Y/N) and name of chain, person responsible for collecting data (RN, technician, administrator, infection-control practitioner or other), who is responsible for infection control (dialysis staff member, hospital infection control practitioner, other), has the center participated in the surveillance system in the past (Y/N).
20. Is participation mandatory or voluntary?	Voluntary
21. List fields related to contributor/participant contact information	On the agreement to participate form: primary contact person: name, title and signature; Medical director or administrator, name, title and signature
22. List fields related to facility contact information (include type of facility, teaching status, id information)	Fields include: name of dialysis center, address, phone, fax, email address, HCFA provider number, ownership of center (for profit, not for profit, government), location (hospital based, freestanding, freestanding but owned by a hospital), part of a chain or not (Y/N) and name of chain, has the center participated in the surveillance system in the past (Y/N).
23. List fields related to distributor contact information	N/A
24. List fields related to manufacturer contact information	No information related to manufacturer contact, data is collected on the brand names of dialysis catheters used in the facility and includes Permanent (cuff, tunneled) catheters: manufacturer and model; Temporary (noncuffed, nontunneled) catheters (manufacturer and model)
E. Fields related to Provider of Care Information:	
25. List fields related to Provider of Care identification	#3 Provider number is requested on each form submitted
26. List fields that identify types of care providers included in system	Name of dialysis center and type, see #19, #22 above
F. Fields related to Patient Information:	
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	A log form is provided to collect information on the patient, but is NOT to be sent to CDC, information collected includes patient name, date of admission (mm/dd), the problem prompting admission. #5 Log number is captured on incident form. The incident forms have 2 versions: Option A relates to recording each hospitalization or outpatient IV antimicrobial start; Option B form is for each IV antimicrobial course. Hospital

Reporting or Database System: Program ID:	Dialysis Surveillance Network (DSN)
	admissions where the patient does not return to the outpatient dialysis unit on an IV antimicrobial are not recorded under Option B. On Option A and B forms, #1.the name of the patient (First, MI, last and #2 identification number (may use hospital number, social security number, or any unique identification number, if forms are sent on paper, this information is removed from the forms if alcotronically sent name is optional)
28. List fields related to patient contact information (e.g. address, zip code, county,	form; if electronically sent, name is optional) None
region) 29. List fields related to patient demographics (e.g. age, sex, race)	None
30. What patient identification is retained after	If patient name transmitted, information protected as previously noted.
31. List fields related to pre-existing conditions and/or medical history of patient	None
32. List fields that capture the clinical condition of patient at time of event	None
33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)	
34. List any other types of information collected about the patient	None
G. Fields related to Event/Error/Product Information:	
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	Potential infection as a result of vascular access and dialysis
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy)	None
37. List fields associated with medical device-	<ul><li>#7. Vascular access (circle all that the patient has): 1=graft,</li><li>2=fistula, 3=temporary catheter, 4=port access device</li></ul>
38. List fields associated with vaccine related events	N/A
events	#6. Incident type: H for hospitalization, A for an in-unit IV antimicrobial start, or both if the IV antimicrobials were started in the unit and the patient was subsequently admitted to the hospital.If an in-unit IV amtimicrobial start, answer: IV vancomycin started? Y/N
40. List fields associated with any other type of event. List type of event.	None
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	<ul> <li># 8. Problems that led to hospitalization or IV antimicrobial start (circle all that apply):</li> <li>a. Pus, redness, or increased swelling at vascular access site</li> <li>b. Vasculary access problem without infection (clotting,</li> </ul>

Reporting or Database System: Program ID:	Dialysis Surveillance Network (DSN)
	bleeding, etc.) c. Fever (100F oral or 101 rectal) d. Wound (not related to vascular access) with pus or increased redness e. Cellulitis (skin redness, heat, or pain without open wound) f. Pneumonia (a new infiltrate or pneumonia seen on chest x-ray) g. Respiratory infection not meeting above criteria for pneumonia (e.g. bronchitis) h. Urine culture with >100,000 organisms/ml with not more than 2 species isolated i. Cardiovascular event (chest pain, heart attack, other heart
42. List fields associated with when the event	problems, stroke, etc.) j. Other, specify: Date: the month, day and year (mm/dd/yyyy) of the
occurred 43. List fields associated with tracking the time between the event, when reported, when acted upon etc.	hospitalization or IV antimicarobial start. Date: the month, day and year (mm/dd/yyyy) of the hospitalization or IV antimicrobial start. On incident form A and B, include all IV antimicrobial starts. If IV antimicrobials are stopped for less than 21 days and then restarted, this is NOT considered a new event, if they are stopped for 21 days or more, this is considered a new incident.
44. List fields associated with where the event occurred	#6 Incident type: H hospitalization, A in unit IV antimicrobial start
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event	<ul> <li>#9. Blood culture: 0=not done, 1=positive, 2=negative,</li> <li>3=unknown</li> <li>9a. If positive, suspected source of positive blood culture:</li> <li>1=vascular access 2=a source other than the vascular access</li> <li>3=contamination 4=uncertain</li> <li>9b. If blood cultures were positive, List organisms isolated from blood and antimicrobial susceptibility (methicillin, oxacillin or nafcillin) and Vancomycin (codes S=susceptible, I=Intermediate, R=resistant)</li> </ul>
46. List fields related to follow-up of event that are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event)	N/A
<ul><li>47. List fields related to the outcome of event</li><li>48. List any other fields related to the event or any other information collected by the reporting system (e.g. root cause analysis, investigations etc)</li></ul>	
H. Implications	
49. Integration with other systems	
50. Methods used to de-identify data	
51. Technical Information	
Other	Reporting burdened estimated at 1 hour per report

<b>Reporting or Database System:</b>	
Program ID:	

**Part II: Data Structure & Storage:** The data structure for the Dialysis Surveillance system is in the process of being redesigned as part of a modernization effort. Accordingly, we did not review the data storage/structure of this system since the findings would be of limited utility with respect to development of an integrated system.

Part III: Data	Use a	& Anal	ysis:
----------------	-------	--------	-------

78. System Contact	Dr. Jerry Tokars
79. Contact Address	1600 Clifton Rd MS E-69 Atlanta, GA 30333
80. Contact Phone	
81. Contact Email	jit1@cdc.gov
82. Hardware Platform	
83. Operating System	
84. Who is the developer?	
85. Who is responsible for the system architecture?	web-enabled front-end for data collection, access
86. User Types	participating facilities use web front-end and can generate site- specific statistics. Internal staff generate summary reports
87. What is the frequency of reports?	monthly event reporting - internal reporting is ad-hoc, monthly, quarterly, and yearly
88. Who generates the report?	internal staff
89. What is the method of access?	
90. What is the turnaround time?	
91. What is the level of automation?	
92. Type Of Reports	Summary level standard reports, facility (masked) comparisons to norms
93. What is the unit of observation?	The reported event within facility
94. What are the available data fields?	facility, date, incident type, vascular access, problem report, blood info
95. Is there a controlled vocabulary?	yes
96. Exportability	
97. User Profile	participating facility QI staff, CDC staff (no public release of data?)
98. How are the reports used?	trends, facility to norm comparisons, facility rates
99. Report Dissemination	participating facilities, public reporting of summary data
100. What is the primary goal?	
101. Integration/Linkable to Detail	no
102. HIPAA Compliant	yes

ESRD	
Reporting or Database System:	CMS End Stage Renal Disease (ESRD) Network
	Consolidated Renal Operations Web-based Network (CROWN)
A. General Information	
1. Report Title	
2. Internet Location: http://	http://www.esrdnetworks.org http://www.hcfa.gov/quality/5d.htm
3. Host Organization(s)	Centers for Medicare & Medicaid Services (CMS)
4. Primary contact information (e.g. Address, Phone)	Dennis Stricker (410) 786-2031 <u>DStricker@cms.hhs.gov</u> Bill Crochunis (410) 786-6740 <u>BCrochunis@cms.hhs.gov</u> Roger Milam (410) 786-0613 <u>RMilam1@cms.hhs.gov</u>
B. Overall System Features	
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	The Renal Beneficiary and Utilization System (REBUS) is the repository for the ESRD program data. It contains data covering the medical and demographic information for the ESRD population. Dialysis facilities and transplant centers report patient data through the Vital Information System to Improve Outcomes in Nephrology (VISION) to 1 of 18 ESRD Network Organizations. These network organizations are connected to one another and to the REBUS through the Standard Information Management System (SIMS). The 18 Networks are currently in immediate contact with 4,153 dialysis facilities and 242 transplant centers, serving approximately 276,106 patients.
	The REBUS is in the process of migration to a new system called the Renal Management Information System (REMIS). CMS is working to build an integrated ESRD system called Consolidated Renal Operations in a Web- Enabled Network (CROWN). This new system will include VISION, SIMS, and REMIS, and will be implemented about June 30, 2002. CROWN and REBUS will continue to work in parallel until September 30, 2002, the termination date of REBUS.
6. What is the geographic scope of data collection (national, state, local, facility etc)?	National
<ol> <li>What is the unit of data entry (e.g., event, patient, product)?</li> </ol>	Patient
8. Who is allowed/required to input information?	Physician at Dialysis or Transplant facility.
9. What are the regulations/laws affecting reporting?	1972 Amendment to Title XVIII of Social Security Act extended Medicare Part A and Part B benefits to all individuals with ESRD regardless of age. 1978 Public Law 95-292, section (c)(1)(A) mandated the establishment of renal disease medical information system. The resulting system, REBUS, merged from an existing patient dialysis registry, a transplant registry, and Medicare claims and eligibility data from the SSA. 1987 Congress mandated the formation of 18 ESRD Networks to assist in the collection and verification of patient, facility, and provider data.

Reporting or Database System:	CMS End Stage Renal Disease (ESRD) Network Consolidated Renal Operations Web-based Network (CROWN)
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	No.
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	ESRD facility to ESRD Network: Print forms or Electronic transport in HL7 XML format.
12. What are the methods of editing information (e.g. correcting/add more information to records)	
13. Where is the collected data stored (name of database, number of data storage locations)?	18 ESRD Network Organizations. SIMS Central repository, REBUS, and REMIS at CMS Data Center
14. How often is the system revised (annual, semi-annual etc)?	
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	
17. What new features are being planned and/or are on wish lists?	
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	
D. Fields related to contributor/participant Information:	
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	<ul> <li>(N) Physician Identification</li> <li>(N) Physician Signature</li> <li>(S) UPIN of Physician</li> <li>(N) Attending Physician and Phone Number</li> <li>(N) Name of Provider</li> <li>(S) Medicare Provider Number</li> </ul>
20. Is participation mandatory or voluntary?	Mandatory
<ul> <li>21. List fields related to contributor/participant contact information</li> <li>22. List fields related to facility contact information(include type of facility, teaching status, id information)</li> </ul>	

Reporting or Database System:	CMS End Stage Renal Disease (ESRD) Network
23. List fields related to distributor contact information	Consolidated Renal Operations Web-based Network (CROWN)
24. List fields related to manufacturer contact information	
E. Fields related to Provider of Care Information:	
25. List fields related to Provider of Care identification	<ul> <li>(S) Medicare Provider Number for Provider</li> <li>(P) Primary Dialysis Setting</li> <li>(N) Name of Transplant Hospital</li> <li>(S) Medicare Provider Number for Transplant Hospital</li> <li>(N) Name of Preparation Hospital</li> <li>(S) Medicare Provider Number for Preparation Hospital</li> <li>(N) Name of Training Provider (for self-dialysis training)</li> </ul>
26. List fields that identify types of care providers included in system	(S) Medicare Provider Number for Training Provider
F. Fields related to Patient Information:	
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	<ul><li>(N) Patient Name</li><li>(S) Health Insurance Claim Number</li><li>(S) Social Security Number</li></ul>
28. List fields related to patient contact information (e.g. address, zip code, county, region)	(N) Full Address (N) Phone Number
29. List fields related to patient demographics (e.g. age, sex, race)	<ul><li>(FF) Date of birth</li><li>(P) Sex</li><li>(P) Ethnicity</li><li>(P) Race</li></ul>
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)?	All Contact Information
31. List fields related to pre-existing conditions and/or medical history of patient	(N) Laboratory Values Prior to First Dialysis Treatment or Transplant
32. List fields that capture the clinical condition of patient at time of event	(P) Primary Type of Dialysis
<ul> <li>33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage</li> <li>Medicare, Medicaid, private, CHAMPUS, uninsured etc)</li> </ul>	(P) Medical Coverage

Reporting or Database System:	CMS End Stage Renal Disease (ESRD) Network Consolidated Renal Operations Web-based Network (CROWN)
34. List any other types of information collected about the patient	<ul> <li>(N) Primary Cause of Renal Failure; Height; Dry Weight</li> <li>(FF) Date Regular Dialysis Began</li> <li>(FF) Date Patient Started Chronic Dialysis at Current Facility</li> <li>(FF) Date Dialysis stopped</li> <li>(FF) Date of Death</li> <li>(FF) Date of Transplant</li> <li>(FF) Date patient was admitted to Hospital (in anticipation of transplant)</li> <li>(P) Current Status of Transplant</li> <li>(FF) If Nonfunctioning, Date of Return to Regular Dialysis</li> <li>(FF) Date Training Began (for self-dialysis)</li> <li>(P) Completion of Training</li> <li>(FF) Date Training Completed</li> </ul>
G. Fields related to Event/Error/Product Information:	
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer)	
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer) cont'd	
37. List fields associated with medical device-related events (e.g. brand name of device, type of device, usage, manufacturer name, operator of device)	
38. List fields associated with vaccine related events.	
39. List fields associated with infection related events.	
40. List fields associated with any other type of event. List type of event.	
<ul> <li>41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)</li> <li>42. List fields associated with when the</li> </ul>	
event occurred	
43. List fields associated with tracking the time between the event, when reported, when acted upon etc	
44. List fields associated with where the event occurred	

L ~	
Reporting or Database System:	CMS End Stage Renal Disease (ESRD) Network Consolidated Renal Operations Web-based Network (CROWN)
45. List fields associated with patient	consolidated Reliar Operations web based Network (CROWIN)
diagnosis, care, treatment, tests, and	
other follow-up provided to patient	
because of the event	
46. List fields related to follow-up of	
event that are not associated with a	
particular	
patient(medication/manufacturing/policy	
actions to correct/update event)	
47. List fields related to the outcome of	
event	
48. List any other fields related to the	
event or any other information collected	
by the reporting system (e.g. root cause	
analysis, results of investigations etc)	
H. Implications	
49. Integration with other systems	
50. Methods used to de-identify data	
51. Technical Information	
Part II. Data Structura & Starage	
Part II. Data Structure & Storage:	
I. Facility/Location	
52. What is the address of storage	CMS Data Center
facility?	7500 Security Boulevard
	Baltimore, Maryland 21244-1850.
	CMS contractors and agents at various locations.
53.What type of facility is used to store	CMS Data Center
the data (3rd party data center, secured	
computer room, someone's cubicle)?	
computer room, someone's cubicie):	
54. Is there a network interconnect for	SIMS Virtual Private Network and CMS Wide Area Network
physically distributed systems?	
	T JDN T
55. What type (private lines, VPN,	VPN
Internet) of network interconnect?	
56.What is the network protocol	TCP/IP
(TCP/IP, IPX, etc.)?	
57. What is the bandwidth of network	N/A
	N/A
interconnect (dial-up, ISDN, T1, T3,	
etc.)?	
58. What is the network (WAN)	Currently, 4,153 dialysis facilities and 242 transplant centers transmit data
topology, including diagram if	to 18 ESRD Network Organizations via the Internet or mail. These 18
available?	Organizations are interconnected through CMS VPN and connected to
	SIMS central repository. Data from SIMS central repository is fed into
	REBUS and REMIS.
59. Who designed the system? Who	CMS and ESRD Network Organizations
operates the system?	
· ·	

Reporting or Database System:	CMS End Stage Renal Disease (ESRD) Network Consolidated Renal Operations Web-based Network (CROWN)
J. Data Storage System / Server	This information is for REBUS and REMIS, the main repositories of all ESRD data. Individual facilities and organizations have their own data storage systems.
60. Who is the manufacturer (Sun, HP, IBM, Compaq, etc.)?	IBM
61. What is the model number (Sun Enterprise 10000, HP 9000, etc.)?	SP - RS/6000 RISC
62. What is the number / speed (Mhz) of processors?	4 processors; 375 MHz
63. How much memory is available (Gb)?	Shared 4 Gb
64. What is the disk - Manufacturer, amount (Gb) & type (SAN, RAID	EMC Storage Devices
65. What is the operating system (e.g. Sun Solaris 2.6.1)?	IBM AIX 4.3.3 ptf set 9
K. For Each Application	
66. What commercial off-the-shelf (COTS) software (e.g. RDBMS, Query/Reporting Tools, etc.) is utilized?	REBUS: Model 204 Database REMIS: Oracle 8i Database
67. What custom-programmed application software is utilized? Using which language(s) (e.g. C,C++, PERL,	SIMS uses Crystal Reports for data analysis. REMIS will be using Oracle Discoverer and probably SAS.
68. Which categories best describe this system?	
- Is there an operational data store?	No
- Is there an all-encompassing data warehouse versus focused data mart(s)?	No
- Is there an Online Transaction Processing (OLTP) system utilizing a normalized relational database design?	No
- Is there a data warehouse utilizing a normalized relational database design?	Yes
- Is there a Dimensional Data Warehouse utilizing a star schema design?	No
- Is there a statistical analysis system utilizing flat files, either raw data or in a format intrinsic to the system (e.g. SAS	No
- Is there an Online Analytical Processing (OLAP) utilizing denormalized relational design such as star-schema or snowflake schema?	No
- Is there an OLAP system utilizing multidimensional design (e.g. hypercubes)?	No
- Are there other structured data formats, such as XML, HTML, or other?	No

Reporting or Database System:	CMS End Stage Renal Disease (ESRD) Network Consolidated Renal Operations Web-based Network (CROWN)
69. How is data structured?	Econsolidated Rehal Operations webbased Retwork (EROWR) Each table is a person table with one row per person, linked by Social Security number. The SIMS network of patient information is composed of the following tables: DEATH NOTICE (Date, place, and cause of death) FACILITY CERTIFICATION (Annual provider-specific treatment and transplant data) IDENTIFICATION (Basic beneficiary information, entitlement, and ESRD termination date) INPATIENT STAY (Hospital stay dates, provider number, surgery information) MEDICAL EVIDENCE (Medical conditions, lab results) METHOD SELECTION (ESRD payment method chosen by home dialysis patients) PATIENT STATUS (Verified status, dialysis type, most recent treatment setting) QUARTERLY DIAGNOSIS (Aggregated information for all dialysis claims in quarter) TRANSPLANT (Date of transplant, organ donor data) TRANSPLANT FOLLOW-UP (Tracks status of beneficiary transplant)
- Is there an event occurrence (EO) table with one row per event?	
- Is there a person table with one row per person, linked to events by PERSONID?	
- Is there an adverse-event (AE) taxonomy table, with one row per event type, linked one-to-many to the EO table by AEID?	
	Total for SIMS Repository: 18 Gigs
71. How much disk space is available on this system?	Unknown
L. For Each Major Data Structure	
72. What is the width of the table / file / subject data area (bytes)?	
73. How many data elements (approximate) in the table / file / subject data area?	
74. What is the raw data record size (bytes) or structured raw data such as HTML or XML?	
75. What is the approximate number of rows in the table, or observations?	
76. What time period is currently represented in the database? Projected change over the next 1-3 years?	
77. Are there any theoretical maximums that cannot be exceeded? (e.g. # providers, # recipients, etc.)	

HCUP		
Reporting or Database System:	Healthcare Cost and Utilization Project	
Part I. Data Acquisition:		
A. General Information		
1. Report Title	N/A	
2. Internet Location: http://	http://www.ahrq.gov/data/hcup/	
3. Host Organization(s)	Agency for Healthcare Research and Quality	
4. Primary contact information (e.g. Address, Phone)	Jenny Schnaier, Project Officer Agency for Healthcare Research and Quality 2101 East Jefferson St., Suite 605	
<b>B.</b> Overall System Features		
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	Under the leadership of the Agency of Healthcare Research and Quality (AHRQ), the fourth phase of the Healthcare Cost and Utilization Project (HCUP) aims to bring together the data collection efforts of state data agencies, hospital associations, private data organizations, and the federal government to expand the multifaceted HCUP health services databases from 1988 through 2003. HCUP databases serve a unique function and are being tapped by analysts and researchers interested in hospital utilization, access, charges, quality, and outcomes. Researchers rely on HCUP data to identify, track, analyze, and compare trends at the national, regional, and State levels. Because of their large size, the HCUP databases are used to describe patterns of care for rare as well as common diseases; analyze infrequent as well as common hospital procedures; and track utilization for population subgroups, such as minorities, children, women, and the uninsured. HCUP databases contain a core set of clinical and non-clinical information on all patients, regardless of payer—including persons covered by Medicare, Medicaid, private insurance, and uninsured—translated into a uniform format to facilitate both multi-State and national/State comparisons and analyses. The HCUP databases are available for intramural research within AHRQ. Many of the HCUP databases are available for intramural research within AHRQ. Many of the HCUP databases are available for intramural research within AHRQ. Many of the HCUP databases represent 100% of the records in the intramutal databases. Because the participating data organizations. In general, the restricted access, public release through the AHRQ-sponsored HCUP Central Distributor or through the National Technical Information on the restricted access, public release databases represent 100% of the records in the intramural databases. Because the participating data organizations dictate the release of specific data elements, the data elements on the restricted access, public release databases are a subs	

Reporting or Database System:	Healthcare Cost and Utilization Project
	medical error reporting. AHRQ has created a set of Quality Indicators to "highlight potential quality concerns, identify areas that need further study and track changes over time". One set of Quality Indicators currently available: Prevention QI's (identifying potentially avoidable admissions). Inpatient QI's under development (mortality medical condition and procedure, utilization of procedures that may be underused/overused/misused, volume of procedures for procedures where high volume associated with lower mortality). Patient Safety QI's under development.
6. What is the geographic scope of data collection (national, state, local, facility etc)?	The Healthcare Cost and Utilization Project (HCUP) is a Federal-State-industry partnership to build a standardized, multi-State health data system. HCUP is maintained by the Agency for Healthcare Research and Quality (AHRQ, formerly the Agency for Health Care Policy and Research). AHRQ has taken the lead in developing HCUP databases, Web-based products, and software tools and making them available for restricted access public release. HCUP comprises a family of administrative longitudinal databases—including State-specific hospital-discharge databases and a national sample of discharges from community hospitals—and powerful, user-friendly software that can be used with both HCUP data and with other administrative databases.
7. What is the unit of data entry (e.g., event, patient, product)?	HCUP databases contain patient-level information compiled in a uniform format with privacy protections in place. The Nationwide Inpatient Sample (NIS) includes inpatient data from a national sample of over 1,000 hospitals. The State Inpatient Databases (SID) cover inpatient care in community hospitals in participating States that represent more than half of all U.S. hospital discharges. The State Ambulatory Surgery Databases (SASD) contain data from ambulatory care encounters. The project's newest restricted access public release is the Kids' Inpatient Database (KID), containing hospital inpatient stays for children 18 years of age and younger.
8. Who is allowed/required to input information?	N/A
9. What are the regulations/laws affectingreporting?	Protecting the security and confidentiality of information within the HCUP databases is paramount. Federal and state laws, limitations imposed by the statewide data organizations, and MEDSTAT policies govern the use of data used constructing HCUP files. Federal restrictions are described in Privacy Act of 1974 and the Public Health Service Act (42 U.S.C. 299c-3(c)). AHRQ restrictions are described in attachments to the HCUP Memorandum of Agreement (MOA), "HCUP Data Confidentiality Guidelines for AHRQ Staff and Programming Support Contractors" and "HCUP Confidentiality Guidelines for Restricted Access, Publicly Distributed Databases AHRQ-CODS." Before handling HCUP data, MEDSTAT staff and subcontractors are required to sign the AHRQ Staff/Programming Support Contractor Data Security Agreement. A copy of this document is also attached to the HCUP MOA.Restrictions imposed by the HCUP Partner data organizations are specified in Partner-specific MOA. One example is the South Carolina MOA that cites and attaches the South Carolina Code of Law, Section 44-6-170 through 44-6-200 to the HCUP MOA.MEDSTAT policies are detailed in a proprietary document: "Data Privacy and Confidentiality Policies and Procedures Manual for Employees." The key components of this manual are summarized in the document entitled "Summary of Principles, Policies and Procedures Related to the Privacy, Confidentiality and Security of Person-level and Other Confidential Data". A summary of this proprietary document is included in Deliverable #144 Securing Data During HCUP Processing."
10. Does the system allow for/require anonymous input? If	No

Reporting or Database System:	Healthcare Cost and Utilization Project
yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	State Data files received by submission of formal request to state. Data arrives at MEDSTAT in CD-ROM; ASCII (.tx)- Flat text, format.
12. What are the methods of editing information (e.g. correcting/add more information to records)	N/A
13. Where is the collected data stored (name of database, number of data storage locations)?	Physical copies of source data are stored within locked offices or within locked cabinets. On the HCUP servers, source data files are stored separate from other data, on a dedicated partition. This allows source files to be backed up and deleted independent of SAS programs and other HCUP data. Source data files are stored by data type, state, and year. Interim SAS working files re stored separate from copies of source data and final HCUP files. The interim files are stored with copies of the programs used to create and manipulate these files. These files are stored by data type, state, and year. Post-production data files are stored separate from copies of source data, processing programs, and interim SAS working files. Sensitive data development files are also stored separately. The post-production data files are stored by data type, state, and year. Hard copy listings or logs generated from computer runs are stored within locked offices or within locked cabinets.
14. How often is the system revised (annual, semi-annual etc)?	Each year of the HCUP contract involves recruiting additional Partners and obtaining additional types of data from existing Partners.
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	Design under contract with customer input.
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	N/A
17. What new features are being planned and/or are on wish lists?	N/A
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	Yes. Hospital information is linked to Hospital Association files.
D. Fields related to contributor/participant Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)

Reporting or Database System:	Healthcare Cost and Utilization Project
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	State Hospital Organizations / Data Organizations
20. Is participation mandatory or voluntary?	Mandatory
21. List fields related to contributor/participant contact information	N/A
22. List fields related to facility contact information (include type of facility, teaching status, id information)	N/A
23. List fields related to distributor contact information	N/A
24. List fields related to manufacturer contact information	N/A
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
25. List fields related to Provider of Care identification	Expected principal and secondary payers
26. List fields that identify types of care providers included in system	
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system- assigned ID etc)	N/A
28. List fields related to patient contact information (e.g. address, zip code, county, region)	admission type, admission source, admission year
29. List fields related to patient demographics (e.g. age, sex, race)	age in years, age in days, age in months, sex, race,
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)	N/A
<ul> <li>31. List fields related to pre- existing conditions and/or medical history of patient</li> <li>32. List fields that capture the</li> </ul>	N/A principal and secondary diagnoses, principal and secondary procedures,
clinical condition of patient at time of event	

Reporting or Database System:	Healthcare Cost and Utilization Project
33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)	length of stay, admission type, admission source,
34. List any other types of information collected about the patient	If provided by data organization: birth weight, birth month, birth year, medical record number, zip code,
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	N/A
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer)	N/A
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer) continued	N/A
37. List fields associated with medical device-related events (e.g. brand name of device, type of device, usage, manufacturer name, operator of device)	N/A
38. List fields associated with vaccine related events.	N/A
39. List fields associated with infection related events.	N/A
40. List fields associated with any other type of event. List type of event.	
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	N/A
42. List fields associated with when the event occurred	N/A
43. List fields associated with tracking the time between the event, when reported, when acted upon etc	N/A
44. List fields associated with where the event occurred	N/A

Reporting or Database System:	Healthcare Cost and Utilization Project
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the	N/A
event	
46. List fields related to follow- up of event that are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event)	,
47. List fields related to the outcome of event	N/A
48. List any other fields related to the event or any other information collected by the reporting system (e.g. root cause analysis, results of investigations etc)	N/A
H. Implications	
49. Integration with other systems	
50. Methods used to de-identify data	
51. Technical Information	
Part II. Data Storage:	
For Each Facility / Location	
	MEDSTAT / AHRQ
53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?	3rd party data center, secured computer.
54. Is there a Network	Site party data center, secured computer.
Interconnect for physically distributed systems?	No
55. What type (private lines, VPN, Internet) of network	
	No
	No
	No
58. What is the network (WAN) topology, including diagram if available?	No
59. Who designed the system? Who operates the system?	AHRQ/MEDSTAT
J. For Each Data Storage System / Server	

Reporting or Database System:	Healthcare Cost and Utilization Project
60. Who is the manufacturer (Sun, HP, IBM, Compaq, etc.)?	Compaq
61. What is the model number (Sun Enterprise 10000, HP	
9000, etc.)?	AS-6?-10
62. What is the number / speed (Mhz) of processors?	700 Mhz -1.2 Ghz
63. How much memory (Gb) is available?	10 GB
64. What is the disk - Manufacturer, amount (Gb) & type (SAN, RAID Array, etc.)?	RAID Array
65. What is the operating system (e.g. Sun Solaris 2.6.1)?	NT/2000
K. For Each Application	
66. What commercial off-the- shelf (COTS) software (e.g. RDBMS, Query/Reporting Tools, etc.) is utilized?	SAS
67. What custom-programmed	
application software is utilized? Using which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	SAS
68. Which categories best	
	Statistical analysis system.
- Is there an operational data store?	No
- Is there an all-encompassing	
data warehouse versus focused	
data mart(s)?	No
- Is there an Online Transaction Processing (OLTP) system utilizing a normalized relational	
	No
- Is there a data warehouse utilizing a normalized relational	
6	No
- Is there a dimensional data	
warehouse utilizing a star	
schema design	No
- Statistical analysis system	
utilizing flat files, either raw	
data or in a format intrinsic to	
the system (e.g. SAS or SPSS	V
internal system format)	Yes
- Online Analytical Processing (OLAP) utilizing denormalized	
relational design such as star-	
schema or snowflake schema	No

Reporting or Database System:	Healthcare Cost and Utilization Project
- Is there an OLAP system utilizing multidimensional design (e.g. hypercubes)?	No
- Are there other structured data formats, such as XML, HTML, or other?	No
69. How is the data structured?	Core files
- Is there an event occurrence (EO) table with one row per event?	N/A
- Is there a person table with one row per person, linked to events by PERSONID	N/A
- Is there an adverse-event (AE) taxonomy table, with one row per event type, linked one-to- many to the EO table by AEID?	No
70. How much disk space is currently allocated to the system?	200 GB
71. How much disk space is available on this system?	500 GB
L. For Each Major Data Structure	
72. What is the width of the table / file / subject data area (bytes)?	~ 300 bytes
73. How many data elements (approximate) in the table / file / subject data area?	~100
74. What is the raw data record size (bytes) or structured raw data such as HTML or XML?	N/A
75. What is the approximate number of rows in the table, or observations?	100,000-3,000,000
76. What time period is currently represented in the database? Projected change over the next 1-3 years?	1998-2001
77. Are there any theoretical maximums that cannot be exceeded? (e.g. # providers, # recipients, etc.)	No
Part III. Data Use & Analysis:	
78. System Owner	AHRQ, CODS?
79.System Contact	Anne Elixhauser

Reporting or Database System:	Healthcare Cost and Utilization Project
80. Contact Phone	301-594-6815
81. Contact Email	aelixhau@ahrq.gov
82. Hardware Platform	Set of SAS data files in PC format that can be put on any system (may need to be translated if necessary). Publicly available files in ASCII format. Data packaged as set of CD-ROMs.
83. Operating System and version	N/A
84. Who is the developer?	AHRQ with assistance from MEDSTAT
85. Who is responsible for the architecture?	N/A
maintainers, analysts, policy	Multiple users conducting a variety of research /analysis, primarily unrelated to medical errors. Use of data to create Patient Safety QI's being assessed by UCSF-Stanford Evidence-based Practice Center. Draft report received.
	No users of HCUP data identified who currently/regularly produce medical error- related reports.
88. Who generates (requested) by (system, user, etc) the reports?	N/A
89. What is the method of access to request report (dedicated terminal, remote, service bureau	Person must request for, and complete a Data Use Agreement.
90. What is the turnaround time for report?	N/A
91. Level of Automation (canned, custom)?	N/A
92. Type of Reports (hard copy, electronic, screen view only, etc)	Available in electronic and hard copy formats.
93. What is the unit of observation?	Inpatient hospital stay or ambulatory surgery
	Many hospital, patient demographic and hospital-discharge related fields available in data set.
95. Is there a controlled vocabulary used for all (any) fields?	N/A
96. Exportability	N/A
97. User profile (Agency	
	N/A
98. How are the reports used (support of regulations, research, legal, etc.)	Support of research
_	N/A
100. What is the primary goal or objective of reports?	Support health services research and hospital operation by making comprehensive, standardized, high quality hospital data sets available.
101. Is the data linkable to detail?	N/A

MAUDE		
Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices	
Part I. Data Acquisition:		
A. General Information		
1. Report Title	MedWatch - FDA Mandatory safety information and adverse event reporting program - Devices only	
2. Internet Location: http://	http://www.fda.gov/cdrh/maude.html http://www.fda.gov/cdrh/mdr.html	
3. Host Organization(s)	The Food and Drug Administration (FDA), Center for Devices and Radiological Health (CDRH)	
4. Primary contact information (e.g. Address, Phone)	Primary Contact - Joyce Siwarski - 301-594-4550 x166; JCS@CDRH.FDA.GOV Marilyn Flack - MNF@CDRH.FDA.GOV Jim Motz for data structure	
<b>B.</b> Overall System Features		
<ul> <li>5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)</li> <li>6. What is the geographic scope of data</li> </ul>	The MAUDE database consists of data representing adverse event reports involving medical devices. The term Medical Device Reporting (MDR) is often used to refer to this program and is the mechanism for the FDA to receive significant medical device adverse events from manufacturers, importers and user facilities to assure the safety, effectiveness, and proper labeling of medical and radiation emitting devices. The FDA has the authority to send out warnings, to stop distribution, and/or to recall devices based upon the level of problem severity. The FDA also has regulatory authority for enforcement of MDR. Manufactures, importers, distributors and device user facilities (hospital, LTC facility, ambulatory surgical facility, outpatient treatment facility and outpatient diagnostic facility, but not physician, dentist, chiropractor, optometrist, nurse practitioner, school-based clinic, employee health clinic or free-standing care unit) are required to complete Form 3500a (mandatory reporting) which is submitted by mail, fax, phone (ie. hardcopy) to MedWatch. Contractor, Logistics Applications, triages reports to MAUDE (medical devices) or AERS (drugs/biologics). For device reports, contractor alerts CDRH of high priority reports per set criteria, will assign patient/device/evaluation codes (kept in system in addition to user submitted codes), assigns product code ("procodes" indicating product class), QA's for missing data etc. Contractor is audited by FDA re: data quality. MAUDE also contains voluntary reports from consumers and health professionals received either on line, mail, fax, phone, processed by MedWatch and forwarded to Logistics Applications. Patient, device and evaluation codes not included in voluntary reports. Logistics Applications assigns patient and device codes.	
collection (national, state, local, facility etc)?	The unit of optimic op advance arout and side a wedie of the interview.	
7. What is the unit of data entry (e.g., event, patient, product)?	The unit of entry is an adverse event associated with a medical device.	

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
8. Who is allowed/required to input information?	Mandatory input Form 3500A - Manufactures, importers, and device user facilities (hospital, LTC facility, ambulatory surgical facility, outpatient treatment facility and outpatient diagnostic facility, but not physician, dentist, chiropractor, optometrist, nurse practitioner, school-based clinic, employee health clinic or free-standing care unit) are required to complete this form within certain time periods based upon the severity of the event. For example, user facilities are required to report a death related to a device both to the FDA and to the manufacturer within 10 days of the death. Manufacturers and importers are required to report adverse events "whenever they receive or otherwise become aware of information that reasonably suggests that a device has or may have caused or contributed to the death, serious illness, or serious injury of a patient in the facility" within 30 days of the event. This includes device malfunction and user error. JCAHO monitors compliance with MDR during site visits to user facilities. See Sheet 2 on this spreadsheet for a summary of device-related reporting requirements by group and severity of event. See http://www.fda.gov/cdrh/manual/mdrman.html for details on reporting requirements by manufacturers. See http://www.fda.gov/cdrh/mdruf.pdf for reporting requirements by
	user facilities.
9. What are the regulations/laws affecting reporting?	Section 519 of the Food and Drug Administration Modernization act of 1997 is the Statute that affects device reporting and discusses general rules of reporting by group 21 CFR Sec 803 Subpart A-F establishes the reporting requirements for medical device reporting. Says that user facilities, importers and manufacturers must report deaths and serious injuries and that distributors (defined in 803.3) must maintain records of incidents. Sec 803.21 discusses the Medwatch mandatory reporting coding manual with codes for hundreds of adverse events for use with Form 3500a.
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	For FDA Device Reporting - FDA will disclose to a patient requesting a report, all information in the report concerning them, except for trade secret and confidential commercial information. FDA has promulgated a regulation [21 CFR §20.63(2)] that extends protection against disclosure of voluntary reports held by medical device, pharmaceutical, and biologics manufacturers by preempting state discovery laws. User facility name will not be released to the public under the FDA Modernization Act. FDA will also not release the identity of the patient or any information that can be used to identify the patient, such as the serial number of an implanted device. Nor will it release the name of any person other than the MDR contact. The name of the reporter and facility are deleted from disclosed data. Please note that the FDA is required under the Freedom of Information and Privacy Acts (SEC 552, Title 5, USC) (PL 93-579) to delete, prior to public disclosure, any information that constitutes trade secrets, and confidential, commercial, or financial information; and any personal, medical and similar information that would constitute a clearly unwarranted invasion of personal privacy. Included in the deletion requirements are all identification of the reporters and user facilities associated with the events.

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	Submitted via paper - mail, fax, or phone Food and Drug Administration Center for Devices and Radiological Health Medical Device Reporting P.O. Box 3002 Rockville, MD 20847-3002 301-827-0360 All submitted on Form 3500a 5-day Report - if action is being taken by the manufacturer 10-day Report - UF report medical device death or serious adverse event 30-day Report - Manufacturer Report Follow-up Report for manufacturers or user facilities - any time period
12. What are the methods of editing information (e.g. correcting/add more information to records)	The 3500a form allows follow-up information for device manufacturers. According to 21 CFR 803.56 - In supplemental reports, the manufacturer shall indicate on the form and the envelope that the reprint form is a supplemental report, provide appropriate id numbers of the report that will be updated with supplemental information (e.g. original mfr report number and user facility report number if applicable), and include only new or change information in the supplement. See item 46 for details on fields.
13. Where is the collected data stored (name of database, number of data storage locations)?	MAUDE - Obtain data structure info from FDA staff member - Jim Motz
14. How often is the system revised (annual, semi-annual etc)?	No scheduled revisions - based upon need
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	Federal register notice - public comments for changing reporting requirements. Revisions are made based upon discussions between FDA users and OSM staff.
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	No minimum. Form 3500A can be written out and mailed to FDA.
•	<ul> <li>*Analysis modules that can use algorithms and data mining techniques to analyze data - replace ad hoc reporting requests from contractors for MAUDE.</li> <li>*Addition of Race field to better meet federal reporting requirements</li> <li>*MedSun pilot is project to allow electronic submission of device event reporting for selected user facilities</li> <li>*Scanning of reports to reduce paper storage. Would still require data entry by LAI staff.</li> </ul>
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	No links to state systems. Older data is stored in MDR database. There is no system link, but there is a process link between LAI Data Acquisition for MAUDE and that of CMS-Medical Restraints. See template for CMS- Medical Restraints for more information.
D. Fields related to contributor/participant Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF - Fixed Format (e.g. date)

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	Medical Devices         (P)E.2 - Health professional. If you are not a health professional, write         NA         Yes         No         (N) E.3 - Occupation         F-User Facility/Distributor info - Note distributor is no longer required to report         (P) F.1 Type of Reporter         (N) F.3 User facility of distributor name/address         (N) F.5 Phone number         G-Manufacturer info         (N) G.1 - Contact Office (name/address and manufacturing site)         (N) G.2 - Phone number         (P) G.3 - Manufacturer Report source (check all that apply) -         How the manufacturer [contact office] became aware of the reported adverse event or from where the information about the adverse event originated.         Foreign - foreign country etc         Study - study that involves a systematic collection of adverse events from a protocol         Literature - If the report source is the scientific literature or an unpublished manuscript, a copy of the article or manuscript must be attached. Foreign language articles should be translated into English.         Record the date of the article as the date of the event (block B3), and provide a full literature citation in block H10;Drugs and Biologics: A separate 3500A form must be completed         for each identifiable patient described in the article or manuscript.         Consumer - recommend help of care provider;         Health professional         Company rep<
20. Is participation mandatory or voluntary?	Other - Any source not covered by the previous categories. Mandatory for user facilities, manufacturers, and importers. User facilities must report deaths to both FDA and manufacturer and serious injuries to manufacturer or to FDA if manufacturer unknown. See questions 8 and 9. Also note that JCAHO measures User Facility compliance with reporting. Voluntary (via MedWatch direct reporting) for health care professionals and consumers.
21. List fields related to contributor/participant contact information	(N)E.1 - Reporter Address and Phone #
22. List fields related to facility contact information (include type of facility, teaching status, id information)	(N) F.3 User facility or distributor address (N) F.5 Contact Person Phone number- This is the person designated by the facility's most responsible person as the device user facility/distributor (importer) contact for this requirement. FDA will conduct its MDR correspondence with this individual. The contact person may or may not be an employee of the facility. However, the facility and its responsible officials will remain the parties ultimately responsible for compliance with the MDR requirements

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
23. List fields related to distributor contact information	See Item 22
24. List fields related to manufacturer contact information	<ul> <li>G. Manufacturers</li> <li>(N) G.1 - Contact Office (name/address and manufacturing site)</li> <li>(N) G.2 - Phone number</li> <li>(N) F.14 - Manufacturer Name/Address - full name and address of the device manufacturer, if available</li> <li>Manufacturer Report Number</li> </ul>
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF - Fixed Format (e.g. date)
25. List fields related to Provider of Care identification	(P) D.4 Operator of Device - Indicate the type (NOT the name) of person operating or using the suspect medical device on the patient at the time of the event as follows health professional lay person other
26. List fields that identify types of care providers included in system	Some of this could be in event description and some could be in lab and diagnostic test information. See item 25
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	<ul> <li>(N)A.1 - Identifier - patient's initials or some other type of information that will allow you, the reporter to readily locate the case if you are contacted for more information. Do not use patient's name or SSN. Report has ID # assigned to it.</li> <li>(N) D.6 - Product Identification No Serial # of device - removed as part of de-identification because it is specific to a particular device and can be tracked back to a patient</li> </ul>
28. List fields related to patient contact information (e.g. address, zip code, county, region)	N/A
29. List fields related to patient demographics (e.g. age, sex, race)	<ul> <li>(N)A.2 - Age at time of event OR Date of Birth - provide the most precise information available. For age, indicate time units (3 years+-use years, less than 3 years old, use months; less than 1 month old, use days)</li> <li>(P)A.3 - Sex (if congenital anomaly, report sex of the child)</li> <li>Female</li> <li>Male</li> <li>(N)A.4 - Weight (in lbs OR kg)</li> <li>**Race could be included by reporter in medical history of patient, but not a separate field (see question 31)</li> </ul>
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)	D.6 Serial# and patient initials or other reporter assigned ID are entered in database but removed during de-identification

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
31. List fields related to pre-existing conditions and/or medical history of patient	<ul> <li>(N) Medical Devices - D.10 - Concomitant medical products and therapy dates (exclude tx of event)</li> <li>List and provide therapy dates for any other medical products (drugs, biologics, medical devices, etc.) that a patient was using at or around the time of the event. DO NOT include products used to treat the event.</li> <li>(N)B.7 - Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)</li> <li>(P)Categories for race:</li> <li>Am. Indian – Alaska Native= American Indian or Alaska Native Asian= Asian Continent to include Indian Subcontinent</li> <li>Native Hawaiian or other Pacific Islander= Native Hawaiian or other Pacific Islander</li> <li>Black= Black, not of Hispanic origin</li> <li>Hispanic= Hispanic</li> <li>White= White, not of Hispanic origin</li> </ul>
32. List fields that capture the clinical condition of patient at time of event	Some of this could be entered in B.5 - adverse event description (N) B.7 - Other relevant history, including preexisting medical conditions: (N) D.10 - Concomitant medical products and therapy dates - product names and therapy dates for any other medical products (drugs, biologics, medical devices, etc.) that the patient was using at the time of the event. DO NOT include products used to treat the event.
33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)	N/A
34. List any other types of information collected about the patient	(P) B.2 - Outcome attributed to adverse event death (date in fixed format) life-threatening hospitalization - initial or prolonged disability congenital anomaly required intervention to prevent permanent impairment/damage other (narrative description)

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	Medical Devices including in vitro diagnostics (P) H.1 - Type of reportable events Death: Check ONLY if the death was an OUTCOME of the adverse event Serious injury: An adverse event that is life-threatening; results in permanent impairment of a body function or permanent damage to a body structure; or necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure; or necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure Malfunction: See the guidelines. ("See the guidelines" refers to the applicable sections in 21 CFR Part 803 reporting guidelines Other: This option is intended to capture reports that the manufacturer believes the agency should be aware of that are not covered by death, serious injury, or malfunction as these terms are defined by the statute, regulation, or guidelines. Use rarely. (P) B.2 Outcomes attributed to adverse event: Indicate ALL that apply to the reported event: death (date in fixed format) life-threatening hospitalization - initial or prolonged disability congenital anomaly required intervention to prevent permanent impairment/damage
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy)	other (narrative description) N/A
37. List fields associated with medical	<ul> <li>(N) B.5 - Describe event or problem</li> <li>Description of details of the event, summary of all relevant clinical information (medical status prior to the event; signs and/or symptoms; differential diagnosis for the event in question; clinical course; treatment; outcome, etc.). If available and if relevant, synopses of any office visit notes or the hospital discharge summary. Copies of relevant info with any confidential information deleted. If reuse of a medical device labeled for single use may have caused or contributed to an adverse patient outcome, report the facts of the incident in B5 and the perceived contribution of reuse to the occurrence. For a product problem: Description of the problem (quality, performance, or safety concern) in sufficient detail so that the circumstances surrounding the defect or malfunction of the medical product can be understood. If available, the results of any evaluation of a malfunctioning device and, if known, any relevant maintenance/service information should be included in this section (S-Brand name - D.1 - Brand Name. The trade or proprietary name of the suspect medical device as used in product labeling or in the catalog (N)D.2 - Type of Device. The generic or common name of the suspect medical device or a generally descriptive name (e.g., urological catheter, heart pacemaker, patient restraint, etc.).DO NOT use broad generic terms such as "catheter", "valve", "screw", etc.</li> <li>(N)D.3 - Manufacturer name and address [user facility/distributor only]</li> <li>(P)D.4 - Operator of Device. Indicate the type (NOT the name) of person</li> </ul>

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
	Health professional = physician, nurse, respiratory therapist, etc., Lay user/patient = person being treated, parent/spouse/friend of the patient,
	Other = nurses' aide, orderly, etc.
	(FF)D.5 - Expiration date (mo/day/yy) D.6 - Product Identification Information
	(S)Model # Found on the device label or accompanying packaging
	(S)Catalog# Exact number as it appears in the manufacturer's catalog, device labeling, or packaging.
	(S)Serial # Found on the device label or accompanying packaging; it is assigned by the manufacturer
	<ul><li>(S)Lot# This number can be found on the label or packaging material.</li><li>(S)Other# Any other applicable identification number</li></ul>
	(N)D.7 - Implant date (if any) For medical devices that are implanted in the patient, provide the implant date. If day is unknown, month and year
	are acceptable. If month and day are unknown, year is acceptable D.8 - If explanted, give date: If an implanted device was removed from the patient, provide the explant date or best estimate. If day is unknown, month and year are acceptable. If month and day are unknown, year is
	acceptable (P)H.8 - Usage of device - If reused, the appropriate manufacturer Result codes for reuse are also to be entered into H6.
	Initial use of device
	Reuse
	Unknown (P) D.9 - Device available for evaluation
	yes, no, returned to manufacturer on date (FF)
	G.5 - (S-NDA) (A)NDA#, (S-IND)IND #
	(FF)PLA#
	(P) Pre-1938? - yes
	(P) OTC product? – yes
	G.6 - If IND, then (N)protocol#,
	(FF)H.4 - Device manufacture date (mm/day/yy)
	(P)H.5 - Labeled for single use? Yes
	No(N)
	F.9 - Approximate age of device
38. List fields associated with vaccine related events	N/A
39. List fields associated with infection	(N) B.5 - Describe event or problem
related events	(N) B.6 - Relevant tests/laboratory data, including dates
	Include: relevant negative test and laboratory findings, in order to most completely convey how the medical work-up/ assessment led to strong
	consideration of medical product-induced disease as etiology for clinical
	status, as other differential diagnostic considerations were being eliminated; relevant baseline laboratory data prior to the administration or
	use of the medical product; laboratory data used in diagnosing the event; available laboratory data/engineering analyses (for devices) that provide further information on the course of the guest
	further information on the course of the event If available, include: any pre- and post-event medication levels and dates (if applicable);synopses of any relevant autopsy, pathology, engineering,
	or lab reports.

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
40. List fields associated with any other type of event. List type of event.	N/A
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	<ul> <li>(N) B.5 - Describe event or problem</li> <li>(P) F.10 - Event problem codes (see http://www.fda.gov/cdrh/mdr/appendixc.pdf - Note: UF is supposed to complete. Mfr fills in if missing.)</li> <li>Patient codes - describe what happened to the patient as a result of the event <ul> <li>approximately 1600 codes (device and patient mixed)</li> <li>Device codes - device problems or failures encountered during the event (S-MedDRA, WHOART or custom) G.8 - Adverse event term(s) - Include a list of adverse event terms that most accurately characterize the adverse event described</li> <li>in narrative format in block B5. Terms should be listed with the most important term(s) first. The terminology may be an accepted standard(e.g., MedDRA or WHOART),</li> </ul> </li> </ul>
42. List fields associated with when the event occurred	MedDRA (FF) B.3 - Date of event (mo/day/yr) - Provide the actual or best estimate of the date of first onset of the adverse event. If day is unknown, month and year are acceptable. If day and month are unknown, year is acceptable. When a newborn baby is found to have a congenital anomaly, the event onset date is the date of birth of the child. When a fetus is aborted because of a congenital anomaly, or is miscarried, the event onset date is the date pregnancy is terminated. If information is available as to time during pregnancy when exposure occurred, indicate that information in narrative block B5.
43. List fields associated with tracking the time between the event, when reported, when acted upon etc	(FF) B.3 - Date of event(FF) B.4 - Date of this report (initial reporter)(FF) F.6 - Date user facility or distributor became aware of event(FF) F.8 - Date of this report (User/Distributor)(FF) G.4 - Date received by manufacturer (manufacturer)(P) G.7 - Type of report5-day10-day15- dayinitial - Check if the report is the first submission of a manufacturer report. For devices, this is the 30-day report periodicfollow-up, enter number of original report. (see Question 46) Initial:
44. List fields associated with where the event occurred	(P) F.12 - Location where event occurred Hospital Home Nursing Home Outpatient treatment facility Outpatient diagnostic facility Ambulatory surgical facility Other

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
45. List fields associated with patient	B.5 - Describe event or problem
	(N)B.6 - Relevant tests/laboratory data (with dates)
follow-up provided to patient because of	Include: relevant negative test and laboratory findings, in order to most
the event	completely convey how the medical work-up/ assessment led to strong
	consideration of medical product-induced disease as etiology for clinical
	status, as other differential diagnostic considerations were being
	eliminated; relevant baseline laboratory data prior to the administration or
	use of the medical product; laboratory data used in diagnosing the event;
	available laboratory data/engineering analyses (for devices) that provide
	further information on the course of the event
	If available, include: any pre- and post-event medication levels and dates
	(if applicable); synopses of any relevant autopsy, pathology, engineering,
	or lab reports.
46. List fields related to follow up of	*
46. List fields related to follow-up of event that are not associated with a	(P)E.4 - Initial reporter also sent report to FDA? Yes, No, unknown
	(P) F.7 Type of report - one of the choices is for follow-up with number
particular patient	[User facility/distributor only]
	(P) G.7 Type of report - one of the choices is for follow-up with number
to correct/update event)	[manufacturer only]
	Follow-up: Check if the report is a follow-up to a previously submitted
	report.
	Provide additional or corrected information on the previously reported
	event.
	Follow-up reports on drugs and biologics should contain information that
	was
	submitted in the original report if the information is still correct.
	(P)H.2 - If follow-up, what type? [manufacturer only]
	Correction: Changes to previously submitted information.
	Additional information: Information not know when the original report
	was submitted
	Response to FDA request: Additional information requested by FDA
	concerning the device/event
	Device evaluation: analysis of event
	(P) D.9 - Device available for evaluation? Indicate if the device was
	returned to the manufacturer and,
	if so, the date of the return. DO NOT send the device to FDA. Yes, No
	Returned to manufacturer on (mm/day/yr)
	(P) H.3 - Device evaluated by mfr?
	Not returned to mfr
	Evaluation summary attached
	No (attach page to explain or supply code from instructions)
	(S-FDA Evaluation Codes for Manufacturers) H.6 - Evaluation codes (4
	codes per subtype
	see http://www.fda.gov/cdrh/mdrcode.pdf for list of codes - approx 50
	codes) Enter the applicable
	codes from the codes manual for one or more of the categories listed.
	Conclusion codes
	must be entered even if the device was not evaluated. If the reuse of a
	device may have caused
	or contributed to the adverse event, then the appropriate manufacturer
	Result codes are to
	be entered from the codes manual. Applicable reuse codes are 230-233
	and may be used
	alone or with any other applicable results codes. (see H8).
	Method - Enter Source of evaluated device, type of evaluation performed
	(4 codes)

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
	Results - Enter type of result code (see www.fda.gov/cdrh/mdr/appendixd.pdf - approx 350 codes) Conclusions - Enter conclusions code (approx 20 codes)
46. List fields related to follow-up of event that are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event) cont'd	(P)H.7 - If remedial action initiated, check type Recall Repair Replace Relabeling Notification Inspection Patient monitoring Modification/adjustment OtherIndicate the applicable action(s). If other, specify the type of action in the space provided. Most of these terms are defined or further explained in the Act or in the FDA regulations concerning remedial action (see 21 USC 360h and 21 CFR Parts 7, 803 and 806). (FF)H.9 - If action reported to FDA under 21 USC 360I(f), list correction/removal reporting number - If action reported to FDA under 21 USC 360i(f), list correction/removal reporting number: Enter the number that FDA assigned to the corrective action. If a number has not yet been assigned by FDA, the number assigned by the firm for the action may be used. (P)H.10 - Additional manufacturer narrative OR Corrected data: Provide the following additional, corrected, or missing information, identifying each data item by the applicable section and block number: (1) Any information missing on the user facility or distributor (importer) report, including any missing or incomplete event codes required by block F10 (2) Information corrected on the user facility or distributor (importer) report form after verification, including any corrected event codes required by section D (e.g., D6: model number) (3) For each event represented by the code is addressed in the device labeling, and (4) An explanation of why any required information was not provided and the steps taken to obtain such information. (P) F.11 Report sent to FDA? Yes, No, Date [To track duplicate reports in the FDA database](P) F.13 Report sent to manufacturer? Yes, No, Date(FF)F.2 - UF/Dist Report number (Filled in by UF/Dist) Enter the complete number of the report exactly as entered in the upper right corner of the front page. For a follow-up report, the UF/Distributor (Importer) report number must be identical to the number assigned to the initial rpt
47. List fields related to the outcome of event (patient)	<ul> <li>(P) B.2 - Outcome attributed to adverse event death (date in fixed format) life-threatening hospitalization - initial or prolonged disability congenital anomaly required intervention to prevent permanent impairment/damage other (narrative description)</li> <li>(N) B.5 - Describe event or problem</li> <li>(N) B.6 - Relevant tests/laboratory data, including dates</li> <li>(S) F.10 - Event problem codes (refer to coding manual) patient code device code</li> <li>(S) H.6 - Evaluation codes (refer to coding manual) methods results</li> </ul>

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
48. List any other fields related to the event or any other information collected by the reporting system (e.g. root cause analysis, investigations etc)	Autopsy reports are sometimes sent to MAUDE, forwarded to analysts to look at when reviewing a certain medical device event.
H. Implications	
49. Integration with other systems	Baseline reports are submitted on Form 3417 when the device model is first reported in an event. Each baseline report should be updated annually. There was discussion at the meeting that baseline reporting information was intended to be used to link records from the various systems, but does not work as well as expected. May be point of further discussion with technical group. MAUDE uses an algorithm looking at UF and manufacturer information and date of event to try to identify multiple reporting of same event. Importance of the system is for detecting signals - provides an effective way to start an entire risk management analysis process which may or may not end up in a recall, MedWatch alert etc.
50. Methods used to de-identify data	The name of the reporter and facility are deleted from disclosed data before release of the report. In addition, an automated process is used to delete the following fields and any proper names in narrative fields (this often must be done manually by an analyst). Double checked by an analyst:A.1 - Patient identifier A.2 - Age at time of event or Date of birth A.3 - Sex A.4 - WeightB.6 - Relevant tests/laboratory data, including dates B.7 - Other relevant history, including preexisting medical conditionsD.7 - If implanted, give date D.8 - If explanted, give date E.1 - Name, address & phone # E.3 - Occupation F.2 - UF/Dist/Importer report number F.3 - User facility or distributor/Importer name & address F.4 - Contact person F.5 - Phone Number F.10 - Event problem codes H.6 - Evaluation codes
51. Technical Information	

## Part II. Data Structure & Storage:

I. Facility / Location	
52. Address of data storage facility	2098 Gaither Road Rockville, MD 20850
53. What type of facility is used to store	
data (3rd party data center, secured computer room, someone's cubicle)?	Secured Computer Room
54. What is the network interconnect for	
physically distributed systems?	Multimode fiber cable connects the server and the switch.
55. What type (private lines, VPN,	
	The server is behind the firewall. Users from home can dial-up directly
used?	into the network or VPN through their ISP.
56. What is the network protocol	
(TCP/IP, IPX, etc.)?	TCP/IP
57. What is the bandwidth of network	
interconnect (dial-up, ISDN, T1, T3,	
etc.)	FDDI (100Mbps) connection to the server

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
<ul><li>58. What is the network (WAN) topology, including diagram if available</li><li>59. Who designed the system? Who</li></ul>	Two FDDI rings (each can transfer100Mbps). Dual Fast Ethernet connections to the NCC of the FDA.
operates the system?	
J. Data Storage System / Server	
60. Who is the manufacturer (Sun, HP, IBM, Compaq, etc.)?	Compaq
61. What is the model number (Sun Enterprise 10000, HP 9000, etc.)?	AlphaServer 4100
62. What is the number / speed (Mhz) of processors?	4/600
	gb 4
64. What is the disk - manufacturer, amount (Gb) & type (SAN, RAID Array, etc.)?	Compaq StorageWorks 610GB net RAID
65. What is the operating system (e.g. Sun Solaris 2.6.1)	OpenVMS 7.2-1
K. For Each Application	
	Oracle RDBMS Oracle Forms SQR ReportWriter
67. What custom-programmed application software is utilized? Using which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	C/VB
68. Which categories best describe this system?	
- Is there an Operational Data Store?	Yes
- Is there an all-encompassing data warehouse versus focused data mart(s)?	No
- Is there an Online Transaction Processing (OLTP) system utilizing a normalized relational database design	No
Is Decision Support Normalized?	Yes
- Is there a Dimensional Data Warehouse utilizing a star schema design	No
- Is there a statistical analysis system utilizing flat files, either raw data or in a format intrinsic to the system (e.g. SAS or SPSS internal system format)?	No

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
- Is there an Online Analytical Processing (OLAP) utilizing denormalized relational design such as star-schema or snowflake schema?	No
- Is there an OLAP system utilizing multidimensional design (e.g. hypercubes)?	No
- Are there other structured data formats, such as XML, HTML, or other?	No
<ul><li>69. How is data structured?</li><li>- Is there an event occurrence (EO) table with one row per event?</li></ul>	
- Is there a person table with one row per person, linked to events by PERSONID?	
- Is there an adverse-event (AE) taxonomy table, with one row per event type, linked one-to-many to the EO table by AEID?	
70. How much disk space is currently allocated to the system?	10.5 gb
71. How much disk space is available on this system?	6.1 gb
L. For Each Major Data Structure	
72. What is the width of the table / file / subject data area (bytes)?	Approximately 4-3000
73. How many data elements (approximate) in the table / file / subject data area?	Approximately 1-50
74. What is the raw data record size (bytes) or structured raw data such as HTML or XML?	N/A
75. What is the approximate number of rows in the table, or observations?	Approximately 224
76. What time period is currently represented in the database? Projected change over the next 1-3 years?	
77. Are there any theoretical maximums that cannot be exceeded? (e.g. # providers, # recipients, etc.)	

Reporting or Database System:	FDA-CDRH: MAUDE –Manufacture and User Data Experience- Medical Devices
Part III. Data Use & Analysis:	
78. System Contact	Pat Kingsley (Division of Post-Market Surveillance), Howard Press (Division of Surveillance Systems), Suzanne Rich (Division of Post-Market Surveillance)
79. Contact Address	1350 Piccard Drive, Rockville, MD, 20850
80. Contact Phone	PK: 301-594-2784, HP: 301-827-2983 SR: 301-594-2581
81. Contact Email	PK: pak@cdrh.fda.gov HP: <u>hap@cdrh.fda.gov</u>
82. Hardware Platform	VAX Cluster
83. Operating System	
84. Who is the developer?	CDRH
85. Who is responsible for the system architecture?	Relational database
86. User Types	CDRH Clinical Specialists
87. What is the frequency of reports?	As needed to investigate specific adverse event reports.
88. Who generates the report?	MAUDE Users
89. What is the method of access?	MAUDE software
90. What is the turnaround time?	Real time
91. What is the level of automation?	N/A – through MAUDE software
92. Type Of Reports	Two main components: workload module, query/reporting function. Workload module allows analysts to schedule and track follow up on specific adverse event reports. No structured, regular summary reports from MAUDE. Semi-structured query facility used to investigate specific issues. Focus is on individual event reports. MAUDE query functions facilitate look up of reports on same manufacturer, device, device-type, event code. Can print standardized report from query function. Ad hoc querying/reporting also available. Statistical reporting more difficult in MAUDE since there is less consistency between reports than in ASR. Frequency counts and basic cross-tabulations are available. MAUDE data also available to other internal FDA users through APPS (gateway to several FDA databases). Read only. Summary and individual report information available (standardized) as well as query function. Series of data files available on web containing FOI releasable data (see notes for details) for all voluntary reports since June, 1993, user facility reports since 1991, distributor reports since 1993 and manufacturer reports since Aug. 1996. Note that patient, device and evaluation codes are not included in data sets. Also contains base data re: manufacturer and device characteristics. Separate files available containing device data, patient data and text data (linked through a MDR REPORT KEY). Data updates also available separately. Files covering different time periods (eg. 2001, current quarter etc.) also available. FDA does not receive information re: nature of use of data sets by outside parties.
93. What is the unit of observation?	can be requested (e.g., CDC did request data). Individual medical device-related event reported on Form 3500 (voluntary) and 3500a (mandatory). EVENT KEY links reports from multiple reporters for the same event.

Reporting or Database System:	FDA-CDRH: MAUDE – Manufacture and User Data Experience- Medical Devices
94. What are the available data fields?	Key fields are patient codes (describing effect on patient), device codes (describing nature of failure/event) and three evaluation codes (method, results, conclusions – describing evaluation of problem by manufacturer). User facility submitted reports may not contain evaluation codes. Manufacturer submitted reports may not contain patient and/or device codes. Two main sets of data: complete data set available internally within FDA, and FOI releasable data elements.
95. Is there a controlled vocabulary?	Yes, lists updated regularly for patient, device, evaluation and product codes by CDRH
96. Exportability	Yes. Facility provide through MAUDE software. Frequently done to further define a specific problem and its impacts. Primarily exporting to Excel.
97. User Profile	FDA - Division of Post-Market Surveillance. Division of Surveillance Systems. Office of Device Evaluation, Office of Compliance, Office of Science and Technology and Office of Health Industry Programs. No ongoing users outside FDA of non-FOI data. Others (e.g., CDC) may request data.
98. How are the reports used?	Clinical specialists review reports and generally either 1) monitor 2) follow up with firm (i.e., requesting additional information for an emerging problem) or send investigator (last resort). Urgent reports, per established criteria, followed up immediately. FDA analysts use MAUDE history by type of device, exact device, similar problems with similar devices from other manufacturers, problems with devices from same manufacturer, problems within specific populations groups etc.). Each analyst determines how best to conduct follow up analysis. This may involve use of other databases. Can access pre-market approval/application information through APPS (510k and PMA), which includes design changes. If report is of sufficient concern, investigator may be asked to follow up. FACTS system contains information regarding the activities of the regional offices of the Office of Compliance. Recalls initiated by Office of Compliance and tracked in a separate system. Recalls assigned Class 1, 2 or 3. May also ask Epidemiology Branch to conduct a broader analysis. Epidemiology Branch can also initiate its own analysis regarding specific devices/problems and provide consultative services to pre-market group (eg. Examining use of device within "non-perfect" populations). Epidemiology Branch may access other databases to conduct specific analyses. Evaluation Codes (one each for Methods, Results, Conclusions) indicate the follow up undertaken by manufacturer. FDA actions can be of many forms including labeling modification, recall, re-engineering of product. Manufacturers often take action of their own accord. Office of Device Evaluation (pre-market assessment), Office of Compliance (focus at manufacturer level re: ensuring compliance to FDA reporting
99. Report Dissemination	research) and Office of Health Industry Programs access MAUDE data through APPS. FDA analysts use reporting capabilities to investigate adverse event reports.
100. What is the primary goal?	Special statistical analyses prepared for management on ad hoc basis. Detecting/assessing emerging medical device problems and initiating appropriate action within scope of FDA authority.

Reporting or Database System:	FDA-CDRH: MAUDE –Manufacture and User Data Experience- Medical Devices
101. Integration/Linkable to Detail/Overlap	<ul> <li>MAUDE uses an algorithm looking at UF and manufacturer information and date of event to try to identify multiple reporting of same event.</li> <li>Only information in MAUDE is from 3500 and 3500a reports. Reports received related to medical restraints that are medical devices are entered into MAUDE and then forwarded to CMS. CMS does not use MAUDE database. FDA staff do not access CMS Medical Restraint database.</li> <li>Facilities reporting to MedSuN may previously have reported to MAUDE. Manufacturers still required to report to MAUDE (through MedWatch). Therefore, if a manufacturer becomes aware of an adverse event within a MedSuN participating facility, it is possible that a report of the same adverse event would be made to MAUDE by the manufacturer and MedSuN by the facility.</li> <li>Epidemiology Branch of Division of Post-Market Surveillance purchases access to other databases to conduct research (eg. Society of Thoracic Surgeons database of complications). May use CMS database.</li> </ul>
102. HIPAA Compliant	No direct patient identifiers, may contain services dates and DOB
Future	Analysis modules that can use algorithms and data mining techniques to analyze data - replace ad hoc reporting requests from contractors for MAUDE.
Notes	Baseline reports are submitted on Form 3417 when the device model is first reported in an event. Each baseline report should be updated annually. FDA in process of integrating its recall systems.
	Approx. 53,000 total non-ASR reports received of which 48,000 from manufacturers, 2,000 from user facilities, 3,000 voluntary reports
	Desired Information: Denominator information (I.e., number of a specific device in use) Only mandatory for User Facilities to report deaths to FDA. MAUDE does not get User Facility injury reports directly.
	Patient and event codes generally completed by User Facility, evaluation codes by manufacturer. Reports from manufacturer may not contain patient and/or event codes (I.e., if manufacturer doesn't know what patient impact was). Similarly, User Facility reports may not contain evaluation codes (identifying manufacturer methods/results/conclusions.

MDS	
Reporting or Database System:	Minimum Data Set (MDS)
Part I. Data Acquisition:	
A. General Information	
1. Report Title	
2. Internet Location: http://	http://www.hcfa.gov/medicaid/oasis/oasishmp.htm
3. Host Organization(s)	Centers for Medicare & Medicaid Services (CMS)
4. Primary contact information (e.g. Address, Phone)	Dennis Stricker (410) 786-2031 DStricker@cms.hhs.gov John Williams JWilliams2@cms.hhs.gov
B. Overall System Features	
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	The minimum data set (MDS) is a uniform set of elements extracted from the resident assessment instrument, or RAI. The MDS is designed to collect data about an individual nursing home resident which will ultimately lead to a comprehensive, outcome-oriented care plan for that resident; it consists of specific questions about a resident in several areas. The questions cover factors that place a resident at risk for an adverse outcome. MDS information is transmitted electronically by nursing homes to the MDS database in their respective states. MDS information from the state databases is captured into the national MDS database at CMS.
6. What is the geographic scope of data collection (national, state, local, facility etc)?	national
7. What is the unit of data entry (e.g., event, patient, product)?	patient
8. Who is allowed/required to input information?	Nursing home staff member
9. What are the regulations/laws affecting reporting?	
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	NO
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	Mail or electronic form
12. What are the methods of editing information (e.g. correcting/add more information to records)	Correction Request Form
13. Where is the collected data stored (name of database, number of data storage locations)?	CMS Data Center

Reporting or Database System:	Minimum Data Set (MDS)
14. How often is the system revised (annual, semi-annual etc)?	
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	
17. What new features are being planned and/or are on wish lists?	
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	
D. Fields related to contributor/participant Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	Authorized Nursing Home Staff Member
20. Is participation mandatory or voluntary?	mandatory
21. List fields related to contributor/participant contact information	
22. List fields related to facility contact information(include type of facility, teaching status, id information)	(S) Facility Provider Numbers – State and Federal
23. List fields related to distributor contact information	
24. List fields related to manufacturer contact information	
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
25. List fields related to Provider of Care identification	(N) Signature and Title of Nursing Home Staff Member
26. List fields that identify types of care providers included in system	

Reporting or Database System:	Minimum Data Set (MDS)
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	<ul><li>(N) Resident Name</li><li>(N) Social Security Number and Medicare Number</li><li>(N) Medicaid Number</li></ul>
28. List fields related to patient contact information (e.g. address, zip code, county, region)	<ul><li>(N) Resident Name</li><li>(N) Room number</li><li>(N) Zip Code of Prior Primary Residence</li></ul>
29. List fields related to patient demographics (e.g. age, sex, race)	<ul><li>(N) Gender</li><li>(N) Birthdate</li><li>(N) Race/Ethnicity</li></ul>
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)?	All identification
31. List fields related to pre-existing conditions and/or medical history of patient	<ul><li>(P) Reasons for Assessment</li><li>(P) Continence in Last 14 Days</li><li>(P) Special Treatments and Procedures</li></ul>
32. List fields that capture the clinical condition of patient at time of event	<ul> <li>(P) Cognitive Patterns</li> <li>(P) Communication / Hearing Patterns</li> <li>(P) Vision Patterns</li> <li>(P) Mood and Behavior Patterns</li> <li>(P) Psychosocial well-being</li> <li>(P) Physical Functioning and Structural Patterns</li> <li>(P) Disease Diagnoses</li> <li>(P) Health Conditions</li> <li>(P) Oral/Nutritional Status</li> <li>(P) Oral/Dental Status</li> <li>(P) Skin Condition</li> <li>(P) Activity Pursuit Patterns</li> <li>(P) Medications</li> <li>(P) Discharge Potential and Overall Status</li> <li>(P) Current Payment Sources for Nursing Home Stay</li> </ul>
information (e.g. length of stay, charge	<ul><li>(P) Current Payment Sources for Nursing Home Stay</li><li>(N) Assessment Reference Date</li><li>(N) Date of Reentry</li></ul>
34. List any other types of information collected about the patient	(P) Responsibility/Legal Guardian
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Pick list items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	

Reporting or Database System:	Minimum Data Set (MDS)
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer)	
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer) cont'd	(N) List of all Medications given (name and dose, route of administration, frequency, amount administered, PRN, NDC Code)
37. List fields associated with medical device-related events (e.g. brand name of device, type of device, usage, manufacturer name, operator of device)	(P) Special Treatments and Procedures – Devices and Restraints
38. List fields associated with vaccine related events.	N/A
39. List fields associated with infection related events.	(P) Disease Diagnoses - Infections
40. List fields associated with any other type of event. List type of event.	<ul> <li>(P) Disease Diagnoses <ol> <li>Endocrine/Metabolic/Nutritional</li> <li>Heart/Circulation</li> <li>Musculoskeletal</li> <li>Neurological</li> <li>Psychiatric/Mood</li> <li>Pulmonary</li> <li>Sensory</li> <li>Other (Allergies, Anemia, Cancer, Renal Failure)</li> </ol> </li> </ul>
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	0. Other (Finlergies, Finlenna, Cancer, Rohar Fanare)
42. List fields associated with when the event occurred	
43. List fields associated with tracking the time between the event, when reported, when acted upon etc	
44. List fields associated with where the event occurred	
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event	
46. List fields related to follow-up of event that are not associated with a particular patient(medication/manufacturing/policy actions to correct/update event)	

Reporting or Database System:	Minimum Data Set (MDS)
47. List fields related to the outcome of	
event	
48. List any other fields related to the	
event or any other information collected	
by the reporting system (e.g. root cause analysis, results of investigations etc)	
anarysis, results of investigations etc)	
H. Implications	
49. Integration with other systems	
50. Methods used to de-identify data	
51. Technical Information	
Part II. Data Structure & Storage:	
I. Facility/Location	
52. What is the address of the data	CMS Data Center
storage facility?	7500 Security Boulevard Politimore Maguland 21244 1850
	Baltimore, Maryland 21244-1850. CMS contractors and agents at various locations.
53. What type of facility is used to store	CMS Data Center
the data (3rd party data center, secured	
computer room, someone's cubicle)?	
54. What is the network interconnect for	CMS Wide Area Network
physically distributed systems?	
55. What type (private lines, VPN,	VPN
Internet) of network interconnect is	
used?	
56. What is the network protocol	TCP/IP
(TCP/IP, IPX, etc.)?	
57. What is the bandwidth of network	
interconnect (dial-up, ISDN, T1, T3, etc.)?	
58. What is the network (WAN)	
topology, including diagram if	
available?	
59. Who designed the system? Who	
operates the system?	
J. Data Storage System/ Server	
60. Who is the manufacturer (Sun, HP,	IBM
IBM, Compaq, etc.)?	
L	1

Reporting or Database System:	Minimum Data Set (MDS)
61. What is the model number (Sun	SP - RS/6000 RISC
Enterprise 10000, HP 9000, etc.)?	Sr - K5/0000 KISC
62. What is the number/speed (Mhz) of processors?	4 processors; 375 MHz
63. How much memory is available (Gb)?	Shared 4 Gb
64. What is the disk - Manufacturer, amount (Gb) & type (SAN, RAID Array, etc.)?	EMC – SAN approximately 1 terabyte for the MDS/HHA project
65. What is the operating System (e.g. Sun Solaris 2.6.1)?	IBM AIX 4.3.3 ptf set 9
K. For Each Application	
66. What commercial off-the-shelf (COTS) software (e.g. RDBMS, Query/Reporting Tools, etc.) is utilized?	
67. What custom-programmed application software is utilized? Using which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	RAVEN (Resident Assessment Validation and Entry System Software)
68. Which categories best describe this system?	
- Is there an operational Data store?	
- Is there an all-encompassing data warehouse versus focused data mart(s)?	
- Is there an Online Transaction Processing (OLTP) system utilizing a normalized relational database design?	
- Is there a data warehouse utilizing a normalized relational database design?	
- Is there a Dimensional Data Warehouse utilizing a star schema design?	
- Is there a statistical analysis system utilizing flat files, either raw data or in a format intrinsic to the system (e.g. SAS or SPSS internal system format)?	Yes
- Is there an Online Analytical Processing (OLAP) utilizing denormalized relational design such as star-schema or snowflake schema?	
- Is there an OLAP system utilizing multidimensional design (e.g. hypercubes)?	
- Are there other structured data formats, such as XML, HTML, or other?	

Reporting or Database System:	Minimum Data Set (MDS)
69. How is the data structured?	
- Is there an event occurrence (EO) table with one row per event?	
- Is there a person table with one row per person, linked to events by PERSONID?	Yes
- Is there an adverse-event (AE) taxonomy table, with one row per event type, linked one-to-many to the EO table by AEID?	
70. How much disk space is currently allocated to the system?	
71. How much disk space is available on this system?	
L. Major Data Structure	
72. What is the width of the table/file/subject data area (bytes)?	1814 bytes when converted to character as per the input data specifications
73. How many data elements (approximate) in the table / file / subject data area?	Approximately 750 data elements
74. What is the raw data record size (bytes) or structured raw data such as HTML or XML?	
75. What is the approximate number of rows in the table, or observations?	Approximately 53 million assessments
76. What time period is currently represented in the database? Projected change over the next 1-3 years?	Assessments are submitted at the approximate rate of 1.5+ million per month
77. Are there any theoretical maximums that cannot be exceeded? (e.g. # providers, # recipients, etc.)	The intent is to maintain 5 years of data

Medical Restraints

Medical Restraints	Madical Destroints (CMS)
Reporting or Database System:	Medical Restraints (CMS)
Part I. Data Acquisition:	
A. General Information	
1. Report Title	
2. Internet Location: http://	http://www.fda.gov/medwatch/ http://www.hcfa.gov/quality/11c.htm
3. Host Organization(s)	Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration
4. Primary contact information (e.g. Address, Phone)	David Eddinger, (410) 786-3429 Fax (410) 786-3517 deddinger@cms.hhs.gov Anna Gibson (410) 786-3505 agibson1@cms.hhs.gov - Division of Lab and Acute Care Services Joan Todd (FDA), (301) 594-3174
B. Overall System Features	
<ul> <li>5. System purpose/mandate <ul> <li>(any information on role in mission,</li> <li>leadership support, integration with quality</li> <li>assurance activities and history)</li> </ul> </li> <li>6. What is the geographic scope of data <ul> <li>collection (national, state, local, facility etc)?</li> </ul> </li> </ul>	This program was started as part of the FDA-led Hospital Bed Safety Work Group initiatives and to meet the Medicare requirement that institutions must report incidents of harm to patients involving the use of physical and other restraints as a condition of participation in the program. Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA sends the received reports to CMS for input into their death reporting log. According to CMS flow chart - when a report is only for CMS, FDA will forward the original report. When a report is for both FDA and CMS, FDA will send a copy of the report to CMS. In addition to forwarding reports from facilities, the FDA has agreed to run reports regarding bed rail deaths/serious injuries from FDA data. National
7. What is the unit of data entry (e.g., event, patient, product)?	Physical Restraint - related adverse event. CMS definition - "physical restraints under Interpretive Guidance in the State Operations Manual as: "any manual method or physical or mechanical device, material, or equipment attached or adjacent to the individual's body that the individual cannot remove easily which restricts freedom of movement or normal access to one's body." FDA's definition - "a device, including but not limited to a wristlet, anklet, vest, mitt, straight jacket, body/limb holder, or other type of strap that is intended for medical purposes and that limits the patient's movements to the extent necessary for treatment, examination, or protection of the patient or others"

Reporting or Database System:	Medical Restraints (CMS)
8. Who is allowed/required to input information?	The hospital must report by phone to CMS regional office (by the following business day) any death that occurs while a patient is restrained or in seclusion or where it is reasonable to assume that a patient's death is a result of such an intervention. The hospital is also required to send in a Form 3500A to FDA as backup paperwork to the original report via phone. The hospital send the form to CMS and marks the report with CMS at the top of the form as well as on the envelope and sends to the FDA address given below. LAI staff identify the CMS forms, fax them to CMS, and keep a log of all CMS reports received. Each month, FDA compares the log with the items received at CMS, then the original forms are destroyed.
9. What are the regulations/laws affecting reporting?	The Centers for Medicare and Medicaid Services issued guidelines interpreting the agency's patient rights conditions of participation for hospitals that participated in Medicare and Medicaid which was published as an interim final rule on July 2, 1999. 42 C.F.R.ß 482.13(F). FDA: 21 CFR Section 803 - gives reporting requirements for FDA
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	According to guidelines, CMS will accept anonymous reporting of this information, but the hospital has to report so they are not anonymous. Then it will be investigated (survey) by CMS staff onsite and a report is written and they have to respond within 60 days. For FDA Device Reporting - FDA will disclose to a patient requesting a report, all information in the report concerning them, except for trade secret and confidential commercial information. FDA has promulgated a regulation [21 CFR §20.63(2)] that extends protection against disclosure of voluntary reports held by medical device, pharmaceutical, and biologics manufacturers by preempting state discovery laws. User facility name will not be released to the public under The Federal Food Drug and Cosmetic Act. FDA will also not release the identity of the patient or any information that can be used to identify the patient, such as the serial number of an implanted device. Nor will it release the name of any person other than the MDR contact. The name of the reporter and facility are deleted from disclosed data. Please note that the FDA is required under the Freedom of Information and Privacy Acts (SEC 552, Title 5, USC) (PL 93-579) to delete, prior to public disclosure, any information that constitutes trade secrets, and confidential, commercial, or financial information, and any personal, medical and similar information that would constitute a clearly unwarranted invasion of personal privacy. Included in the deletion requirements are all identification of the reporters and user facilities associated with the events.

Reporting or Database System:	Medical Restraints (CMS)
11. What is the mode of data acquisition or	Submitted via paper - mail, fax, or phone
input (mail, web form, phone etc)?	Food and Drug Administration
	Center for Devices and Radiological Health
	Medical Device Reporting
	P.O. Box 3002
	Rockville, MD 20847-3002 301-827-0360
	CMS instructs users to mark the front of the envelope with 'User Report-CMS' to indicate that this should be sent to CMS. FDA contract staff have also been trained to search for words such as physical restraint, confinement etc and to pull those reports as potential CMS reports. Reporting started in Summer 2001 - not much reporting of this information so far. Hospitals are required to send in the form by close of business the next day following the death. They are to report the death by phone to their CMS Regional office during the same time period. According to instructions - if user enter to CMS do not have to submit an additional report to FDA
12. What are the methods of editing	The 3500A form allows follow-up information by checking a box on
information (e.g. correcting/add more information to records)	the form (See item 46)
13. Where is the collected data stored	Restraint seclusion death log which is maintained at CMS - Baltimore
(name of database, number of data storage	Centers for Medicare and Medicaid Services
locations)?	Survey and Certification Group
	7500 Security Blvd. S2-12-25
	Baltimore, MD 21244-1850
	Attn: Anna Gibson
14. How often is the system revised (annual, semi-annual etc)?	System originated 4/01. No steps to revise. No database involved.
15. What are the methods for system	N/A
revisions (e.g. internal review and design	
only, design under contract, with or without	
customer input)?	
16. What are the minimal interface	No minimum. Form 3500A can be filled out and mailed to FDA.
requirements for contributors (e.g. phone, internet access, certain level of PC memory)	
17. What new features are being planned	None at this time.
and/or are on wish lists?	tone at this time.
C. Potential to link to other information systems	
	No. LAI staff at FDA (under Office of Surveillance and Biometrics)
other systems (including State or other	pull out 'suspected' CMS reports based upon markings on envelope or
Federal Reporting Systems? If yes, which	keywords in the narrative of the event report - e.g. physical restraint.
data is linked?	These reports are faxed to CMS, not entered into MAUDE. It is
	possible that MAUDE will receive reports on the same event, but would typically come from Manufacturer.
	Use the following codes to classify each identified field in the
D. Fields related to contributor/participant Information:	reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF - Fixed Format (e.g. date)
19. What types of contributors are included	Hospitals reporting to meet condition of participation requirements for
	i tospitais reporting to meet condition of participation requirements for
in data acquisition? List fields that indicate	Medicare. See item 9.

Reporting or Database System:	Medical Restraints (CMS)
21. List fields related to	
contributor/participant contact information	
22. List fields related to facility contact	(N)E.1 - Reporter Name, Address and Phone # - filled out by person
information (include type of facility,	completing the form
teaching status, id information)	(P)E.2 - Health professional. If you are not a health professional, write
	NA
	Yes
	No
	(N) E.3 - Occupation
	F. User Facility (Hospital) - devices only If a restraint device was
	cause/suspected cause of death, or could be associated with the death, or
	was in place at time of death, then F should be completed.
	(P) F.1 Type of Reporter
	User facility - Check this Distributor
	(N) F.3 User facility or distributor name/address
	(N) F.4 Contact Person
	(N) F.5 Phone number
23. List fields related to distributor contact	N/A
information	
24. List fields related to manufacturer	N/A
contact information	
E Fields veloted to Provider of Core	Use the following codes to classify each identified field in the
E. Fields related to Provider of Care Information:	reporting system. P-Picklist items (list); S-Industry Standard
information;	(identify) ; N-Narrative; FF - Fixed Format (e.g. date)
25. List fields related to Provider of Care	N/A
identification	
26. List fields that identify types of care	Some of this could be in event description and some could be in lab and
providers included in system	diagnostic test information.
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the
	reporting system. P-Picklist items (list); S-Industry Standard
	(identify) ; N-Narrative; FF - Fixed Format (e.g. date)
27. List fields related to identifying patient -	(N)A.1 - Identifier - patient's initials or some other type of information
initial data entry (e.g. SSN, initials, system-	that will allow you, the reporter to readily locate the case if you are
assigned ID etc)	contacted for more information. Do not use patient's name or SSN.
28. List fields related to patient contact	N/A
information (e.g. address, zip code, county,	
region)	(N) A 2 A se at time of second OB Data of Dirth amorida the most
29. List fields related to patient demographics (e.g. age, sex, race)	(N)A.2 - Age at time of event OR Date of Birth - provide the most precise information available. For age, indicate time units (3 years+-use
demographics (e.g. age, sex, race)	years, less than 3 years old, use months; less than 1 month old, use
	days)
	(P)A.3 - Sex (if congenital anomaly, report sex of the child)
	Female
	Male
	(N)A.4 - Weight (in lbs OR kg)
	**Race could be included by reporter in medical history of patient, but
	not a separate field (see question 31)
30. What patient identification is retained	No traceable data - patient initials or other reporter assigned ID are
after verification of event information (e.g.	entered in database.
all contact information or pseudo id	
assigned, is patient ID available for follow-	
up/outcome information)	

Reporting or Database System:	Medical Restraints (CMS)
31. List fields related to pre-existing	(N) Medical Devices - D.10 - Concomitant medical products and
conditions and/or medical history of patient	therapy dates (exclude tx of event)
	List and provide therapy dates for any other medical products (drugs,
	biologics, medical devices, etc.) that a patient was using at or around
	the time of the event. DO NOT include products used to treat the event.
	(N)B.7 - Other relevant history, including preexisting medical
	conditions (e.g., allergies, race, pregnancy, smoking and alcohol use,
	hepatic/renal dysfunction, etc.) - fill out only if it is believed that this
	was associated with or a contributing factor to the death.
32. List fields that capture the clinical	Some of this could be entered in B.5 - adverse event description
condition of patient at time of event	
33. List fields related to financial/charge	N/A
information (e.g. length of stay, charge or	
payment for care, insurance coverage -	
Medicare, Medicaid, private, CHAMPUS,	
uninsured etc)	
34. List any other types of information	(P) B.2 - Outcome attributed to adverse event - <check death="" for="" td="" this<=""></check>
collected about the patient	report>
	death (date in fixed format)
	life-threatening
	hospitalization - initial or prolonged
	disability
	congenital anomaly
	required intervention to prevent permanent impairment/damage
	other (narrative description)
G. Fields related to	Use the following codes to classify each identified field in the
	nonouting gustom D Dialist itoms (list), C Industry Standard
Event/Error/Product Information:	reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial	(identify) ; N-Narrative; FF- fixed format (e.g. date)
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication-	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication-	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication-	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength)</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form</li> <li>3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency &amp; route used. Describe how the</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency &amp; route used. Describe how the product was used by the patient. For reports involving overdoses,</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency &amp; route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency &amp; route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	<ul> <li>(identify) ; N-Narrative; FF- fixed format (e.g. date)</li> <li>Physical restraint-related event as defined in Item 7 above</li> <li>If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency &amp; route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started (or best estimate) and the date stopped (or best estimate). If no dates are</li> </ul>
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency & route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started (or best estimate) and the date stopped (or best estimate). If no dates are known, an estimated duration is acceptable or if therapy was less than
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency & route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started (or best estimate) and the date stopped (or best estimate). If no dates are known, an estimated duration is acceptable or if therapy was less than one day, then duration is appropriate. (P) C.5 - Event abated after
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency & route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started (or best estimate) and the date stopped (or best estimate). If no dates are known, an estimated duration is acceptable or if therapy was less than one day, then duration is appropriate. (P) C.5 - Event abated after medication use stopped or dose reduced Yes No Doesn't apply(N) C.6 -
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency & route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started (or best estimate) and the date stopped (or best estimate). If no dates are known, an estimated duration is acceptable or if therapy was less than one day, then duration is appropriate. (P) C.5 - Event abated after medication use stopped or dose reduced Yes No Doesn't apply(N) C.6 - Lot # (if known). If known, include the lot number(s) with all product
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency & route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started (or best estimate) and the date stopped (or best estimate). If no dates are known, an estimated duration is acceptable or if therapy was less than one day, then duration is appropriate. (P) C.5 - Event abated after medication use stopped or dose reduced Yes No Doesn't apply(N) C.6 - Lot # (if known). If known, include the lot number(s) with all product problem reports, or any adverse event report with a biologic or
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency & route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started (or best estimate) and the date stopped (or best estimate). If no dates are known, an estimated duration is acceptable or if therapy was less than one day, then duration is appropriate. (P) C.5 - Event abated after medication use stopped or dose reduced Yes No Doesn't apply(N) C.6 - Lot # (if known). If known, include the lot number(s) with all product problem reports, or any adverse event report with a biologic or medication(N) C.7 - Exp. Date (if known). Include with all product
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency & route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started (or best estimate) and the date stopped (or best estimate). If no dates are known, an estimated duration is acceptable or if therapy was less than one day, then duration is appropriate. (P) C.5 - Event abated after medication use stopped or dose reduced Yes No Doesn't apply(N) C.6 - Lot # (if known). If known, include the lot number(s) with all product problem reports, or any adverse event report with a biologic or medication(N) C.7 - Exp. Date (if known). Include with all product problem reports ONLY.(P) C.8 - Event reappeared after reintroduction
<b>Event/Error/Product Information:</b> 35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc) 36. List fields associated with medication- related events (e.g. drug name, dose, dates of	(identify) ; N-Narrative; FF- fixed format (e.g. date) Physical restraint-related event as defined in Item 7 above If it is believed that a medication was associated with, or a contributing factor to, the patient's death, then completer section C on Form 3500A.A separate form should be submitted for each individual product problem report.(S - drug trade name) C.1 - Name (give labeled strength and mfr/labeler, if known) Use the trade name as marketed. If unknown use the generic name (with the manufacturer or labeler's name, if known). For quality problem reports, include the manufacturer's name and the labeled strength for both prescription and non-prescription products.(N)C.2 - Dose frequency & route used. Describe how the product was used by the patient. For reports involving overdoses, overdose amt, not prescribed amount.(N)C.3 - Therapy dates (if unknown, give duration). Provide the date administration was started (or best estimate) and the date stopped (or best estimate). If no dates are known, an estimated duration is acceptable or if therapy was less than one day, then duration is appropriate. (P) C.5 - Event abated after medication use stopped or dose reduced Yes No Doesn't apply(N) C.6 - Lot # (if known). If known, include the lot number(s) with all product problem reports, or any adverse event report with a biologic or medication(N) C.7 - Exp. Date (if known). Include with all product

Reporting or Database System:	Medical Restraints (CMS)
37. List fields associated with medical	If a restraint device was cause/suspected cause of death or could be
device-related events (e.g. brand name of	associated with the death, or was in place at the time of death, complete
device, type of device, usage, manufacturer	Section D.
name, operator of device)	(S-Brand name) D.1 - Brand Name. The trade or proprietary name of
	the suspect medical device as used in product labeling or in the catalog
	(N)D.2 - Type of Device. The generic or common name of the suspect
	medical device or a generally descriptive name (e.g., urological
	catheter, heart pacemaker, patient restraint, etc.).DO NOT use broad
	generic terms such as "catheter", "valve", "screw", etc.
	(N)D.3 - Manufacturer name and address
	(N)F.14 - Manufacturer name/address [user facility/distributor only]
	(P)D.4 - Operator of Device. Indicate the type (NOT the name) of
	person
	Health professional = physician, nurse, respiratory therapist, etc.,
	Lay user/patient = person being treated, parent/spouse/friend of the
	patient,
	Other = nurses' aide, orderly, etc.
	(FF)D.5 - Expiration date (mo/day/yy)
	D.6 - Product Identification Information
	(S)Model # Found on the device label or accompanying packaging
	(S)Catalog# Exact number as it appears in the manufacturer's catalog,
	device labeling, or packaging.
	(S)Serial # Found on the device label or accompanying packaging; it is
	assigned by the manufacturer
	(S)Lot# This number can be found on the label or packaging material.
	(S)Other# Any other applicable identification number
	(N)D.7 - Implant date (if any) For medical devices that are implanted in
	the
	patient, provide the implant date. If day is unknown, month and year are
	acceptable. If month and day are unknown, year is acceptable
	(P) D.9 - Device available for evaluation evaluation $(P) D.9 - Device available for evaluation evaluation (FE) (N) E 0. Approximate area of device$
	manufacturer on date (FF)(N) F.9 - Approximate age of device
38. List fields associated with vaccine related	N/A
events	
39. List fields associated with infection	N/A
	1N/A
related events	
40. List fields associated with any other type	N/A
of event. List type of event.	

Reporting or Database System:	Medical Restraints (CMS)
41. List fields that allow input and/or	(P) B.1 - Classification
classification of the event/harm (narratives,	Adverse Event - only check this one
problem codes, adverse event terms)	Product Problem (defects/malfunctions) - not used for death
	(N) B.5 - Describe event or problem
	Provide a complete description of event. Do not use the name of any
	person. If space is inadequate, use continuation sheet as necessary.
	Enter name and address of hospital where event occurred. Enter all of
	the statements that may apply:
	1. Death while in physical restraint
	2. Death while drug/medication restraint in use
	3. Death while in seclusion
	4. Death after restraint discontinued, could be associated with event
	while in restraint
	5. Death after seclusion discontinued, could be associated with event
	while in seclusion
	(P) F.10 - Event problem codes (see
	http://www.fda.gov/cdrh/mdr/appendixc.pdf - Note: UF is
	supposed to complete. Enter up to 3 patient and 3 device codes that
	most accurately describe the event. Place one code in each box. Patient
	codes describe what happened to the patient as a result of the event and
	device codes describe device failures or problems during the event.
42. List fields associated with when the event	t(FF) B.3 - Date of event (mo/day/yr) - Provide the actual or best
occurred	estimate of the death. If day is unknown, month and year are acceptable.
	If day and month are unknown, year is acceptable.
43. List fields associated with tracking the	(FF) B.3 - Date of event provide the actual or best estimate of death. If
-	day is unknown, month and year are acceptable. If day is unknown,
acted upon etc	month and year are acceptable, If day and month are unknown, year is
	acceptable.
	(FF) B.4 - Date of this report (initial reporter) - date when report was
	submitted
44. List fields associated with where the	(P) F.12 - Location where event occurred
event occurred	Hospital
	Home
	Nursing Home
	Outpatient treatment facility
	Outpatient diagnostic facility
	Ambulatory surgical facility
	Other
45. List fields associated with patient	(N)B.6 - Relevant tests/laboratory data (with dates)
diagnosis, care, treatment, tests, and other	If it is believed that this was associated with or a contributing factor to,
follow-up provided to patient because of the	the patient's death, complete this section: otherwise enter N/A
event	(D) $\Sigma$ 7 Thurst of respect to any of the sheat of the first in the first $11$
46. List fields related to follow-up of event	(P) F.7 Type of report - one of the choices is for follow-up with
that are not associated with a particular	number. If follow-up report, record the user facility or distributor initial
patient (medication/manufacturing/policy	report number in block F.2 and the sequence number of this follow-up in the blank after "follow up" are for first follow up enter "1" for
actions to correct/update event)	in the blank after "follow-up" e.g. for first follow-up enter "1", for
	second enter "2". Do not repeat pervious submitted information on a follow-up report. (P) F.11 Report sent to FDA? Yes, No, Date [To track]
	duplicate reports in the FDA database](P) F.13 Report sent to
	manufacturer? Yes, No, Date(FF) User facility report number in format
	NNNNNNNN-YYYY-XXXXX where N is 10-character CMS
	number of user facility; Y is year of report and X is 4 or 5 digit
	sequence number of the report. In block "FDA Use Only" type the
	letters "CMS" to alert FDA that this is a CMS reportable event.

Reporting or Database System:	Medical Restraints (CMS)
	(P) B.2 - Outcome attributed to adverse event [CHECK DEATH]
	death (date in fixed format)
	life-threatening
	hospitalization - initial or prolonged
	disability
	congenital anomaly
	required intervention to prevent permanent impairment/damage
	other (narrative description)
	(N) B.5 - Describe event or problem -
	<ul><li>(N) B.6 - Relevant tests/laboratory data, including dates</li><li>(S) F.10 - Event problem codes (refer to coding manual)</li></ul>
	patient code
	device code
48. List any other fields related to the event	(FF)F.2 - UF/Dist Report number (Filled in by UF/Dist) Enter the
or any other information collected by the	complete number of the report
reporting system (e.g. root cause analysis,	exactly as entered in the upper right corner of the front page.
investigations)	
H. Implications	
49. Integration with other systems	
50. Methods used to de-identify data	CMS uses this information to send a survey team to the hospital. The
	results of the survey are public information. Currently, the 3500A forms
	are not stored in a database and only a log is kept of their receipt so
	there is no direct public release of the form data.
51. Technical issues	
Part II. Data Structure & Storage	
Facility / Location	
I. Facility / Location	
52. What is the address of the data storage	Centers for Medicare and Medicaid Services
52. What is the address of the data storage	Survey and Certification Group
	Survey and Certification Group 7500 Security Blvd. S2-12-25
52. What is the address of the data storage	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850
52. What is the address of the data storage facility?	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson
<ul><li>52. What is the address of the data storage facility?</li><li>53. What type of facility is used to store the</li></ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from
<ul><li>52. What is the address of the data storage facility?</li><li>53. What type of facility is used to store the</li></ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a certain time period (45 days?).
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?</li> <li>54. What is the network interconnect for</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a certain time period (45 days?).
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?</li> <li>54. What is the network interconnect for physically distributed systems?</li> <li>55. What type (private lines, VPN, Internet)</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a certain time period (45 days?).
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?</li> <li>54. What is the network interconnect for physically distributed systems?</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a certain time period (45 days?). N/A
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?</li> <li>54. What is the network interconnect for physically distributed systems?</li> <li>55. What type (private lines, VPN, Internet) of network interconnect is used?</li> <li>56. What is the network protocol (TCP/IP,</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a certain time period (45 days?). N/A
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?</li> <li>54. What is the network interconnect for physically distributed systems?</li> <li>55. What type (private lines, VPN, Internet) of network interconnect is used?</li> <li>56. What is the network protocol (TCP/IP, IPX, etc.)?</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a certain time period (45 days?). N/A
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?</li> <li>54. What is the network interconnect for physically distributed systems?</li> <li>55. What type (private lines, VPN, Internet) of network interconnect is used?</li> <li>56. What is the network protocol (TCP/IP, IPX, etc.)?</li> <li>57. What is the bandwidth of network</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a certain time period (45 days?). N/A
<ul> <li>52. What is the address of the data storage facility?</li> <li>53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?</li> <li>54. What is the network interconnect for physically distributed systems?</li> <li>55. What type (private lines, VPN, Internet) of network interconnect is used?</li> <li>56. What is the network protocol (TCP/IP, IPX, etc.)?</li> </ul>	Survey and Certification Group 7500 Security Blvd. S2-12-25 Baltimore, MD 21244-1850 Attn: Anna Gibson Rather than CMS creating a new event reporting form and process, the FDA offered to accept physical restraint event reports from hospitals/health care facilities via the FDA Mandatory MedWatch Form 3500a. The FDA faxes the received reports to Anna Gibson at CMS for input into a death reporting log. There is no database for this information at CMS. Each time one of these is reported, CMS sends out a field person (from the regional office) to investigate and make recommendations. Facilities must respond to recommendations within a certain time period (45 days?). N/A N/A

Reporting or Database System:	Medical Restraints (CMS)
	N/A
including diagram if available?	
59. Who designed the system? Who operates	
the system?	
J. Data Storage System / Server	
60. Who is the manufacturer (Sun, HP, IBM,	N/A
Compaq, etc.)?	
61. What is the model Number (Sun	
Enterprise 10000, HP 9000, etc.)	
62. What is the number/speed (Mhz) of	
processors?	
63. How much memory is available (Gb)?	
64. What is the disk - manufacturer, amount $(Ch)$ is true (SAN, BAID, Amount 2)	
(Gb) & type (SAN, RAID Array, etc.)?	
65. What is the Operating System (e.g. Sun	
Solaris 2.6.1)?	
K. For Each Application	
66. What commercial off-the-shelf (COTS)	N/A
software (e.g. RDBMS, Query/Reporting	
Tools, etc.) is utilized?	
67. What custom-programmed application	
software is utilized? Using which language(s)	
(e.g. C,C++, PERL, ASP, VB/COM)?	
68. Which categories best describe this	Paper forms
system?	
- Is there an Operational Data Store?	
- Is there an all-encompassing data	
warehouse versus focused data mart(s)?	
- Is there an Online Transaction Processing	
(OLTP) system utilizing a normalized	
relational database design?	
- Is there a data warehouse utilizing a	
normalized relational database design?	
- Is there a dimensional data warehouse	
utilizing a star schema design?	
- Is there a statistical analysis system	
utilizing flat files, either raw data or in a	
format intrinsic to the system (e.g. SAS or	
SPSS internal system format)?	
- Is there an Online Analytical Processing	
(OLAP) utilizing denormalized relational	
design such as star-schema or snowflake	
schema?	
- Is there an OLAP system utilizing	
multidimensional design (e.g. hypercubes)?	
- Are there other structured data formats,	
such as XML, HTML, or other?	
	L

Reporting or Database System:	Medical Restraints (CMS)
69. How is the data structured?	See FDA Form 3500A
	http://www.fda.gov/medwatch/safety/3500a.pdf
- Is there an event occurrence (EO) table	
with one row per event?	
- Is there a person table with one row per person, linked to events by PERSONID?	
- Is there an adverse-event (AE) taxonomy	
table, with one row per event type, linked	
one-to-many to the EO table by AEID?	
70. How much disk space is currently allocated to the system?	N/A
71. How much disk space is available on this system?	N/A
L. For Each Major Data Structure	
72. What is the width of the table / file /	N/A
subject data area (bytes)?	
73. How many data elements (approximate) in the table / file / subject data area?	N/A
74. What is the raw data record size (bytes)	N/A
or structured raw data such as HTML or XML?	
in the table, or observations?	N/A
76. What time period is currently represented	Started 4/2001.
in the data base? Projected change over the next 1-3 years?	
77. Are there any theoretical maximums that	
cannot be exceeded? (e.g. # providers, #	
recipients, etc.)	
	restraint-related harm to patients are relatively rare – with approximately
	e data do not lend themselves to statistical analysis, they are used to
initiate case review and investigations.	

Reporting or Database System:	FDA-CDRH: MedSun
Part I. Data Acquisition:	
A. General Information	
1. Report Title	Medical Product Surveillance Network
2. Internet Location: http://	http://www.fda.gov/cdrh/postsurv/MedSun.html - Discusses design of system https://www.MedSun.net for information https://www.MedSun.fda.gov for login (must have valid id and pw)
3. Host Organization(s)	Contractor: CODA - research organization (http://www.codares.com) that will be responsible for recruiting, training, initial follow-up on reports, and project analysis. U of MD is designing the web data entry system and the database.
4. Primary contact information (e.g. Address, Phone)	Primary Contact - Joyce Siwarski - 301-594-4550 x166; JCS@CDRH.FDA.GOV Coordinating development and implementation of MedSun - Marilyn Flack - 301-594-3661; MNF@CDRH.FDA.GOV
<b>B. Overall System Features</b>	
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	Section 213 of the FDA Modernization Act of 1997 required the FDA to explore options for designing a national surveillance system based on a representative sample of medical device user facilities. This new reporting system will eventually replace the mandatory reporting by all user facilities of medical device related deaths and serious injuries. The Medical Device Surveillance Network (MeDSuN) is the project that CDRH has sponsored to meet this requirement. MeDSuN is designed to collect data from user facilities (hospitals, nursing homes and other health care facilities required to report under the Safe Medical Devices Act (SMDA)). Initially, CDRH will invite 50 acute care hospitals to participate. Eventually, several hundred facilities will participate and other types of health care facilities may be included. In order to participate, a hospital must be willing to: *Designate at least 2 MedSuN representatives - one from their QI or Risk Management team; one from their biomedical or clinical engineering team; *Agree to participate in the pilot study for 12 months; *Have the representatives participate in a 4 hour study orientation session; *Agree to report medical device adverse events (as required by 21 CFR 803) and events involving problems in the use or operation of a medical device where the potential for serious injury or illness exists. Participates. They will also receive special feedback from CDRH via newsletters and will be able to request special analyses of the MeDSun database once enough data has been received. The goal is to improve the protection of the health and safety of patients, users and others by: reducing the occurrence of medical device related events, serving as an

Reporting or Database System:	FDA-CDRH: MedSun
	advanced warning system from the clinical community, improving the frequency and quality of reporting by user facilities, developing feedback and benchmarking information based upon reported incidents and promoting the use of analyzed, aggregated AE reports to improve medical facilities' internal quality systems. It will also allow the FDA to apply the knowledge from reported data to the device approval process and to prevention and control problems.
6. What is the geographic scope of data collection (national, state, local, facility etc)?	The data is collected from medical facilities initially invited by CDRH, but eventually based upon their willingness to meet certain participation criteria (see criteria in item 5).
7. What is the unit of data entry (e.g., event, patient, product)?	The unit of data entry is a medical device adverse event that involves problems in the use or operation of a medical device (including malfunctions), which result in serious illness, injury or death. In addition, the participants agree to report events involving problems in which the potential for serious injury, illness or death exists.
8. Who is allowed/required to input information?	Medical facilities selected and agreeing to participate in the MeDSuN pilot project.
9. What are the regulations/laws affecting reporting?	The Safe Medical Device Act of 1991 requires that user facilities report incidents that reasonably suggest that a medical device has caused or contributed to the death of a patient or to serious injury or illness of a patient. Section 519 of the Food and Drug Administration Modernization act of 1997 requires the FDA to find innovative ways to improve surveillance reporting - MedSun is a response to that requirement. 21 CFR Sec 803 Subpart A-F establishes the reporting requirements for medical device reporting. Says that user facilities, importers and manufacturers must report deaths and serious injuries and that distributors (defined in 803.3) must maintain records of incidents. Sec 803.21 discusses the Medwatch mandatory reporting coding manual with codes for hundreds of adverse events for use with Form 3500a.

Reporting or Database System:	FDA-CDRH: MedSun
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	A major focus of the system is to create a blameless and voluntary system with a third party intervening in the process so that the facilities are not reporting directly to the regulators, similar to the process used by ASRS (NASA). For voluntary reporting - CODA (contractor) will de-identify data after a brief period of time, if requested to do so by reporter (applied to National Archives for 30 days-awaiting approval) to allow for follow-up when CODA staff have questions about individual reports. Data will be categorized by type and size of facility. For mandatory reports (deaths and serious injuries) reports will not be deidentified. Completely anonymous reports can only be made by phone. In addition, the FDA is required under the Freedom of Information and Privacy Acts (SEC 552, Title 5, USC) (PL 93- 579) to delete, prior to public disclosure, any information that constitutes trade secrets, and confidential, commercial, or financial information; and any personal, medical and similar information that would constitute a clearly unwarranted invasion of personal privacy. Included in the deletion requirements are all identification of the reporters and user facilities associated with the events. All CODA employees and consultants are required to sign an "Assurance of Confidentiality" where they pledge to keep all information about reporters confidential.
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	All data is input via web screens that have been developed by Univ. of MD. Initial access is available via an FDA assigned user id and password that is given to the selected medical facilities. Each user must change the initial entry password to one that is known only to them. For any reports that are either called in or mailed in, CODA staff will manually enter into the system.
12. What are the methods of editing information (e.g. correcting/add more information to records)	When the hospital representative enters a report, they can "hold" the report for later edits or they can "submit" the report to FDA. Reports that are held are still in the MedSun database. Deletions of the report can only be made by special request. Every 6 months, those reports that are in 'hold' mode, but have not been submitted, will be purged. Once the hospital rep clicks the submit button, only authorized users from CODA will be able to see the report. If the user needs to make changes, they will have to contact CODA. Follow up reports may also be filed and indicated on the data entry for the report. CODA staff will view the electronic reports and screen them for completeness. CODA will contact the facility if more information is needed, and CODA can edit the report. Once completed, the report is 'released' to FDA nurse analysts who then have access to the completed reports. If the report is mandatory under SMDA and manufacturer is known, then the report will be sent to the manufacturer with the identity of the reporting facility. If the report is not mandatory, then the hospital indicates this during data entry. See items 20 and 50.

Reporting or Database System:	FDA-CDRH: MedSun
13. Where is the collected data stored (name of database, number of data storage locations)?	User facilities participating in MedSun will access this database via the Internet webserver and database within the FDA firewall (clinic webserver sits in a service segment at FDA and the database and internal web server sit within the FDA firewall. There is also a designated "MedSun room" at CODA for data processing. Information about reports (reports, notes, etc.) that identifies the facilities or persons that submitted the reports will be kept in the locked MedSun project office.
14. How often is the system revised (annual, semi- annual etc)?	The user guide and screens were just created in 2/02. System revisions are expected to be made on an ongoing basis based upon feedback from users, and FDA analysts and consultants.
	Informal meetings between project coordinator and system designers. Users are encouraged to provide feedback. A MedSun Representatives' conference is scheduled to provide a forum for participants and FDA to discuss ways they have used the project and data in their patient safety efforts as well as suggestions for improvement.
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	Reports can be made via internet, fax, mail, email, or phone. If by computer, then user needs internet connection and browser such as Internet Explorer v5.0 or higher or Netscape v6.0 or higher.
17. What new features are being planned and/or are on wish lists?	High-level search-engine tool; additional questions for In-vitro Diagnostic Devices; improved FDA interface; automatic didaction
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	CDRH is planning to merge data from the MedSun system into the MAUDE database, but not in initial project phases.
D. Fleids related to contributor/participant	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF - Fixed Format (e.g. date)
acquisition? List fields that indicate who/what facility submitted the data.	Only authorized users who have signed the FDA Rules of Behavior are allowed to enter MedSun reports online. Each will have a unique id and password (known only to the user) and a facility ID kept by CODA. (N) User Facility name (corresponds to F.3 on paper MedWatch form) (N) Name of initial reporter (E.1) (N) Contact Name (F.4) (N) Occupation of Contact (E3)

Reporting or Database System:	FDA-CDRH: MedSun
20. Is participation mandatory or voluntary?	This system will use a combination of mandatory and voluntary reporting. Under the SMDA, facilities are obliged to report adverse events to FDA and to the manufacturer. Facilities will be able to satisfy these requirements through MedSun reporting. They will also encourage the voluntary reporting of close calls and near misses by utilizing incentives and reducing barriers. One field in the input discusses voluntary reporting: (P) If you did not mark death or serious injury above, this is a voluntary report. Please indicate below if we may release the contact person's identification and your hospital as the reporting facility for this incident when we release this report to the manufacturer. (New Field) Do not release this report to manufacturer; Release this report to the manufacturer, including information that identifies the hospital and contact person
21. List fields related to contributor/participant contact information	<ul><li>(N) Name of initial reporter - E.1</li><li>(N) Address of initial reporter - E.1</li></ul>
22. List fields related to facility contact information(include type of facility, teaching status, id information)	(N) User facility address - F.3 from Form 3500A (N) Contact name - F.4 (N) Contact phone# - F.5(N) Contact fax# - New(N) Contact's email - New There is an internal table in the database that stores type of facility, size, etc.
23. List fields related to distributor contact information	N/A
24. List fields related to manufacturer contact information	<ul><li>(N) Device manufacturer's name - F.14</li><li>(N) Device manufacturer's address - F.14</li><li>City, State, Zip</li></ul>
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF - Fixed Format (e.g. date)
25. List fields related to Provider of Care identification	If answer Yes to (P) "Was someone directly operating the device?" Y,N, then go to (P) "Who was operating the device?" D.4 but more options specified doctor, nurse, allied health provider, family member/visitor, patient, other- DO NOT want person identified personally If select Other from "Who was operating the device?", then go to If you selected other, please describe the type of person who was operating the device (not the person's name)
26. List fields that identify types of care providers included in system	Some of this could be in event description and some could be in lab and diagnostic test information.
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF - Fixed Format (e.g. date)
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	<ul> <li>(N) "Patient Identifier (use something that will help you remember who the patient is, but not the patient's name or SSN):"</li> <li>A.1</li> <li>(N) Device Serial # D.6 (this may identify patient when the device is an implanted device)</li> </ul>
28. List fields related to patient contact information (e.g. address, zip code, county, region)	N/A

Reporting or Database System:	FDA-CDRH: MedSun
29. List fields related to patient demographics (e.g. age, sex, race)	<ul> <li>(FF) Patient's Age - days, weeks, months, years, date of birth A.2</li> <li>(P) Patient's Sex - Male, Female A.3</li> <li>(FF) Patient's Weight - ounces, pounds, kilograms, grams A.4</li> <li>(P) Patient's Ethnic Background(optional) - American Indian, Black or African American, Native Hawaiian or other Pacific Islander, Asian, Hispanic or Latino, White, Unknown (Could have been in B.7 before)</li> </ul>
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)	Product Serial# of an implanted device and patient identifier (which is <b>not</b> the patient name or SS#)
31. List fields related to pre-existing conditions and/or medical history of patient	(P) Did the patient have any of the following preexisting characteristics that may have contributed to the event (check all that apply): B.7, but more choicesAllergies, Alcohol/drug use, COPD, Coronary heart disease, Diabetes, Hepatic/renal dysfunction, Hypertension, Immuno-compromised, Morbidly obese, Pneumonia, Pregnancy, Premature infant, Smoking Status, post total hysterectomy or salpingioherectomy, Stroke, Surgery, Relevant accident (e.g. Hit head), Other", text box for relevant patient allergies, text box for "other characteristics or medical injuries," and for "other pertinent patient information"(N) Please list the relevant patient allergies. e.g. latex allergy; a particular medication allergy; allergy to a particular material or biomaterial, etc(N) Please describe the relevant accident preceding the event:(N) Other ; Also, (N) Describe event or problem (B5)
32. List fields that capture the clinical condition of	(N)Other characteristics or medical conditions
patient at time of event 33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)	Also see 31 above and 36 below. N/A
34. List any other types of information collected about the patient	<ul> <li>(N) Other pertinent patient information</li> <li>(P) Did this event cause (Check all that apply): H.1 with new options</li> <li>Death (date//), Serious injury, Potential harm to a health care provider [indicates voluntary report], Minor injury to the patient or health care provider [Indicates voluntary report], Potential for patient harm [Indicates voluntary report]; If you checked serious injury, then go to the following 3 questions.</li> <li>(P) Was intervention required to prevent permanent impairment or damage? Yes No</li> <li>(P) Outcomes attributed to serious injury (check all that apply): Life threatening, Hospitalization, initial or prolonged, Congenital anomaly, Disability, Other; If you checked "Other," above, please describe the outcome. B.2</li> </ul>
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF - Fixed Format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	Adverse medical events associated with medical devices as well as close calls and near misses - can include concomitantly used drugs that may have interacted with the device.

Reporting or Database System:	FDA-CDRH: MedSun
36. List fields associated with medication-related	(P) Were there other therapies being used on the patient at the
events (e.g. drug name, dose, dates of therapy)	time of the event that may have caused or contributed to the event
	(check all that apply)? D.10, but more specific
	Cardiac Drugs, Chemo Therapy (date:), Dialysis
	(date:), Hormonal Replacement Therapy, Immuno
	Therapy, Long-Term Antiobiotics, Prenatal medication, Other,
	No other therapies/Not applicable
	If the user selects other above, then go to
	(N) List other therapies used on the patient at the time of the
37. List fields associated with medical device-	event that may have caused or contributed to the event (N) Device brand name D.6
related events (e.g. brand name of device, type of	(N) Type of device D.6
device, usage, manufacturer name, operator of	(N) Approx. age of device D.6
device)	(N) Device Numbers D.6
device)	(N) Device serial #s D.6
	(N) Device model #s D.6
	(N) Device lot # D.6
	(N) Device catalog # D.6
	(N) Other device # D.6
	(N) Expiration date D.5
	(P) Has facility discontinued use of device due to event? Y N
	(FF) If the device was implanted, give implant date (mo/day/year)
	D.7
	(FF) If the device was explanted, give explant date (mo/day/year)
	D.8
	(P) Is device avail. for evaluation? Y N D.9
	(P) Check all of the factors you think may have contributed to the
	event: [New, Optional] - Inadequate equipment, Inadequate
	systems, Other, Poor device design, Poor device maintenance,
	Training, Unfamiliar environment, Unfamiliarity with the device,
	Not Applicable
	(N) What other factors do you think may have contributed to the
	event [New, Optional]?
	(P) Check all the factors you think could prevent future
	occurrences of this type of event: [New, Optional] Better
	equipment, Appropriate training, Better device maintenance, New
	or improved devices, Other, Not applicable
	If answered above, then go to
	(N) What other equipment do you think would prevent future
	occurrences of the event? [new, Optional]
	(P) Was there a problem with the device (such as a defect,
	malfunction, break, etc.)? H.1 Yes No
	If yes, then go to
	(P) What problem did the user have (check all that apply): New
	Device failed (e.g. broke, couldn't get it to work or stopped
	working), Device malfunction, that is, the device did not do what
	it was supposed to do, Device was hard to use, Other;
	(N) Were there other devices being used on the patient at the time
	of the event that may have caused or contributed to the event?
	D.10
38. List fields associated with vaccine related	Only if listed as other therapies used on the patient at the time of
events	the event that may have caused or contributed to the event
39. List fields associated with infection related	(N) Describe the event or problem B.5
59. List fields associated with infection related	(11) Deserve une event of problem D.5

Reporting or Database System:	FDA-CDRH: MedSun
40. List fields associated with any other type of event. List type of event.	N/A
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	<ul> <li>(N) Describe the event or problem. B.5</li> <li>(P) Check all of the factors you think may have contributed to the event [New, Optional] inadequate equipment, inadequate systems, other, poor device design, poor device maintenance, training, unfamiliar environment, unfamiliarity with the device, not applicable If answer above, then go to</li> <li>(N) What other factors do you think may have contributed to the event? [New, Optional] Also, there will be problem codes that CODA will assign - patient problem codes (MedSRA codes), procode (type of device) and device problem codes (in development)</li> </ul>
42. List fields associated with when the event occurred	<ul><li>(P) Time of event (New, Optional):</li><li>Morning, afternoon, evening, night, not known</li><li>(FF) When did this event happen? (date) B.3</li></ul>
43. List fields associated with tracking the time between the event, when reported, when acted upon etc	(FF) When did this event happen? (date) B.3(P) How many days ago did you first become aware of the event? (New)Less than or equal to 10 days, More than 10 days ago(FF) Date of this report (mo/day/year) B.4(P) This report is: F.7Initial, Follow-up, Initial Report #
44. List fields associated with where the event occurred	<ul> <li>(N) User Facility name F.3</li> <li>(P) Where did this event occur? F.12</li> <li>Hospital (where in hosp?), home, nursing home, home, outpatient treatment facility, outpatient diagnostic facility, ambulatory surgical facility, other)</li> </ul>
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event	<ul><li>(N) Describe the event or problem. B.5</li><li>(N) Please enter all relevant tests/laboratory data. B.6</li><li>(N) Other pertinent patient information (New)</li></ul>
46. List fields related to follow-up of event that d not involve patient intervention (medication/manufacturing/policy actions to correct/update event) cont'd	<ul> <li>o (P) Check all the factors you think could prevent future occurrences of this type of event: [New, Optional] Better equipment, Appropriate training, Better device maintenance, New or improved devices, Other, Not applicable</li> <li>If answered above, then go to</li> <li>(N) What other equipment do you think would prevent future occurrences of the event? [New, Optional]</li> <li>(N) What other factors do you think would prevent future occurrences of the event? [New, Optional]</li> <li>(P) This report is: F.7</li> <li>Initial, Follow-up, Initial Report #</li> </ul>

Reporting or Database System:	FDA-CDRH: MedSun
<ul> <li>47. List fields related to the outcome of event (patient)</li> <li>48. List any other fields related to the event or any other information collected by the reporting system (e.g. root cause analysis, investigations</li> </ul>	<ul> <li>(P) Did this event cause (Check all that apply): H.1 with new options</li> <li>Death (date//), Serious injury, Potential harm to a health care provider [indicates voluntary report], Minor injury to the patient or health care provider [Indicates voluntary report], Potential for patient harm [Indicates voluntary report]; If you checked serious injury, then go to the following 3 questions.</li> <li>(P) Was intervention required to prevent permanent impairment or damage? Yes No</li> <li>(P) Outcomes attributed to serious injury (check all that apply): Life threatening, Hospitalization, initial or prolonged, Congenital anomaly, Disability, Other; If you checked "Other," above, please describe the outcome. B.2</li> <li>(N) Describe event or problem B.5</li> <li>(N) Please enter all relevant tests/laboratory data B.6</li> </ul>
etc) H. Implications	
49. Integration with other systems	Is expected to link to MAUDE - no date set probably not for at
50. Methods used to de-identify data	least 3 years Currently, the information is manually redacted according to FOIA regulations before it is released to the public. All information that has the potential to identify a particular patient is removed. The goal is to create an automated solution to the redaction of data such as is currently available under MAUDE.(P) If you did not mark death or serious injury above, this is a voluntary report. Please indicate below if we may release the contact person's identification and your hospital as the reporting facility for this incident when we release this report to the manufacturer; Release this report to the manufacturer but do not include information that identifies the hospitaland contact person; Release this report to the manufacturer, including information that identifies the hospital and contact person.
51. Technical issues - User interface	
Part II. Data Structure & Storage	
I. Facility / Location	
52. What is the address of the data storage facility	
<ul><li>53. What type of facility is used to store data (3rd party data center, secured computer room, someone's cubicle)?</li><li>54.Is there a network interconnect for physically distributed systems?</li></ul>	secured computer room Internet
55. What type (private lines, VPN, Internet) of network interconnect is used?	Internet
56. What is the network protocol (TCP/IP, IPX, etc.)?	TCP/IP

Reporting or Database System:	FDA-CDRH: MedSun
57. What is the bandwidth of network interconnect (dial-up, ISDN, T1, T3, etc.)?	100 Mbps
58. What is the network (WAN) topology, including diagram if available?	Fast Ethernet (100baseT)
59. Who designed the system? Who operates the system?	
J. For Each Data Storage System / Server	Quantity = 2 Web Servers, 1 internal, 1 external
60.Who is the manufacturer (Sun, HP, IBM, Compaq, etc.)?	(1) Compaq (2) Compaq
61. What is the model number (Sun Enterprise 10000, HP 9000, etc.)?	(1) ProLiant DL830 (2) ProLiant DL830
62.What is the number / speed (Mhz) of processors?	(1) 2 - PIII 1Ghz (2) 2 - PIII 1Ghz
63. How much memory is available (Gb)?	(1) 896 Mb SDRAM (2) 1.1Gb SDRAM
64. What is the Disk - Manufacturer, amount (Gb) & type (SAN, RAID Array, etc.)?	(1) 18Gb (2) 54Gb
65. What is the Operating System (e.g. Sun Solaris 2.6.1) used?	(1) & (2) Windows 2000 Server Release: V5.0 (Build 2195 Service Pack 2)
K. For Each Application	
66. What commercial off-the-shelf (COTS) software (e.g. RDBMS, Query/Reporting Tools, etc.) is utilized?	MS IIS 5.0, SQL Server Enterprise
67. What custom-programmed application software is utilized? Using which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	ASP, JavaScript, VBScript
68. Which categories best describe this system?	
- Operational Data Store	No
- Is there an all-encompassing data warehouse versus focused data mart(s)?	
- Is there an Online Transaction Processing (OLTP) system utilizing a normalized relational database design?	Yes
- Is there a data warehouse utilizing a normalized relational database design?	No
- Is there a Dimensional Data Warehouse utilizing a star schema design?	No
- Is there a Statistical analysis system utilizing flat files, either raw data or in a format intrinsic to the system (e.g. SAS or SPSS internal system format)?	

Reporting or Database System:	FDA-CDRH: MedSun
- Is there an Online Analytical Processing (OLAP) utilizing denormalized relational design such as star-schema or snowflake schema?	No
- Is there an OLAP system utilizing multidimensional design (e.g. hypercubes)?	No
- Are there other structured data formats, such as XML, HTML, or other?	No
69. How is the data structured?	In table of file form.
- Is there an event occurrence (EO) table with one row per event?	
- Is there a person table with one row per person, linked to events by PERSONID?	
- Is there an adverse-event (AE) taxonomy table, with one row per event type, linked one-to-many to the EO table by AEID?	
70. How much disk space is currently allocated to the system?	3.7Gb
71. How much disk space is available on this system?	21 Gb
L. For Each Major Data Structure	
72. What is the width of the table / file / subject data area (bytes)?	
73. How many data elements (approximate) in the table / file / subject data area?	Approximately 5-20 data elements in the table.
74. What is the raw data record size (bytes) or structured raw data such as HTML or XML?	N/A
75. What is the approximate number of rows in the table, or observations?	Approximately 0-6,000 rows or observations.
76. What time period is currently represented in the database? Projected change over the next 1-3 years?	
77. Are there any theoretical maximums that cannot be exceeded? (e.g. # providers, # recipients, etc.)	
Part III. Data Use & Analysis:	
78. System Contact	Marilyn Flack
79. Contact Address	
80. Contact Phone	301-594-3661
81. Contact Email	MNF@CDRH.FDA.GOV
82. Hardware Platform	
83. Operating System	
84. Who is the developer?	University of Maryland

Reporting or Database System:	FDA-CDRH: MedSun
85. Who is responsible for the system architecture?	
	CDRH has just received the first reports submitted by User Facilities. MedSuN project team will be primary users during pilot phase. FDA staff currently using MAUDE/ASR may also use or contribute to the assessment of MedSun data (i.e., Division of Surveillance Systems, Division of Post-Market Surveillance
87. What is the frequency of reports?	n/a, reporting/query function in development
88. Who generates the reports?	n/a, reporting/query function in development
89. What is the method of access?	n/a, reporting/query function in development
90. What is the turnaround time?	Will be real time
91. What is the level of automation?	n/a, reporting/query function in development
	Can print report reflecting data entered regarding an individual event. Currently, no other "canned" reports. University of Maryland team currently developing structured query function containing multiple selection criteria, search/sort functions etc Pilot participants will receive MedSuN newletters, CDRH alerts/advisories/recall notices, annual summary report and will be able to request special analyses of MeDSuN and MAUDE databases. As with MAUDE, FDA will make FOI releasable data publicly available.
93. What is the unit of observation?	Adverse event associated with use of operation of a medical device which results in serious illness, injury or death (mandatory reporting) or in which the potential for serious injury, illness or death existed (voluntary).
94. What are the available data fields?	The MedSuN system will collect the data elements on FDA Form 3500A that are pertinent to user facilities, with a few additional data elements included (e.g., time of day, who was operating device). See Data Input template for more detail.
95. Is there a controlled vocabulary?	Yes
96. Exportability	n/a, reporting/query function in development
97. User Profile	User Facilities participating in pilot, CDRH staff
98. How are the reports used?	Initially, reports/queries will be used primarily to assess pilot program
	n/a, reporting/query function in development. Individual event report sent by FDA to manufacturer (mandatory). For voluntary reports, User Facility has option to have report forwarded to manufacturer.
	To improve the protection of the health and safety of patients, users and others by: reducing the occurrence of medical device related events, serving as an advanced warning system from the clinical community, improving the frequency and quality of reporting by user facilities, developing feedback and benchmarking information based upon reported incidents and promoting the use of analyzed, aggregated AE reports to improve medical facilities' internal quality systems. It will also allow the FDA to apply the knowledge from reported data to the device approval process and to prevention and control problems. A key potential benefit of obtaining a representative sample of User Facilities is to facilitate estimation of national incidence of adverse events.

Reporting or Database System:	FDA-CDRH: MedSun
101. Integration/Linkable to	Manufacturers are still required to report qualifying adverse
Detail/Integration/Overlap	events through Form 3500a to MAUDE. Participating User
	Facilities would report same event to MedSuN but not MAUDE.
	Non-participating User Facilities currently required to report
	adverse events to MAUDE. Post MedSuN implementation,
	intention is to remove mandatory reporting requirement from
	non-participating facilities. CDRH is planning to merge data
	from the MedSun system into the MAUDE database at some
	later point. Note that MedSuN developed device codes based on
	ECRI codes and patient codes are based on MedDRA. These
	codes are different from corresponding MAUDE codes. Product
	codes are the same as MAUDE ("procodes").
102. HIPAA Compliant	Yes, no patient identifying detail captured in MedSuN.
Note:	No "denominator" information (I.e., number of a specific device
	in use and extent of use) currently tracked in MedSuN

MedWatch	
Reporting or Database System:	FDA-CDER: MedWatch
Part I. Data Acquisition:	
A. General Information	-
1. Report Title	MedWatch - FDA direct reporting program
2. Internet Location: http://	http://www.fda.gov/medwatch/
3. Host Organization(s)	Food and Drug Administration (FDA) Center for Devices and
	Radiologic Health FDA-CDER
	FDA Center for Biologics Evaluation and Research FDA-CBER
	FDA Center for Food Safety and Applied Nutrition FDA-CFSAN
4. Primary contact information (e.g.	Primary Contact: Norman Marks: 301-827-7246
Address, Phone)	MARKSN@CDER.FDA.GOV
<b>B. Overall System Features</b>	
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	<ul> <li>FDA has the responsibility for assuring the safety and efficacy of all regulated marketed medical products, including: drugs, biologics, medical and radiation-emitting devices, and special nutritional products (e.g. medical foods, dietary supplements, and infant formulas.</li> <li>FDA Safety Information and Adverse Event Reporting Program has four goals: <ol> <li>To increase awareness of drug and device-induced disease.</li> <li>To clarify what should (and should not) be reported to the agency.</li> <li>To make it easier to report by operating a single system for health professionals to report adverse events and product problems to the agency.</li> <li>To provide regular feedback to the health care community about safety issues involving medical products.</li> </ol> </li> <li>MedWatch is an FDA post market surveillance program for reporting adverse events associated with all medical products).</li> <li>MedWatch is an FDA post market surveillance program for reporting serious adverse events (death, life-threatening, hospitalization, disability, congenital anomaly, required intervention to prevent permanent damage) associated with all medical products (drugs, medical devices, biologics, and special nutritional products). It is to react to use a superior of a special nutritional products.</li> </ul>
	targeted toward reporting of events by individual health professionals and consumers. Consumers and Health Care professionals fill out voluntary input form 3500. The 3500 form gets triaged by AERS system Central Triage Unit and sent to either MAUDE (medical devices), AERS (drug/biologic) or SNAEMS (special nutrition). MedWatch acts as the interface between the submitters and CTU. E- mail confirmation sent to reporter. Web-based back-end module
6. What is the geographic scope of data	enables the MedWatch Office to view, print, and distribute (manually) the voluntary report to the respective FDA Center/Office. All analysis and data use by FDA is done from AERS, MAUDE or SNAEMS databases. No regular reports are produced from the MedWatch software.
collection (national, state, local, facility etc)?	
7. What is the unit of data entry	Event - drug, device, special nutritional products (dietary supplements,
(e.g., event, patient, product)?	medical foods/infant formulas), blood products - The 3500 form gets triaged by AERS system Central Triage Unit. Food reports go to Center

Reporting or Database System:	FDA-CDER: MedWatch
	for Food Safety. Device reports go to MAUDE. Drugs and biologics
	reports go to AERS
8. Who is allowed/required to input information?	Voluntary input Form 3500 - Consumers and Health Care professionals fill out voluntary input form 3500. Consumers are encouraged to consult with a health care provider prior to submitting. Healthcare professionals are encouraged to report serious adverse events and product problems with all medical products (i.e. drugs, biologics, medical devices, and special nutritional products) See http://www.fda.gov/medwatch/report/consumer/consumer.htm and
	http://www.fda.gov/medwatch/report/hcp.htm for details on voluntary reporting
9. What are the regulations/laws affecting reporting?	No regulatory mention of voluntary reporting
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	<ul> <li>(P)E.5 (Form 3500) - Option not to disclose identity to manufacturer to avoid FDA providing reporter name, address and phone number to manufacturer of a suspect device.</li> <li>Any report in FDA's control, including an FDA record of a telephone report, is subject to public disclosure in response to a Freedom of Information (FOI) request. However, before public disclosure, FDA will delete from the report:</li> <li>*any information that constitutes trade secret, commercial confidential or financial information;</li> <li>*any personal, medical, and similar information (including the serial number of implanted devices) which would constitute *an unwarranted invasion of personal privacy; and *any names and other identifying information of a third party voluntarily submitting an MDR report. This includes</li> <li>*physicians, health care professionals, or other hospital employees unless they are the designated MDR contact person.</li> <li>Please note that the FDA is required under the Freedom of Information and Privacy Acts (SEC 552, Title 5, USC) (PL 93-579) to delete, prior to public disclosure, any information that constitutes trade secrets, and confidential, commercial, or financial information; and any personal, medical and similar information that would constitute a clearly unwarranted invasion of personal privacy. Included in the deletion requirements are all identification of the reporters and user facilities</li> </ul>
	associated with the events.
input (mail, web form, phone etc)?	Reports can be sent to MedWatch (18,000 per year) by: Mail: use postage-paid MedWatch form to CTU Phone: 1-800-FDA-1088 to MedWatch RX Fax: 1-800-FDA-0178 to MedWatch Rx On-line via the MedWatch homepage: https://www.accessdata.fda.gov/scripts/medwatch/MedWatch Rx Couriered to CTU
12. What are the methods of editing information (e.g. correcting/add more information to records)	Informal: can send an attachment, phone or fax update with reference that was reported again. Can search by reporter name and patient identifier to track it down. No field on Form 3500 that indicates follow- up.
13. Where is the collected data stored (name of database, number of data storage locations)?	Data from MedWatch is triaged by PSI, Inc (contractor) and sent to the appropriate drug or biologics (AERS), device (MAUDE), quality, blood (BPD), medication error (AERS), or food database
semi-annual etc)?	No scheduled revisions
15. What are the methods for system revisions (e.g. internal review and design	Federal register notice - public comments

Reporting or Database System:	FDA-CDER: MedWatch
only, design under contract, with or without	
customer input)?	
16. What are the minimal interface requirements for contributors (e.g. phone,	No minimum. Form 3500 can be filled in manually and mailed to FDA.
internet access, certain level of PC	
memory)?	
17. What new features are being planned and/or are on wish lists?	Having on-line reports go directly into AERS.
C. Potential to link to other information systems	_
	The voluntary system feeds into MAUDE (Manufacturer and User
other systems (including State or other	Facility Device Experience Database) and AERs based upon type of
Federal Reporting Systems? If yes, which	event. AERS data that is coded with a preferred term "medication
data is linked?	error" is entered to a separate database in the Office of Drug Safety on a monthly basis.
	Use the following codes to classify each identified field in the
D. Fields related to	reporting system. P-Picklist items (list); S-Industry Standard
contributor/participant Information:	(identify) ; N-Narrative; FF - Fixed Format (e.g. date)
19. What types of contributors are included	(N)E.1 - Reporter Name
in data acquisition? List fields that indicate	(P)E.2 - Health professional. If you are not a health professional, write
who/what facility submitted the data.	NA
	Yes
	No ND E 2 Occurrentian
20. Is participation mandatory or voluntary?	(N) E.3 - Occupation Voluntery for ModWatch
21. List fields related to	(N) E.1 Reporter Address and Phone number
contributor/participant contact information	( <b>N</b> ) Reporter Contact information if follow-up is necessary. This person will also receive an acknowledgment letter from the MedWatch program.
22. List fields related to facility contact	N/A
information (include type of facility,	
teaching status, id information)	
23. List fields related to distributor contact	N/A
information	
24. List fields related to manufacturer contact information	N/A
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
25. List fields related to Provider of Care identification	N/A
26. List fields that identify types of care	Some of this could be in event description and some could be in lab
providers included in system	and diagnostic test information.
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF - Fixed Format (e.g. date)
27. List fields related to identifying patient -	(N)A.1 - Identifier - patient's initials or some other type of information
initial data entry (e.g. SSN, initials, system-	that will allow you, the reporter to readily locate the case if you are
assigned ID etc)	contacted for more information. Do not use patient's name or SSN.
28. List fields related to patient contact	N/A
information (e.g. address, zip code, county,	
region) 29. List fields related to patient	(N)A.2 - Age at time of event OR Date of Birth - provide the most
	$\pi_1 \pi_1 \pi_2 = \pi_2 \pi_2 \pi_1$ at time of event OK Date of Diffi = Divine the most
demographics (e.g. age, sex, race)	precise information available. For age, indicate time units (3 years+-

Reporting or Database System:	FDA-CDER: MedWatch		
	use years, less than 3 years old, use months; less than 1 month old,		
	days)		
	(P)A.3 - Sex (if congenital anomaly, report sex of the child)		
	Female		
	Male (N)A.4 - Weight (in lbs OR kg)		
	**Race could be included by reporter in medical history of patient, but		
	not a separate field (see question 31)		
30. What patient identification is retained	No traceable data - patient initials or other reporter assigned ID are		
after verification of event information (e.g.	entered in database.		
all contact information or pseudo id			
assigned, is patient ID available for follow-			
up/outcome information)			
31. List fields related to pre-existing	(N)Drugs, Biologics and Medical Devices - C.10, D.10 - Concomitant		
conditions and/or medical history of patient	medical products and therapy dates (exclude tx of event) List and provide therapy dates for any other medical products (drugs,		
	biologics, medical devices, etc.) that a patient was using at or around		
	the time of the event. DO NOT include products used to treat the event.		
	(N)B.7 - Other relevant history, including preexisting medical		
	conditions (e.g., allergies, race, pregnancy, smoking and alcohol use,		
	hepatic/renal dysfunction, etc.)		
	(P)Categories for race:		
	Am. Indian – Alaska Native= American Indian or Alaska Native		
	Asian= Asian Continent to include Indian Subcontinent Native Hawaiian or other Pacific Islander= Native Hawaiian or other		
	Pacific Islander		
	Black= Black, not of Hispanic origin		
	Hispanic= Hispanic		
	White= White, not of Hispanic origin		
32. List fields that capture the clinical	(N) C.4 - Diagnosis for use of medicationSome of this could be entered		
condition of patient at time of event	in B.5 - adverse event description		
33. List fields related to financial/charge information (e.g. length of stay, charge or	n/a		
payment for care, insurance coverage -			
Medicare, Medicaid, private, CHAMPUS,			
uninsured etc)			
34. List any other types of information	(P) B.2 - Outcome attributed to adverse event		
collected about the patient	death (date in fixed format)		
	life-threatening		
	hospitalization - initial or prolonged		
	disability congenital anomaly		
	required intervention to prevent permanent impairment/damage		
	other (narrative description)		
G. Fields related to	Use the following codes to classify each identified field in the		
Event/Error/Product Information:	reporting system. P-Picklist items (list); S-Industry Standard		
	(identify) ; N-Narrative; FF- fixed format (e.g. date)		
35.Type of events included (e.g. drug,	Adverse outcome in a patient can be due to:		
device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	Medication (drug or biologic); Medical device (including in vitro diagnostics);		
intection, surgery misnaps, etc)	Special nutritional product (e.g., dietary supplement, infant formula or		
	medical food)		
	Product problems include, but are not limited to, such concerns as:		
	Suspected contamination;		
	Questionable stability; Defective components; Therapeutic failures;		
	Product confusion (caused by		

Reporting or Database System:	FDA-CDER: MedWatch	
	name, labeling, design or packaging); Suspected super potent or	
	subpotent medication;	
	Labeling problems caused by printing errors/omissions	
36. List fields associated with medication-	A separate form should be submitted for each individual product	
related events (e.g. drug name, dose, dates of		
therapy)	(S - drug trade name) C.1 - Name (give labeled strength and	
	mfr/labeler, if known) Use the trade name as marketed.	
	If unknown use the generic name (with the manufacturer or labeler's	
	name, if known). For quality problem reports, include the	
	manufacturer's name and the labeled strength for both prescription and	
	non-prescription products. $(\mathbf{N}) \subset 2$ . Does from any $\mathbf{k}$ route used. Describe how the product uses	
	(N)C.2 - Dose frequency & route used. Describe how the product was used by the patient.	
	For reports involving overdoses, overdose amt, not prescribed amount.	
	(N)C.3 - Therapy dates (if unknown, give duration). Provide the date	
	administration was started	
	(or best estimate) and the date stopped (or best estimate). If no dates	
	are known, an estimated	
	duration is acceptable or if therapy was less than one day, then duration	
	is appropriate.	
	(P) C.5 - Event abated after medication use stopped or dose reduced	
	Yes	
	No	
	Doesn't apply	
	(N) C.6 - Lot # (if known). If known, include the lot number(s) with all	
	product problem reports,	
	or any adverse event report with a biologic or medication	
	(N) C.7 - Exp. Date (if known). Include with all product problem	
	reports ONLY.	
	(P) C.8 - Event reappeared after reintroduction	
	Yes, No, doesn't apply	
	(S-NDC codes) C.9 - NDC# - for product problems only (if known)	
37. List fields associated with medical	National drug code	
device-related events (e.g. brand name of	(S-Brand name)D.1 - Brand Name The trade or proprietary name of the suspect medical device as used in product labeling or in the catalog	
device, type of device, usage, manufacturer	(N)D.2 - Type of Device The generic or common name of the suspect	
name, operator of device)	medical device or a generally descriptive name (e.g., urological	
	catheter, heart pacemaker, patient restraint, etc.).DO NOT use broad	
	generic terms such as "catheter", "valve", "screw", etc.(N)D.3 -	
	Manufacturer name and address( <b>P</b> )D.4 - Operator of Device Indicate	
	the type (NOT the name) of person Health professional = physician,	
	nurse, respiratory therapist, etc., Lay user/patient = person being	
	treated, parent/spouse/friend of the patient, Other = nurses' aide,	
	orderly, etc.(FF)D.5 - Expiration date (mo/day/yy) D.6 - Product	
	Identification Information(S)Model # Found on the device label or	
	accompanying packaging(S)Catalog# Exact number as it appears in the	
	manufacturer's catalog, device labeling, or packaging.(S)Serial # Found	
	on the device label or accompanying packaging; it is assigned by the	
	manufacturer(S)Lot# This number can be found on the label or	
	packaging material.(S)Other# Any other applicable identification	
	number(N)D.7 - Implant date (if any) For medical devices that are	
	implanted in the patient, provide the implant date. If day is unknown,	
	month and year are acceptable. If month and day are unknown, year is	
	acceptable(N)D.8 Explant date (if any) If an implanted device was removed from the patient, provide the explant date. If day is unknown,	
	month and year are acceptable. If month and day are unknown, year is	
	month and year are acceptable. If month and day are unknown, year is	

Reporting or Database System:	FDA-CDER: MedWatch	
	acceptable.(P)D.9 - Device available for evaluation?yes, no, returned to	
	manufacturer on date(FF)	
38. List fields associated with vaccine	n/a	
related events		
39. List fields associated with infection	n/a	
related events		
40. List fields associated with any other type	n/a	
of event. List type of event.		
41. List fields that allow input and/or	(P) B.1 - Classification	
classification of the event/harm (narratives,	Adverse Event	
problem codes, adverse event terms)	Product Problem (defects/malfunctions)	
	(N) B.5 - Describe event or problem	
	For an adverse event:	
	Describe the event in detail, including a summary of all relevant	
	clinical information (medical status prior to the event; signs and/or	
	symptoms; differential diagnosis for the event in question; clinical	
	course; treatment; outcome, etc.). If available and if relevant, include	
	synopses of any office visit notes or the hospital discharge summary.	
	Attach copies of these records with any confidential information	
	deleted. If it is determined that reuse of a medical device labeled for	
	single use may have caused or contributed to an adverse patient	
	outcome, report the facts of the incident in B5 and the perceived	
	contribution of reuse to the occurrence.	
	For a product problem:	
	Describe the problem (quality, performance, or safety concern) in	
	sufficient detail so that the circumstances surrounding the defect or	
	malfunction of the medical product can be understood.	
	If available, the results of any evaluation of a malfunctioning device	
	and, if known, any relevant maintenance/service information should be	
	included in this section For a medication or special	
	nutritional product problem, please indicate if you have retained a	
	sample that would be available	
	-	
42. List fields associated with when the	to FDA.	
	(FF) B.3 - Date of event (mo/day/yr) - Provide the actual or best	
event occurred	estimate of the date of first onset of the adverse event. If day is	
	unknown, month and year are acceptable. If day and month are	
	unknown, year is acceptable. When a newborn baby is found to have a	
	congenital anomaly, the event onset date is the date of birth of the	
	child. When a fetus is aborted because of a congenital anomaly, or is	
	miscarried, the event onset date is the date pregnancy is terminated. If	
	information is available as to time during pregnancy when exposure	
	occurred, indicate that information in narrative block B5.	
43. List fields associated with tracking the	(FF) B.3 - Date of event	
time between the event, when reported,	(FF) B.4 - Date of this report (initial reporter)	
when acted upon etc		
44. List fields associated with where the	n/a	
event occurred		
45. List fields associated with patient	(N)B.6 - Relevant tests/laboratory data (with dates) Include: relevant	
diagnosis, care, treatment, tests, and other	negative test and laboratory findings, in order to most completely	
	convey how the medical work-up/ assessment led to strong	
event	consideration of medical product-induced disease as etiology for	
	clinical status, as other differential diagnostic considerations were	
	being eliminated; relevant baseline laboratory data prior to the	
	administration or use of the medical product; laboratory data used in	
	diagnosing the event; available laboratory data/engineering analyses	
	(for devices) that provide further information on the course of the event	

<b>Reporting or Database System:</b>	FDA-CDER: MedWatch		
	If available, include: any pre- and post-event medication levels and		
	dates (if applicable);synopses of any relevant autopsy, pathology,		
	engineering, or lab reports		
46. List fields related to follow-up of event	(P)E.4 - Report also sent to		
that are not associated with a particular	Manufacturer		
patient(medication/manufacturing/policy	User facility		
actions to correct/update event; distribution	Distributor		
of report to other places)			
47. List fields related to the outcome of	(P) B.2 - Outcomes attributed to adverse event (check all that apply)		
event	Death: Check ONLY if you suspect that the death was an OUTCOME		
	of the adverse event, and include the date if known.		
	Hospitalization (initial or prolonged): Check if admission to the		
	hospital or prolongation of hospitalization was a result of the adverse		
	event.		
	Disability: Check if the adverse event resulted in a substantial		
	disruption of a person's ability		
	to conduct normal life functions.		
	Congenital anomaly: Check if you suspect that exposure to a medical		
	product prior to conception		
	or during pregnancy may have resulted in an adverse outcome in the		
	child.		
	Required intervention to prevent permanent impairment/damage: Check if you believe that medical		
	or surgical intervention was necessary to:		
	Preclude permanent impairment of a body function or prevent permanent damage to a body		
	structure, either situation suspected to be due to the use of a medical		
	product.		
48. List any other fields related to the event	Triage unit sequence #		
or reporting system			
H. Implications			
49. Integration with other systems			
50. Methods used to de-identify data			
51. Technical issues			

**Part II. Data Structure & Storage:** MedWatch is essentially a clearinghouse that routes incoming information to appropriate Centers within the FDA and to domain-specific databases (e.g., AERS, MAUDE). Since there is no permanent data storage, we did not collect information regarding the data structures and technical architecture associated with MedWatch.

## Part III. Data Use & Analysis:

78. System Contact	Norman Marks
79. Contact Address	
80. Contact Phone	301-827-7246
81. Contact Email	MARKSN@CDER.FDA.GOV
82. Hardware Platform	Front-end on FDA Application server at UUNet. Upon submission a text based file is created an placed on FDA Application server that will be pulled across FDA firewall to back end. Back end resides on NT server at CDER/OIT.
83. Operating System	see above
84. Who is the developer?	Front and back end web processes developed by Booz, Allen, Hamilton.
85. Who is responsible for the system architecture?	ColdFusion for web. Oracle *I database at back end.

Reporting or Database System:	FDA-CDER: MedWatch
86. User Types	MedWatch acts as the interface between report submitters and CTU. All analysis and data use by FDA is done from AERS, MAUDE or SNAEMS databases. No regular reports are produced from the MedWatch software.
87. What is the frequency of reports?	N/A
88. Who generates the reports?	N/A
89. What is the method of access?	N/A
90. What is the turnaround time?	N/A
91. What is the level of automation?	N/A
92. Type Of Reports	N/A
93. What is the unit of observation?	N/A
94. What are the available data fields?	N/A
95. What is the controlled vocabulary?	N/A
96. Exportability	N/A
97. User Profile	N/A
98. How are the reports used?	N/A
<ul> <li>99. Report Dissemination</li> <li>100. Primary Goal</li> <li>101. Linkable to Detail</li> <li>102. HIPAA Compliant</li> </ul>	<ul> <li>Note: website serves as a consumer/health professional information dissemination point and contains safety alerts, Class 1 recalls and safety-related labeling changes. Also contains continuing education articles etc E-mail notifications sent to 200 key organizations and 20,000 individuals when safety alert issued. E-mail confirmation sent to reporters who send in online reports. Reporters submitting by mail, phone or fax receive a mailed confirmation. MedWatch to Manufacturer Program sends voluntary reports received by MedWatch to manufacturers if specific conditions met (report must be serious, on a New Molecular Entity, reporter must have given permission etc.).</li> <li>To support the submission of FDA Form 3500 (voluntary) reports by health professionals and consumers on line and to transfer information to the Central Triage Unit for entry into the appropriate FDA system.</li> <li>MedWatch feeds into AERS, MAUDE and SNAEMS.</li> <li>Both MEDWATCH mandatory and voluntary reporting forms ask reporter to provide a patient identifier that "will allow both the submitter and initial reporter to locate the case if contacted for follow-</li> </ul>
Future	<ul> <li>up. DO NOT use the patient's name or SSN."</li> <li>Having on-line reports go directly into AERS (ie. Electronic vs current hardcopy). Develop on line capability for manufacturers/user facilities to submit mandatory reporting form 3500a.</li> </ul>
Notes:	<ul> <li>18,000 reports from professionals/consumers received last year by mail (approx 25%), fax (40%), phone (5%) and on line (30%). On line and phone converted to paper form and sent to CTU. Fax and mail go directly CTU</li> <li>Example list of product problems in instructions is: suspected contamination, questionable stability, defective components, therapeutic failures, product confusion (cause by name, labeling, design or packaging), suspected super or sub potent medication, labeling problems caused by printing errors/omissions)</li> </ul>

MERP		
Reporting or Database System:	MedMARx	Medication Error Reporting System (MERS) or Medication Error Reporting Program (MERP)
Part I. Data Acquisition:		
A. General Information		
1. Report Title		
2. Internet Location: http://	http://www.medmarx.com//mmx2_j sp/index.jsp and http://www.usp.org	<u>http://www.usp.org/</u> (See Practitioner Reporting)
3. Host Organization(s)	The US Pharmacopeia	The US Pharmacopeia
4. Primary contact information (e.g. Address, Phone)	Diane Cousins, (301) 816-8215	Diane Cousins, USP, (301) 816-8215 Dr. Jerry Phillips, FDA, (301) 827- 3242 Carol Holquist, FDA, (301) 827-0195
B. Overall System Features		
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	MedMARx is a proprietary subscription service and Internet- accessible database program whereby hospitals can contribute reports on actual and potential medication errors in their facilities in return for anonymity and feedback of comparisons with all hospitals subscribing to the program. About 500 of the 6,200 hospitals currently subscribe. MedMARx differs from the USP MERP and FDA MEDWATCH in that MedMARx lets hospitals internally monitor their progress toward error prevention and maintain awareness of problems and solutions reported by other institutions. USP is exploring ways for both FDA and ISMP to access the MedMARx database.	MERS is a Web-based error reporting system for health care practitioners and students who encounter actual or potential medication errors to report confidentially to USP. USP reviews all reports for health hazards and sends all reports to the FDA, the manufacturer, and to the Institute for Safe Medication Practices, either anonymously or with identification of the reporter with the reporter's permission. This system is a precursor of MedMARx and was established to collect information on problems with medication products. The data elements and definitions are similar to MedMARx.
6. What is the geographic scope of data collection (national, state, local, facility etc)?	The MedMARx database covers about 500 subscribing U.S. hospitals.	The scope of data reported though the MERS covers the whole nation.
7. What is the unit of data entry		The unit of data entry is in-hospital
(e.g., event, patient, product)?	medication adverse events.	medication adverse events.
8. Who is allowed/required to input information?	Only health care professionals in subscribing hospitals can report to MedMARx.	Any health care professional in any setting and consumers.
9. What are the regulations/laws affecting		Voluntary reporting - no USP
reporting?	MedMARx come primarily from State laws of "discoverability" or "privilege". Only internal peer review, quality improvement processes in hospitals enjoy	response on regulations affecting.

Reporting or Database System:	MedMARx	Medication Error Reporting System (MERS) or Medication Error Reporting Program (MERP)
	protection from legal discovery in many States. As soon as identifiable information on a case is released outside of the peer review activities of the hospital to any other entity,	
	the information can be discovered through court processes. Only anonymous reporting (with respect to the reporter, patient, and institution) will fully protect the institution against discoverability in	
for reporting, confidentiality policies that apply to entered data)	anonymous input. Total anonymity of the program overcomes one of the major obstacles (legal discoverability) to reporting and sharing incident report information and experiences among facilities. (See item 9 above.)	The MERS allows reporters to submit anonymously, but this is rarely done. The system asks for reporter identification but not institution where error occurred. Reporter may maintain confidentiality beyond USP for data sent onto FDA, manufacturers and ISMP.
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	-	Form via Web, mail, phone, or fax.
12. What are the methods of editing information (e.g. correcting/add more information to records)	subscribing hospital through a PIN-	USP does all data entry, verification, and modification. Reporters can submit follow up information to USP.
13. Where is the collected data stored (name of database, number of data storage locations)?	On USP servers.	On USP servers.
14. How often is the system revised (annual, semi-annual etc)?	1 1	
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?		
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?		Any one of: phone, Internet access, or fax access.
17. What new features are being planned and/or are on wish lists?	No response from USP.	No response from USP.

Reporting or Database System:	MedMARx	Medication Error Reporting System (MERS) or Medication Error Reporting Program (MERP)
C. Potential to link to other information systems		
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	FDA reporting systems.	MERS data are shared once a week with FDA. Copies of all reports received at USP are sent via courier to the FDA offices where AERS contract staff enter the information into the AERS database. The information is also coded into NCCMERP codes and stored in an Office of Drug Safety Oracle database where it is further analyzed. No report-level data or information moves from FDA to USP.
D. Fields related to contributor/participant Information:		
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	Hospitals (see below).	See 21 below.
20. Is participation mandatory or voluntary?	Voluntary	Voluntary
21. List fields related to contributor/participant contact information		Name, title, department or facility name, address, and phone number.
22. List fields related to facility contact information (include type of facility, teaching status, id information)	Facility Type (drop down menu, includes category for "teaching facility"), Facility demographics (drop down menu), # of beds, ALOS, ADC.	Type of institution (see below)
23. List fields related to distributor contact information	None	N/A
24. List fields related to manufacturer contact information	manufacturer name.	Brand name of product, generic name, manufacturer, labeler, dosage form, strength/concentration, type and size of container, NDC number. Also, optional data elements requested include product label, copy of prescription order, and other relevant material.
E. Fields related to Provider of Care Information:		
25. List fields related to Provider of Care identification	See facility type, above.	"What type of staff or health care practitioner made the initial error?" "Please describe the error. Include sequence of events, personnel involved, and work environment"
26. List fields that identify types of care providers included in system	See facility type, above.	Level of staff or other individual that made error, Level of staff or other individual that discovered error.

Reporting or Database System:	MedMARx	Medication Error Reporting System (MERS) or Medication Error Reporting Program (MERP)
F. Fields related to Patient Information:		
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	None	"If available, please provide relevant patient information (age, gender, diagnosis, etc.). Patient identification not required." (narrative form)
28. List fields related to patient contact information (e.g. address, zip code, county, region)	None	None
29. List fields related to patient demographics (e.g. age, sex, race)	Age, gender	See 27 above.
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)	None	No patient identification required.
31. List fields related to pre-existing conditions and/or medical history of patient	None	See 27 above.
32. List fields that capture the clinical condition of patient at time of event	None unless choose to include in narrative part of error reports	See 27 above.
33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)	None	None
34. List any other types of information collected about the patient	None	None
G. Fields related to Event/Error/Product Information:		
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	Mostly drug; some devices, biologics, and vaccines.	Mostly drug; some devices, biologics, and vaccines.
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy)	narrative description of error, node in medication process at which error occurred, location where initial error occurred, location detail for facility use only, type of error, cause of error, contributing factors,	requested include product label, copy of prescription order, and other relevant materials.
device-related events (e.g. brand name of device, type of device, usage, manufacturer name, operator of device)	μν/ Α	μν/ Α
38. List fields associated with vaccine	N/A	See 36 above.

Reporting or Database System:	MedMARx	Medication Error Reporting System (MERS) or Medication Error Reporting Program (MERP)
related events		
39. List fields associated with infection related events	N/A	N/A
40. List fields associated with any other	N/A	N/A
type of event. List type of event.		
41. List fields that allow input and/or		
classification of the even/harm.		
42. List fields associated with when the		
event occurred		
43. List fields associated with tracking		
the time between the event, when		
reported, when acted upon etc.		
44. List fields associated with where the	Setting - where the initial error	"Where did the error occur (e.g.,
event occurred		hospital, outpatient or retail
		pharmacy, nursing home, patient's home)?"
45. List fields associated with patient	The levels of intervention differ	Whether patient counseling was
diagnosis, care, treatment, tests, and other		provided before or after the event was
follow-up provided to patient because of	0,	discovered.
the event	intervention needed, error did not	
	reach the patientCategory B: As	
	error was detected before reaching	
	the patient, no intervention needed	
	(on behalf of the patient)Category	
	C: As patient was not harmed by	
	the error, only diagnoses-related follow-up care (to determine that no	
	further harm has or will	
	occur)Category D: Patient subjected	
	to increased level of monitoring or	
	observation after errorCategory E:	
	Patient's therapy/treatment may be	
	changedCategory F: Patient's	
	therapy/treatment changed, hospital	
	stay may be lengthenedCategory G:	
	Patient will need rehabilitative	
	treatment after errorCategory H:	
	Emergency resuscitative measures	
	taken, patient's treatment possibly	
	changed, hospitalization	
	increasedCategory I: No follow-up,	
	issue a death certificateAlso, level	
	of care administered to patient as result of error.	
46. List fields related to follow-up of	Actions taken to avoid an actual or	"Suggest any recommendations you
event that are not associated with a		have to prevent recurrence of this
particular patient		error or describe policies or
(medication/manufacturing/policy actions		procedures you have instituted to
to correct/update event)		prevent future
L /		similar errors."
47. List fields related to the outcome of		Error outcome categories:
event		A: "No error circumstances or
	events that have capacity to cause	events that have capacity to cause
	error	error

Reporting or Database System:	MedMARx	Medication Error Reporting System (MERS) or Medication Error Reporting Program (MERP)
	B: "Error occurred, but medication	B: "Error occurred, but medication
	did not reach the patient"	did not reach the patient"
	C: "Error occurred, but caused no harm"	C: "Error occurred, but caused no harm"
	D: "Error occurred that resulted in	D: "Error occurred that resulted in the
	the need for increased patient	need for increased patient monitoring
	monitoring - no patient harm"	- no patient harm"
	E: "Error occurred that resulted in	E: "Error occurred that resulted in
	need for treatment or intervention -	need for treatment or intervention -
	temporary patient harm"	temporary patient harm"
	F: "Error occurred that resulted in	F: "Error occurred that resulted in
	initial or prolonged hospitalization -	initial or prolonged hospitalization -
	temporary patient harm"	temporary patient harm"
	G: "Error occurred that resulted in	G: "Error occurred that resulted in
	permanent patient harm"	permanent patient harm"
		H: "Error occurred that resulted in a
	near-death event"	near-death event"
	I: "Error occurred that resulted in	I: "Error occurred that resulted in
	patient death"	patient death"
48. List any other fields related to the event		
H. Implications		
49. Integration with other systems	USP views one advantage of	MERS reports are already submitted
	Internet-access and Internet-based	to FDA for MedWatch. See 18. No
	systems as ease of integration. A	information is sent back to USP.
	few ideas from USP are:	
	1) Contractor for collection of	
	medication errors reports to the	
	government with electronic transfer	
	of data. 2) Electronic data transfer	
	under contract for USP data. 3)	
	USP database access for Federal	
	staff under contract.	
50. Methods used to de-identify data		
51. Technical issues	Definition of medication error:	
	Medication Error Definition	
	"A medication error is any	
	preventable event that may cause or	
	lead to inappropriate medication	
	use or patient harm while the medication is in the control of the	
	health care professional, patient or	
	consumer. Such events may be	
	related to professional practice,	
	health care products, procedures	
	and systems, including prescribing;	
	order communications; product	
	labeling, packaging and	
	nomenclature; compounding;	
	dispensing; distribution;	
	administration; education;	
	monitoring; and use." (NCCMERP)	

		Medication Error Reporting
Reporting or Database System:	MedMARx	System (MERS) or Medication
		Error Reporting Program (MERP)

**Part II. & III:** MERP is a privately operated system maintained by USP. Information about the data model and technical architecture is proprietary in nature and not publicly available. Thus, data collection forms for data structures/storage were not populated.

86. User Types	Subscribing hospitals can access	FDA, ISMP, manufacturers (for
	their own data, aggregations of	reports related to their products, and
	other subscribing hospitals, and	USP staff.
	drill down to protected record-level	
	data of other hospitals.	
	Besides subscribers, only USP staff	
	have access to the full database.	
88. Who generates the reports?	USP produces an annual summary	No response.
	report. Hospitals can generate	•
	spreadsheet, charts/graphs, and	
	download data sets for study at the	
	hospital level.	
94. What are the available data fields?	Subscribing hospitals have access	No response.
	to record-level and summarized	L
	data with decisions support	
	software tools.	
98. How are the reports used?	For internal quality improvement	For improvement of safety and
1 I	only by hospitals. For improvement	
		regulatory requirements of FDA.
	by USP.	
Comments:	USP has adapted NCCMERP	USP has adapted NCCMERP
	taxonomy for MEDMARx. Though	
		classes are applied at FDA, Office of
	form requires a written/typed	Drug Safety.
	answer, there are some pull-down	
	menus with the NCCMERP	
	classification.	
1		

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
Part I. Data Acquisition:	
A. General Information	
1. Report Title	Event Discovery Report Transfusion Service QA Sysop Investigation Report Worksheet - available after discovery report is submitted Root Cause Analysis Report Worksheet - available after discovery report is submitted
2. Internet Location: http://	http://www.mers-tm.net
3. Host Organization(s)	The National Heart, Lung, and Blood Institute, in cooperation with FDA The MERS-TM project is primarily based at Columbia University, with Harold S. Kaplan, MD as the Principal Investigator.
4. Primary contact information (e.g. Address, Phone)	Harold S. Kaplan, MD; hsk18@columbia.edu Columbia University, Harkness 4-418, 622 West 168 St, NY, NY 10032 Quay Mercer - Quay.Mercer@UTSouthwestern.edu - 214-648-8448 Barbara Rabin Fastman - bf216@pop.columbia.edu - 212-305-8719
<b>B.</b> Overall System Features	
5. System purpose/mandate ( any information on role in mission, leadership support, integration with quality assurance activities and history)	The Medical Event Reporting System for Transfusion Medicine (MERS-TM) is an event reporting system developed for transfusion services and blood centers to collect, classify, and analyze events that could potentially compromise transfusion safety. It is offered to organizations as a means to meet FDA regulations and American Association of Blood Bank Standards related to implementing a transfusion related event reporting system. In addition to basic reporting, MERS-TM provides the opportunity to study and monitor both actual and near-miss events to facilitate process improvement efforts. MERS-TM will be most successful in organizations that provide a "just" safety culture which encourages event reporting while affording a safe environment in which to report. The goal is not to punish people for errors, but rather to prevent the events from recurring. There are three levels of reporting which are designed to be integrated into existing QA activities without undue additional burden. The Event Discovery Report collects information on the discovery of the event and the event itself. The QA Sysop Investigation Report is completed by a trained QA staff member who classifies the event and determines the need for further review based upon a calculated risk assessment index. The Root Cause Analysis report is filled out in those cases where the organization is try to improve processes by identifying the precursors which led up to the event under analysis.
6. What is the geographic scope of data collection (national, state, local, facility etc)?	Accommodates international reporting. Currently, hospitals from Canada and the US participate in the program, but there is interest from many other countries.
7. What is the unit of data entry (e.g., event, patient, product)?	The unit of entry is an adverse or potential adverse event associated with the collection, manufacturing, testing, storage, distribution and administration of blood and blood products.

MERS-TM

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
8. Who is allowed/required to input information?	The transfusion service or blood center assigns the individual who will input data. This is usually a QA Systems Operator who are encourage to take the on-line training available via the MERS-TM web site. The system allows the QA SysOp to add new users with levels of user security based upon individual profiles.
9. What are the regulations/laws affecting reporting?	On November 7, 2000, the U.S. Food and Drug Administration (FDA) published a final rule expanding the requirement for the reporting of errors and accidents in the manufacturing of biological products to include unlicensed registered blood establishments and transfusion services, in addition to licensed manufacturers. The rule, effective May 7, 2001, requires that hospitals and blood centers maintain a method to report, investigate, and track errors and accidents. Both the American Association of Blood Banks and JCAHO have established their own standards - included in these is the requirement to create an adverse event reporting system. In addition, individual countries have regulations relating to the reporting of blood component and transfusion events.
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	Yes. Hospitals/Blood Centers may collect identifying information, but there are no fields for entry into the database. Policies on the collection and reporting of patient or facility identifying data are specific to the organization.
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	An ID and PW are required for input to the system via an on-line web form.
12. What are the methods of editing information (e.g. correcting/add more information to records)	Edits/additions are made online by authorized users who have editing privileges (as specified by user profiles). Edits can be made by searching for a record by accession number and making changes.
13. Where is the collected data stored (name of database, number of data storage locations)?	The database for an organization's event information is stored on one server at MERS-TM Each organization's data is stored on in a unique database, but Staff at MERS-TM do not have the ability to match each database with the particular reporting organization that supplies the data. Currently, the MERS-TM research group aggregates the data into two major groups - one set of data belongs to the core group of blood centers and transfusion services that worked on the initial research project, the other set belongs to those who have joined the program since it went on-line in December 2001. As of 1/2002, 11 organizations had registered for IDs and passwords to the on-line database.
14. How often is the system revised (annual, semi-annual etc)?	As needed.
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	MERS-TM staff make revision decisions based on experience and user input.
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	Internet Explorer v.5.x or above. On-line training requires download of Adobe Acrobat and Flash plug-in.

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
17. What new features are being planned and/or are on wish lists?	The system has only been up since December 2001. Current efforts are focused on increasing participation in the system, and providing education and supporting new members. In the near future, MERS- TM staff will be shifting focus to begin analyzing the data that has been collected to look for trends and identify important areas for further review. They will also use the data to deal with the hypotheses presented in their original grants. For example, one of their hypotheses was " The safety culture of an organization will change as an event reporting system is implemented." They performed a survey to obtain a baseline of cultural factors for those hospitals that chose to implement MERS-TM. They plan to do a follow-up to determine whether their hypothesis was correct. They have also received a grant from AHRQ to generalize their tool to overall hospital events, to focus on the patient as reporter, and to look at simulation methods. For status report, see 2002_progess_report.doc under Task 3 - FDA Reporting Systems folder
C. Potential to link to other information systems	
18. Is information from this system linked to other systems? If yes, which data is linked?	No. Currently there is a feasibility study underway to link to FDA's BPD system.
D. Fields related to contributor/participant Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	As stated above, there are no fields that capture the reporting facility and MERS-TM purposely avoids identification of data source to increase likelihood of reporting. If MERS-TM maintained this information they would be subject to Discovery laws in some states and would be required to turn over error reporting information and source as evidence.
20. Is participation mandatory or voluntary?	Current FDA regulations and accrediting groups (e.g. AABB and JCAHO) require transfusion services and blood centers to maintaining an event reporting system is mandatory, but do not require the use of a particular reporting system. MERS-TM meets and exceeds reporting requirements for these accrediting and regulatory bodies. It also includes features beyond the reporting of the event which assist in process improvements - the investigation report and the root cause analysis report.

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
21. List fields related to contributor/participant contact information	<ul> <li>(P) A.5 - Discoverer's job description: - Describe the person who actually discovered the event. First, professional training (i.e. MT, RN etc) is described using one of the categories provided. The 'other' choice is to be used when none of the professional training categories apply. If the discoverer is a supervisory-level person or a qa/qc staff member, also mark 'supervisor.'</li> <li>Clerk</li> <li>House staff</li> <li>MD/DO</li> <li>MLT</li> <li>MT</li> <li>QA/QC</li> <li>RN</li> <li>LVN/LPN</li> <li>Supervisor</li> <li>Other</li> </ul>
22. List fields related to facility contact information(include type of facility, teaching status, id information)	When registering as a participating organization, the facility does not enter its name or other identifying information. Demographic information includes: (N) Center code name - assigned by center (P) Geographic Setting - Urban, Suburban, Rural (P) Academic - Y,N (P) Pediatric - Y,N (P) Number of FTES 1-2 3-10 11-20 21-30 >30 (P) Number of RBC Units transfused per year <500 501-1000 1001-3000 3001-5000 5001-10000 10001-20000 >20000 (P) Number of samples processed per year <1000 1001-2000 2001-5000 5001-10000 1001-2000 2001-5000 5001-10000 10001-20000 >20000 (P) Collect blood on site - Y,N (P) Perform viral testing - Y,N (P) Country - US, CA (N) Code name of parent site, if applicable - assigned by center
23. List fields related to distributor contact information	N/A
24. List fields related to manufacturer contact	N/A

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
information	
	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
25. List fields related to Provider of Care identification	See Item 26. No specific identification of a particular person
	(P) B.4 - Persons involved (with event) Clerk House staff MD/DO MLT MT QA/QC RN LVN/LPN Supervisor Other
F. Fleids related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system- assigned ID etc)	N/A
28. List fields related to patient contact information (e.g. address, zip code, county, region)	N/A
29. List fields related to patient demographics (e.g. age, sex, race)	N/A
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)	N/A
31. List fields related to pre-existing conditions and/or medical history of patient	Could be in Narrative of event descriptions, but users are trained not to include patient identifiers
	Could be in Narrative of event descriptions, but users are trained not to include patient identifiers
33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)	N/A
34. List any other types of information collected about the patient	N/A

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	This system was developed for transfusion services and blood centers to collect, classify, and analyze events that could potentially compromise transfusion safety. Events to be monitored and study include both actual and near-miss events.
36. List fields associated with medication- related events (e.g. drug name, dose, dates of therapy)	Could be in Narrative of event descriptions
37. List fields associated with medical device- related events (e.g. brand name of device, type of device, usage, manufacturer name, operator of device)	Could be in Narrative of event descriptions
38. List fields associated with vaccine related events	N/A
39. List fields associated with infection related events.	Could be in Narrative of event descriptions
40. List fields associated with any other type of event. List type of event.	N/A
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	<ul> <li>(N) A.7 - Describe briefly the event you discovered - Factual description of what was discovered from the discoverer's viewpoint. (4 lines).</li> <li>(N) A.8 - How did you discover this event? - Circumstances of the discovery, i.e. routine review process that allowed capture of the event, or did someone discover the event by chance? <b>Investigation Report Fields</b></li> <li>(S) 1. Consequent (Discovery) Code (6 digits) - From left to right - first space record event type 1-no recovery, harm;2-no recovery, no harm;3-near miss, unplanned recovery;4- near miss, planned recovery. Two middle spaces are for the consequent process code (where the event was discovered. Three spaces are for the subprocess code that further describes the event. Use Event Codes for this - (~100 codes for transfusion services; ~200 codes for blood centers)</li> <li>(S) 2. Antecedent (1st Occurrence) Code - From left to right - first two spaces are for the subprocess code that further describes the event. Use Event Codes for this - see #1 above)</li> <li>(S) 3. Significant Antecedent (Occurrence) Code - Same as 2 except this code describes the antecedent event the QA Sys Op feels is most amenable to a system improvement. Use Event codes for this - see #1 above)</li> <li>(N) 4. Additional description of the event - add key descriptors about the event not contained in A.7 or A.8 on the Event Discovery Report.</li> <li>(No thesaurus used)</li> <li>(P) 5. Risk Assessment QES99 .90 .75 .50 .25 .1 quantified estimate of severity of actual or potential harm to a patient</li> </ul>

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
	QEP99 .90 .75 .50 .25 .1 quantified estimate of the probability of this event recurring
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms) (cont'd)	<ul> <li>(P) 6. Organizational Risk - Hi, Low, N/A</li> <li>(FF) 7. Final RAI Calculation that either the QA Sys Op or the system can calculate. Multiply the QES and QEP risk values.</li> <li>(QASys Op Investigation Report #5). This is the initial Risk Index.</li> <li>b. refer to the event type Investigation Report #1, a number (1-4) on far left). If the event is a near miss, unplanned recovery (3), then add 0.1 to the initial risk index. c. refer to 'Was product issued?' (Event Discovery Report, B.7). If the product was issued, add 0.2 to the initial risk index. d. The Final RAI is the initial risk assessment, plus</li> </ul>
	b and c above. <b>Root Cause Analysis Report</b> (Filled out after causal tree built Root cause identified) -
	<ul> <li>Accession Number</li> <li>(S) Consequent Event Code (6 digit code) (N) Describe what happened - associated with consequent event code</li> <li>(S) Antecedent Event Code 1 (5 digit code) + (S) Cause Code 1a, 1b, 1c -(N) Describe what happened - associated with antecedent event</li> <li>(P) Are there additional root causes for antecedent event 1? Yes, No</li> <li>(S) Antecedent Event Code 2 (5 digit code) + (S) Cause Code 2a, 2b, 2c (N) Describe what happened - associated with antecedent</li> </ul>
	event (P) Are there additional root causes for antecedent event 2? Yes, No
42. List fields associated with when the event occurred	[Above repeated for Event Code 3 and Event Code 4] (FF) B.1 - Date the event occurred (mo/day/yr) - Date the first antecedent event occurred.
	<ul> <li>(P) B.2 - Time event occurred - Time of day the first antecedent event occurred.</li> <li>12-4am</li> <li>4-8am</li> <li>8-12noon</li> <li>12-4pm</li> <li>4-8pm</li> <li>8-12mid</li> <li>(P) B.3 - Day of event - weekday, weekend/holiday</li> </ul>
	(P) B.5 - When in process the event first occurred - Captures where in the process of transfusion the initial antecedent event originated. product check in patient/product request order entry sample collection sample handling
	sample testing product storage product selection product manipulation available for issue product issue product administration

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
between the event, when reported, when acted upon etc	<ul> <li>(FF) A.1 - Report Date (mo/day/yr) - Date the Event Discovery Report is completed.</li> <li>(FF) A.2 - Discovery date (mo/day/yr) - Date the consequent event is detected.</li> <li>(P) A.3 - Day of discovery - weekday, weekend/holiday</li> <li>(P) A.4 - Discovery time - 12-4am</li> <li>4-8am</li> <li>8-12noon</li> <li>12-4pm</li> <li>4-8pm</li> </ul>
44. List fields associated with where the event occurred	8-12mid (P) B.6 - Where event occurred - Captures general location where the first antecedent event occurred. Trans service OR ER ICU L&D Clinic Hosp. Ward Other Location Code (optional) - Any combination of alpha and numeric characters can be entered that will help an organization further identify the location of the initial antecedent.
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event	(P) A.10 Product/Record action: Floor/Clinic notified Additional testing Pt. sample recollected
46. List fields related to follow-up of event that are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event)	<ul> <li>(P) A.10 Product/Record action:</li> <li>Product retrieved</li> <li>Product destroyed</li> <li>Floor/Clinic notified</li> <li>Other</li> <li>From Investigation Report <ul> <li>(P) 8. Follow up - Based on the results of the Final RAI, select a recommended action(s).</li> <li>Propose Action - Further directions for choosing propose change, consider change and/or monitor are on the RAI tool.</li> <li>Consider Action</li> <li>Monitor</li> <li>External report to other dept/org - External report indicates that the event was discussed /formally reported to another department or organization.</li> <li>FDA reportable - FDA Reportable is selected if the event meets the criteria for a report to the FDA - requires reporting of any event associated with manufacturing, to include testing, processing, packing, labeling, or storage, or with the holding or distribution of a licensed biological product or a blood or a blood component, in which the safety, purity, or potency of a distributed product may be affected.</li> </ul> </li> </ul>

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event) <i>continued</i>	<ul> <li>(N) 9. If appropriate, describe the long-term preventive action to be taken - MERS-TM encourages preventive actions based on aggregate data rather than an individual event. However, occasionally there will be a very simple preventive action that can be easily implemented without assessing the effects of the change. This area is for the description of such a preventive action. (4 lines)</li> <li>(P) 10. What type of investigation will this event receive? -An expanded investigation is recommended in the following circumstances: events with a Final RAI of greater than or equal to 0.5; a high Organizational Risk estimate; if in the QA Sys Ops expert opinion, the benefit of doing an expanded investigation outweighs the cost. The investigation decision may be changed in either direction based on information obtained from the software tools in Database Functions.</li> <li>Rough or linked? Y, N</li> <li>(S) Rough/link cause code 1 - Enter an 'R' if the following root cause code fields contain estimated root cause codes. The event has neither undergone an expanded investigation nor is it linked to a previous event that did undergo an expanded investigation. Enter an 'L' if: the event has been found to be similar to previous events by the software tools in Database Functions, and the event has been linked to one of the previous events that has undergone an expanded investigation. Enter an 'L' indicates the root cause codes listed in this section have been transcribed from root cause analysis of the previous event. Enter up to 4 root cause codes listed in this section have been transcribed from root cause codes listed in the Eindhoven Classification Model – Medical Version (total of 20 codes). Rough root cause analysis, but they have an idea of what caused the event. Linked root cause codes are transcribed to the current event from a previous event that has had a root cause analysis.</li> <li>(S) Rough/link cause code 2</li> <li>(S) Rough/link cause code 3</li> <li>(S) Rough/link cause code 4</li> <li>Link to Acc</li></ul>

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
47. List fields related to the outcome of event	<ul> <li>(P) B.7 Product issued? Yes, No</li> <li>If the event involved a product and the product left the control of the transfusion service, then yes.</li> <li>If the event involved a product and was discovered before it left the transfusion service, then no.</li> <li>If the event did not involve a product, then no.</li> <li>(P) B.8 Product administered? Yes, No</li> <li>If the event involved a product and the product was administered to the patient, then yes. If the event involved a product and the product and was discovered before administering it to the patient, then no. If the event did not involve a product, then no. If the event did not involve a product, then no. If the event did not involve a product, then no.</li> <li>Investigation Report</li> <li>(S) 1. Consequent (Discovery) Code (6 digits) - From left to right - first space record event type 1-no recovery, harm;2-no recovery, no harm;3-near miss, unplanned recovery;4- near miss, planned recovery. Two middle spaces are for the consequent process code (where the event was discovered. Three spaces are for the subprocess code that further describes the event. Use Event Codes for this - (~100 codes for transfusion services; ~200 codes for blood centers)</li> </ul>
48. List any other fields related to the event or any other information collected by the reporting system (e.g. root cause analysis, investigations)	Accession Number - used to track this record Fields related to event DISCOVERY (P) A.6 Where discovered - Captures general location of where the event was discovered. Trans service OR ER ICU L&D Clinic Hosp. Ward Other Location Code (optional) - organization user defined field (P) A.9 - This event was discovered - Captures where in the process the event was captured. Events that affected the safety, purity, potency and/or efficacy of the product should be categorized according to where the product was at time of discovery. If the event did not affect safety, purity, potency or efficacy, then categorize according to the process that was being carried out at the time of discovery. If the event did not involve a patient or product, mark the choice 'event did not involve a product.' product check in before testing patient sample after pt test verif/before xmatch during xmatch/processing after xmatch/processing after administration subsequent pt test event did not involve a product other

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
H. Implications	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
49. Integration with other systems	Looking at feasibility of linking to BPD at FDA. What is status of this?
50. Methods used to de-identify data	Individual databases without knowing identity of source - only basic demographic information is taken during registration
51. Technical Information	To be completed by data storage staff
Part II. Data Structure & Storage:	
I. Facility/Location	
52. Address of data storage facility	600 W. 168 St. NY 10032
53. What type of facility is used to store data (3rd party data center, secured computer room, someone's cubicle)?	Secured Computer Room
54. Is there a network interconnect for physically distributed systems?	SSL
55. What type (private lines, VPN, Internet) of network interconnect?	Internet
56. What is the network protocol (TCP/IP, IPX, etc.)?	SSL over TCP/IP
57. What is the bandwidth of network interconnect (dial-up, ISDN, T1, T3, etc.)?	T1
58. What is the network (WAN) topology, including diagram if available?	
59. Who designed the system? Who operates the system?	
J. Data Storage System / Server	
60. Who is the manufacturer (Sun, HP, IBM, Compaq, etc.)?	Dell
61. What is the model number (Sun Enterprise 10000, HP 9000, etc.)?	PowerEdge 2450
62. What is the number/speed (Mhz) of processors?	2 x1GHz
63. How much memory is available (Gb)?	1 GB
64. What is the disk - manufacturer, amount (Gb) & type (SAN, RAID Array, etc.)?	9 x 18 GB
65. What is the operating system (e.g. Sun Solaris 2.6.1)?	Windows 2000
K. For Each Application	
66. What commercial off-the-shelf (COTS) software (e.g. RDBMS, Query/Reporting Tools, etc.) is utilized?	IBM DB2

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
67. What custom-programmed application software is utilized? Using which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	Java Servlets
68. Which categories best describe this system?	
- Is there an Operational Data Store?	No
- Is there an all-encompassing data warehouse versus focused data mart(s)?	No
-Is there Online Transaction Processing (OLTP) system utilizing a normalized relational database design?	No
- Is there a data warehouse utilizing a normalized relational database design?	Yes
- Is there a dimensional Data Warehouse utilizing a star schema design?	No
- Is there a statistical analysis system utilizing flat files, either raw data or in a format intrinsic to the system (e.g. SAS or SPSS internal system format)?	No
- Is there an Online Analytical Processing (OLAP) utilizing denormalized relational design such as star-schema or snowflake schema?	No
- Is there an OLAP system utilizing multidimensional design (e.g. hypercubes)?	No
- Are there other structured data formats, such as XML, HTML, or other?	No
69 How is the data structured?	
- Is there an event occurrence (EO) table with one row per event?	Yes. Centers - 1 row per hospital or center PK: CenterId
- Is there a person table with one row per person, linked to events by PERSONID?	Yes. Users - 1 row per user, PK: centerId+userId
- Is there an adverse-event (AE) taxonomy table, with one row per event type, linked one- to-many to the EO table by AEID?	Yes. EventDiscovery: 1 row per event. PK: centerId+report_accession_no
70. How much disk space is currently allocated to the system?	QaSysopReport 1 row per event PK: centerId+report_accession_no
	RCAReport - 0 or 1 root cause analysis per event PK: centerId+report_accession_no
L. Major Data Structure	MERS-TM
72. What is the width of the table/file/ subject data area (bytes)?	<ol> <li>(1) EventDiscovery table 1100 bytes per record/event</li> <li>(2) RootCause table 1000 bytes per record/event</li> <li>(3) QA Sysops 1000 bytes per record/event.</li> <li>(4) users 55 bytes per record/user.</li> <li>(5) Centers 65 bytes per record/center</li> <li>(6) Authorization ~50 bytes per record</li> </ol>
73. How many data elements (approximate) in the table / file / subject data area?	

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
74. What is the raw data record size (bytes) or structured raw data such as HTML or XML?	
75. What is the approximate number of rows in the table, or observations?	
76. What time period is currently represented in the database? Projected change over the next 1-3 years?	
77. Are there any theoretical maximums that cannot be exceeded? (e.g. # providers, # recipients, etc.)	
Part III. Data Use & Analysis	
78. System Contact	Harold S. Kaplan, MD, Quay Mercer and Barbara Rabin Fastman, Ron Levitanat. System Location: on-site at hospital participants. System Owner: Columbia University, with Univ. Kansas and UT Southwestern - grant form NHLBI
79. Contact Address	
80. Contact Phone	Ron - 917-566-3716
81. Contact Email	
82. Hardware Platform	Web-based
83. Operating System	Server: Windows 2000 or Red Hat Linux 7.2; IBM DB2 7.2
84. Who is the developer?	Columbia Univ. with Univ. Kansas and UT Southwestern
85. Who is responsible for the architecture?	Web Browser -> Java Servlet Engine -> RDBMS (DB2)
86. User Types	Hospital transfusion services, blood centers, FDA, researchers
87. What is the frequency of reports?	Done in real time, interactively
88. Who generates the reports?	User
89. What is the method of access?	Interactive web page
90. What is the turnaround time?	Done in real time
91. What is the level of automation	1. Single click (find similar cases); 2. Query by form (find cases that match one or more form values); 3. Parameterized canned (frequency distributions, trend charts); 4. SQL for power users
92. Type Of Reports	HTML links to forms in result set; screen view with graphics, exportable downloads
93. What is the unit of observation?	the reported event
94. What are the available data fields?	see web-based forms??
95. Is there a controlled vocabulary?	yes
96. Exportability	ASCII, XLS (MS Excel), .MDB (MS Access) (DB2 tables - can create nearly any export format, ODBC?)
97. User Profile	Hospital/University, blood center staff; FDA; researchers - primarily internal hospital
98. How are the reports used?	Support of regulations and standards, Quality Assurance, Quality Improvement, Risk Management, research

Reporting or Database System:	Medical Event Reporting System for Transfusion Medicine (MERS-TM)
99. Report Dissemination	Reports are user-generated and distributed. All participants are granted access to the aggregate (multi-hospital) database for report generation and benchmarking.
100. What is the primary goal?	Quality Assurance; Process improvement leading to patient safety
101. Linkable to Detail	no
102. HIPAA Compliant	yes
Comments:	<ul> <li>MERS-TM has a unique way of protecting identity of facility. Each facility has its own database on the MERS-TM server, but MERS-TM has no way to identify which database belongs to a particular database</li> <li>MERS-TM uses Eindhoven Classification coding system for error classification, also has event codes – more broad than NCCMERP</li> <li>Reporting system uses fuzzy matching and conjunctive for identifying related errors and improving relevance of reporting. Also uses Accession number to link discovery reports, investigation reports, and RCAs. Prefix can be applied to accession number to further assist in classification</li> <li>Access to databases by MERS-TM staff allows them to monitor coding practices, event reporting practices and guide organizations toward more standardized methods. MERS-TM staff can send users 'broadcast' messages without knowing identity of organization Differences between their system and the FDA Biologics Product Deviation Reporting System. One - MERS-TM uses more standard fields, codes vs.</li> <li>'fill in the blanks' to make it easier to sort and analyze data. Two - they developed and standardized the entry for root cause analysis so that it was much easier to identify what major CAUSES of errors and to work on ways to do something about them. FDA BPD system (like the other FDA systems) focuses on the what, when, where, but not on the why?</li> </ul>

## MPSMS

 Reporting or Database System:
 CMS Medicare Patient Safety Monitoring System (MPSMS)

**Part I. & III:** The MPSMS system is in the process of being developed, and at the time of our inquiry few details were available with respect to the specific measures, data structures, and analyses. As a result, data collection forms are incomplete for several aspects of the system.

## Part II. Data Structure & Storage:

I. Facility/Location	
1. System Description	The MPSMS is a new system, which is currently in the conceptualization phase, that is being considered for pilot stage development by CMS and its partners on the Patient Safety Task Force. The overall goal of the MPSMS is to produce rates of adverse patient events and risk factors that contribute to them among the Medicare population.
52. Address of data storage facility	Qualidigm, 100 Roscommon Drive, Middletown, CT 06457-1591
53. What type of facility is used to store data (3rd party data center, secured computer room, someone's cubicle)?	
54. Is there a network interconnect for physically distributed systems?	
55. What type (private lines, VPN, Internet) of network interconnect is used?	
56. What is the network protocol (TCP/IP, IPX, etc.)?	
57. What is the bandwidth of network interconnect (dial-up, ISDN, T1, T3, etc.)?	
58. What is the network (WAN) topology, including diagram if available?	
59. Who designed the system? Who operates the system?	
J. Data Storage System/Server	
60. Who is the manufacturer (Sun, HP, IBM, Compaq, etc.)?	
61. What is the model number (Sun Enterprise 10000, HP 9000, etc.)?	
62. What is the number/speed (Mhz) of processors?	
63. How much memory is available (Gb)?	
64. What is the disk - manufacturer, amount (Gb) & type (SAN, RAID Array, etc.)?	
65. What is the operating system (e.g. Sun Solaris 2.6.1)	MS Windows NT, 2000, or XP
Other COTS	

Reporting or Database System:	CMS Medicare Patient Safety Monitoring System (MPSMS)
K. For Each Application	
66. What commercial off-the-shelf (COTS) software (e.g. RDBMS, Query/Reporting Tools, etc.) is utilized?	Access database
67. What custom-programmed application software is utilized? Using which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	MedQuest Clinical Data Collection Design System
system?	Statistical analysis system utilizing flat files, either raw data or in a format intrinsic to the system (e.g. SAS or SPSS internal system format)
- Is there an Operational Data Store?	
- Is there an all-encompassing data warehouse versus focused data mart(s)?	
- Is there an Online Transaction Processing (OLTP) system utilizing a normalized relational database design?	
- Is there a Data warehouse utilizing a normalized relational database design?	
-Is there a Dimensional Data Warehouse utilizing a star schema design?	
- Is there a statistical analysis system utilizing flat files, either raw data or in a format intrinsic to the system (e.g. SAS or SPSS internal system format)?	
-Is there an Online Analytical Processing (OLAP) utilizing denormalized relational design such as star-schema or snowflake schema?	
- Is there an OLAP system utilizing multidimensional design (e.g. hypercubes)?	
- Are there other structured data formats, such as XML, HTML, or other?	
- Data Mart	
69.How is the data structured?	A person table with one row per person, linked to events by Provider Number (or HIC ?)
- Is there an event occurrence (EO) table with one row per event?	
- Is there a person table with one row per person, linked to events by PERSONID?	

Reporting or Database System:	CMS Medicare Patient Safety Monitoring System (MPSMS)
- Is there an adverse-event (AE) taxonomy table, with one row per event type, linked one-to-many to the EO table by AEID?	
70. How much disk space is currently allocated to the system?	
71. How much disk space is available on this system?	
L. Major Data Structure	
72. What is the width of the table/file/subject data area (bytes)?	
73. How many data elements (approximate) in the table / file / subject data area?	(According to draft data dictionary) 183 fields
74. What is the raw data record size (bytes) or structured raw data such as HTML or XML?	
75. What is the approximate number of rows in the table, or observations?	55 - 60 K (approximately 1100 taken from each state; a 10% random sample)
76. What time period is currently represented in the database? Projected change over the next 1-3 years?	
77. Are there any theoretical maximums that cannot be exceeded? (e.g. # providers, # recipients, etc.)	

NHANES		
Reporting or Database System:	National Health and Nutrition Examination Survey	
Part I. Data Acquisition:		
A. General Information		
1. Report Title	N/A	
2. Internet Location: http://	http://www.cdc.gov/nchs/nhanes.htm	
3. Host Organization(s)	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention	
4. Primary contact information (e.g. Address, Phone)	National Center for Health Statistics Division of Data Services Hyattsville, MD 20782-2003 (301) 458-4636	
B. Overall System Features		
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	The National Health Survey Act, passed in 1956, provided the legislative authorization for a continuing survey to provide current statistical data on the amount, distribution, and effects of illness and disability in the United States.	
	To comply with the 1956 act, the National Center for Health Statistics (NCHS), a branch of the U.S. Public Health Service in the U.S. Department of Health and Human Services, has conducted seven separate examination surveys to collect interview and physical examination data.	
	The first three of these national health examination surveys (NHES) were conducted in the 1960s: NHES I focused on selected chronic disease of adults aged 18-79. NHES II and NHES III focused on the growth and development of children. The NHES II sample included children aged 6-11, while NHES III focused on youths aged 12-17. All three surveys had an approximate sample size of 7,500 individuals.	
	<ul> <li>Beginning in 1970 a new emphasis was introduced. The study of nutrition and its relationship to health status had become increasingly important as researchers began to discover links between dietary habits and disease. In response to this concern, under a directive from the Secretary of the Department of Health, Education and Welfare, the National Nutrition Surveillance System was instituted by NCHS. The purpose of this system was to measure the nutritional status of the U.S. population and changes over time. A special task force recommended that a continuing surveillance system include clinical observation and professional assessment as well as the recording of dietary intake patterns. Thus, the National Nutrition Surveillance System was combined with the National Health Examination Survey to form the National Health and Nutrition Examination Survey (NHANES). Four surveys of this type have been conducted since 1970:</li> <li>The goals of NHANES are as follows:</li> </ul>	
	1. To estimate the number and percent of persons in the U.S. population and designated subgroups with selected diseases and	

Reporting or Database System:	National Health and Nutrition Examination Survey
<ul><li>6. What is the geographic scope of data collection (national, state, local, facility etc)?</li></ul>	<ul> <li>risk factors;</li> <li>2. To monitor trends in the prevalence, awareness, treatment, and control of selected diseases;</li> <li>3. To monitor trends in risk behaviors and environmental exposures;</li> <li>4. To analyze risk factors for selected diseases;</li> <li>5. To study the relationship between diet, nutrition, and health;</li> <li>6. To explore emerging public health issues and new technologies; and</li> <li>7. To establish a national probability sample of genetic material for future genetic testing.</li> </ul>
7. What is the unit of data entry (e.g., event, patient, product)?	Patient responses to questionnaires. As in the previous NHANES people are screened using sample selection. This is followed by detailed household interviews. Sample persons are invited to receive physical examinations and health and dietary interviews in mobile examination centers (MECs).
	Home examinations consisting of a subset of exam components are offered to those sample persons who are unwilling or unable to come to the MEC for the full examination. Various medical tests and procedures are conducted to enable analysis of the relationship between health and nutrition status and disease risk factors, to measure the prevalence and comorbidity of diseases and disorders, to establish reference standards, and to monitor secular trends in health and nutrition status.
8. Who is allowed/required to input information?	Interviewers/Researchers
9. What are the regulations/laws affecting reporting?	Information is gathered and protected according to requirements of Federal Laws: the Public Health Service Act (42 USC 242K) authorizes collection and Section 308 (d) of that law (42 USC 242m) and the Privacy Act of 1974 (5 USC 552A) Prohibits screeners from giving out information that identifies individuals or their family without their consent, even if a court of law asks for it. When researchers are allowed use of the survey data, code numbers are used to replace names or other facts that could identify persons. Individual answers are combined with those from thousands of other people. Survey findings are reported in percentages and totals to protect the privacy of those who took part in the survey.
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	N/A

Reporting or Database System:	National Health and Nutrition Examination Survey
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	Selected persons are invited to take part in the survey by being interviewed in their homes. Household interview data is collected via Computer Assisted Personal Interviewing (CAPI) and includes demographic, socioeconomic, dietary, and health-related questions. Upon completion of the interview, sample persons are asked to participate in a physical examination. The examination will be conducted in a specially equipped and designed Mobile Examination Center (MEC), consisting of four trailers. The MEC houses all of the state-of-the are equipment for the physical exam and test conducted. The trailers are divided into rooms to assure the privacy of exact study participant during the examination and interview. This examination includes a physical and dental examination conducted by a physician and a dentist, laboratory tests, x-rays, and other health interviews conducted by highly trained medical personnel.
12. What are the methods of editing information (e.g. correcting/add more information to records)	When an interview has been completed, interviewers will edit their work, carefully reviewing all forms for completeness and legibility. To insure the accuracy and completeness of the survey, all of interviewer work will be edited by the field office staff, and then validated by recontacting respondents.
13. Where is the collected data stored (name of database, number of data storage locations)?	Some NCHS data systems and surveys are ongoing annual systems while others are conducted periodically. NCHS has two major types of data systems: systems based on populations, containing data collected through personal interviews or examinations; and systems based on records, containing data collected from vital and medical records.
14. How often is the system revised (annual, semi-annual etc)?	Annually (Current NHANES is a continuous national sample)
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	Internal review
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	Data collection involves at least 3 sources: (1) Direct interview (2) clinical tests, measurements, and physical examinations on sample persons; and (3) places where persons received medical care such as hospitals, clinics, and doctors offices.

Reporting or Database System:	National Health and Nutrition Examination Survey
17. What new features are being planned and/or are on wish lists?	The National Nutrition Monitoring and Related Research Act of 1990 set goals and mechanisms to bring about greater coordination of nutrition monitoring across agencies. In 1998 the leadership of DHHS and USDA identified a more comprehensive integration of these two surveys as a major priority. The framework for this integration includes a common dietary intake methodology and processing system provided by USDA and the sample and data collection capability provided by the National Health and Nutrition Examination Survey (NHANES) of DHHS. Survey integration will occur in phases to permit successful testing and implementation of the new USDA Automated Dietary Intake System into the NHANES, to decide on what dietary and related nutrition information should be included in data collection to meet policy and program needs of users, and to prepare data processing and release plans. In 2001, considered to be the testing and implementation phase, the new USDA Automated Multiple- Pass Method is being adapted for implementation into the NHANES integrated survey information system and operationally tested on 100 individuals. Dietary data collection for the integrated survey is scheduled to begin in NHANES 2002.
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	Beginning in 1999, NHANES is a continuous, annual survey that can be linked to related Federal Government surveys of the general United States (U.S.) population, specifically, the National Health Interview Survey (NHIS) and, in the future, the U.S. Department of Agriculture's (USDA) Continuing Survey of Food Intakes by Individuals (CSFII). NHANES is linked to NHIS at the Primary Sampling Unit (PSU) level (i.e., the same counties, but not necessarily the same individuals, will be in both surveys). NHANES is linked to NHIS with regard to questionnaire content of the household interview, for selected topics. Links to Medicare and National Death Index records will permit longitudinal/historical studies of disease. These interrelationships with existing surveys and databases follow the Department of Health and Human Services' Survey Integration Plan. Beginning in January 2002, the USDA CSFII study will merge with NHANES. The merged survey sample will be composed of the NHANES examination sample and an additional sample whose characteristics will be defined at a later date. The integrated survey—the National Food and Nutrition Survey (NFNS) will provide comprehensive information on health and nutrition characteristics of the U.S. population. NCHS and USDA are working to finalize the NFNS sample design, core questionnaires, dietary interview protocol, and data processing and reporting plans.

Reporting or Database System:	National Health and Nutrition Examination Survey
D. Fields related to contributor/participant Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify); N-Narrative; FF- fixed format (e.g. date)
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	<ul> <li>There are two levels of field organizations for this study-the home office staff and the field staff.</li> <li>(1) Home Office Staff from Westat- Project staff from Westat are responsible for overseeing the field work.</li> <li>(2) Field Staff- Field staff consists of three groups of employees: The stand office staff, the interviewers, and the MEC staff.</li> </ul>
	The number of people examined in a 12-month period will be about the same as in previous NHANES, about 7,000 persons per year in 15 locations.
	Data collection for NHANES main survey began in early 1999. Westat has been contracted to conduct the study for approximately six years at 88 locations (stands) across the United States. Nearly 7,000 individuals per year of all ages in households across the United States will be randomly selected to participate in the main survey. The study respondents include whites as well as an over sample of blacks and Mexican Americans. The study design also includes a representative sample of these groups by age, sex, and income level. Adolescents, older persons, and pregnant women will also be over sampled.
	Survey questionnaires are administered in person at the respondents home and in the MEC. Data is collected by Household interviewers and MEC interviewers. Depending on the context of the data, data collected in the MEC can also be collected with the use of CAPI and ACASI (audio computer assisted self interview) technique so that the participant can answer the question in total privacy.
20. Is participation mandatory or voluntary?	Participation is not mandatory. Participants are selected through a complex statistical process using the most current Census information. In simple terms, NHANES divides the United States into communities. The communities are divided into neighborhoods. The neighborhoods are selected at random. From each neighborhood, housing units are selected at random. Selected households are approached by our interviewers who ask residents a few short questions to determine if their household is eligible for the study.
	You have a unique health profile; if you are selected to be a participant, no other person can be substituted for you. You were selected based on your age, gender, and racial/ethnic background. No one can take your place in this survey.
21. List fields related to contributor/participant contact information	(P)- random selection of participants

Reporting or Database System:	National Health and Nutrition Examination Survey
information(include type of facility, teaching status, id information)	To discuss any aspect of the survey, you can make a free call to Dr. Kathryn Porter at the U.S. Public Health Service office at 1- 800-452-6115. If you have questions about your rights as a survey participant, call Dr. Lester R. Curtin at 1-800-223-8118. Staff - The NHANES staff consist of professional individuals
	with a variety of health, research, and academic backgrounds. The staff at the mobile examination center include: a doctor, a dentist, a phlebotomist, health technicians and highly trained interviewers. The home interviewers have varied backgrounds in fields such as social work, the military, and education. The staff at headquarters include: medical doctors, PhDs, nurses, health educators, and engineers.
23. List fields related to distributor contact information	Public Use Data Files for the third National Health and Nutrition Examination Survey will be available from the National Technical Information Service (NTIS). Information regarding a bibliography on disk of journal articles citing data from all the NHANES and the availability of NHANES III data in CD- ROM/SETS software format can be obtained from the Data Dissemination Branch (301) 436-8500 or by writing to: Data Dissemination Branch National Center for Health Statistics Room 1018 6525 Belcrest Road Hyattsville, Maryland 20782
24. List fields related to manufacturer contact information	N/A
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
25. List fields related to Provider of Care identification	N/A
26. List fields that identify types of care providers included in system	N/A
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system- assigned ID etc)	
28. List fields related to patient contact information (e.g. address, zip code, county, region)	Address, zip code, county, region
29. List fields related to patient demographics (e.g. age, sex, race)	Sample weights, age, race, sex, ethnic background, household composition, individual characteristics, health insurance, family background, occupation of family head, housing characteristics, family characteristics, orientation.

Reporting or Database System:	National Health and Nutrition Examination Survey
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)	Psuedo id is assigned
31. List fields related to pre-existing conditions and/or medical history of patient	Diabetes questions, high blood pressure and cholesterol questions, cardiovascular disease questions, musculoskeletal conditions, physical functioning questions, gallblader disease questions, Kidney conditions, respiratory and allergy questions, diet questions, alcohol and drug use, reproductive health.
32. List fields that capture the clinical condition of patient at time of event	Blood pressure measurements; vision questions, hearing questions, diet questions
33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)	N-Who in the "family" is covered by health insurance or some other kind of health care plan (including government programs like Medicare and Medicaid)? Type of coverage (does it include dental care, is it an HMO, IPA, PPO, POS, Other)?
34. List any other types of information collected about the patient	
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer)	
37. List fields associated with medical device- related events (e.g. brand name of device, type of device, usage, manufacturer name, operator of device)	N/A
38. List fields associated with vaccine related events.	N/A
39. List fields associated with infection related events.	N/A
40. List fields associated with any other type of event. List type of event.	N/A
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	
42. List fields associated with when the event occurred	
43. List fields associated with tracking the time between the event, when reported, when acted upon etc	
44. List fields associated with where the event occurred	N/A

Reporting or Database System:	National Health and Nutrition Examination Survey
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event	N/A
46. List fields related to follow-up of event that are not associated with a particular patient(medication/manufacturing/policy actions to correct/update event)	N/A
47. List fields related to the outcome of event	N/A
48. List any other fields related to the event or any other information collected by the reporting system (e.g. root cause analysis, results of investigations etc)	The results of surveys, analyses, and studies are made known through a number of data release mechanisms including publications, mainframe computer data files, CD-ROMs (Search and Retrieval Software, Statistical Export and Tabulation System (SETS)), and the Internet (http://www.cdc.gov/nchswww/nchshome.htm).
H. Implications	
49. Integration with other systems	The National Nutrition Monitoring and Related Research Act of 1990 set goals and mechanisms to bring about greater coordination of nutrition monitoring across agencies. In 1998 the leadership of DHHS and USDA identified a more comprehensive integration of these two surveys as a major priority. The framework for this integration includes a common dietary intake methodology and processing system provided by USDA and the sample and data collection capability provided by the National Health and Nutrition Examination Survey (NHANES) of DHHS. Survey integration will occur in phases to permit successful testing and implementation of the new USDA Automated Dietary Intake System into the NHANES, to decide on what dietary and related nutrition information should be included in data collection to meet policy and program needs of users, and to prepare data processing and release plans. In 2001, considered to be the testing and implementation phase, the new USDA Automated Multiple- Pass Method is being adapted for implementation into the NHANES integrated survey information system and operationally tested on 100 individuals. Dietary data collection for the integrated survey is scheduled to begin in NHANES 2002.
50. Methods used to de-identify data	
51. Technical Information	

**Part II. & III.:** NHANES and NHIS are families of surveys and other information collected from subsets of the general population rather than the specific populations (e.g., Medicare patients) and events (e.g., biological product deviations, adverse drug events) that comprise other data systems. Although results from NHANES and NHIS are designed to be generalizable, the sample-based design is such that it does not facilitate linkage of records across systems. Thus, we did not explore the data storage and data structure components of these systems. We did not populate the data use and analysis form since these are research databases with virtually limitless uses and possible analyses.

NHIS	
Reporting or Database System:	National Health Interview Survey
Part I. Data Acquisition:	
A. General Information	
1. Report Title	N/A
2. Internet Location: http://	http://www.cdc.gov/nchs/nhis.htm
3. Host Organization(s)	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention
4. Primary contact information (e.g. Address, Phone)	For publications and information: Data Dissemination Branch National Center for Health Statistics Centers for Disease Control and Prevention 6525 Belcrest Road, Room 1064 Hyattsville, Maryland 20782-2003 (301) 458-4636 Internet home page address: www.cdc.gov/nchs/
B. Overall System Features	
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	The main objective of the NHIS is to monitor the health of the United States population through the collection and analysis of data on a broad range of health topics. A major strength of this survey lies in the ability to display these health characteristics by many demographic and socioeconomic characteristics. The NHIS covers the civilian noninstitutionalized population of the United States living at the time of the interview. Because of technical and logistical problems, several segments of the population are not included in the sample or in the estimates from the survey. Persons excluded are patients in long-term care facilities; persons on active duty with the Armed Forces (though their dependents are included); and U.S. nationals living in foreign countries.
6. What is the geographic scope of data collection (national, state, local, facility etc)?	National The National Health Interview Survey (NHIS) is the principal source of information on the health of the civilian noninstitutionalized population of the United States and is one of the major data collection programs of the National Center for Health Statistics (NCHS). The National Health Survey Act of 1956 provided for a continuing survey and special studies to secure accurate and current statistical information on the amount, distribution, and effects of illness and disability in the United States and the services rendered for or because of such conditions. The survey referred to in the Act, now called the National Health Interview Survey, was initiated in July 1957. Since 1960, the survey has been conducted by NCHS, which was formed when the National Health Survey and the National Vital Statistics Division were combined.

Reporting or Database System:	National Health Interview Survey
7. What is the unit of data entry (e.g., event, patient, product)?	Person response to questionnaire.
(e.g., event, patient, product)?	All the counties in the United States, as reported in the 1990 Decennial Census, are examined. From each group, one or more counties is selected to represent all of the counties in the group. The selected counties are called primary sampling units (PSU). Within each PSU small land areas and groups of addresses are selected and referred to as segments. Each segment contains addresses which are assigned for interview in one or more quarterly samples.
8. Who is allowed/required to input information?	Interviewers/Researchers
9. What are the regulations/laws affecting reporting?	The National Health Interview Survey is part of the National Health Survey, which began in May 1957. Despite extensive research on individual diseases in the years 1937-1957, one important element had been missing. We had piece-meal information from the people themselves on their illness and disability, or the medical care they obtained. Many persons, although sick or injured, never became a "health statistic" because requirements for reporting illnesses were limited to hospitalized illnesses and certain contagious diseases. In recognition of the fact that current information on the Nation's health was inadequate, and that national and regional health statistics are essential, the Congress authorized a continuing National Health Survey (Public Law 652 of the 84th Congress). Since May 1957, the United States Public Health Service has regularly collected health statistics under Congressional authority.
	Information is gathered and protected according to requirements of Federal Laws: the Public Health Service Act (42 USC 242K) authorizes collection and Section 308 (d) of that law (42 USC 242m) and the Privacy Act of 1974 (5 USC 552A) Prohibits screeners from giving out information that identifies individuals or their family without their consent, even if a court of law asks for it. When researchers are allowed use of the survey data, code numbers are used to replace names or other facts that could identify persons.
	Individual answers are combined with those from thousands of other people. Survey findings are reported in percentages and totals to protect the privacy of those who took part in the survey.
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	N/A

Reporting or Database System:	National Health Interview Survey
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	Data are collected through a personal household interview conducted by interviewers employed and trained by the U.S. Bureau of the Census according to procedures specified by NCHS.
	For the Family Core component of the Basic module, all adult members of the household 17 years of age and over who are at home at the time of the interview are invited to participate and to respond for themselves. For children and for adults not at home during the interview, information is provided by a responsible adult family member (18 years of age and over) residing in the household. For the Sample Adult questionnaire, one adult per family will be randomly selected; this individual must respond for themselves to the questions in this section. Information for the Sample Child questionnaire will be obtained from a knowledgeable adult in the household.
	The Bureau of the Census under a contractual agreement is the data collection agent for the NHIS. Nationally, the NHIS uses about 400 interviewers, trained and directed by health survey supervisors in each of the 12 Bureau of the Census Regional Offices. The supervisors are career Civil Service employees whose primary responsibility is the National Health Interview Survey. The interviewers are part-time employees, selected through an examination and testing process. Interviewers receive thorough training in basic interviewing procedures and in the concepts and procedures unique to the NHIS.
	In the past the NHIS interview have been conducted using paper and pencil. The revised NHIS questionnaire is conducted using a computer assisted personal interviewer (CAPI). The CAPI version of the NHIS questionnaire is administered using a laptop computer and interviewers enter responses directly into the computer during the interview. This computerized mode offers distinct advantages in terms of timeliness of the data and improved data quality.
12. What are the methods of editing information (e.g. correcting/add more information to records)	N/A
13. Where is the collected data stored (name of database, number of data storage locations)?	In the past the NHIS interview have been conducted using paper and pencil. The revised NHIS questionnaire is conducted using a computer assisted personal interviewer (CAPI). The CAPI version of the NHIS questionnaire is administered using a laptop computer and interviewers enter responses directly into the computer during the interview. This computerized mode offers distinct advantages in terms of timeliness of the data and improved data quality.
14. How often is the system revised (annual, semi-annual etc)?	The National Health Interview Survey is conducted annually by the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). Each week a probability sample of the civilian non-institutionalized population of the United States is interviewed by personnel of the U.S. Bureau of the Census.

Reporting or Database System:	National Health Interview Survey
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	The NHIS is a personal visit survey, not a telephone survey. Households must be visited to conduct the interviews. Telephone contacts may be used-once the initial personal contact has been made-to complete partial interviews, complete the HIS-2A(PT) Immunization Form, or to collect other missing parts of the interview for which a callback has been made.
17. What new features are being planned and/or are on wish lists?	N/A
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	The NHIS also has a central role in the ongoing integration of household surveys in DHHS. The designs of two major DHHS national household surveys are already linked to the NHIS, the National Survey of Family Growth and the Medical Expenditure Panel Survey. Other DHHS surveys will be linked to the NHIS in the future. These linked surveys will use the NHIS respondent sample as a sampling frame, will obtain additional information from their sample drawn from the NHIS, and will then combine that data with the information collected in the original NHIS interview.
D. Fields related to contributor/participant Information:	
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	The National Health Interview Survey is authorized by title 42, Unites States Code, section 242k. All information that would permit identification of the individual is held strictly confidential, seen only by persons engaged in the National Health Interview Survey (including related studies carried out by the Public Health Service) and not disclosed or released to others for any other purpose without the written consent of the individual.
20. Is participation mandatory or voluntary?	The fact that participation in the NHIS is voluntary does not diminish interviewers responsibility to convert reluctant respondents. Remind the participant of the confidential nature of the survey. Inform them that they can refuse to answer any question they feel is too personal.
21. List fields related to contributor/participant contact information	It would be too costly and time-consuming to interview everyone in the United States and therefore a sample of addresses was selected. The respondent lives at one of the representative addresses picked. The selection was not based on who lives at the address, nor whether they have problems with their health. Each person represents approximately 2,500 other persons. Taken as a group, the people living at these sample addresses will represent the total population of the United States in the health statistics produced and published by the U.S. Public Health Service.
22. List fields related to facility contact information (include type of facility, teaching status, id information)	

Reporting or Database System:	National Health Interview Survey
23. List fields related to distributor contact	-
information 24. List fields related to manufacturer contact information	N/A
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
25. List fields related to Provider of Care identification	N/A
26. List fields that identify types of care providers included in system	N/A
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system- assigned ID etc)	
28. List fields related to patient contact information (e.g. address, zip code, county, region)	Address, zip code, county, region
29. List fields related to patient demographics (e.g. age, sex, race)	name, age, race, sex, place of birth, citizenship status, education, main activity last week, hours worked last week, total earnings in last calendar year.
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)	
31. List fields related to pre-existing conditions and/or medical history of patient	
32. List fields that capture the clinical condition of patient at time of event	Questions regarding limitations due to physical, mental, or emotional problems.
33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)	N-Who in the "family" is covered by health insurance or some other kind of health care plan (including government programs like Medicare and Medicaid)? Type of coverage (does it include dental care, is it an HMO, IPA, PPO, POS, Other)?
34. List any other types of information collected about the patient	Questions regarding injuries or poisonings that may have occurred in the past three months which caused a person to get medical advice or treatment.
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N-Narrative; FF- fixed format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	N/A
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer)	N/A

Reporting or Database System:	National Health Interview Survey
37. List fields associated with medical device-	N/A
related events (e.g. brand name of device, type of	
device, usage, manufacturer name, operator of	
device)	
38. List fields associated with vaccine related	N/A
events.	
39. List fields associated with infection related	N/A
events.	
40. List fields associated with any other type of	N/A
event. List type of event.	
41. List fields that allow input and/or	N/A
classification of the event/harm (narratives,	
problem codes, adverse event terms)	
42. List fields associated with when the event	N/A
occurred	
43. List fields associated with tracking the time	N/A
between the event, when reported, when acted	
upon etc	
44. List fields associated with where the event	N/A
occurred	
45. List fields associated with patient diagnosis,	N/A
care, treatment, tests, and other follow-up	
provided to patient because of the event	
46. List fields related to follow-up of event that	N/A
are not associated with a particular patient	
(medication/manufacturing/policy actions to	
correct/update event)	
47. List fields related to the outcome of event	N/A
48. List any other fields related to the event or any	,
other information collected by the reporting	
system (e.g. root cause analysis, results of	
investigations etc)	
H. Implications	
	NUUC data are used and data through out the Department of Health
49. Integration with other systems	NHIS data are used widely throughout the Department of Health
	and Human Services (DHHS) to monitor trends in illness and disability and to track progress toward achieving national health
	objectives. The data are also used by the public health research
	community for epidemiologic and policy analysis of such timely
	issues as characterizing those with various health problems,
	determining barriers to accessing and using appropriate health
	care, and evaluating Federal health programs.
	care, and evaluating rederar nearth programs.
	The NHIS also has a central role in the ongoing integration of
	household surveys in DHHS. The designs of two major DHHS
	national household surveys are already linked to the NHIS, the
	National Survey of Family Growth and the Medical Expenditure
	Panel Survey. Other DHHS surveys will be linked to the NHIS in
	the future. These linked surveys will use the NHIS respondent
	sample as a sampling frame, will obtain additional information
	from their sample drawn from the NHIS, and will then combine
	that data with the information collected in the original NHIS
1	interview.

Reporting or Database System:	National Health Interview Survey
50. Methods used to de-identify data	
51. Technical Information	
general population rather than the specific populat deviations, adverse drug events) that comprise oth designed to be generalizable, the sample-based des systems. Thus, we did not explore the data storage	of surveys and other information collected from subsets of the ions (e.g., Medicare patients) and events (e.g., biological product er data systems. Although results from NHANES and NHIS are sign is such that it does not facilitate linkage of records across and data structure components of these systems. We did not e are research databases with virtually limitless uses and possible

## NHSN

The NHSN is in the process of being developed, and at the time of our inquiry few details were available with respect to the specific data elements, architecture, and reporting functions. Although essentially a revision of the NNIS and Dialysis Surveillance systems, the design is sufficiently different from either of the existing systems. As a result, data collection forms are incomplete for this system.

NNIS		
Reporting or Database System:	The National Nosocomial Infections Surveillance System (NNIS)	
Part I. Data Acquisition:		
A. General Information		
1. Report Title	NNIS	
2. Internet Location: http://	http://www.cdc.gov/ncidod/hip/nnis/@nnis.htm	
3. Host Organization(s)	Center for Disease Control	
4. Primary contact information (e.g. Address, Phone)	Teresa C. Horan, MPH, CIC (404) 498-1114 thoran@cdc.gov	
B. Overall System Features		
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	The National Nosocomial Infections Surveillance (NNIS) System is a cooperative effort that began in 1970 between the Centers for Disease Control and Prevention (CDC) and participating hospitals to create a national nosocomial infections database. The database is used to: describe the epidemiology of nosocomial infections, describe antimicrobial resistance trends, and produce nosocomial infection rates to use for comparison purposes. The data are collected uniformly by trained infection control personnel using explicitly defined terms and surveillance protocols that target inpatients at high risk of infection and are reported monthly to CDC where they are aggregated into the database. Participation in the NNIS System is voluntary and involves only acute care general hospitals with an average daily census of at least 100 patients in the United States. Long term care facilities, such as rehabilitation, mental health, and nursing homes are not included in the NNIS System. At the beginning of 2000, approximately 315 hospitals were participating in the NNIS System is not accepting new applications for membership at this time, but plans to expand participation with the new system. The data from the NNIS System are reported annually in the NNIS Report located on the NNIS web page and in the November-December issue of the American Journal of Infection Control.	
6. What is the geographic scope of data collection (national, state, local, facility etc)?	National scope; over represented in the Mid Atlantic and South Atlantic US; under represented in the West North Central and West South Central US.	
7. What is the unit of data entry (e.g., event, patient, product)?	Patient, event, location within the hospital; also to calculate rates, there are data elements on overall utilization that are required, e.g. number of patient days in ICU vs. number of central line days. The ICU, high-risk nursery, surgical site infections and antimicrobial use and resistance surveillance are all components that require denominator data for analysis.	
8. Who is allowed/required to input information?	Infection control professionals who have been trained on the system, protocols etc.	
9. What are the regulations/laws affecting reporting?		

Reporting or Database System:	The National Nosocomial Infections Surveillance System (NNIS)
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	Patients and organizations are identified through codes (patient by the hospital; hospital by NNIS assigned code) In accordance with Sections 304, 306, and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and m(d), the information obtained for the surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution.
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	Currently, through the IDEAS (DOS based microcomputer system) data is entered, then transmitted to CDC by modem for aggregation in the NNIS database
12. What are the methods of editing information (e.g. correcting/add more information to records)	Corrections and additions to previously entered data may be made at any time through the IDEAS system.
13. Where is the collected data stored (name of database, number of data storage locations)?	CDC stores the data; data from each hospital is available at their site and facilities can grant other users access to their data.
14. How often is the system revised (annual, semi-annual etc)?	Currently under revision.
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	Since 1986, data is entered through the IDEAS system, Interactive Data Entry and Analysis system, which will be replaced by the NHSN.
17. What new features are being planned and/or are on wish lists?	Currently in major revision to move to the new National Healthcare Safety Network (NHSN) using the National Electronic Disease Surveillance System as the architectural foundation and the Program Area Modules that include NNIS, National Surveillance System for Hospital Healthcare Workers and Dialysis Surveillance Network; revisions include forms, data elements, web access, technology, format etc.
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	
D. Fields related to contributor/participant Information:	
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	Those infection control professionals who have been trained on the system; CDC assigns a unique 3-digit identification number to each NNIS hospital at the time of enrollment; it is automatically attached through IDEAS to each record
20. Is participation mandatory or voluntary?	Voluntary, but in order to remain a NNIS hospital, hospitals are required to file for six months of a 12 month period, and present a monthly surveillance Plan that indicates use of the surveillance components for the month, send data for the month that are consistent with the options of the surveillance components listed on the plan and satisfy data quality acceptance checks applied to the data upon receipt at CDC.

Reporting or Database System:	The National Nosocomial Infections Surveillance System (NNIS)
21. List fields related to contributor/participant contact information	A unique 3-digit identification number is assigned by CDC to each NNIS hospital at the time of enrollment; it is automatically attached to each record via IDEAS system. NNIS has a hospital personnel list that asks about name/contact info for the NNIS primary contact person, administrative responsibility, infection control committee chair, hospital epidemiologist, director of microbiology laboratory, and other infection control professional and support staff (form is under redesign and will be incorporated into the enrollment process).
22. List fields related to facility contact information (include type of facility, teaching status, id information)	Participation is limited to hospitals with 100 beds or more providing general medical-surgical inpatient services to adults or children requiring acute care. To participate, there are minimum staffing requirements for infection control 1 FTE/100 occupied beds and 1 FTE for additional 250 beds (these restrictions will be eliminated under the new system). Surveys have been done to determine hospital characteristics (1999).
23. List fields related to distributor contact information	N/A
24. List fields related to manufacturer contact information	N/A
E. Fields related to Provider of Care Information:	
25. List fields related to Provider of Care identification	Same as #21
26. List fields that identify types of care providers included in system	The name or code of the nursing care area where the patient was assigned is required, including specific ICU designation (Y/N) 12 codes for different ICUs provided for pick list; NICU is a separate category
F. Fields related to Patient Information:	
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	Patient identifier assigned by the hospital and may consist of any combination of no more than 12 letters and/or numbers (may be patient admission number, medical record number or social security number); patient name is optional, not required; admission date (mm/dd/yy)
28. List fields related to patient contact information (e.g. address, zip code, county, region)	None
29. List fields related to patient demographics (e.g. age, sex, race)	Sex is required (enter M, F); age of patient in years, months, days; birth weight in grams (pick list of 4 ranges)
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)?	Patient identifier assigned by the hospital

Reporting or Database System:	The National Nosocomial Infections Surveillance System (NNIS)
31. List fields related to pre-existing conditions and/or medical history of patient	If the patient underwent an operation (Y/N); defined as a surgeon makes at least one incision through the skin or mucous membrane and closes the incision before the patient leaves the OR and performs at least one NNIS operative procedure (defined by ICD9 codes); the principal operative procedures are presented in a hierarchy of highest risk by abdominal, thoracic, neurosurgical spine, neurosurgical braine.g.in abdominal category, organ transplant is #1; laparotomy is #22; some conditionally required fields for surgery include date of operation (mm/dd/yy), duration of operation (hrs min), wound class (clean, clean contaminated, contaminated, dirty/infected, unknown); general anesthesia (Y/N); ASA classification (1-5); if it were an emergency (Y/N); trauma (Y/N), endoscopic approach (Y/N), multiple procedures. NNIS has a risk index based on ASA preoperative assessment score, if the operation lasts. Additionally, there is a risk index for SSI rate and use of laproscope.
32. List fields that capture the clinical condition of patient at time of event	Unique identification number of each nosocomial infection reported to NNIS; consists of the year the infection was acquired and the infection sequence number. The service is a required data field and has defined codes (Burn, trauma, cardiac surgery, otolaryngology, general surgery, urology, gynecology, high risk nursery, medicine, neurosurgery, obstetric, medical oncology, ophthalmology, orthopedic, pediatric, plastic surgery, well baby nursery).
<ul> <li>33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)</li> </ul>	
34. List any other types of information collected about the patient	
G. Fields related to Event/Error/Product Information:	
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	For urinary tract infections: ASB for asymptomatic bacteriuria; SUTI symptomatic urinary tract infection, OUTI other urinary tract infection; For surgical site infection: a list of 23 codes designating specific organ/space site For infections other than UTI, SSI, PNEU, BSI anatomical body system groupings (9 codes) For infections other than UTI, SSI, PNEU, BSI, anatomical location or type of infection within the grouping 40 codes
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy)	N/A

Reporting or Database System:	The National Nosocomial Infections Surveillance System (NNIS)
37. List fields associated with medical	For urinary tract infections: was an indwelling urinary catheter in place
device-related events (e.g. brand name	(Y/N); other bladder instrumentation $(Y/N)$
of device, type of device, usage,	For pneumonia, was the patient on a ventilator (Y/N)
manufacturer name, operator of device)	For blood stream infection BSI, was a vascular access device terminated at or near the heart or in one of the great vessels within 48 hours before the development of the infection BSI: Central line (Y/N) For blood stream infection, did the patient have a vascular access device in place in a peripheral vessel within the 48 hour period before developing the
	infection BSI: Peripheral line: (Y/N) For BSI, did patient have total parenteral nutrition therapy either central or
	peripheral within 48 hours BSI:TPN: (Y/N)
	For BSI: did the patient have an umbilical catheter (Y/N) For BSI: what is the location of the avit site of the central or paripharal
	For BSI: what is the location of the exit site of the central or peripheral line: central line EC, peripheral line EP, Arterial line EA, central line-
	associated tunnel T, central line-associated pocket site infection P; none of the above N
	For BSI: for only select hospitals (Central line No) participating in a study For infections other than UTI, SSI, PNEU, BSI; did patient have an invasive device or procedure within 48 hrs. (Y/N) and what was the
	location central line EC, peripheral line, EP, arterial line EA, central line tunnel T, central line pocket P none of the above N For infections other than UTI, SSI, PNEU, BSI; the number of the central
	line (for select hospitals)
38. List fields associated with vaccine related events	N/A
39. List fields associated with infection related events	The areas of NNIS Surveillance Components include: Adult and pediatric intensive care units surveillance, high risk nursery surveillance, surgical patient surveillance (in the past Hospital-wide surveillance was done, but is no longer because of burden and lack of comparative integrity because of small numbers)
	There are major and specific sites of nosocomial infections have unique codes that were developed for NNIS: urinary tract infections: 3 codes; surgical site infections 7 general codes, pneumonia 1 code, BSI 2 codes, bone and joint infection 3 codes, central nervous system infection 3 codes, cardiovascular system infections 4 codes, eye ear nose throat or mouth 6 codes, gastrointestinal 5 codes, lower respiratory tract infections 2 codes, reproductive tract infection 4 codes, skin and soft tissue 8 codes, systemic
	infections 1 code For each nosocomial infection, up to four pathogens can be reported to NNIS; the system offers a complete pathogen list and a two to five character code for each pathogen.
40. List fields associated with any other type of event. List type of event.	
41. List fields that allow input and/or classification of the event/harm	There are explicit key terms used in the NNIS System with specific definitions.
(narratives, problem codes, adverse event terms)	NNIS operative procedure categories use ICD9CM codes that are specified and a list of ICD9CM that DO NOT qualify as NNIS operative procedures. All infection sites are categorized into major and specific infection sites by using standard CDC definitions that include laboratory and clinical criteria.
42. List fields associated with when the event occurred	For surgery: date of operation, infection date (mm/dd)
43. List fields associated with tracking	For surgery: date of operation, infection date (mm/dd)
the time between the event, when	For surgical site infection: detected during A admission, P post-discharge
reported, when acted upon etc	surveillance, R readmission to the hospital

Reporting or Database System:	The National Nosocomial Infections Surveillance System (NNIS)	
44. List fields associated with where the event occurred	Data is collected on all sites of nosocomial infection in patients located in <b>ICUs</b> , as well as ICU-specific denominator data. Site specific infection rates can be calculated by using as a denominator the number of patients at risk, patient days, and days of indwelling urinary catheterization, central vascular cannulation (central line) or ventilation. Data is collected on all sites of nosocomial infection in patients in the <b>High risk nursery</b> Data is collected on operative procedures from the NNIS operative procedure list, which includes <b>surgical patients throughout the organization</b> .	
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event	For diagnosis of pneumonia (PNEU), the contribution of a chest xray (Def- shows evidence, Poss-possibility, Neg-negative, Not done)For Blood stream infection, laboratory confirmed bloodstream infection LCBI or clinical sepsis CSEPFor secondary bloodstream infection the patient has a culture- confirmed bloodstream infection and a related nosocomial infection at another site : Secondary infection (Y/N)The laboratory method used to identify the pathogen causing the infection: Laboratory diagnosis C culture, A antigen/antibody test, V visualization, N noneThe specimen from which the pathogen was identified: 12 codes listedThe etiologic agent of the nosocomial infection: Pathogen (3 codes), susceptibility of pathogen to antimicrobial agents; antibiogram (3 codes)	
<ul> <li>46. List fields related to follow-up of event that are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event)</li> <li>47. List fields related to the outcome of event</li> </ul>	In addition to the above infection related items, did the patient die during the hospital admission: Died (Y/N) Relationship of the infection to patient's death: Four codes CA caused the	
48. List any other fields related to the event or any other information collected by the reporting system (e.g. root cause analysis, investigations etc)	death, CO contributed to death, NR not related, U unknown Secondary bloodstream infection: (Y/N)	
H. Implications		
<ul><li>49. Integration with other systems</li><li>50. Methods used to de-identify data</li><li>51. Technical Information</li></ul>		
of a modernization effort. Accordingly,	he data structure for the NNIS is in the process of being redesigned as part we did not review the data storage/structure of this system since the respect to development of an integrated system.	
Part III. Data Use and Analysis:	Part III. Data Use and Analysis:	
78. System Contact	Teresa Horan	
79. Contact Address	CDC	
80. Contact Phone	(404) 498-1114	
81. Contact Email	thoran@cdc.gov	
82. Hardware Platform	PC based (moving to more robust platform)	
83. Operating System	DOS based (IDEAS with PRODAS)	

Reporting or Database System:	The National Nosocomial Infections Surveillance System (NNIS)
84. Who is the Developer?	CDC
85. Who is responsible for the architecture?	closed DOS-based
86. User Types	internal participating facility experts with training, CDC staff
87. What is the frequency of reports?	annual CDC report of summary level info, facilities can do ad hoc analysis as needed
88. Who generates the report?	on-site users, CDC staff
89. What is the method of access?	
90. What is the turnaround time?	
91. What is the level of automation?	SAS is used to do most CDC analyses
92. Type Of Reports	scheduled production reports, ad hoc using SAS
93. What is the unit of observation?	the reported event, infection/procedure/ICU/facility
94. What are the available data fields?	ICU type, Procedure, various utilization stats, Selected antimicrobial resistant pathogens associated with nonsocomial infections, dates
95. Is there a controlled vocabulary?	yes
96. Exportability	yes
97. User Profile	facility QI staff, CDC staff
98. How are the reports used?	quality improvement
99. Report Dissemination	public summary reports are public, facilities have access to all their own data
100. What is the primary goal?	describe the epidemiology of nosocomial infections and describe antimicrobial resistance trends
101. Is the system linkable to detail?	no
102. HIPAA Compliant	yes

OASIS	
Reporting or Database System:	Outcome and Assessment Information Set (OASIS)
Part I. Data Acquisition:	
A. General Information	
1. Report Title	
2. Internet Location: http://	http://www.hcfa.gov/medicaid/oasis/oasishmp.htm
3. Host Organization(s)	Centers for Medicare & Medicaid Services (CMS)
4. Primary contact information (e.g. Address, Phone)	Dennis Stricker (410) 786-2031 <u>DStricker@cms.hhs.gov</u> John Williams JWilliams2@cms.hhs.gov
B. Overall System Features	
5. System purpose/mandate (any information on role in mission, leadership support, integration with quality assurance activities and history)	The OASIS is a group of 79 data elements that represent core items of a comprehensive assessment for an adult home health care patient and form the basis for measuring patient outcomes for purposes of outcome-based quality improvement. Medicare-certified home health agencies (HHAs) report OASIS data to their local state organization. These state organizations report to the national repository with capabilities to store, access, and provide billing information and analysis of patient data. Under current CMS requirements, all Medicare certified home health agencies have been collecting, encoding and transmitting data on all Medicare and Medicare data state organizations and analysis of patient space.
6. What is the geographic scope of data collection (national, state, local, facility etc)?	Medicare and Medicaid skilled patients since August 24, 1999. Home health agencies report to their state organizations. State organizations then report to a national repository.
7. What is the unit of data entry (e.g., event, patient, product)?	Patient
8. Who is allowed/required to input information?	Care providers
9. What are the regulations/laws affecting reporting?	CMS HHA Condition of Participation requires that HHAs report OASIS data. One of the goals for OASIS automation is to fulfill the HHA provisions of the Balanced Budget Act (BBA) of 1997. The BBA includes a Medicare requirement for HHA prospective payment that depends on the data acquired by the OASIS system.
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributo for reporting, confidentiality policies that apply to entered data)	No
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	Electronic transmission via Home Assessment Validation and Entry System Software (HAVEN)
12. What are the methods of editing information (e.g. correcting/add more information to records)	Corrections can be made to assessments that have been previously completed, locked, and exported. The user can specify the type of correction (e.g., inactivation), and make the necessary changes. There is an OASIS correction policy which HAVEN enforces.

Reporting or Database System:	Outcome and Assessment Information Set (OASIS)
13. Where is the collected data stored (name of database, number of data storage locations)?	At each HHA, HAVEN utilizes a Microsoft Access database. On the national level, data is stored at CMS Data Center.
14. How often is the system revised (annual, semi-annual etc)?	
15. What are the methods for system revisions (e.g. internal review and design only, design under contract, with or without customer input)?	
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	
17. What new features are being planned and/or are on wish lists?	
C. Potential to link to other information systems	
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	
D. Fields related to contributor/participant Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify); N- Narrative; FF- fixed format (e.g. date)
	<b>Note</b> : There are four versions of the OASIS form (each is used where appropriate): Start of Care, Follow-Up, Transfer, and Discharge. Unless indicated, a field occurs on all versions.
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	<ul><li>(S) Agency Medicare Provider Number</li><li>(S) Agency Medicaid Provider Number</li></ul>
20. Is participation mandatory or voluntary?	Mandatory for Medicare certification
21. List fields related to contributor/participant contact information	<ul><li>(S) Agency Medicare Provider Number</li><li>(S) Agency Medicaid Provider Number</li></ul>
22. List fields related to facility contact information(include type of facility, teaching status, id information)	N/A
23. List fields related to distributor contact information	N/A
24. List fields related to manufacturer contact information	N./A
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
25. List fields related to Provider of Care identification	

Reporting or Database System:	Outcome and Assessment Information Set (OASIS)
	<ul> <li>(L) Primary Caregiver (Start of Care and Follow-Up only)</li> <li>(L) Type of Assistance (Start of Care and Follow-Up only)</li> <li>Caregiver Management of Equipment (Start of Care and Follow-Up only)</li> </ul>
26. List fields that identify types of care providers included in system	
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	<ul> <li>.(S) Patient ID Number</li> <li>(N) Patient Name</li> <li>(S) Patient Medicare Number (if there is one)</li> <li>(S) Social Security Number</li> <li>(S) Medicaid Number (if there is one)</li> </ul>
information (e.g. address, zip code, county, region)	Patient State of Residence Patient Zip Code
29. List fields related to patient demographics (e.g. age, sex, race)	Birth Date Gender (L) Race/Ethnicity (Start of Care only) (L) Current Payment Sources for Home Care
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)?	Patient ID number
31. List fields related to pre-existing conditions and/or medical history of patient	<ul> <li>(L) Inpatient discharge in last 14 days, diagnoses, and treatments</li> <li>(L) Prior conditions (Start of Care and Follow-Up only)</li> <li>(L) Prior therapies (Start of Care and Follow-Up only)</li> </ul>
32. List fields that capture the clinical condition of patient at time of event	<ul> <li>(L) Overall Prognosis (Start of Care only)</li> <li>(L) Rehabilitative Prognosis (Start of Care only)</li> <li>(L) Life Expectancy (Start of Care and Follow-Up only)</li> <li>(L) High Risk Factors (Start of Care and Follow-Up only)</li> <li>(L) Vision (Start of Care and Follow-Up only)</li> <li>(L) Speech and Oral Expression (Start of Care and Follow-Up only)</li> <li>(L) Frequency of Pain (Start of Care and Follow-Up only)</li> <li>(L) Integumentary Status (Ulcers or Surgical Wounds, Start of Care and Follow-Up Only)</li> <li>(L) Respiratory Status (Start of Care and Follow-Up only)</li> <li>(L) Respiratory Status (Start of Care and Follow-Up only)</li> <li>(L) Respiratory Status (Start of Care and Follow-Up only)</li> <li>(L) Elimination Status (Start of Care and Follow-Up only)</li> <li>(L) Neuro/Emotional/Behavorial Status (Start of Care and Follow-Up only)</li> <li>(L) Emergent Care (Transfer and Discharge only)</li> <li>(L) Inpatient Facility (Transfer and Discharge only)</li> <li>(L) Inpatient Facility Admission Information (Transfer and Discharge only)</li> <li>(L) Discharge/Transfer/Death Date (Transfer and Discharge only)</li> </ul>
<ul> <li>33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS, uninsured etc)</li> </ul>	<ul> <li>(L) Current Payment Sources for Home Care</li> <li>(L) Financial Factors limiting Patient/Family to meet basic health needs</li> </ul>

Reporting or Database System:	Outcome and Assessment Information Set (OASIS)
34. List any other types of information collected about the patient	<ul> <li>(L) Current Residence (Start of Care and Follow-Up only)</li> <li>(L) Structural Barriers (Start of Care and Follow-Up only)</li> <li>(L) Safety Hazards (Start of Care and Follow-Up only)</li> <li>(L) Sanitation Hazards (Start of Care and Follow-Up only)</li> <li>(L) Patient Lives With (Start of Care and Follow-Up only)</li> <li>(L) Grooming, Bathing, Ability to Dress (Start of Care and Follow-Up only)</li> <li>(L) Feeding or Eating (Start of Care and Follow-Up only)</li> <li>(L) Feeding or Eating (Start of Care and Follow-Up only)</li> <li>(L) Transportation (Start of Care and Follow-Up only)</li> <li>(L) Shopping (Start of Care and Follow-Up only)</li> <li>(L) Shopping (Start of Care and Follow-Up only)</li> <li>(L) Ability to Use Telephone (Start of Care and Follow-Up only)</li> <li>(L) Management of Medications (Start of Care and Follow-Up only)</li> <li>(L) Patient Management of Equipment (Start of Care and Follow-Up only)</li> </ul>
G. Fields related to Event/Error/Product Information:	Use the following codes to classify each identified field in the reporting system. P-Pick list items (list); S-Industry Standard (identify) ; N- Narrative; FF- fixed format (e.g. date)
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	N/A
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer)	N/A
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy, manufacturer) cont'd	N/A
37. List fields associated with medical device-related events (e.g. brand name of device, type of device, usage, manufacturer name, operator of device)	N/A
38. List fields associated with vaccine related events.	N/A
39. List fields associated with infection related events.	N/A
40. List fields associated with any other type of event. List type of event.	N/A
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	N/A
42. List fields associated with when the event occurred	N/A

Reporting or Database System:	Outcome and Assessment Information Set (OASIS)
43. List fields associated with tracking the time between the event, when reported, when acted upon etc	N/A
44. List fields associated with where the event occurred	N/A
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event	N/A
46. List fields related to follow-up of event that are not associated with a particular patient(medication/manufacturing/policy actions to correct/update event)	N/A
47. List fields related to the outcome of event	N/A
48. List any other fields related to the event or any other information collected by the reporting system (e.g. root cause analysis, results of investigations etc)	N/A
H. Implications	
49. Integration with other systems	
50. Methods used to de-identify data	
51. Technical Information	
Part II. Data Structure & Storage:	
I. Facility/Location	
52. Address of data storage facility	CMS Data Center 7500 Security Boulevard Baltimore, Maryland 21244-1850. CMS contractors and agents at various locations.
53. What type of facility is used to store the data (3rd party data center, secured computer room, someone's cubicle)?	CMS Data Center
54. What is the network interconnect for physically distributed systems?	Home health agencies use dial-up access to Medicare Data Communication Network (MDCN, operated by AT&T Global Services). State organizations are on the CMS wide area network.
55. What type (private lines, VPN, Internet) of network interconnect is used?	private lines, SecureIP
56. What is the network protocol (TCP/IP, IPX, etc.)?	TCP/IP

Reporting or Database System:	Outcome and Assessment Information Set (OASIS)
57. What is the bandwidth of network	
interconnect (dial-up, ISDN, T1, T3,	
etc.)?	
58. What is the network (WAN)	
topology, including diagram if	
available?	
59. Who designed the system? Who	
operates the system?	
J. Data Storage System/ Server	
60. Who is the manufacturer (Sun, HP,	IBM
IBM, Compaq, etc.)?	
61. What is the model number (Sun	SP - RS/6000 RISC
Enterprise 10000, HP 9000, etc.)?	
62. What is the number/speed (Mhz) of	4 processors; 375 MHz
processors?	
63. How much memory is available (Gb)?	Shared 4 Gb
64. What is the disk - Manufacturer,	EMC – SAN approximately 1 terabyte for the MDS/HHA project
amount (Gb) & type (SAN, RAID	
Array, etc.)?	
65. What is the operating System (e.g.	IBM AIX 4.3.3 ptf set 9
Sun Solaris 2.6.1)?	
K. For Each Application	
66. What commercial off-the-shelf	
(COTS) software (e.g. RDBMS,	
Query/Reporting Tools, etc.) is utilized?	
67. What custom-programmed	HAVEN (Resident Assessment Validation and Entry System Software),
application software is utilized? Using	Designed with MedQuest
which language(s) (e.g. C,C++, PERL, ASP, VB/COM)?	
68. Which categories best describe this	
system?	
- Operational Data Store	
-Is there an all-encompassing data	
warehouse versus focused data mart(s)?	
-Is there an Online Transaction	
Processing (OLTP) system utilizing a	
normalized relational database design?	
-Is there a data warehouse utilizing a	
normalized relational database design?	
-Is there a Dimensional Data Warehouse	
-Is there a Dimensional Data Warehouse utilizing a star schema design?	

Reporting or Database System:	Outcome and Assessment Information Set (OASIS)
-Is there a Statistical analysis system	Yes
utilizing flat files, either raw data or in a	105
format intrinsic to the system (e.g. SAS	
or SPSS internal system format)?	
-Is there an Online Analytical	
Processing (OLAP) utilizing	
denormalized relational design such as	
star-schema or snowflake schema?	
-Is there an OLAP system utilizing	
multidimensional design (e.g.	
hypercubes)?	
-Is there any other structured data	
format, such as XML, HTML, or other?	
69. How is the data structured?	
- Is there an event occurrence (EO)	
table with one row per event?	
- Is there a person table with one row	Yes
per person, linked to events by	165
PERSONID?	
- Is there an adverse-event (AE)	
taxonomy table, with one row per event	
type, linked one-to-many to the EO	
table by AEID?	
70. How much disk space is currently	
allocated to the system?	
anocated to the system.	
71. How much disk space is available	
on this system?	
L. Major Data Structure	
72. What is the width of the	1448 bytes when converted to character as per the input data specifications
table/file/subject data area (bytes)?	
73. How many data elements	Approximately 350 data elements
(approximate) in the table / file / subject	
data area?	
74. What is the raw data record size	
(bytes) or structured raw data such as	
HTML or XML?	
75. What is the approximate number of	Approximately 27 million assessments
rows in the table, or observations?	
76. What time period is currently	Assessments are submitted at the approximate rate of 900,000 per month.
represented in the database? Projected	rissessments are submitted at the approximate rate of 900,000 per month.
change over the next 1-3 years?	
	The intent is to maintain 5 years of data
77. Are there any theoretical maximums that cannot be exceeded? (e.g. #	The intent is to maintain 5 years of data.
providers, # recipients, etc.)	
$p_{10}, m_{10}, m_{1$	

**Reporting or Database System:** Vaccine Adverse Event Reporting System (VAERS) Part I. Data Acquisition: **A. General Information** 1. Report Title Assumptions in this document are made based on the Form VAERS-1 (FDA) 2. Internet Location: http:// http://www.vaers.org/ 3. Host Organization(s) Co-administered: US Food and Drug Administration and Center for Disease Control (CDC focuses on collective reports for detection of unusual epidemiologic trends/associations. FDA reviews reports to assess whether event is reflected in product labeling and to report trends for vaccine manufacturers and vaccine lots.) Analytical Sciences, Inc. (ASI) provides operational support for VAERS and has complied the VAERS data into 52 relational databases so it can be queried and summarized. Scott Campbell, RN, MSN sic3@CDC.gov 404 639-8834 fax 404 639-4. Primary contact information (e.g. Address, Phone) 8579 phone reviewed this form Project Officer for VAERS at CDC is Dr. John Iskander **B.** Overall System Features 5. System purpose/mandate 'The Vaccine Adverse Event Reporting System (VAERS) is a tool for (any information on role in mission, post-marketing safety surveillance (monitoring after a product has been leadership support, integration with approved and is on the market) of US licensed vaccines. Although quality assurance activities and history) extensive studies are required for licensure of new vaccines, postmarketing research and surveillance are necessary to identify safety issues that may only be detected following vaccination of a much larger and more diverse population. Rare events may not come to light before licensure. Sometimes an event is noted, but the evidence may not be adequate to conclude that a noted event is due to the vaccine." 'VAERS is a program created as an outgrowth of the National Childhood Vaccine Injury Act of 1986 (NCVIA) and is administered by the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC). VAERS accepts reports of adverse events that may be associated with U.S. licensed vaccines from health care providers, manufacturers, and the public. The FDA continually monitors VAERS reports for any unexpected patterns or changes in rates of adverse events." Actual meaningful rates cannot be calculated alone from this data because no denominator of vaccines are calculated to be able to derive a rate. The system is a first pass detection screen. Biologics Surveillance Summary produced by DHHS provides # of vaccine units sold/distributed/etc, but not # of doses administered. VAERS receives approximately 800-1000 reports each month with 125.000 since 1991 collected. The de-identified database can be downloaded from the web site in one year increments. All reports are coded and entered into the VAERS database. The adverse events described in each report are coded utilizing the FDA's Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) which are key words representing the medical condition(s) described in the case report. An individual report in these files may include up to a total of 8 vaccines administered and 20 COSTART terms describing the event.

VAERS

Reporting or Database System:	Vaccine Adverse Event Reporting System (VAERS)			
6. What is the geographic scope of data	National, on occasion manufacturers provide information from foreign			
collection (national, state, local, facility etc)?	y subsidiaries, often not reliable.			
7. What is the unit of data entry (e.g., event, patient, product)?	Adverse events (side effects) following vaccine administration			
8. Who is allowed/required to input information?	Anyone including consumers (vaccine recipients or parents/guardians), health professionals, vaccine manufacturers, state health agencies. Patients/parents/guardians are encouraged to seek help of health care professional in reporting to VAERS.			
0. With stars the up substitute of the second				
9. What are the regulations/laws affecting reporting?	In 1986, Congress passed the National Childhood Vaccine Injury Act to ensure vaccine safety, availability and to compensate people injured by vaccination. The Act established the National vaccine Injury Compensation Act to ensure vaccine safety, availability and compensate people injured by vaccination. Applicable regulations:			
	21 CFR 600.80(c)(1) Reporting Requires the licensed manufacturer to report each adverse experience that is both serious and unexpected, regardless of source, as soon as possible but in any case within 15 working days of initial receipt of the information.			
	21 CFR 600.80(c)(2) Reporting Requires the licensed manufacturer to report all adverse experiences in a narrative summary, not reported under paragraph (c) (1) (i) at quarterly intervals for 3 years from the date of issuance of the product license, and then at annual intervals. 21 CFR 600.80(c) Reporting Requires the licensed memory features to			
	21 CFR 600.80(e) Reporting Requires the licensed manufacturers to submit a 15-day Alert report obtained from a postmarketing clinical study only if there is a reasonable possibility that the product caused the adverse experience.			
	21 CFR 600.81 Reporting Requires the licensed manufacturers to report semiannually the quantity of the product distributed under the product license, including the quantity distributed to distributors.			
	21 CFR 600.90 Reporting Requires the licensed manufacturer to submit a waiver request with supporting documentation for waiving the requirements under 21 CFR 600.80 and 600.81.			
	Refer to the Reportable Events Table (RET) for events mandated for reporting by law.			
	To protect the privacy of the individual, the Freedom of Information Act restricts public access to certain information in reports submitted to the government. After the removal of identifying information such as the patient's name, compiled VAERS data are made available to the public for			
	a fee, through the National Technical Information Service. The data file containing information from VAERS is updated through NTIS on a monthly basis.			
	These data are used to increase understanding of adverse events following vaccination and become a part of the CDC Privacy Act System 09-20-0136, Epidemiologic Studies and Surveillance of Disease Problems".			
	Information identifying the person who received the vaccine or that person's legal representative will not be made available to the public, but may be available to the vaccinee or legal representative.			
	§ 164.512 Uses and disclosures for which consent, an authorization, or opportunity to agree or object is not required. A covered entity may use or disclose protected health information without the written consent or			
	authorization of the individual as described in §§ 164.506 and 164.508, respectively, or the opportunity for the individual to agree or object as described in § 164.510, in the situations covered by this section, subject to the applicable requirements of this section. When the covered entity is			
	required by this section to inform the individual of, or when the individual			

Reporting or Database System:	Vaccine Adverse Event Reporting System (VAERS)				
	may agree to, a use or disclosure permitted by this section, the covered				
	entity's information and the individual's agreement may be given orally.				
10. Does the system allow for/require anonymous input? If yes, describe. (include any consequences to contributor for reporting, confidentiality policies that apply to entered data)	While not encouraged, the system does allow anonymous input. Any information sent is retained in the database. The National Childhood Vaccine Injury Act of 1986 provides liability protection through the Vaccine Injury Compensation Program. In light of this protection, practitioner liability is unaffected by the VAERS reporting requirement. This system requires that no information can be used for any purpose other than the purpose for which it was supplied, nor be published or released in an identifiable format unless the establishment or person				
11. What is the mode of data acquisition or input (mail, web form, phone etc)?	supplying the information or described in it has consented to such release. Surface mail with business reply mail provided, fax, call 800 number for assistance in completing the form if the submitter cannot read/write, plan is to move to web-based, beta test underway for electronic reporting				
12. What are the methods of editing	ASI sends requests for follow up information directly to the person who				
information (e.g. correcting/add more information to records)	filled out the original form; all data that was submitted by the reporter is edited in follow up forms, thereby maintaining the integrity of the original submission Box G- P Type of secondary reportinitial, follow up, mfrs.15 day Letters to follow-up serious reports and obtain the recovery status are mailed to the reporters at 60 days and 1 year after vaccination.				
	For composite form reporting to the agencies: FDA gets daily reports for deaths, weekly summary reports for data integrity issues; CDC also reviews summary information for patterns and data integrity; these composite reports are edited and revised based on internal review from the users group (of FDA, CDC and contractor representatives)				
13. Where is the collected data stored (name of database, number of data storage locations)?	Analytical Sciences, Inc. (ASI) provides operational support for VAERS and has complied the VAERS data into 52 relational databases so it can be queried and summarized.				
14. How often is the system revised (annual, semi-annual etc)?	There has been no revisions since Nov 1990 form; in process of updating				
15. What are the methods for system	FDA provides request for public comment through the Federal Register; internal reviews are ongoing to modify and refine the system reports from the contractor.				
16. What are the minimal interface requirements for contributors (e.g. phone, internet access, certain level of PC memory)?	Access to form, surface mail				
	Web based reporting; modification of the form in process (VAERS-1); the COSTART (FDA developed classification system is going away, to be replaced by MedRA; they are standardizing the Contractor nurse follow up with the patients e.g. pediatric, neurological questions. Improved denominator data via incorporation of VAERS module into immunization registries.				
C. Potential to link to other information systems	-				
18. Is information from this system linked to other systems (including State or other Federal Reporting Systems? If yes, which data is linked?	Concerns surfaced by VAERS information are investigated through CDC project (Vaccine Safety Datalink VSD). VSD is a large-liked database including six million people, for vaccine safety studies and hypothesis testing. No electronic linkages available.				

Reporting or Database System:	Vaccine Adverse Event Reporting System (VAERS)			
D. Fields related to contributor/participant Information:	Narrauve; FF-fixed format (e.g. date)			
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data.	Form completed by (Name) Relation to patient P-vaccine provider, patient/parent, manufacturer, other			
20. Is participation mandatory or voluntary?	Both: "The Reportable Events Table (RET) reflects what is reportable by law (42 USC 300aa-25) to the Vaccine Adverse Event Reporting System (VAERS) including conditions found in the manufacturers package insert. In addition, individuals are encouraged to report any clinically significant or unexpected events (even if you are not certain the vaccine caused the event) for any vaccine, whether or not it is listed on the RET. Manufacturers are also required by regulation (2ICFR 600.80) to report to the VAERS program all adverse events made known to them for any vaccine. Effective December 18, 1999" The RET conditions by vaccine is attached. Under FDA regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and unexpected (i.e. not in product labeling), they are required to submit it to VAERS.			
21. List fields related to contributor/participant contact information	Name Address (if different from patient or provider) City, State, Zip Telephone number Only for reports submitted by manufacturer/immunization project: #24 Mfr.Imm proj report no, #25 Date received by mfr/imm proj, #26 15 day report? Yes, no, #27 Report type initial, follow up			
22. List fields related to facility contact information(include type of facility, teaching status, id information)	Facility name/address City State Zip Telephone no. #15, Vaccinated at: P private doctor's office, military clinic/hospital, public health clinic/hospital, other/unknown			
23. List fields related to distributor contact information	none			
24. List fields related to manufacturer contact information	<ul> <li>#13 Enter all vaccines given on date listed in no. 10: Vaccine (type),</li> <li>Manufacturer, Lot number, route/site, No. previous doses</li> <li>#14 Any other vaccinations within 4 weeks prior to the date listed in no.</li> <li>10: Vaccine (type), manufacturer, Lot number, route/site, No. Previous doses, date given</li> </ul>			
E. Fields related to Provider of Care Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF-fixed format (e.g. date)			
25. List fields related to Provider of Care identification				
26. List fields that identify types of care providers included in system	#15 Vaccinated at :P- private doctor's office/hospital, public health clinic/hospital, military clinic/hospital, other/unknown.			
F. Fields related to Patient Information:	Use the following codes to classify each identified field in the reporting system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF-fixed format (e.g. date)			
27. List fields related to identifying patient - initial data entry (e.g. SSN,	Patient's last name, first name, middle initial #3 Date of birth mm/dd/yy			

Reporting or Database System:	Vaccine Adverse Event Reporting System (VAERS)		
initials, system-assigned ID etc)	Patient age		
	Sex P-M F		
28. List fields related to patient contact	Address; City, State, Zip; Telephone number		
information (e.g. address, zip code,			
county, region)			
29. List fields related to patient	#3 Date of birth mm/dd/yy		
demographics (e.g. age, sex, race)	#4 Patient age		
	#5 Sex P: M F		
	Only for children 5 and under #22 birth weight lboz #23 No of brothers and sisters		
30. What patient identification is	Everything recorded is a retained image with the contractor's office.		
retained after verification of event	Information provided to FDA and CDC is stripped of all personal		
information (e.g. all contact information	identification (age and gender are provided but not DOB) and a number is		
or pseudo id assigned, is patient ID	linked backed to the original information.		
available for follow-up/outcome			
information)			
31. List fields related to pre-existing	#18 N-Illness at time of vaccination (specify)		
conditions and/or medical history of	#19 N-Pre-existing physician-diagnosed allergies, birth defects, medical		
patient	conditions (specify)		
	#17 N-Other medications		
	#21 Adverse event following prior vaccination (check all applicable,		
	specify) P in patient, in brother or sister: adverse event, onset age, type		
	vaccine, dose No. in series		
32. List fields that capture the clinical	#12 could collect this information; relevant diagnostic and laboratory data		
condition of patient at time of event	and # 17 other medications; some reporters use these fields to document		
	clinical condition unrelated to the event.		
33. List fields related to financial/charge	#16 Vaccine purchased with: P-private funds, public funds, military funds,		
information (e.g. length of stay, charge	other/unknown		
or payment for care, insurance coverage			
- Medicare, Medicaid, private, CHAMPUS, uninsured etc)			
34. List any other types of information	Though not specified on the form, sometimes medical record data is		
collected about the patient	requested if the event is severe enough and follow up investigations are		
concercu about the patient	pursued.		
G. Fields related to	Use the following codes to classify each identified field in the reporting		
Event/Error/Product Information:	system. P-Picklist items (list); S-Industry Standard (identify) ; N- Narrative; FF-fixed format (e.g. date)		
35.Type of events included (e.g. drug,	n/a		
device, biologic, vaccine, nosocomial			
infection, surgery mishaps, etc)			
36. List fields associated with	n/a		
medication-related events (e.g. drug			
name, dose, dates of therapy)			
37. List fields associated with medical	n/a		
device-related events (e.g. brand name			
of device, type of device, usage,			
manufacturer name, operator of device)			
38. List fields associated with vaccine	#7 N-Describe adverse event(s) (symptoms, signs, time course) and		
related events	treatment, if any		
	#10 Date of vaccination mm/dd/yy TimeAM, PM		
	#11 Adverse event onset mm/dd/yy TimeAM, PM		
	#12 Relevant diagnostic tests/laboratory data		
39. List fields associated with infection	n/a		
related events			

Reporting or Database System:	Vaccine Adverse Event Reporting System (VAERS)			
40. List fields associated with any other	n/a			
type of event. List type of event.				
41. List fields that allow input and/or classification of the event/harm (narratives, problem codes, adverse event terms)	All narrative text taken from VAERS reports are coded and entered into the VAERS database using FDA's Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART), which are key words representing the medical condition described in the report. Reporters are encouraged to use an accepted standard (e.g. MedDRA or COSTART)			
42. List fields associated with when the	#10 Date of vaccination mm/dd/yy TimeAM, PM			
event occurred	#11 Adverse event onset mm/dd/yy TimeAM, PM			
43. List fields associated with tracking the time between the event, when reported, when acted upon etc.	<ul> <li>#10 Date of vaccination_mm/dd/yy: timeAM, PM</li> <li>#11 Adverse event onset mm/dd/yy</li> <li>#6 Date form completed_mm/dd/yy</li> <li>#20 Have you reported this adverse event previously? P no, to health department, to doctor, to manufacturer</li> </ul>			
44. List fields associated with where the event occurred				
45. List fields associated with patient diagnosis, care, treatment, tests, and other follow-up provided to patient because of the event				
46. List fields related to follow-up of event that are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event)	no fields, but ad hoc disease/patient specific investigations are done for mitigating factors e.g. SIDS			
47. List fields related to the outcome of event	#8 Check all appropriate: P Patient died (date mm/dd/yy) Life threatening illness Required emergency room/doctor visit Required hospitalization (days) Resulted in prolongation of hospitalization Resulted in permanent disability None of the above #9 Patient recovered P yes, no, unknown			
48. List any other fields related to the event				
H. Implications				
49. Integration with other systems				
50. Methods used to de-identify data				
51. Technical issues	receives 12,000 reports/yr. Database has appx 125,000 reports since November 1991, resides with the contractor			
Definitions	There are no definitions of an adverse event; it is consumer driven and by design there are no limits/restrictions for deciding what constitutes adverse event. No near miss information is collected.			
Comments on integration with other systems	" It is well people oriented, would not be a good match for inpatient, so few vaccines given inpatient, bias toward a healthy population" AERS/VAERS are the most logical integration, would make it easier for one stop shopping for consumers. But for administrative simplification, no economies of scale could be realized; each system needs resources it has. VSD is complementary, but data sources are differentHMO over time.			
Part III. Data Use and Analysis:				
78. System Contact	Scott Campbell			

Reporting or Database System:	Vaccine Adverse Event Reporting System (VAERS)			
79. Contact Address	Atlanta, GA mailstop E61			
80. Contact Phone	(404) 639-8579			
81. Contact Email	Sic3@cdc.gov			
82. Hardware Platform	Windows NT server			
83. Operating System	NT 4.0 Server			
	McKesson/HBOC initial developer - redesigned by ASI (complete new			
84. Who is the developer?	design)			
85. Who is responsible for the system				
architecture	SQL Server 7 relational			
	internal only - FDA and CDC staff for internal purposes. External research			
86. User Types	is ad hoc via CDC/FDA as intermediary			
87. What is the frequency of reports?	calendar year up to prior quarter (01/01 - 9/30 available now) 1990-2001 available (123,000 + reports total) daily extracts sent to FDA/CDC as SAS dataset. No other internal reporting done by ASI, but some extracts are coordinated through them (but CDC/FDA sends data).			
88. Who generates the reports?	daily reports are system generated and extracts are created			
89. What is the method of access?	LAN or VPN access to subset of data (strict security)			
90. What is the turnaround time?	varies, but can very short			
	moving to highly automated for daily extracts, ad hoc require manual			
91. What is the level of automation?	intervention (manual de-identification of paper reports)			
92. Type Of Reports	Both the CDC and the FDA review data reported to VAERS. The FDA reviews reports to assess whether a reported event is adequately reflected in product labeling, and closely monitors reporting trends for individual vaccine lots. Copies of published reviews are available from VAERS. Many different types of events occur after vaccination. Approximately 85% of the reports describe mild events such as fever, local reactions, episodes of crying or mild irritability, and other less serious experiences. The remaining 15% of the reports reflect serious adverse events involving life-threatening conditions, hospitalization, permanent disability, or death, which may or may not have been truly caused by an immunization.			
	the reported event, at the patient level with provider identification - Vaccine			
93. What is the unit of observation?	info/manufacturer is available			
94. What are the available data fields				
95. Is there a controlled vocabulary?	yes, COSTART			
96. Exportability	yes, standard datasets are available on-line for free (stripped of identifiers)			
	internal staff - FDA looks at events, CDC looks at trends; external - various			
97. User Profile	research topics			
98. How are the reports used?	passive surveillance, trend identification, vaccine labeling issues			
	primarily internal to FDA/CDC. Review summaries available upon request,			
99. Report Dissemination	standard data available on line			
100. What is the primary goal?	The primary purpose for maintaining the database is to serve as an early warning or signaling system for adverse events not detected during pre- market testing. The FDA reviews reports to assess whether a reported event is adequately reflected in product labeling, and closely monitors reporting trends for individual vaccine lots. The National Childhood Vaccine Injury Act (NCVIA) requires health care providers to report: Any event listed by the vaccine manufacturer as a contraindication to subsequent doses of the vaccine. Any event listed in the Reportable Events Table that occurs within the specified time period after vaccination.			
101. Linkable to Detail	yes, although linkage would be complex			
102. HIPAA Compliant	yes			

VSD **Reporting or Database System:** Vaccine Safety Datalink (VSD) Part I. Data Acquisition: A. General Information 1. Report Title 2. Internet Location: http:// http://www.cdc.gov/nip/vacsafe/vsd/default.htm http://www.who.int/bulletin/pdf/2000/issue2/bu0338.pdf 3. Host Organization(s) The Centers for Disease Control and Prevention (CDC), National Immunization Program 4. Primary contact information (e.g. Robert Davis, MD, MPH (206) 685-4028 Address, Phone) Robert Chen, MD, MA (404) 639-8256 rte1@cdc.gov **B.** Overall System Features 5. System purpose/mandate The Vaccine Safety Datalink began in 1990 as a collaborative effort (any information on role in mission, involving the CDC and several large health-maintenance organizations. leadership support, integration with The VSD project prospectively collects computerized medical record data quality assurance activities and history) under a joint protocol at HMOs on vaccinations, medical outcomes (e.g. outpatient visits, emergency room visits, hospitalizations, and deaths), and covariates (e.g. birth certificates, census data). The data are then linked under joint protocol at multiple health maintenance organizations for analysis. Approximately 6 million persons (2% of the U.S. population) are members of the HMOs that participate in the VSD; the population size for children is 500,000+ (0 to 6 years), both vaccinated and not vaccinated. The databases and infrastructure created for the VSD have provided opportunities to address vaccination coverage and cost effectiveness related to immunization. The VSD enables large eipdemiologic studies of vaccine adverse events, captures information on less commonly occurring types of adverse events, and helps determine whether an event is linked with a vaccine or with some other cause. The VSD allows for planned vaccine safety studies as well as timely investigations of hypotheses. All vaccines administered within the study population are recorded. Available data include vaccine type, date of vaccination, concurrent vaccinations (those given during the same visit), the manufacturer, lot number and injection site. Medical records are then monitored for potential adverse events resulting from immunization. The VSD project allows for planned vaccine safety studies as well as timely investigations of hypotheses. At present, the VSD project is examining potential associations between vaccines and a number of serious conditions. The database is also being used to test new vaccine safety hypotheses that result from the medical literature, VAERS, changes in the immunization schedule or from the introduction of new vaccines. This project is a powerful and cost-effective tool for the on-going evaluation of vaccine safety. 6. What is the geographic scope of data Seven HMOs including Group Health Cooperative of Puget Sound, collection (national, state, local, facility Seattle WA; Kaiser Permanente Northwest, Portland OR; Kaiser etc)? Permanente Medical Care Program of Northern California, Oakland, CA; Southern California Kaiser Permanente Health Care Program, Los Angeles, CA, Harbour Medical Center LA The VSD links medical event information, vaccine history, and selected 7. What is the unit of data entry (e.g., event, patient, product)? demographic information. 8. Who is allowed/required to input Data are only derived from participating HMOs.

Reporting or Database System:	Vaccine Safety Datalink (VSD)			
information?	(152)			
9. What are the regulations/laws affecting				
reporting?				
10. Does the system allow for/require	Health service use information for each patient is computerized and			
anonymous input? If yes, describe.	continuously compiled by each HMO indexed by a unique identifier.			
(include any consequences to contributor	Each site encodes their patients' clinical data with these unique study			
for reporting, confidentiality policies that	identifiers before shipping the data to the CDC annually for merging and			
apply to entered data)	analysis, thereby preserving patient confidentiality. Institutional review			
	boards at each HMO have approved only analyses with aggregate data for			
	presentation.			
	Confidentiality policy: This system requires that no information can be			
	used for any purpose other than the purpose for which it was supplied, nor			
	be published or released in an identifiable format unless the establishment			
	or person supplying the information or described in it has consented to			
	such release.			
11. What is the mode of data acquisition	Vaccination data are derived from computerized immunization tracking			
or input (mail, web form, phone etc)?	systems maintained by each HMO.			
12. What are the methods of editing	The individual HMO inpatient databases are both routinely and specially			
information (e.g. correcting/add more	audited for quality control purposes, data quality is high because of staff			
information to records)?	training, standardized coding protocols, reliability monitoring and routine			
	audits. In addition to routine checks, a random 2% sample of the study			
	populations is selected periodically to review the quality of automated			
	vaccination and diagnostic data.Quality control comparisons of the			
	computerized immunization data with information recorded in the paper			
	medical record have shown high levels of agreement.			
13. Where is the collected data stored	All VDS data are stored at the CDC			
(name of database, number of data				
storage locations)?				
14. How often is the system revised (annual, semi-annual etc)?				
15. What are the methods for system				
revisions (e.g. internal review and design				
only, design under contract, with or				
without customer input)?				
16. What are the minimal interface				
requirements for contributors (e.g. phone,				
internet access, certain level of PC				
memory)?				
17. What new features are being planned	Issues with Congress surrounding confidentiality; system as is today may			
and/or are on wish lists?	change.			
C. Potential to link to other				
information systems				
-	The detahase is considered on example of a large listed detahase (LDD)			
•	The database is considered an example of a large-linked database (LLDB)			
to other systems (including State or other Federal Reporting Systems? If yes, which	including information on more than six million people. No links to other databases in other federal systems; however, the VSD			
data are linked?	and VAERS are complementary methods of monitoring data. VAERS is a			
	signal generator, designed to provide clues that there may be problems			
	with specific lots of vaccine that require more investigation. VSD			
	provides actual incident rate of diseases and events that occur around the			
	time of vaccination and at times, not linked to vaccination, making it			
	possible to evaluate whether the vaccine actually caused the adverse event			
	and, if so, the magnitude of the problem. VSD can help FDA and the			
	Vaccine Injury Compensation Program.			
	······································			

Reporting or Database System:	Vaccine Safety Datalink (VSD)				
D. Fields related to contributor/participant Information:	There is no publicly available form (and therefore no fields) connected with the VSD per se. Data are shipped as files to the CDC where the database is constructed.				
19. What types of contributors are included in data acquisition? List fields that indicate who/what facility submitted the data					
20. Is participation mandatory or voluntary?	Voluntary due to nature of partnership between HMOs and CDC				
21. List fields related to contributor/participant contact information					
22. List fields related to facility contact information (include type of facility, teaching status, id information)	Assumed that the system has all pertinent data on facilities due to partnership with HMOs				
23. List fields related to distributor contact information					
24. List fields related to manufacturer contact information	Manufacturer name and lot number				
E. Fields related to Provider of Care Information:					
25. List fields related to Provider of Care identification					
26. List fields that identify types of care providers included in system					
F. Fields related to Patient Information:					
27. List fields related to identifying patient - initial data entry (e.g. SSN, initials, system-assigned ID etc)	"Each site encodes their patient's clinical data with unique study identifiers before shipping the data to the CDC annually for merging and analysis, thereby preserving patient confidentiality." (Chen et al. 1997)				
28. List fields related to patient contact information (e.g. address, zip code, county, region)	ZIP code, street address, census tract blocks. "additional information on socioeconomic status is obtained on the VSD study cohort by linking the ZIP codes and street addresses of the patients with their respective census tract blocks via 'geocode.'" (Chen et al. 1997)				
29. List fields related to patient demographics (e.g. age, sex, race)	Birth date, gender are recorded. Race and/or ethnicity data are not collected				
30. What patient identification is retained after verification of event information (e.g. all contact information or pseudo id assigned, is patient ID available for follow-up/outcome information)					
31. List fields related to pre-existing conditions and/or medical history of patient	Past medical diagnoses- ICD 9, codes for prior hospitalizations				
32. List fields that capture the clinical condition of patient at time of event	Laboratoryselected results of pathogen-specific cultures and other diagnostic tests Ancillary proceduresselected procedures (e.g. CT scans; MRI) Pharmacydrug use by classification (e.g. anticonvulsants)				
33. List fields related to financial/charge information (e.g. length of stay, charge or payment for care, insurance coverage - Medicare, Medicaid, private, CHAMPUS,	Selection of staff model prepaid health plans minimized potential bias resulting from data generated from FFS claims, the information includes single provider health care systems and Medicaid programs.				

Reporting or Database System:	Vaccine Safety Datalink (VSD)			
uninsured etc)				
34. List any other types of information	Birth certificates, review of state death certificates, chart review, start and			
collected about the patient	stop dates of enrollment in the study, reason for stopping, selected procedures.			
G. Fields related to Event/Error/Product Information:				
35.Type of events included (e.g. drug, device, biologic, vaccine, nosocomial infection, surgery mishaps, etc)	Immunization, medical outcomes, potential confounders (factors that affect both vaccination status and incidents of medical events)			
36. List fields associated with medication-related events (e.g. drug name, dose, dates of therapy)	All vaccines administered within the study population are recorded. Available data include vaccine type, date of vaccination, concurrent vaccinesthose given during the same visit), the manufacturer, lot number and injection site.			
37. List fields associated with medical device-related events (e.g. brand name of device, type of device, usage, manufacturer name, operator of device)	N/A			
38. List fields associated with vaccine related events	Immunization records, vaccine type, date of administration, vaccine manufacturer, lot number, site of vaccination (all information required by the National Childhood Vaccine Injury Act of 1986).			
39. List fields associated with infection related events	Laboratoryselected results of pathogen-specific cultures and other diagnostic tests Pharmacydrug use by classification (e.g. anticonvulsants).			
40. List fields associated with any other type of event. List type of event.				
41. List fields that allow input and/or classification of the event/harm	Medical records are monitored for potential adverse events resulting from immunization captured using ICD 9 codes. VSD focused its initial efforts on examining potential associations between immunizations and 34 serious neurologic, allergic, hematologic, infectious/inflammatory, metabolic conditions. Other outcomes include site abscesses, persistent crying, collapse-hypotonic hyporesponsive episodes, breath holding, SIDS, Apnea, vaccine adverse events and practices such as simultaneous/combine vaccinations and observations of contraindications.			
42. List fields associated with when the event occurred.	Date of vaccination			
43. List fields associated with tracking the time between the event, when reported, when acted upon, etc.				
44. List fields associated with where the event occurred	Outcome- hospital and emergency dept. visits (all sites), outpatient clinic visits (2 sites only)			
	Ancillary information: procedureselected procedures such as CT and MRI; laboratoryselected results of pathogen-specific cultures and other diagnostic tests; pharmacydrug use by classification (e.g. anticonvulsants)			
46. List fields related to follow-up of event that are not associated with a particular patient (medication/manufacturing/policy actions to correct/update event)	Multiple research studies testing ad hoc vaccine safety hypothesis are performed arising from medical literature, VAERS, changes in immunization schedules, introduction of new vaccines. Examples include risk of hospitalization because of aseptic meningitis after MMR vaccine of children ages 1-2; safety of 2nd dose of MMR for children 4-6 & 10- 11; safety of revaccination with pneumococcal polysaccharide vaccine; varicella serology among school-age children with a negative or uncertain hx of chickenpox; impact of the inactivated poliovirus vaccine/oral poliovirus vaccine sequential schedule on vaccination coverage.			

Reporting or Database System:	Vaccine Safety Datalink (VSD)
47. List fields related to the outcome of	
event	
event or any other information collected by the reporting system (e.g. root cause	Hypothesis testing via formal research methods attempts to discover causal relationship between adverse outcomes and vaccination from a macro-population oriented perspective, not from an individual patient perspective.
H. Implications	
49. Integration with other systems	
50. Methods used to de-identify data	
51. Technical issues	

Part III. Data Use and Analysis:					
78. System Contact	Dr. Bob Davis				
79. Contact Address					
80. Contact Phone	(206) 685-4028				
81. Contact Email	rad2@cdc.gov				
82. Hardware Platform	n/a				
83. Operating System	n/a				
84. Who is the developer?	n/a				
85. Who is responsible for the system architecture?	n/a				
86. User Types	n/a				
87. What is the frequency of reports?	on-going analysis as needed, annual summaries				
88. Who generates the reports?	SAS ad-hoc analysis				
89.What is the method of access?	CDC - SAS analysis				
90. What is the turnaround time?					
91. What is the level of automation?					
92. Type Of Reports	internal reports vary by HMO, CDC receives data annually for merging/analysis				
93. What is the unit of observation?	the vaccine (antigen), patient, event				
94. What are the available data fields?	standard HMO clinical, claim (utilization), membership, plus CDC/VSD standard format and 34 standard outcomes				
95. Is there a controlled vocabulary?	yes				
96. Exportability	yes				
97. User Profile	HMO -researchers, QI staff, QM staff, CDC- internal staff				
98. How are the reports used?	QI, QM, research				
Report Dissemination public via CDC summary reports, internal HMO as needed					
100. What is the primary goal?	improve post-licensure monitoring of drug safety (vaccines)				
101. Linkable to Detail	yes at HMOs only				
102. HIPAA Compliant	yes				

### Appendix C Members of the External Advisory Panel

Geri Amori, Communicating HealthCare Anne Berdahl, AHA Robert Crane, Kaiser Foundation Health Plan Tim Flaherty, AMA Denise Love, National Association of Health Data Organizations David Marx, David Marx Consulting Nancy Foster, AHA Tom Safranek, Nebraska Department of Health and Human Services Paul Schyve, JCAHO Karen Shoos-Lipton, American Association of Blood Banks Mary Wakefield, University of North Dakota

# Appendix D Goals for Integrated Reporting System as Derived from EAP Working Sessions

Identify links between locations, procedures, history and events over time-create episode of care.

Minimize burden of reporting on reporters.

Identify opportunities for patient safety improvement.

Reduce risk of harm to patients.

Identify and address data gaps.

Federal agencies should perform level of analysis and provide more timely dissemination of information.

Provide public with assurance that the federal government is tracking errors and designing solutions.

FDA and other individual agencies would be able to analyze big picture – denominators, background rates.

Improved access to users who might use it in interest of safety – improve public health and reduce individual avoidance of harm.

To combine or eliminate individual systems to reduce burden on agency, burden of ownership (e.g. administrative simplification) and increase efficiency and effectively both at State and Federal level.

Discover causal links between latent errors and adverse events and between adverse events and longer term use of services, patient outcomes and costs.

New system should maximize the input of data; easy to report, minimize cost of report (including fear), maximize benefit of reporting.

Facilitate retrieval of info to serve as pt safety mgt tool for healthcare facilities and organizations to improve local system.

Uniform standardized access protections for reporting of information and feedback to public. New integrated database would provide a standard means of protection for public accountability – release of information is done in a standard manner and protection of information is done in a standardized way. Currently, varying levels of protection of the disparate databases.

Release of information for public accountability.

Aggregated information will be forcing function for alignment of the disparate systems, common taxonomy, and so forth.

Reduce training requirements and learning curves.

Better allocation of fed resources for attacking issues important to all of HHS (e.g., allocation of dollars and set priorities in a rational way).

One set of patient safety coding standards, indicator standards and transaction standards

Systematic feedback loop to reporting facilities and individuals

Use as an assessment of the success of federal pt safety interventions - evaluative function over time

Increase accountability of government actions regarding patient safety—easier to take action. Will also provide info to private agencies for use in the public good. Will be better able to see latent errors, will promote informed decision-making. Assume will take action, create a prudent purchaser/ regulator.

Identify which reporting systems should be grouped together.

Improve and demonstrate ROI for the reporting systems.

Provide a research base to identify risks and hazards for patient care.

Eliminate existing standalone databases if possible.

Ensuring patient safety can mean 'law suits', help consumers select providers; help states evaluate providers, help identify levels of practice.

# Appendix E Anticipated and Potential User Groups Affected by Development of Integrated System

Patients

Purchasers of healthcare, insurance co, employers, government-state, federal

Agencies involved in quality improvement and /or patient safety (e.g., public and private, accreditation agencies)

PSTF agencies (i.e., CMS, FDA, CDC, AHRQ)

Public policy makers-local, state, and federal agencies, congress

Patient safety improvement team at point of care - any facility

State departments of health in regulatory responsibilities

Media

Lawyers--plaintiff and defense attorneys

Health services researchers

Pharmaceutical companies, manufacturers, PHRMA and others who currently use reporting systems based upon compliance with regulations

Federal and state agencies from regulatory perspective (e.g. attorneys general)

PROs and quality improvement organizations

State and Federal executive branches

Educational institutions and students

Other countries, international policy makers

Commercial vendors of products, services, Rx companies, consultants

Labor unions (as health care purchasers and representatives of employees)

Managed care organizations

Health care organizations and associations (AHA, AMA)

Hospital boards of directors

Medical liability insurers

Local departments of health

Executive management team at a health care facility (e.g., CEO, CIO)

Legislative fiscal analysts - prepare budgets, state and federal government legislation

Patient care givers

Alternative medicine care givers

Patient families and/or personal representatives

Advocacy groups

Patient representatives

Non-governmental funders of research, foundations

Public (not necessarily in healthcare)

State board of professionals licensing responsibility

Providers conducting research for their own practice

Medical record coders

Standards organizations (e.g., ISO, ANSI, ICH)

Other industries, benchmarking (e.g., aviation, high risk industries for sharing best practices)

Accreditation agencies

Risk managers, underwriters, actuaries- who are looking to purchase liability insurance

Anyone with FOIA request

Hospital supply purchasers

Federal agencies

Medical staff offices

### Appendix F Sample Data Collection Forms

FDA Form 3500

	U.S. Department of Health and Human Services	For VOLUN7 adverse events an	CARY reporting of d product problems		Form Approved: OMB No. 0910-0291 Expires: 04.80.03 See OMB statement on reverse FDA Use Only Triage unit sequence ≢	
	The FDA Safety Information and Adverse Event Reporting Program	Page	_ of			
PLEASE TYPE OR USE BLACK INK	A. Patient information         1. Patient identifier       2. Age at time of event: of event: of event: of event: of event: of birth:       3. Sex if female if male if the second of the second		C. Suspect medic C. Suspect medic I. Name (give labeled strength #1 #2 C. Dose, frequency & route u #1 #2 4. Diagnosis for use (indication #1 #2 6. Lot # (if known) #1 #2 9. NDC # (for product problem:	sed 3. #1 #2 5 on) 7. Exp. date #1 #2 s only) - bducts and the cal device	Therapy dat from/to (or best en (if known) erapy dates (e	<ul> <li>5. Event abated after use stopped or dose reduced</li> <li>#1yesnoapply</li> <li>#2yesnodoesn't apply</li> <li>8. Event reappeared after reintroduction</li> <li>#1yesnodoesn't apply</li> <li>#2yesnodoesn't apply</li> </ul>
	6. Relevant tests/laboratory data, including	dates	model #			7. If implanted, give date
			serial # lot # 0ther # 9. Device available for evaluation? (Do not send to FDA)		- (moldaylyr) - 8. If explanted, give date (moldaylyr) d to FDA) uurer on	
	Mail to: MEDWAT 5600 Fishers Rockville, MI	Lane 1-800-FDA-0178	2. Health professional?     3.     yes no     no     f. If you do NOT want your i     the manufacturer, place a			4. Also reported to manufacturer user facility distributor

FDA Form 3500

Submission of a report does not constitute an admission that medical personnel or the product caused or contributed to the event.

### ADVICE ABOUT VOLUNTARY REPORTING

#### Report adverse experiences with:

- medications (drugs or biologics)
- medical devices (including in-vitro diagnostics)
- special nutritional products (dietary supplements, medical foods, infant formulas)
- cosmetics
- medication errors

### **Report product problems** – quality, performance or safety concerns such as:

- suspected contamination
- questionable stability
- defective components
- poor packaging or labeling
- therapeutic failures

### Report SERIOUS adverse events. An event is serious when the patient outcome is:

- death
- life-threatening (real risk of dying)
- hospitalization (initial or prolonged)
- disability (significant, persistent or permanent)
- · congenital anomaly
- required intervention to prevent permanent impairment or damage

#### Report even if:

- you're not certain the product caused the event
- you don't have all the details

#### How to report:

- · just fill in the sections that apply to your report
- use section C for all products except medical devices
- attach additional blank pages if needed
- use a separate form for each patient
- report either to FDA or the manufacturer (or both)

**Confidentiality:** The patient's identity is held in strict confidence by FDA and protected to the fullest extent of the law. FDA will not disclose the reporter's identity in response to a request from the public, pursuant to the Freedom of Information Act. The reporter's identity, including the identity of a self-reporter, may be shared with the manufacturer unless requested otherwise.

#### If your report involves a serious adverse event

with a device and it occurred in a facility outside a doctor's office, that facility may be legally required to report to FDA and/or the manufacturer. Please notify the person in that facility who would handle such reporting.

#### Important numbers:

- 1-800-FDA-0178 to FAX report
- 1-800-FDA-1088 to report by phone or for
- 1-800-822-7967 for a VAERS form for vaccines

#### To Report via the Internet:

https://www.accessdata.fda.gov/scripts/medwatch/

The public reporting burden for this collection of information has been estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

DHHS Reports Clearance Office Paperwork Reduction Project (0910-0291) Hubert H. Humphrey Building, Room 531-H 200 Independence Avenue, S.W. Washington, DC 20201 Please DO NOT RETURN this form to this address.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service • Food and Drug Administration

FDA Form 3500-back

#### Please Use Address Provided Below – Just Fold In Thirds, Tape and Mail

#### Department of Health and Human Services Public Health Service

Food and Drug Administration Rockville, MD 20857

Official Business Penalty for Private Use \$300

### BUSINESS REPLY MAIL

FIRST CLASS MAIL PERMIT NO. 946 ROCKVILLE, MD

POSTAGE WILL BE PAID BY FOOD AND DRUG ADMINISTRATION









The FDA Safety Information and Adverse Event Reporting Program Food and Drug Administration 5600 Fishers Lane Rockville, MD 20852-9787

հոհվհանվանվանինությունների

### Form 3500A

ι	J.S. Department of He	alth and Human Services						Form Appr	oved: OMB No. 0910-0291 Expires: 04/30/03
	MEDWATCH			đ	For use by user-facilities, distributors and manufacturers for			Mfr report #	See OMB statement on reverse
		nformation and		u		TORY reporting		UF/Dist report #	
		eporting Program	I		Page	of			FDA Use Only
	A. Patient ir	nformation				C. Suspect media	cation	(s)	
1	. Patient identifier			3. Sex	4. Weight	1. Name (give labeled streng			
		or Date		female	or lbs	#1			
	In confidence	of birth:		male	kgs	#2 2. Dose, frequency & route	used	3. Therapy da	tes (if unknown, give duration)
	B. Adverse	event or produ	ICt proble roduct problen		(malfunctions)	#1		from/to (or best of #1	estimate)
2	2. Outcomes attribu	ited to adverse event	disability	(e.g., deletic	manufictionicy	#2		#2	
	(check all that app	uy)	-	al anomaly		4. Diagnosis for use (indicat	ion)		5. Event abated after use stopped or dose reduced
	life-threatenin	(mo/day/yr) ng		intervention to nt impairment/c		#1			#1 Tives Tipo Tidoesn't
	hospitalizatio	n – initial or prolonged	other:			#2			#2 yes no doesn't
:	3. Date of event		4. Date of this report			<ol> <li>Lot # (if known)</li> <li>#1</li> </ol>	7. Exp. #1	date (if known)	8. Event reappeared after
	(mo/day/yr)	r problem	(mo/day/yr)			#2	#2		reintroduction
ľ						9. NDC # – for product proble		known)	#1 yes no doesn't
						- 10. Concomitant medical pr	-	dithorom: -t-t- (	#2 yes no doesn't
						10. Concomitant medical pr	oducts an	d therapy dates (	exclude treatment of event)
ž									
ξ									
3LA						D. Suspect medie	cal dev	vice	
ISE						1. Brand name			
اي ا						2. Type of device			
PLEASE TYPE OR USE BLACK INK						3. Manufacturer name & add	dress		4. Operator of device
E									health professional
EAS									other:
E									
						6.			5. Expiration date (mo/day/yr)
						model #			-
e	6. Relevant tests/la	boratory data, including	g dates			catalog #			7. If implanted, give date (mo/day/yr)
						serial #			-
						lot #			8. If explanted, give date
						other #			
						9. Device available for evalue	_	(Do not se turned to manufa	
						10. Concomitant medical pro	_		(mo/day/yr)
-	Other relevant bi	story, including preex	isting medical	conditions (o	a allergies				
ľ		smoking and alcohol use							
						E. Initial reporter			
						1. Name & address		hone #	
							L		
L		Submission of	f a report doe	s not consti	tute an	2. Health professional?	3. Occup	ation	4 Initial reporter also
		admission tha distributor, ma	t medical per	sonnel, user	facility,	yes no			sent report to FDA
F	DA Form 3500A	contributed to							

Medication Experience		ice	an admission that n	oort does not constitute nedical personnel, user nanufacturer or product	U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service • Food and Drug Administration
(continued)			caused or contr	ibuted to the event.	
Refer to guidelin			Page	of	FDA Use Only
F. For use b	by user faci	lity/distributo	or – devices only	H. Device manufactu	rers only
1. Check one			report number	1. Type of reportable event	2. If follow-up, what type?
user facility	distributo	r		death	
3. User facility or	distributor name	e/address		serious injury	additional information
, .				malfunction (see guidelines)	
				other:	device evaluation
				3. Device evaluated by mfr?	4. Device manufacture date
				not returned to mfr.	
4. Contact person			5. Phone Number	yes evaluation summary	5 Labeled for single use?
				no (attach page to explain why or provide code:	
6. Date user facilit	ty or distributor	7. Type of report			yes no
became aware o (mo/day/yr)	of event	initial	(mo/day/yr)	6. Evaluation codes (refer to coding m	- nanual)
		follow-up #	·		·
9. Approximate	10 Event prot	blem codes (refer to		method =	
age of device	patient				
	code	-	-	results -	
	device			conclusions	
	code				
11. Report sent to	FDA?	_	ere event occurred	7. If remedial action initiated	Q. Uppers of device
yes	o/day/yr)	hospital	outpatient diagnostic facility	<ol> <li>If remedial action initiated, check type</li> </ol>	8. Usage of device
no		home	ambulatory	recall notification	initial use of device
13. Report sent to	manufacturer?	<ul> <li>nursing ho outpatient</li> </ul>	surgical facility		reuse
🗌 yes			facility	repair inspection	unknown
no <sup>(m</sup>	o/day/yr)	other:		replace patient mor	nitoring 9. If action reported to FDA under
14. Manufacturer	name/address		specify	relabeling modification	n/ 21 USC 360i(f), list correction/removal
	nume/udul coo			adjustment	reporting number:
				other.	
				10. Additional manufacturer n	narrative and/or 11. Corrected data
G. All man					
1. Contact office -	name/address (&	mfring site for device	es) 2. Phone number		
			3. Report source	71	
			(check all that apply)		
			foreign		
			study		
			literature		
			consumer		
			health		
<ol> <li>Date received by (mo/day/yr)</li> </ol>	/ manufacturer	5. (A)NDA #	professional		
			user facility		
6. If IND, protocol	#	IND #	company		
		PLA #	representative		
		pre-1938	yes distributor		
<ol><li>Type of report (check all that ap</li></ol>	oply)		other:		
		product L	yes	.	
5-day 15	5-day	8. Adverse event	term(s)		
🗌 10-day 🗌 pe	eriodic				
Initial fo	ollow-up #				
9. Mfr. report num	iber				
The public reporting burde	on for this collection	f information has been		Clearance Office "An agency may not co	
hour per response, includi gathering and maintaining	ing the time for review the data needed, and	ring instructions, searchin completing and reviewin	ing existing data sources, Paperwork Red pg the collection of infor- Hubert H. Hump	uction Project (0910-0291) and a person is not requirered Building, Room 531-H a collection of informati	Induct or sponsor, wired to respond to, ion unless it displays form to this address.
athering and maintaining mation. Send comments information, including sug	regarding this burden gestions for reducing	estimate or any other as this burden to:	pect of this collection of 200 Independen Washington, D.	ce Ávenue, Š.W. a currently valid OMB c C. 20201	ontrol number."

FDA Form 3500A - back

\* Indicates Required Information

### Department of Health and Human Services FDA Use Only Date Received:

Food and Drug Administration


### Biological Pro Deviation Repo

duct	Date Reviewed:	
ort	BPD ID:	
	BPD No:	
al Product	Deviation (BPD) Inform	

٦


Facility Informati	lon	в.	Biological Product Deviation (BPD) Inform	
. Reporting Establish	ment Information:	1.	Establishment Tracking #:	
* Reporting Establis	hment Name:	2.	Date BPD Occurred:	
* Street Address Lin	e 1:	3.	* Date BPD Discovered:	
Street Address Line 2	:	4.	* Date BPD Reported:	
* City:		5.	* Description of BPD (use Page 2 for additiona	l space):
* State:	* Zip Code:			
Country:				
* Point of Contact:				
* Telephone #:	E-mail:			
	shment Identification I		* Description of Contributing Factors or Root for additional space):	Cause (us
	l somewhere other than lete this Section and S			
* Establishment Name:				
Street Address Line	1:	7.	* Follow-Up (use Page 4 for additional space):	
Street Address Line	2:			
* City:				
* State:	Zip Code:		* Please Enter the	
* Country:	1		6 character BPD Code:	
		С.	Unit/Product Information	
Establishment Ident FDA Registration #:		CLIA #: 0	lease check the type Blogntinued on Pag f product: Non-Blood (Continued on Pag	


Form FDA 3486 Form Approved: Form Approved: An agency may not initiate a collection activity without first obtaining OMB approval. The apartage of collection instru OMB No: 0910-0458 should display a current and valid OMB control number, expiration date, public protection provision, and a burden (3/01) Expires: 2/29/2004 statement on the approved collection instrument.



Form FDA 3486 (3/01)

Page 2 of 7





Form FDA 3486 (3/01)

Page 4 of 7

Total Number of Units:

C1. Blood Products/Components

\*\* RN = Reverse Notification

Unit #	Collection I (MM/DD/YYYY)	at∉xpiration Date (MM/DD/YYYY)	ProductCode	D <b>Nsptificatri</b> (Y, N, RN*
L.)				
2.)				
3.)				
·.)				
5.)				
5.)				
7.)				
3.)				
9.)				
10.)				
11.)				
12.)				
13.)				
14.)				
15.)				
.6.)				
.7.)				
8.)				

Form FDA 3486 (3/01)

Page 5 of 7


C2. Non-Blood Products

Total Number of Lots:

Lot #	Expiration D (MM/DD/YYYY)	te Product Type	Pro	duct Code D:	s <b>pMostiifiion</b> atio (Y, N)
1.)					
2.)					
3.)					
4.)					
5.)					
6.)					
7.)					
8.)					
9.)					
10.)					
11.)					
12.)					
13.)					
14.)					
15.)					
16.)					
17.)					
18.)					

Form FDA 3486 (3/01)

Page 6 of 7



• •	Name of System Organization Contact Information	Description and Purpose	Information Relevant for Integration
near misses	Department of Veterans Affairs National Center for Patient Safety	Medical Devices Act, JCAHO patient safety standards and OSHA	FDA, and OSHA standards into the severity level categories. Similar to MERS-TM in terms of using a risk assessment index for determining further investigation of an event or near miss.
near misses	Medical Event Reporting System - Transfusion Medicine Sponsored by The National Heart, Lung, and Blood Institute, in cooperation with FDA Primarily based at Columbia University, Harold S. Kaplan, MD as the Principal Investigator. hsk18@columbia.edu Columbia University, Harkness 4-418, 622 West 168 St, NY, NY 10032	information about the event. Selecting an event for more thorough investigation (root cause analysis) involves assessing the risk involved	determining the RAI and using the model

### Appendix G Definitions and Classification Systems

Type of System	Name of System	Description and Purpose	Information Relevant for
	Organization		Integration
	Contact Information		
Adverse events -	MediSpan GPI Code	Proprietary software produce of drugs and drug-diagnosis adverse	
drug-diagnosis		interactions for checking potential interactions. Hierarchical drug codes	3
interactions	MediSpan, Inc.	for identifying drugs down to manufacturer and pill size.	
	8425 Woodfield Crossing		
	Boulevard, Indianapolis, IN 46240.		
	Tel: (800)428-4495		
	http://www.medispan.com/products		
	.htm		
Adverse events -	Durg-Reax and Drug-Dex	Proprietary software information on known adverse drug reactions	
drug-diagnosis		(Drug-Reax and Drug-Dex) and poisonings (Poisindex), among other	
interactions	MicroMedex, Inc.	modules of information. For example, Drug-Reax allows users to	
		search for drug-drug, drug-food, drug-disease, drug-ethanol, drug-	
	http://www.micromedex.com/prod	tobacco, and drug-laboratory-test interactions, along with known	
	ucts/	allergic reactions. It provides information on dosage, pharmacokinetics	,
		cautions, interactions, clinical applications, adverse effects,	
		comparative efficacy, drug of choice information, and orphan drug	
		status. Drug-Dex, the drug-disease module, is based on and documents	
		the evidence related to FDA-approved and investigational prescription	
		and non-prescription drugs, as well as products produced outside the	
		U.S.	
		Module info:	
		http://www.micromedex.com/products/healthcare/druginfo/	
		Drug-Reax Fact sheet:	
		http://www.micromedex.com/products/drugreax/drugreax_factsheet.pd f	
		Drug-Dex Fact sheet:	
		http://www.micromedex.com/products/drugdex/drugdex_factsheet.pdf	

Type of System	Name of System Organization Contact Information	Description and Purpose	Information Relevant for Integration
Adverse events - drugs	COSTART - Coding Symbols for Thesaurus of Adverse Reaction TermsFood and Drug Administration (FDA)Available from National Technical Information Service http://www.ntis.gov/fcpc/cpn5580. htm	COSTART is the terminology developed by the FDA for the coding, filing and retrieving of post-marketing adverse reaction reports. It was designed to reduce the variation in vocabulary used by those who submit adverse event reports to the FDA. Still used by some manufacturers who submit adverse events to FDA, but is being phased out.	FDA AERS (Adverse Event Reporting System) will be creating a regulation soon to require the manufacturers to use MedDRA, especially those who submit information electronically. The other event reporting systems in FDA (e.g. MAUDE, MedWatch, MERS-TM, BPD) do not require the use of MedDRA for classifying events. MAUDE will accept COSTART, MedDRA, or any other classification terminology system. MERS-TM and BPD have their own classification terminologies. MedWatch does not require the use of a terminology by the user. Terminology depends of type of adverse event reported on the MedWatch voluntary form.
Adverse events - drugs	Definitions and Basic Requirements for the Use of Terms for Reporting Adverse Drug Reactions CIOMS: Council for International Organizations of Medical Sciences, Drug Development and Use Program Book and CD are available for purchase at: http://www.cioms.ch/	CIOMS: Council for International Organizations of Medical Sciences, Drug Development and Use Program	CIOMS forms are currently accepted by AERS in place of the form FDA 3500A or VAERS form for foreign serious and unexpected reports only (15 day reports) and should contain, at a minimum, information including an identifiable source, a patient (even if not precisely identified by name and date of birth), a suspect product and a suspect event.

Type of System	Name of System Organization	Description and Purpose	Information Relevant for Integration
	Contact Information		_
		ICH E2B provides a format for transmitting all relevant data elements	Currently used in AERS electronic
drugs		useful to assess an adverse drug reaction or adverse event report. It was	transmission of periodic reports
		created by IFPMA which represents the international pharmaceutical	from select manufacturers (pilot
		industry. The purpose was to standardize data elements for	has 4 members). Not used in other
		transmission of individual case safety reports by identifying, and where	
		necessary or advisable, by defining the data elements for the	and FDA both recommend the
		transmission of all types of individual case safety reports, regardless of	work of the harmonization group.
		source and destination. This included case safety reports for both pre	
		and post approval periods and covers both adverse drug reaction and	ICH E2B categories can be
		adverse event reports.	converted to NCCMERP.
	http://www.ifpma.org/pdfifpma/e2		
	bm.pdf	Data elements include:	
		1. ID of report - e.g. sender, country, date of transmission, type of	
		report, seriousness (criteria=results in death, life-threatening, requires	
		inpatient hospitalization, prolongs hospitalization, results in persistent or significant disability, is congenital/birth defect, other medically	
		important condition, date received, etc	
		2. Primary source - e.g. reporter identifier, reporter address, country,	
		qualifications=physician, pharmacist, other health professional, lawyer,	
		consumer, reference to literature, etc	
		3. Information on sender and receiver of case safety report - e.g. sender	
		with type=drug company, regulatory authority, health professional,	
		regional	
		pharmacovigilance center, WHO collaborating center for drug	
		monitoring, other, sender ID, receiver with type=drug company,	
		regulatory authority, health professional, regional pharmacovigilance	
		center, WHO collaborating center for drug monitoring, other, receiver	
		id, receiver contact info.	
		4. Patient characteristics - e.g. name, MR#, age, weight, height, sex,	
		medical history, concurrent conditions, past drug history, death info (if	
		applicable), parent info (if applicable)5. Reaction/event (narrative,	
		MedDRA term - note use of ICH E2A criteria to classify seriousness of	
		event, dates, duration, outcome)6. Results of tests relevant to AE	
		investigation7. Drug info - e.g. drug id, dosage, route of admin, start	
		date, relatedness of drug to event8. Narrative case summary and further	
		information - e.g. clinical course, reporter comments, sender	
		commentsHas lists for units of measure, time intervals, route of admin,	
		etc codes	

Type of System	Name of System Organization Contact Information	Description and Purpose	Information Relevant for Integration
Adverse events -	National Coordinating Council for	To provide a standard language and structure of medication-error	Besides the major listed categories,
drugs	Medication Error Reporting and	related data for use in developing databases to analyze medication error	
	Prevention (NCC MERP)	reports.	FDA to come up with
	, , , , , , , , , , , , , , , , , , ,		customizations to taxonomy for
	Taxonomy of Medication Errors	Some fields require selection from a defined list of choices and other	classifying errors under the US
		require entry of free text.	Pharmacopeia MERS system. A
	http://www.nccmerp.org	Major categories:	utility takes the data from AERS,
		10 - Patient Information	adds NCCMERP classification to
		20 - The Event;	adverse drug event then transfers to
		21 - Date;	another database. Note: At AHRQ
		22 - Time;	patient safety conference there was
		23 - Setting of initial error;	discussion among patient safety
		24 - Setting where error perpetuated;	grantees that the NCCMERP
		25 - Description of Event	error/harm classification confuses
		30 - Patient outcome;	too many dimensions of the
		31 - No error; 32 - Error, no harm; 33 - Error, harm; 34 - Error, death	problem - harm to the patient,
		50 - Product Information; 51 - General; 52 - Dosage Form; 53 -	severity of the incident etc.
		Packaging - container; 54 - Pharmacologic/therapeutic classification	
		(use AHFS codes or VA codes); 55 - Product information; 56 - status;	
		57 - dosage form; 58 - packaging container;	
		60 - Personnel involved; 61 Initial error made by; 62 - Error	
		perpetuated by; 63 - Error discovered by; 70 - Type - used for errors	
		only, not near misses - examples dose omission, improper dose, wrong	
		dose, wrong time, wrong rate, wrong patient, wrong route of admin,	
		wrong duration, deteriorated drug, wrong strength/concentration,	
		wrong drug, wrong dosage form, wrong technique	
		80 - Causes - 81- Communication; 83 - Name confusion;	
		85 - Labeling; 87 - Human Factors; 89 - Packaging/Design;	
		90 - Contributing Factors (systems related)	

	Name of System Organization Contact Information	Description and Purpose	Information Relevant for Integration
drugs and devices	MedDRA: Medical Dictionary for Regulatory ActivitiesInternational Federation of Pharmaceutical Manufacturers Association (IFPMA)	MedDRA is a standard international terminology for regulatory communication in the registration, documentation, and safety monitoring of medical products throughout all phases of their regulatory cycle. MedDRA, a controlled clinical vocabulary, is used for the electronic transmission and retrieval of adverse event data. It also is applicable to the health effects of devices. The MedDRA system can link with Autocode CS to automatically identify and assign classification terms from narrative text. Unlike ICD or SNOMED, MedDRA was specifically developed to classify the health effects of drugs. For example, instead of identifying abdominal pain as a symptom - MeDDRA has terms for low abdominal pain vs. upper abdominal pain to more clearly reflect the adverse reaction that is occurring as a result of the medication or device. Categories of terms include: symptoms, signs, diseases, diagnoses, therapeutic indications, names and qualitative results of investigations, including pharmacokinetics, surgical and medical procedures, medical/social/family history. The structure is:System organ class (SOC) - highest level of hierarchy (26 broad concepts for data retrieval), including etiology (e.g., infections and infestations); manifestation site (e.g., gastrointestinal disorders), purpose (e.g., Surgical and medical procedures).High level group term (HLGT) - 333 superordinate descriptors for one or more "high level terms (HLTs)," related by anatomy, pathology, physiology, etiology, or function; used solely for data retrieval.High level term (HLT) - 1,685 superordinate descriptors for the preferred terms(PTs) linked by anatomy, pathology, physiology, etiology or function.Preferred term (PT) - 14,287 single medical concepts for a symptom, sign, disease, diagnosis, therapeutic indication, investigation, surgical or medicalprocedure, medical, social or family history characteristic.Low level term (LLT) - 51,083 termsExcludes equipment, device and diagnostic product and failure terms, patient demographic terms, numeric values ass	CBER and CFSAN are getting ready to use MedDRA. MedDRA is also being considered by CDRH to classify the health effects of devices. Also, recommended as a standard by the ICH E2B committee and regulatory authorities of Europe, US, and Japan as a controlled vocabulary for electronic transmission. MedDRA and ICH E2B are both IPHMA entities. Difficult to obtain details on system due to proprietary nature of product. Cost is \$3000- 10000/year depending on non- profit status and size of company. From the AERS manual for data entry staff, coding the narrative portion of an AE form into key words from MedDRA allows a consistent description of events while retaining the essence of the initial reporter's own words. AERS coders are instructed to code only signs and symptoms of adverse events, reporter assigned diagnoses, relevant lab test results, and significant medical/surgical procedures that provide important information about the AE. Prior medical history should not be coded unless the history was aggravated by the event. There is a crosswalk between MedDRA and
		G - 6	ICD terms, but ICD numeric codes are not used. According to Pat Revelle, MedDRA includes all of COSTART, WHO-ART and

Type of System	Name of System	Description and Purpose	Information Relevant for		
	Organization		Integration		
	Contact Information				
Adverse Events -	Cause of Device-Related Incident	ECRI assigns a "Cause of Device-Related Incident" to each filed	May be valuable as a		
- Devices		report. There are five broad "cause" categories with each having a sub-	comprehensive root cause analysis		
	ECRI	category:	classification for devices.		
		1) Device Factors – design/labeling error; device failure; device			
	http://www.ecri.org/documents/448 interaction; failure of accessory; improper				
	207.htm for product information	maintenance/testing/repair/or lack or failure of incoming inspection;			
		improper modification; invalid device foundation; manufacturing error;			
		packaging error; random component failure; software deficiency.			
		2) External Factors – electromagnetic or radio-frequency interference;			
		environment/temperature/humidity/light; medical gas/vacuum supplies;			
		power supply/including compressed medical gasses; water supply.			
		3) Support System Failures – error in hospital policy; failure to			
		impound; failure to train and/or credential; improper storage; lack of			
		competent accident investigation; lack or failure of incoming and pre-			
		use inspections; poor incident/recall reporting systems; poor pre-			
		purchase evaluation; use of inappropriate devices.			
		4) Tampering and/or Sabotage.			
		5) User Errors – abuse of device; accidental spill; device mis-assembly;			
		failure to perform pre-use inspection; failure to read label; improper			
		connection; inappropriate reliance on an automated feature; incorrect			
		clinical use; incorrect control settings; incorrect programming.			
	Eindhoven Classification Model,	Nineteen codes to classify events based upon the results of a root cause			
transfusion	Medical VersionT.W. Van der	analysis: 1) technical; 2) organizational; and 3) human causes,	training, especially for those with		
medicine	Schaaf - created model for	consistent with latent and active error theory and with the classification			
	chemical industry and adapted it	of human behavior into skill-, rule-, and knowledge-based behavior:	monitoring and guidance to ensure		
	for medicine with J. Battles and	Latent errors, Technical - external, design, construction, materials,	consistency of coding between		
	MERS-TM teamhttp://www.mers-		systems. See article - "A system of		
	tm.net	management priorities, culture	analyzing errors to improve GME		
		Active Errors (Human) Knowledge-based behavior - KB errors Rule-	curricula and programs" for		
		based behavior - qualifications, coordination, verification, intervention,			
			examples.		
		related factors, unclassifiable. In MERS-TM, these categories are			
		assigned as the end result of a formal root cause analysis. Used for			
		searching for errors that are similar.			

Type of System	Name of System	Description and Purpose	Information Relevant for
	Organization		Integration
	Contact Information		
Clinical alerts	HL7 Arden Syntax	The Arden Syntax for Medical Logic Modules (MLMs) is a language	Has been used for generating
		for encoding medical knowledge. It was previously adopted as a	messages to healthcare professional
	Columbia University	standard by ASTM Subcommittee E31.15 on Health Knowledge	regarding clinical practice
		Representation. An MLM produces a message based upon some	guidelines.
	http://www.cpmc.columbia.edu/ard	triggering criteria in an application. MLMs can trigger each other,	Has the potential to be used as a
	en/	perform institution-specific actions and/or communicate with	way to remind staff of important
		applications. Arden Syntax is currently used for sharing of clinical	patient safety considerations - e.g.
		practice guidelines among institutions and for compliance with	length of time from initial admit to
		institution specific quality assurance activities.	initiate antibiotics, test level
		The message (any coded or narrative result) the MLM produces can be	exceeds recommended standards,
		in the following forms:	drug interaction.
		Alert - a clinical message sent to the provider taking care of a patient,	
		warning her of some concern; it is usually flagged in some way;	
		Interpretation - a non-emergent message for the provider, intended to	
		supply passive information;	
		Diagnosis Support Screen - a message sent to a researcher or quality	
		assurance officer informing them of a patient that fits some criteria	
		(often sent over e-mail).	

Type of System	Name of System Organization	Description and Purpose	Information Relevant for Integration
	Contact Information		
Computerized	SNOMED: Systematized	SNOMED CT is the latest release of the SNOMED product. It is a	Rated number 1 by CPRI which
medical records	Nomenclature of Human and	relational database of the entire medical vocabulary including	evaluated all available coding
	Veterinary MedicineCollege of	symptoms, diagnoses, and procedures, created to code information in	systems for their ability to be used
	American Pathologists325	the medical record into machine readable form. Among its purposes: to	
	Waukegan Rd, Northfield, IL	collection of clinical data, linking clinical knowledge databases, case	[Tried to find out more about this
	60093; <u>jnrs@cap.org</u>	retrieval, sharing and exchanging of data, data aggregation and reuse. It	rating from CPRI via email and
	http://www.snomed.org/snomedct.	has been cited as a strong candidate as the standard vocabulary and	phone - no success as of 3/11 -TR]
	html - for product documentation	data model for computer-based patient records. SNOMED International	NCVHS characterized SNOMED
	and information	indicates that it is widely used (e.g., in electronic health records,	as a system that represents a
		clinical laboratory and radiology systems, infectious disease reporting,	convergence of the various
		HEDIS reporting, emergency rooms, case reports for clinical research,	diagnosis, procedure, medical
		cancer registries, literature search, outcomes assessment, telemedicine,	language, nursing, and drug codes
		autopsy databases, and web-based consumer information). SNOMED	(NCVHS, 2000, p. 36), which
		CT is the result of collaboration between the College of American	makes it more comprehensive than
		Pathologists and the National Health Service (NHS) that combined	ICD codes. Should be evaluated
		SNOMED RT (Reference Terminology) and Clinical Terms Version 3	against MedDRA as a standard for
		of the NHS thesaurus of health care terms (Read Codes V3). This	coding narrative text. SNOMED
		product combines the strength of SNOMED RT in specialty medicine,	concepts that can be viewed as
		including pathology, and the richness of Read Codes V3 in primary	adverse events are similar to ICD-
		care. [I made changes to this narrative and column "L"]in primary care.	
			reactions, complications of surgical
			procedures, and injury concepts.
			SNOMED International has not yet
			identified which of these would be
			included in an adverse event
			subset, but anticipate that this may
			be a future project (LaJoie P.
			Personal Communication, February
			27, 2002). Example from UMLS:
			UMLS term - Adverse Effect of
			Medication NOSSNOMED v2 -
			Adverse Drug Effect (F-Y0200),
			drug reactionRead Code 99 - Drug
			Reaction, adverse reaction to
			drugAbove are arrived at through
			different semantic trees. Would be
			true of any selected term.

Type of System	Name of System	Description and Purpose	Information Relevant for
	Organization		Integration
	Contact Information		
Devices	UMDNS: Universal Medical Device Nomenclature System	To facilitate identifying, processing, filing, storing, retrieving, transferring, and communicating data about medical devices.	Adopted by European Union at the recommendation of the European Standards body. Free to nonprofits,
	ECRI		government and device manufacturers, but must sign
	http://www.ecri.org/documents/448 207.htm for product information		license agreement. ECRI and FDA's CDRH agreed in 1997 to harmonize both UMDNS and FDA's device classification system, but was superceded by work with GMDN. FDA is going to adopt GMDN when that becomes available.
Devices	GMDN: Global Medical Device Nomenclature	The GMDN is a collection of internationally recognized terms used to accurately describe and catalogue medical devices into 12 categories. In particular, the products used in the diagnosis, prevention, monitoring, treatment or alleviation of disease or injury in humans. It will be used for: data exchange (e.g. as used in the Eudamed - European Database on Medical Devices); vigilance (transfer of information following specific incidents); conformity assessment (CE marking and certification marks); and procurement More than 70 experts from Europe, Japan and the United States of America, including manufacturers, healthcare authorities and regulators, compiled the GMDN. The work was supported financially	CDRH is participating in CEN sponsored effort to develop this nomenclature system. MedSun Pilot will begin using GMDN after obtaining licensing rights.
		More than 70 experts from Europe, Japan and the United States of	

Type of System	Name of System	Description and Purpose	Information Relevant for
	Organization		Integration
	Contact Information		
Diagnoses	ICD-9 and ICD-10: International	ICD-9 and ICD-10 are used for classification of mortality throughout	Groups in various countries
	Classification of Disease, Ninth	the world. They are the parent system of the US ICD-9-CM and ICD-	(including the US and Australia)
	Edition and Tenth EditionWorld	10-CM and Australian ICD-10-AM. ICD-10 and ICD-10-CM have not	are reviewing how ICD-9 and ICD-
	Health Organization (WHO),	yet been implemented in the US, but have updates to both content and	10 coding systems can be used to
	Collaborating Center for	format. These include: the addition of information relevant to	enhance and/or standardize error
	Classification of Disease for North	ambulatory and managed care encounters; expanded injury codes; the	reporting. See entry for National
	America (located at the USDHHS,	creation of combination diagnosis/symptom codes to reduce the	Center for Classification in Health
	CDC, National Center for Health	number of codes needed to fully describe a condition; the addition of a	and ICD-9-CM entry for details.
	Statistics)http://www.cdc.gov/nchs/	sixth character; incorporation of common 4th and 5th digit	
	icd9.htm	subclassifications; laterality; and greater specificity in code assignment.	
		The new structure will allow further expansion than was possible with	
		ICD-9-CM. See	
		ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD9-	
		CM/2001/ for complete list of terms. Includes over 10,000 diagnoses	
		and 7,000 procedures.	

Or	rganization	Description and Purpose	Information Relevant for Integration
Co Diagnoses and ICI procedures Into Dis Cli Na Sta for Sen http for Do	Dep-CM and ICD-10-CM: ternational Classification of isease, Ninth and Tenth Editions, linical Modification ational Center for Health atistics (NCHS) and the Centers r Medicare and Medicaid ervices (CMS) tp://www.cdc.gov/nchs/icd9.htm	code set is also widely accepted and used by the public and private sector for - data collection, quality of care analysis, resource utilization, research and reimbursements, and statistical reporting. ICD-10-CM has not yet been implemented. ICD-9-CM is also used in Australia and Israel. In addition - ICD-9-CM volume 3 is used for coding of procedures for inpatients. CMS is developing ICD-10-PCS to replace volume 3 procedures. See ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD9- CM/2001/ for complete handbook.	A recent study by the Utah Department of Health (6-2001) attempted to use ICD-9-CM e- codes and n-codes to estimate the

Type of System	Name of System	Description and Purpose	Information Relevant for
	Organization		Integration
	Contact Information		
Diagnoses	ICD-10-AM: International	Used for classification of morbidity and mortality. ICD-10-AM will	To improve classification of
	Statistical classification of Disease,	supersede ICD-9-CM in Australia.	adverse events, NCCH is proposing
	Australia ModifiedNational Center		a third edition of ICD-10-AM to
	for Classification in Health		include a 'flag' for each morbidity
	(Australia)http://www.cchs.usyd.ed		that would indicate whether the
	u.au/ncch/		morbidity occurred before, during,
			or after hospitalization. One such
			scheme in Australia (Victoria) uses
			alphabetic prefixes on each
			diagnosis code to indicate the time
			of occurrence. A few States in
			USA also use a separate flag for
			occurrence of diagnosis in
			discharge records (e.g., NY and
			CA). NCCH proposes to
			implement the flag in Australia by
			July 2002 and included it in the
			National Health Data Dictionary.
Diagnoses and		Listing of clinical problem terms connecting diagnosis to therapy,	Unclear whether there are patient
procedures and		prognosis, and psychosocial issues. Developed to reduce the amount of	
other		time that clinicians take to enter information into a computerized	Potentially, similar function to
	Vanderbilt University	patient record.	HL7-Arden Syntax in that it could
			be used to tie patient condition to
		Authors identified 23,503 problem relations (co-occurrences, sign-	frequently used terms. Listed in
		symptom complexes, and differential diagnoses) and 22,690 modifier	UMLS.
		words that categorize canonical problems.	

Type of System	Name of System	Description and Purpose	Information Relevant for
	Organization		Integration
	Contact Information		
Diagnoses for	<b>ICPCS:</b> International Classification	Modified version of ICD-9 intended for use in general practice. Used ir	Primary care version of ICD plus
primary care	of Health Problems in Primary	the UK and Australia. ICPC-2 Plus was released in 1998 and is	additional information not covered
	Care	specifically designed for use in computerized patient record, disease registers and secondary coding of clinical data. Terminology for	by ICD (see focus).
	World Organization of National	identifying - patient reason for encounter, symptoms, diagnosis,	
	Colleges (WONCA) International	procedures, counseling services, referrals, radiology ordered, and	
	Classification Committee	administrative procedures.	
	http:www.ulb.ac.be/esp/wicc/wicc. html		
	Australian version:		
	http://www.fmrc.org.au/classifi.ht m#3		
Drugs	First Data Bank	Supplier of knowledge bases and software concerning drug, medical, and nutrition information	
Drugs	Multum Lexicon	Codes for all prescription and over the counter drugs approved for	SAMHSA has added illegal drugs
C		marketing in the U.S. The system goes to the level of NDC but with a	for the Drug Abuse Warning
	Multum Information Services		
	http://www.multum.com/Lexicon.h	distributed by Multum. A relational database with all detail on the	currently using the Lexicon for
	tm	NDCs and about 10 to 15 thousand aggregated terms.	data entry and reporting from
			hospital emergency departments
			and medical examiners. And they
			are using the classification system
			for analytic reports.

Type of System	Name of System Organization Contact Information	Description and Purpose	Information Relevant for Integration
Drugs	National Drug CodesFood and Drug Administration	An inventory of commercially available drug products approved for marketing in the U.S. Ten-digit codes are assigned by pharmaceutical manufacturers and are maintained by the FDA. The 10-digit codes can be linked directly to the labeling for the product.	NDCs are not designed to support patient care per se (for example, NDCs do not capture the route, dosage, or frequency of administration). The codes are not readily publicly accessible. There is no hierarchy or classification scheme within the drug codes. Other organizations have enhanced the codes to make them more accessible and useable analytically (e.g., Multum Information Services), but these modifications impede standardization of the codes. In decisions by USDHHS on standards to be used under HIPAA law for electronic transactions, NDCs were selected as the single standard for identifying drugs, with the expectation that a classification would be developed and that the NDCs would become publicly available (NCVHS, 2000). However, CMS objected to the replacement of HCPCS "J-codes" with NDCs due to the technical readjustments needed for reimbursement processes; thus, the NDCs may be rescinded as the one definitive standard. Private sector drug claims now use and will continue to use NDCs. NDCs are not assigned to drugs marketed outside the U.S. and are not assigned to blood products, medical devices, in vitro diagnostic products, dietary supplements, or investigational new drugs
		G - 15	(NCVHS, 2000). Source(s): National Committee on Vital and Health Statistics (NCVHS). Uniform Data Standards for Patien

Type of System	Organization Contact Information	Description and Purpose	Information Relevant for Integration
Functioning and disability	of Functioning and Disability	A classification first issued by the WHO as a common language on disability for clinical use, data collection, and research.	May be relevant for classifying the outcomes of serious adverse events.
Mental illness and substance abuse	DSM: Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Association http://www.psych.org/clin_res/dsm	Terms and codes for diagnoses and treatments related to mental illness and substance abuse problems, developed to facilitate communication, more reliable diagnoses, education in psychopathology, and collection of statistical data about mental disorders.	Incorporated into the ICD-9-CM classification system of diagnosis and procedure codes.
Meta-thesaurus	SystemNational Library of Medicinehttp://umlsks.nlm.nih.gov	The Metathesaurus contains information about biomedical concepts and terms from approximately 60 controlled vocabularies and classifications used in patient records, administrative health data, bibliographic and full-text databases and expert systems. It is meant for use by developers of classification systems. It preserves the meaning, attributes, hierarchal connections, and other relationships between terms in the source vocabularies, while adding certain basic information about each of its concepts and establishing new relationships between concepts from different source vocabulariesThe Metathesaurus 2002 contains about 777,000 concepts and 2.1 million concept names and more than 11 million relationships in over 60 different vocabularies. It is a tool used by a wide range of applications to: link between different clinical or biomedical vocabularies; link patient records to related information in bibliographic, full-text or factual databases; perform natural language processing and automated index searching; assist in information retrieval from databases with human assigned subject indexes. It supplies linking information that computer programs can use to interpret user inquiries, interact with users to refine their questions, identify which databases contain information relevant to particular inquiries, and convert the users' terms into the vocabulary used by a particular information source. Used by developers as a method for improving search strategies and linkages within a particular application.	MedDRA) without obtaining copyright from the source. External system team used UMLS (65 systems) and HISB Inventory of Standard Classification Systems (16 systems) as sources for identifying classification systems here.
Nursing diagnoses	NANDA: North American Diagnosis Association	Nursing diagnoses that describe patient reactions to disease.	
Nursing diagnoses	NIC: Nursing Intervention Classifications	Classification that names and describes treatments performed by nurses.	

	Organization Contact Information	Description and Purpose	Information Relevant for Integration
Nursing	NOC: Nursing Outcomes	A standard language with measures for patient outcomes influenced by	
outcomes	Classification	nursing practices.	
Nursing services	Omaha System	A problem classification system, an intervention scheme, and a problem rating scale for outcomes related to nursing and other	
	Visiting Nurse Association of Omaha	healthcare professional services. A multi-disciplinary model of treatment.	
Nursing services	PCDS: Patient Care Data Set	Compilation of terms actually used in patient records to record patients' problems, therapeutic goals, and care actions. Source material for	
	American Nurses Association	building searchable structure text that closely approximates clinical vernacular.	
	Shared MeaningsAustralian Council for Safety and Quality in Healthcare. Subcommittee: Australia Medical Error Action GroupCouncil Contact: julie.bate@health.gov.au. Subcommittee Contact: Lorraine Long: persistence@bigpond.com http://www.safetyandquality.org/de finition/smhome.htm	care system and to achieve a degree of consistency in how the terms are used.	background analysis for pertinent safety terms. The Sequential List orders terms from most to least useful, given that many terms are closely related to each other terms. The Alphabetic List includes preferred term, alternatives and background information.
Procedures	CPT-4: Current Procedural Terminology, Fourth Edition American Medical Association For purchase: http://webstore.ama- assn.org/Merchandiser/catalog/Cat egory.jhtml?CATID=357	To provide descriptive terms and numeric codes for reporting medical, surgical, and diagnostic services and procedures by doctors and outpatient facilities in the US. Used by Medicare and all third party payors including workers compensation and Medicaid. Hospitals use CPT-4 codes on reimbursement claims for outpatient treatment of Medicare patients. CPT is used as level I of HCPCS (see HIPAA standards below). Over 7300 codes divided into 6 major sections - Evaluation and Management Services, Anesthesia, Surgery, Radiology, Pathology and Medicine. Surgery is divided anatomically. Medicine is divided by medical subspecialties.	Similar problems to ICD-9-CM v.3 in using as a method for coding external causes of injury or complications of procedures. Controversy as to whether HCPCS or CPT would be used as procedure standard in HIPAA. It appears that both will be used.
	HCPCS: HCFA Common Procedure Coding System	A procedure coding system used for classifying treatments and submitting claims for Medicare and Medicaid covered services. Incorporates and expands CPT-4 for supplies, durable medical equipment, and other services not in CPT-4, and for local Medicaid codes.	

Type of System	Organization Contact Information	Description and Purpose	Information Relevant for Integration
Procedures	Edition, Procedures	ICD-10-PCS was developed as a replacement for ICD-9-CM Procedures (Volume 3) for reporting hospital inpatient services. The goal was to improve coding accuracy and precision, reduce training effort, and improve communication with clinicians. ICD-10-PCS has been developed and undergone testing. No date is set for implementation.	Was originally recommended as a HIPAA standard as a replacement for CPT codes. The AMA and other organizations opposed this move due to costs and training issues for physician offices - no patient safety issues involved. From public documents at the NCVHS web site, CPT codes will remain the coding standard for physician offices. ICD-10-PCS will be the standard for institutions. Relevance for patient safety reporting unknown.
Procedures	Classification of Medicine, Crown Copyright UK Department of Health http://www.cams.co.uk/readcode.ht m for description	A comprehensive list of terms intended for use by all healthcare professionals (extensively used by family practitioners in UK) to describe the care and treatment of patients. Read codes enable the capture and retrieval of patient-centered information in natural clinical language within computer systems. They are compiled and updated twice a year for a full release and monthly for drugs. This work is co-coordinated by the NHS Information Authority working closely with all the clinical professions including doctors, nurses, professions allied to medicine and pharmacists. Listed in UMLS. Cross-mapped to ICD-9 and ICD-10 terms, e.g., in use of 'iatrogenic' terms.	In some cases, more specific error related terms from Read could be incorporated into ICD 10. For example, "error: entry deleted" (under administration-patient record status), "acquisition/hardware ECG error" (under inadequate ECG tracing). Note: Read Codes are integrating with SNOMED.
Procedures - radiological	MRI hazard classificationAmerican College of Radiologyhttp://www.acr.org/cgi-	Guidelines on the proper performance of radiology procedures, MRI safety, coverage of the ER, etc. For a list of types of hazards in performing MRI procedures, see http://www.patientsafety.gov/alerts/mri.doc. (J Gosbee, VA)	See MRI Hazard classification from John Gosbee at VA - http://www.patientsafety.gov/alerts /mri.doc. For a list of types of hazards in performing MRI procedures. Maybe applicable to CDRH radiological reports (?)

Type of System	Name of System	Description and Purpose	Information Relevant for
	Organization		Integration
	Contact Information		
Severity of	ASA physical status classification	Used for classifying severity of illness for patients who will undergo	ASPF has also established a data
illness -	system	surgery and anesthesia.	dictionary task force to create a
anesthesia			common language to identify
	American Society of	P1 normally healthy patient	specific perioperative outcomes
	Anesthesiologists	P2 patient with mild systemic disease	that should be investigated; i.e.,
		P3 patient with severe systemic disease	what are the important questions in
	http://www.apsf.org	P4 patient with severe systemic disease that is constant threat to life	anesthesia that should be asked and
		P5 A moribund patient who is not expected to survive without the	answered through data collection
		operation	and analysis to achieve the greatest
		P6 A declared brain-dead patient whose organs are being removed for	immediate patient benefit? No data
		donor purposes	dictionary available on-line. Does
			not appear to be complete. (as of
			2/02)
Test results -	LOINC®: Logical Observation	The LOINC database provides a set of universal names and ID codes	Applicability to patient safety -
laboratory	Identifier Names and Codes	for identifying laboratory and clinical test results. The purpose is to	provides universal codes to
		facilitate the exchange and pooling of results, such as blood	translate lab results from internal
	Regenstrief Institute	hemoglobin, serum potassium, or vital signs, for clinical care,	lab equipment codes to hospital
			information systems. However,
	http://www.regenstrief.org/loinc	using ASTM 1238 or its sister standard, HL7, to send laboratory results	
		electronically from producer laboratories to clinical care systems in hospitals. Most laboratories identify tests in these messages by means	are extensive enough to improve safety.
		of their internal (and idiosyncratic) code values. Receiving medical	salety.
		informatics systems cannot fully "understand" the results they receive	
		unless they either adopt the producer's laboratory codes (which is	
		impossible if they receive results from multiple source laboratories,	
		e.g.; the hospital lab, the local commercial lab, and a nursing home	
		lab), or invest in the work to map each laboratory's code system to their	
		internal code system.	

Type of System	Name of System	Description and Purpose	Information Relevant for
	Organization		Integration
	Contact Information		_
Transaction	HIPAA Health Data	The ASC X12N and NCPDP standards determine the size and format	In its development of standards for
standards for	StandardsUSDHHS with standards	of the transactions being sent between health care claim systems. X12N	the computerized patient record,
health data	setting groups and advisors: NUCC	standards will be required for all electronic claims transactions except	the NCVHS has set compliance
(including drugs)	- National Uniform Claims	for pharmacy claims that will use NCPDP (see below). Nine different	with HIPAA standards as one of its
	Committee; NUBC -National	standards will be required for the different types of information	guiding principles. Those standards
	Uniform Billing Committee. ASC	transmitted (e.g. payroll deduction, claim from a professional, claim	will be used by all health care
	X12N - American Standards	from an institution etc.). The following code sets will be	organizations to submit claims. We
	Committee X12N. NCPDP 0	used:International Classification of Diseases, 9th Edition, Clinical	reviewed those systems for
	National Council for Prescription	Modification (ICD-9-CM) for diagnoses on inpatient hospital claims;	relevance to standardization and
	Drug Programs; NCVHS - National	International Classification of Diseases, 9th Edition, Clinical	coding of errors and related
	Committee on Vital and Health	Modification, (ICD-9-CM), Volume 3 Procedures (including The	information. See entries above and
	Statistics	Official ICD-9-CM Guidelines for Coding and Reporting), as updated	below.
		and distributed by HHS, for the procedures or other actions taken for	
	http://aspe.hhs.gov/admnsimp/faqc	diseases, injuries, and impairments on hospital inpatients reported by	
	ode.htm - FAQ about code sets	hospitals: National Drug Codes (NDC), as updated and distributed by	
	adopted under HIPAA (date	HHS, in collaboration with drug manufacturers, for the following:	
	9/2000)	[Note that Secretary Thompson has indicated in a letter to the NCVHS	
		that HHS will publish an NPRM in the near future proposing to retract	
		the adoption of NDC for all transactions save those for retail	
		pharmacies. See http://www.fda.gov/cder/ndc/index.htm for NDC	
		information. Code on Dental Procedures and Nomenclature, as updated	
		and distributed by the American Dental Association; HCFA Common	
		Procedural Coding System (HCPCS) for services at institutions;	
		Current Procedural Terminology (CPT-4) for physician services.	

Type of System	Name of System	Description and Purpose	Information Relevant for
	Organization		Integration
	Contact Information		
Transaction	International Organization for	"The International Organization for Standardization (ISO) is a	
standards for	Standardization	worldwide federation of national standards bodies from some 140	
health data		countries, one per country member. ISO is a non-governmental	
(including drugs)	See	organization established in 1947. The mission of ISO is to promote the	
	http://www.iso.ch/iso/en/aboutiso/i	development of standards and related activities in the world with a	
	ntroduction/whowork.html – for	view to facilitating the international exchange of goods and services,	
	who does the work of setting	and to developing cooperation in the spheres of intellectual, scientific,	
	standards in ISO	technological and economic activity. "The major responsibility for	
		administrating an ISO standards committee is accepted by one of the	
		national standards bodies that make up the ISO membership - AFNOR,	
		ANSI, BSI, CSBTS, DIN, SIS, etc. The member body holding the	
		secretariat of a standards committee normally appoints one or two	
		persons to do the technical and administrative work. A committee	
		chairman assists committee members in reaching consensus. Generally,	
		a consensus will mean that a particular solution to the problem at hand	
		is the best possible one for international application at that time."	
		Excerpts from Website in contact info	

Data Element	Category Code	Category Definition
Birth Date	CCYYMMDD =	Century/Year/Month/Day
Gender	F =	Female
	M =	Male
	U =	Unknown
Marital Status	B =	Registered Domestic Partner
	D =	Divorced
	I =	Single
	M =	Married
	R =	Unreported
	<b>S</b> =	Separated
	U =	Unmarried (Single or Divorced or
		Widowed, used if status is unknown)
		Widowed
	W =	Legally Separated
	X =	
Race or Ethnicity	7 =	Not Provided
Ş	A =	Asian or Pacific Islander
	B =	Black
	C =	Caucasian
	H =	Hispanic
	I =	American Indian or Alaskan Native
	N =	Black (Non-Hispanic)
	O =	White (Non-Hispanic)
Citizenship Status	1 =	U.S. Citizen
1	2 =	Non-Resident Alien
	3 =	Resident Alien
	4 =	Illegal Alien
	5 =	Alien
	6 =	U.S. Citizen – Non-Resident
	7 =	U.S. Citizen – Resident
Employment Status	AO =	Active Military – Overseas
1 5	AU =	Active Military – USA
	FT =	Full-time
	L1 =	Leave of Absence
	PT =	Part-time
	RT =	Retired
	TE =	Terminated
Student Status	F =	Full-time
	N =	Not a Student
	P =	Part-time

Appendix H HIPAA Standards for Demographic and Other Characteristics of Individuals

## Appendix I NQF and JCAHO Serious Reportable Events

The serious reportable event definitions of the National Quality Forum (NQF) and the Joint Commission on Accreditation of Health Care Organizations (JCAHO) are a useful backdrop for comparing USDHHS medical error reporting and related data systems and for assessing State medical event reporting systems. Table I-1 displays this comparison. When the NQF and JCAHO definitions were slightly different, both are listed and identified. When State definitions are similar but different, they also are noted. When State definitions are more general or entirely different from NQF and JCAHO, the State definitions are listed separately. The USDHHS medical event related data systems are those examined for this study. Our assessment of their relevance to the NQF and JCAHO definitions is based on a cursory review of the systems. Sixteen State systems were reviewed based on several studies of State systems (IOM, 1999; Rosenthal et al., 2001, and Flowers, 2002). The States reviewed include CA, CO, FL, KS, MA, ME, NJ, NY, OH, PA, RI, SC, SD, TN, UT, WA. A few States were excluded because errors were not specifically defined (CT, MS) or systems that existed were not targeted on medical errors (NE, TX).

Table I-1 shows that for 21 of the NQF/JCAHO serious reportable events, there is some type of relevant data in USDHHS systems. For 17 events, multiple USDHHS systems may provide information. Only 9 of the 31 events could not be addressed by any of the USDHHS systems; these relate to surgery errors, criminal events, and delay of care.

Some State collects information related to 19 of the NQF/JCAHO serious reportable events. Multiple States collect data for 16 of the events. Twelve of the NQR/JCAHO events are not collected by any of the States examined. These relate to serious events related to hypoglycemia, hyperbilirubinemia, perinatality, pressure ulcers, and spinal manipulation. Eleven of the events are addressed by both USDHHS systems and State systems. Despite some overlap between DHHS and State systems related to these events, definitions are likely to vary enough to make comparisons problematic.

Domain	Abbreviated Definitions (And alternative language when NQF, JCAHO, and State definitions differ)	NQF	ЈСАНО	USDHHS Medical-Event- Related Data Systems	State Systems
Surgery	Wrong site surgery	X	X		FL, MA, ME, OH, PA, TN, UT, WA
	Surgery on wrong patient	X			FL, MA, ME, OH, PA, RI, TN, UT, WA
	Wrong surgical procedure performed on patient	X			FL, MA, RI, TN
	Foreign object left in a patient after surgery or other procedure	X		HCUP, NNIS	FL, MA, TN
	Intraoperative or immediately post-operative death in an ASA Class I patient (NQF)	X		HCUP, BPD, MERS, MEDMARX, NNIS	CO, NJ
	Anesthesia-related event (JCAHO) Death or near death for anesthesia and			ASA Class I patient designation unlikely to be available.	
	cardiac procedures (NJ)				

# Table I-1. NQF and JCAHO Serious Reportable Events Compared to DHHS and State Error Reporting Systems

Domain	Abbreviated Definitions (And alternative language when NQF, JCAHO, and State definitions differ)	NOF	ЈСАНО	USDHHS Medical-Event- Related Data Systems	State Systems
	[Intra]operative or Post-operative complication		Х	HCUP Often not specific.	RI, TN
	Surgical repair or damage resulted from planned surgical procedure where damage was not disclosed or documented to the patient (FL)				FL
Device	Death or serious disability from use of contaminated drugs, devices, or biologics by facility	X		AERS, ARS, BPD, DSN, MAUDE, MEDSUN, MEDWATCH, MERS, MEDMARX, NNIS, VAERS, VSD	
	Aspiration in non-intubated patient related to conscious/moderate sedation (TN)				TN
	Death or serious disability from use or function of a device in patient care, when other than intended (NQF)	X	X	AERS, ARS, DSN, MAUDE, CMS, MEDSUN, MEDWATCH, MERS, MEDMARX, NNIS	CO, MA, ME, NY, OH, TN
	Medical equipment-related event (JCAHO) Intravascular catheter related events (TN)				
	Death or serious disability from intravascular air embolism during care at a facility	X		AERS, ARS, DSN, MAUDE, MEDSUN, MEDWATCH, MERS, MEDMARX, MPSMS	СО
	Ventilator death or injury		Х		СО
Protection	Infant discharge to the wrong person (NQF) Infant abduction or discharge to wrong family (JCAHO)	X	X		ME, PA, TN, UT, WA
	Death or serious disability from patient disappearance for more than four hours (NQF)	X	Х		CA, CO, NY, PA, SD, TN
	Patient elopement (JCAHO) Patient suicide, or attempted suicide resulting in serious disability, while in a facility (NQF)	X	X	HCUP	MA, ME, PA, SD, TN, UT, WA
Care Manage- ment Events	Patient suicide (JCAHO) Death or serious disability from medication error (e.g. wrong drug, dose, patient, time, rate, preparation, or route (NQF)	X	X	HCUP, MEDSUN, MEDWATCH, MERS, MEDMARX, NNIS, VAERS	MA, ME, PA, TN
	Medication error (JCAHO) Patient death or serious disability associated with a hemolytic reaction due to the administration of ABO-incompatible blood or blood products (NQF) Transfusion error (JCAHO)	X	X	HCUP, BPD, DSN, MEDWATCH, MERS, MEDMARX	CO, MA, ME, PA, TN, WA

Domain	Abbreviated Definitions (And alternative language when NQF, JCAHO, and State definitions differ)	NQF	ЈСАНО	USDHHS Medical-Event- Related Data Systems	State Systems
	Maternal death or serious disability associated with labor or delivery in a low- risk pregnancy while being cared for in a healthcare facility (NQF)	X	X	HCUP, MAUDE, MEDSUN, MEDWATCH, MERS, MEDMARX, NNIS	MA
	Maternal death (JCAHO)				
	Hysterectomy in a pregnant woman, ruptured uterus (TN)				TN
	Birth injury (RI)				RI
	Patient death or serious disability associated with hypoglycemia, the onset of which occurs while the patient is being cared for in a healthcare facility	X		HCUP*, DSN, MAUDE, MEDSUN, MEDWATCH, MERS, MEDMARX	
				*Timing of onset may only be known for a few States in HCUP	
	Death or serious disability (kernicterus) associated with failure to identify and treat hyperbilirubinimia in neonates	X		HCUP, MAUDE, MEDSUN, MEDWATCH, MERS, MEDMARX, NNIS, VAERS	
	Perinatal death or loss of function		Х	HCUP, MAUDE, MEDSUN, MEDWATCH, MERS, MEDMARX, NNIS, VAERS	
	Stage 3 or 4 pressure ulcers acquired after admission to a healthcare facility	X		HCUP*, CMS, MEDSUN, MEDWATCH	
				*Timing of onset may only be known for a few States in HCUP	
	Patient death or serious disability due to spinal manipulative therapy	X		MAUDE, MEDSUN, MEDWATCH	
	Delay in treatment		Х		
	Infectious disease epidemics or outbreaks (CA, FL, MA)				CA, FL, MA
	Infestation by parasites or vectors (CA)				CA
	Death due to malnutrition, dehydration, or sepsis (PA)				PA
Environ- mental Events	Patient death or serious disability associated with an electric shock while being cared for in a healthcare facility	X		AERS, ARS, MAUDE, MEDSUN, MEDWATCH, MERS, MEDMARX	ME
	Any incident in which a line designated for oxygen or other gas to be delivered to a patient contains the wrong gas or is contaminated by toxic substances	X		AERS, ARS, MAUDE, MEDSUN, MEDWATCH, MERS, MEDMARX	
	Death or serious disability from a burn incurred while in facility (NQF) Fire (JCAHO)	X	Х	AERS, ARS, MAUDE, MEDWATCH, MERS, MEDMARX	CA, CO, MA, ME, NJ, NY, TN
	Death from a fall while in facility	Х	Х	MAUDE, CMS, MEDSUN, MEDWATCH, MERS, MEDMARX	

Domain	Abbreviated Definitions (And alternative language when NQF, JCAHO, and State definitions differ)	NQF	ЈСАНО	USDHHS Medical-Event- Related Data Systems	State Systems
	Falls within facility not related to patient treatment that result in serious head injury, coma, or permanent injury or requires significant intervention (ME)				ME, NY, TN
	Less serious complications of surgery, burns, falls, etc. (NY)				
	Falls resulting in radiologically proven fractures, subdural or epidural hematoma, cerebral contusion, etc. (TN)				
	Death or serious disability from restraints or bedrails in a facility (NQF) Patient death or injury due to restraints	X		AERS, ARS, MAUDE, CMS, MEDSUN, MEDWATCH, MERS, MEDMARX	
	(JCAHO)				
Criminal	Patient death associated with transfer Any instance of care ordered by or provided	X	X	HCUP (transfer in only)	
Events	by someone impersonating a physician, nurse, pharmacist or other licensed healthcare provider	Λ			
	Abduction of a patient within or on the grounds of the healthcare facility	X			NY, TN, UT
	Death or significant injury of a patient or staff member from a physical assault (i.e., battery) within or on grounds of facility (NQF)	X	X		CA, CO, ME, NJ, PA, SD, TN, UT, WA
	Assault, rape, or homicide (JCAHO)				
	Accident, abuse, negligence (SD)				
	Poisoning (States shown)				CA, MA, ME, NY, TN
	Any drug for use by resident that is diverted for use by others (CO)				СО
Site- specific outcome events	Any injury that is the result of an occurrence and causes functional loss consistent with spinal cord injuries (temporary or permanent) (CO, FL)				CO, FL
(States only)	Any injuries that occur to the brain and, as a result, cause a change in the level of consciousness and/or loss of bodily function (CO, FL)				CO, FL, RI
	Brain injury, mental impairment (RI) Fracture or dislocation of bones or joint related to medical intervention (FL)				FL

Domain	Abbreviated Definitions (And alternative language when NQF, JCAHO, and State definitions differ)	NQF	ЈСАНО	USDHHS Medical-Event- Related Data Systems	State Systems
	A resulting limitation of neurological, physical, or sensory function resulting from medical intervention and which continues after discharge (FL)				FL, RI
	Incident involving impairment of sight or hearing (RI)				
	Incident resulting in paraplegia, quadriplegia, any type of paralysis, loss or use of limb or organ (RI)				RI, TN, UT
	Intervention resulting in loss or impairment of limb – and impairment is present at discharge or for at least two weeks after occurrence (TN)				
	Intervention resulting in major loss of physical or mental function (UT)				
	Deaths arising from an unexplained cause or under suspicious circumstances that are reportable to the coroner as suspicious or unexplained (CO)				CA, CO, FL, MA, NY, PA, SC, SD, UT, WA
	Death due to unnatural causes (Other States)				
	Treatment to correct adverse incident (FL, TN)				FL, TN
	Transfer required due to adverse incident (FL, PA)				FL, PA
	Serious injury, impairment, death, or further treatment due to adverse incident (States listed)				KS, MA, ME, NY, SC, WA
	Facility failure with potential adverse outcome for patients (TN, WA)				TN, WA

## Appendix J Health Level 7 Reference Information Model

## The Reference Information Model

Entities: Entities involved in health care activities include:

- Living subject (person, non-person living subject (i.e., animals))
- Entity heir
- Place
- Organization
- Material

Manufactured material (device (imaging modality), container)

Roles: Health care providers have people with various roles in the organization:

- Employee
- Access
- Guarantor
- Schedulable resource
- Role heir
- Patient
- Assigned entity
- Certified entity

Acts: Actions taken in delivering health care that have been specified in the Reference Information Model are:

- Acts Clinical
  - Patient encounter
  - o Referral
  - Supply (diet)
  - o Procedure
  - Observation (diagnostic image, public health case)
  - Device task
  - Substance administration
- Acts Financial
  - Financial contract
  - Financial act (account; invoice element, financial transaction)
  - o Act heir
  - Act context

Infrastructure: Infrastructure for documents and messages to be exchanged include:

- Structured documents
  - o Context structure
    - Clinical document
    - Table structure (table cell, table-column structure)
    - Table
    - Local attribute
    - Local markup
    - Link html
- Message control
  - Communication function
  - o Attention line

- o Transmission
  - Batch,
  - Message
  - Acknowledgement
  - Control event
    - Query event
      - Sort control
      - Query specification (parameters, query by parameters/selection, selection expression, etc.)
      - o Query acknowledgement
      - Query continuation

# Appendix K The Unified Medical Language System (UMLS)

The UMLS project is a long-term National Library of Medicine research and development effort designed to facilitate the integration of information from a variety of medical data sources. These data sources include: bibliographic databases, computerized clinical records, factual databanks, expert systems and directories of people and organizations.

The UMLS approach involves the development of "intellectual middleware" that can be used by a wide variety of application programs to compensate for differences in terminology and the scattering of relevant information across many databases. The middleware provides three "knowledge sources":

- The Metathesaurus provides a uniform, integrated distribution format from over 60 biomedical vocabularies and classifications, and links many different names for the same concepts. It interconnects many standard clinical and biomedical vocabularies.
- The Semantic Network contains information about the types or categories (e.g., "Disease or Syndrome," "Virus") to which all Metathesaurus concepts have been assigned and the permissible relationships among these types (e.g., "Virus" causes "Disease or Syndrome").
- The Specialist Lexicon contains syntactic information for many terms, component words, and English words, including verbs, that do not appear in the Metathesaurus.

NLM also distributes associated lexical programs and software helpful in searching, indexing and lexical processing including producing customized versions of the <u>UMLS Metathesaurus</u>. The UMLS system is not designed as "off the shelf" software but rather intended primarily for use by system developers and as a reference tool for database builders, librarians, and other information professionals.

Biomedical categories that are relevant to MERIP and are part of the Metathesaurus include:

- Clinical Classifications Software (CCS) Categories
- Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART)
- Physicians' Current Procedural Terminology (CPT)
- Diagnostic and Statistical Manual of Mental Disorders (DSM)
- HCFA Common Procedure Coding System (HCPCS)
- Health Level Seven Vocabulary (HL7)
- International Classification of Diseases and Related Health Problems (ICD 9, 10)
- Logical Observations Identifiers, Names and Codes (LOINC)
- Medical Dictionary for Regulatory Activities Terminology (MedDRA)
- Systematized nomenclature of medicine (SNOMED)
- Universal Medical Device Nomenclature System (UMD)
- WHO Adverse Drug Reaction Terminology (WHOART)

The UMLS project is directed by a multi-disciplinary team of NLM staff and is support by Apelon, a contractor. NLM makes use of the UMLS Metathesaurus in NLM Gateway and PubMed to enhance MEDLINE searching. UMLS products are distributed annually, free-of-charge under a license agreement.

#### The Metathesaurus

The metathesaurus preserves the names, meanings, hierarchical contexts, attributes, and inter-term relationships present in its source vocabularies; adds certain basic information to each concept; and establishes new relationships between terms from different source vocabularies.

The goal of the development of the Metathesaurus is to supply information that computer programs can use to interpret user inquiries, interact with users to refine their questions, identify which databases contain information relevant to particular inquiries, and convert the users' terms into the vocabulary used by relevant information sources.

The 2002AA edition of the Metathesaurus includes 776,940 concepts and 2.1 million concept names in over 60 different biomedical source vocabularies, some in multiple languages.

The Metathesaurus is used in a wide range of applications including: linking between different clinical or biomedical vocabularies; information retrieval from databases with human assigned subject index terms and from free-text information sources; linking patient records to related information in bibliographic, full-text, or factual databases; natural language processing and automated indexing research; and structured data entry.

### The Specialist Lexicon

The SPECIALIST lexicon has been developed to provide the lexical information needed for the SPECIALIST Natural Language Processing System. It is intended to be a general English lexicon that includes many biomedical terms. Coverage includes both commonly occurring English words and biomedical vocabulary. Lexical information includes parts of speech, inflectional variation (e.g., singular and plural for nouns, the conjugations of verbs, the positive, comparative, and superlative for adjectives and adverbs), and allowable complementation patterns (i.e., the objects and other arguments that verbs, nouns, and adjectives can take). The lexical programs generate a range of variations for English lexical items and are useful for recognizing lexical variation in biomedical terminologies and texts.

#### The Semantic Network

The Semantic Network, through its 134 semantic types, provides a consistent categorization of all concepts represented in the UMLS Metathesaurus<sup>®</sup>. The 54 links between the semantic types provide the structure for the Network and represent important relationships in the biomedical domain. All information about specific concepts is found in the Metathesaurus; the Network provides information about the basic semantic types that are assigned to these concepts, and it defines the relationships that may hold between the semantic types.

Code	Category Description
Y70	Anesthesiology devices with associated adverse events <sup>1</sup>
Y71	Cardiovascular devices associated with associated adverse events <sup>1</sup>
Y72	Otorhinolaryngological devices with associated adverse events <sup>1</sup>
Y73	Gastroenterology and urology devices with associated adverse events <sup>1</sup>
Y74	General hospital and personal-use devices with associated adverse events <sup>1</sup>
Y75	Neurological devices with associated adverse events <sup>1</sup>
Y76	Obstetric and gynecological devices with associated adverse events <sup>1</sup>
Y77	Ophthalmic devices with associated adverse events <sup>1</sup>
Y78	Radiological devices with associated adverse events <sup>1</sup>
Y79	Orthopedic devices with associated adverse events <sup>1</sup>
Y80	Physical medicine devices with associated adverse events <sup>1</sup>
I97.41	Intraoperative and post procedural hemorrhage and hematoma complicating a circulatory procedure
I97.410	Intraoperative hemorrhage of a circulatory system organ or structure during a cardiac catheterization
I97.411	Intraoperative hemorrhage of a circulatory system organ or structure during a cardiac bypass
I97.418	Intraoperative hemorrhage of a circulatory system organ or structure during an other circulatory system procedure
I97.42	Intraoperative hemorrhage of a non-circulatory system organ or structure during a circulatory system procedure
I97.43	Intraoperative hematoma of a circulatory system organ or structure during a circulatory system procedure
I97.44	Intraoperative hematoma of a non-circulatory system organ or structure during a circulatory system procedure
I97.45	Postprocedural hemorrhage of a circulatory system organ or structure following a circulatory system procedure
I97.46	Postprocedural hemorrhage of a non-circulatory system organ or structure following a circulatory system procedure
I97.47	Postprocedural hematoma of a circulatory system organ or structure following a circulatory system procedure
I97.48	Postprocedural hematoma of a non-circulatory system organ or structure following a circulatory system procedure
197.5	Accidental puncture and laceration during a circulatory system procedure
I97.51	Accidental puncture and laceration of a circulatory system organ or structure during a circulatory system procedure
197.52	Accidental puncture and laceration of a non-circulatory system organ or structure during a circulatory system procedure
ICD-10-CM	This chapter contains code extensions to distinguish initial treatment versus
Injury,	subsequent treatment.
poisoning	
chapter	

Appendix L Examples of New ICD-10-CM Codes Related to Medical Misadventures

Type of Error	Category Label	Description			
No Error	А	Circumstances or events that have the capacity to cause error			
	В	An error occurred but the error did not reach the patient (An "error of omission" does reach the patient.)			
Error, No Harm <sup>1</sup>	С	An error occurred that reached the patient, but did not cause patient harm (e.g. medication reaches the patient and is administered or medication reaches the patient but is not administered).			
	D	An error occurred that reached the patient and required monitoring to confirm that it resulted in no harm to the patient and/or required intervention to preclude harm			
	E	An error occurred that may have contributed to or resulted in temporary harm to the patient and required intervention			
Error, Harm	F	An error occurred that may have contributed to or resulted in temporary harm to the patient and required initial or prolonged hospitalization			
	G	An error occurred that may have contributed to or resulted in permanent patient harm			
	Н	An error occurred that required intervention necessary to sustain life			
Error, Death	Ι	An error occurred that may have contributed to or resulted in the patient's death.			

Appendix M NCCMERP Adverse Event Classification Regarding Harm to the Patient

## Appendix N The Aviation Safety Reporting System (ASRS)

Integration of USDHHS medical event reporting system as currently configured would include only adverse events, which are identified by an event (e.g., drug reaction) occurring to a patient. Battles (1998) identified two other situations in which reporting can reduce the *risk* of harm to patients: "no harm" events and "near misses, known collectively as "close calls." "No harm" events occur when an error occurred but there was no adverse effect on the patient. An example would be administration of a medication other than the one prescribed, and the patient had no adverse reaction to the substitute medication. "Near misses" occur when the error was caught before it reached a patient. An example would be dispensing the wrong prescription but noting and retrieving it before it was administered to the patient. It has been widely acknowledged that errors resulting in serious patient harm are merely the tip of an iceberg (IOM, 1999). And much less is known about close calls. Knowledge of them would present opportunities to learn before actual mistakes occur and to take corrective action before patients are injured.

The Aviation Safety Reporting System (ASRS) is designed to identify and prevent safety slips or lapses in the aviation industry. Although aviation is different from medicine, features of the ASRS can be adapted to health care. The Department of Veterans Affairs (VA) has designed its Patient Safety Reporting System (PSRS) after the model of ASRS.

PSRS encourages reporting of medical adverse events, sentinel events, and close calls through a fully anonymous, externally managed system that covers all types of adverse events in the VA health care system and complements the mandatory internal VA reporting system, known as the Patient Safety Information System. Under PSRS, all VA facility staff can voluntarily report any event or concern for patient safety to NASA, a separate and independent agency, which processes these reports to maintain anonymity and confidentiality of the reporter. The PSRS embraces principles of non-punitive reporting.<sup>1</sup> As such, PSRS has the potential to identify many system vulnerabilities. However, specific solutions may not be forthcoming from the PSRS because details of the event or close call are seldom specific enough to allow a root cause analysis of the problem. The mandatory internal system is directed toward root cause analysis and corrective action.

The Patient Safety Reporting System has adopted some and not other characteristics of the ASRS to health care. Features adopted by PSRS include:

- A organization without regulatory or enforcement powers collecting reports
- Strict privacy and confidentiality of the reporter
- Inclusion of "close calls"
- A focus on identifying safety risks, not corrective action for a specific events.

Features of ASRS not adopted by PSRS, but which could be, include:

- Use of the database by agency staff to conduct and disseminate research on medical events.
- Availability of the database on CD-ROM for other researchers (de-identification of the data makes this feasible).
- Agency analyses of ASRS data in response to public queries about aviation safety, with responses returned directly to the inquirers.

These latter features of the ASRS also could be applied to a fully functioning USDHHS integration of medical error reporting, if the system were to expand the definition of events that will be collected through the integrated system.

<sup>&</sup>lt;sup>1</sup> Non-punitive reporting is more feasible in the VA system than in community medicine because VA employees are not subject to personal liability to the same extent as community practitioners and because Veterans who are injured by medical mistakes may receive a workers-compensation-type administrative benefit.

Although the aviation model applies in many ways to health care, it may not apply in all ways. The IOM (1999) identified two potential problems in applying the ASRS to health care. First the volume of reports may be excessive. The number of patients seen in hospitals, physicians' offices and clinics each day means that the volume of adverse and close call reports might be considerably higher in health care than in aviation. Second, effective analysis of event reports will require experts from many medical specialties such as cardiology, internal medicine, and drug therapy, to name a few. Health care is much more specialized than aviation, and experts will be needed to review and understand lessons from the reports. Furthermore, the legal liability of health care providers outside of government, the fear of discoverability even when reporting is anonymously, and the uncertainty around legal protections for reported data make the likelihood of voluntary reporting less for health care than for aviation.